{"generated":"2026-10-21T09:37:27.082Z","total":1789,"checked":1789,"broken":327,"gone":78,"blocked":221,"unreachable":28,"moved":101,"archived":566,"results":[{"url":"http://www.zhhyx.com.cn/","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-10-21","refs":[{"id":"chinese-journal-of-nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","route":"/journals/chinese-journal-of-nuclear-medicine-and-molecular-imaging/","field":"url"}],"archive":"https://web.archive.org/web/20260923093032/https://www.zhhyx.com.cn/"},{"url":"https://businesswire.com/news/home/20251016096352/en/Exelixis-Announces-Results-from-Subgroup-Analysis-of-CABINET-Phase-3-Pivotal-Trial-Evaluating-CABOMETYX-cabozantinib-in-Advanced-Lung-and-Thymic-Neuroendocrine-Tumors-at-ESMO-2025","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-10-21","refs":[{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","field":"links","label":"ESMO 2025 subgroup (Exelixis)"}],"archive":"https://web.archive.org/web/20260122163752/https://www.businesswire.com/news/home/20251016096352/en/Exelixis-Announces-Results-from-Subgroup-Analysis-of-CABINET-Phase-3-Pivotal-Trial-Evaluating-CABOMETYX-cabozantinib-in-Advanced-Lung-and-Thymic-Neuroendocrine-Tumors-at-ESMO-2025"},{"url":"https://dial.uclouvain.be/pr/boreal/object/boreal:213463/datastream/PDF_02/view","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"radium223-abiraterone-caution","kind":"pairing","name":"Radium-223 with abiraterone: a caution, not a combination","route":"/pairings/radium223-abiraterone-caution/","field":"links","label":"Smith et al., ERA-223 primary results, Lancet Oncology 2019 (open-access PDF via UCLouvain)"}],"archiveRequested":false},{"url":"https://indico.ictp.it/event/10205/session/2/contribution/4/material/slides/0.pdf","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"absorbed-dose-term","kind":"term","name":"Absorbed dose and the gray (Gy)","route":"/terms/absorbed-dose-term/","field":"links","label":"ICRU Report 85a via IAEA/ICTP teaching slides: definition of absorbed dose"}],"archive":"https://web.archive.org/web/20240714120324/https://indico.ictp.it/event/10205/session/2/contribution/4/material/slides/0.pdf"},{"url":"https://nuclide-hema.healthbooktimes.org/article/154290-recent-advances-in-radioligand-therapy","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"idea-rlt-plus-parp-inhibitor","kind":"idea","name":"Adding a PARP inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-parp-inhibitor/","field":"links","label":"Recent Advances in Radioligand Therapy: LuPARP recommended phase 2 dose results"}],"archiveRequested":false},{"url":"https://pipelinereview.com/gsk-to-discontinue-manufacture-and-sale-of-the-bexxar-therapeutic-regimen-tositumomab-and-iodine-i-131-tositumomab/","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"i-131-tositumomab","kind":"drug","name":"Iodine-131 tositumomab","route":"/drugs/i-131-tositumomab/","field":"links","label":"GSK: announcement of discontinuation, 6 August 2013"},{"id":"i-131-tositumomab","kind":"drug","name":"Iodine-131 tositumomab","route":"/drugs/i-131-tositumomab/","field":"regulatoryEvents.source (2013-08-06)"}],"archive":"https://web.archive.org/web/20261007112113/https://pipelinereview.com/gsk-to-discontinue-manufacture-and-sale-of-the-bexxar-therapeutic-regimen-tositumomab-and-iodine-i-131-tositumomab/"},{"url":"https://www.301hospital.com.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","route":"/institutions/pla-general-hospital/","field":"links","label":"Chinese PLA General Hospital"},{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","route":"/institutions/pla-general-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260611040912/http://301hospital.com.cn/"},{"url":"https://www.bigagainstbreastcancer.org","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","field":"links","label":"Breast International Group"}],"archive":"https://web.archive.org/web/20260912133906/http://www.bigagainstbreastcancer.org/"},{"url":"https://www.businesswire.com/news/home/20260610511667/en/MTTI-Highlights-Clinical-Experience-in-81-GEP-NETs-Patients-and-Differentiated-Profile-of-Next-Generation-PRRT-Candidate-EBTATE-Following-Presentation-at-SNMMI-2026","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-10-21","refs":[{"id":"molecular-targeting-technologies","kind":"company","name":"Molecular Targeting Technologies","route":"/companies/molecular-targeting-technologies/","field":"links","label":"Business Wire: MTTI highlights clinical experience in 81 GEP-NETs patients and differentiated profile of EBTATE, following presentation at SNMMI 2026"}],"archiveRequested":false},{"url":"https://www.businesswire.com/news/home/20260707936626/en/Molecular-Targeting-Technologies-Presents-First-Clinical-Validation-of-the-Evans-Blue-Platform-Demonstrating-Up-to-15-Day-Tumor-Retention-Using-Approximately-12.5-of-the-Radioactivity-Required-for-Conventional-PRRT","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-10-21","refs":[{"id":"molecular-targeting-technologies","kind":"company","name":"Molecular Targeting Technologies","route":"/companies/molecular-targeting-technologies/","field":"links","label":"Business Wire: Molecular Targeting Technologies presents first clinical validation of the Evans Blue platform (2026)"}],"archive":"https://web.archive.org/web/20260708000901/https://www.businesswire.com/news/home/20260707936626/en/Molecular-Targeting-Technologies-Presents-First-Clinical-Validation-of-the-Evans-Blue-Platform-Demonstrating-Up-to-15-Day-Tumor-Retention-Using-Approximately-12.5-of-the-Radioactivity-Required-for-Conventional-PRRT"},{"url":"https://www.cardinalhealth.com","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-10-21","refs":[{"id":"cardinal-health","kind":"company","name":"Cardinal Health Nuclear & Precision Health Solutions","route":"/companies/cardinal-health/","field":"links","label":"Official website"},{"id":"cardinal-health","kind":"company","name":"Cardinal Health Nuclear & Precision Health Solutions","route":"/companies/cardinal-health/","field":"website"}],"archive":"https://web.archive.org/web/20150421113101/http://www.cardinalhealth.com/"},{"url":"https://www.ccc.ukw.de","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","field":"links","label":"CCC Mainfranken"},{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","field":"website"}],"archive":"https://web.archive.org/web/20150717014740/http://www.ccc.ukw.de:80/"},{"url":"https://www.cccz.ch","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/","field":"links","label":"Comprehensive Cancer Center Zurich"}],"archive":"https://web.archive.org/web/20221129071317/http://cccz.ch/"},{"url":"https://www.charite.de","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/","field":"links","label":"Official website"},{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/","field":"website"}],"archive":"https://web.archive.org/web/20260927122919/https://www.charite.de/"},{"url":"https://www.duchembio.com/","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"duchembio","kind":"company","name":"DuChemBio","route":"/companies/duchembio/","field":"website"}],"archive":"https://web.archive.org/web/20260615052336/http://duchembio.com/"},{"url":"https://www.futurechem.co.kr","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"futurechem","kind":"company","name":"FutureChem","route":"/companies/futurechem/","field":"links","label":"Official website"},{"id":"futurechem","kind":"company","name":"FutureChem","route":"/companies/futurechem/","field":"website"}],"archive":"https://web.archive.org/web/20260923092632/https://www.futurechem.co.kr/"},{"url":"https://www.isotopia.co.il","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"isotopia","kind":"company","name":"Isotopia Molecular Imaging","route":"/companies/isotopia/","field":"links","label":"Official website"},{"id":"isotopia","kind":"company","name":"Isotopia Molecular Imaging","route":"/companies/isotopia/","field":"website"}],"archive":"https://web.archive.org/web/20260514223723/https://www.isotopia.co.il/"},{"url":"https://www.lafe.san.gva.es","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/","field":"links","label":"Homepage"},{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/","field":"website"}],"archive":"https://web.archive.org/web/20251014130117/https://lafe.san.gva.es/"},{"url":"https://www.mri.tum.de","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","field":"links","label":"Homepage"},{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","field":"website"}],"archive":"https://web.archive.org/web/20250312143951/https://www.mri.tum.de/"},{"url":"https://www.msac.gov.au/sites/default/files/2025-07/1657.1_final_psd_-_april_2025_-_redacted.pdf","status":0,"ok":false,"error":"This operation was aborted","checked":"2026-10-21","refs":[{"id":"re-188-sct","kind":"drug","name":"Rhenium-188 skin cancer therapy","route":"/drugs/re-188-sct/","field":"links","label":"Australian MSAC public summary document on Rhenium-188 brachytherapy for skin cancer"}],"archive":"https://web.archive.org/web/20260116005956/https://www.msac.gov.au/sites/default/files/2025-07/1657.1_final_psd_-_april_2025_-_redacted.pdf"},{"url":"https://www.navidea.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","field":"website"}],"archive":"https://web.archive.org/web/20260614203428/https://www.navidea.com/"},{"url":"https://www.nct-wera.de","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","field":"links","label":"NCT WERA"}],"archiveRequested":false},{"url":"https://www.nct-west.de","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","field":"links","label":"NCT West"}],"archiveRequested":false},{"url":"https://www.opendose.org/","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"idea-open-dosimetry-data-commons","kind":"idea","name":"An open data commons linking patient-level radiopharmaceutical dosimetry to outcomes","route":"/ideas/idea-open-dosimetry-data-commons/","field":"links","label":"OpenDose: open-access resources for radiopharmaceutical dosimetry"}],"archive":"https://web.archive.org/web/20250514152033/https://opendose.org/"},{"url":"https://www.quirem.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"quirem-medical","kind":"company","name":"Quirem Medical","route":"/companies/quirem-medical/","field":"website"}],"archive":"https://web.archive.org/web/20250618214959/https://www.quirem.com/"},{"url":"https://www.quirem.com/wp-content/uploads/2022/10/LC-8007204-Administration-Procedure-Manual.pdf","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"quirem-medical","kind":"company","name":"Quirem Medical","route":"/companies/quirem-medical/","field":"links","label":"Quirem: administration procedure manual (PDF)"}],"archive":"https://web.archive.org/web/20240514171937/https://www.quirem.com/wp-content/uploads/2022/10/LC-8007204-Administration-Procedure-Manual.pdf"},{"url":"https://www.sdzlyy.org.cn","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/","field":"links","label":"Shandong Cancer Hospital"},{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/","field":"website"}],"archiveRequested":false},{"url":"https://www.spectrumpharm.com","status":0,"ok":false,"error":"fetch failed","checked":"2026-10-21","refs":[{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","field":"website"}],"archive":"https://web.archive.org/web/20260107160619/http://www.spectrumpharm.com/"},{"url":"https://aacrjournals.org","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/","checked":"2026-10-21","refs":[{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/","field":"links","label":"AACR Journals"}]},{"url":"https://aacrjournals.org/clincancerres","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"clinical-cancer-research","kind":"journal","name":"Clinical Cancer Research","route":"/journals/clinical-cancer-research/","field":"url"}]},{"url":"https://aacrjournals.org/clincancerres/article/22/7/1642/121738/ImmunoPET-with-Anti-Mesothelin-Antibody-in","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"mesothelin","kind":"target","name":"Mesothelin (MSLN)","route":"/targets/mesothelin/","field":"links","label":"Clinical Cancer Research: immunoPET with anti-mesothelin antibody (89Zr-MMOT0530A) in pancreatic and ovarian cancer"}]},{"url":"https://aacrjournals.org/clincancerres/article/29/8/1496/725070/Membranous-NECTIN-4-Expression-Frequently","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"opp-nectin4-imaging-urothelial","kind":"opportunity","name":"A liver-cleared Nectin-4 tracer for urothelial cancer","route":"/opportunities/opp-nectin4-imaging-urothelial/","field":"links","label":"Nectin-4 expression and loss in metastatic progression, Clinical Cancer Research 2023"}]},{"url":"https://academic.oup.com/ejcts/article/36/1/181/2755225","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"split-function-lung-perfusion","kind":"technology","name":"Split-function perfusion scintigraphy before lung resection","route":"/technologies/split-function-lung-perfusion/","field":"links","label":"ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer patients (Brunelli et al. 2009)"}]},{"url":"https://academic.oup.com/jcem/article/110/9/2453/8196671","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"links","label":"2025 Endocrine Society Primary Aldosteronism Clinical Practice Guideline, JCEM"},{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"standardOfCare.guideline (Confirmed primary aldosteronism considering surgery)"},{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"standardOfCare.guideline (Bilateral disease, or lateralizing disease in a non-surgical candidate)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2018.78.5865","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"paper-strosberg-netter1-qol-jco-2018","kind":"paper","name":"Health-related quality of life in the NETTER-1 trial of 177Lu-Dotatate","route":"/key-papers/paper-strosberg-netter1-qol-jco-2018/","field":"links","label":"ASCO Publications: full text"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2020.38.4_suppl.604","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"prrt-plus-captem","kind":"pairing","name":"PRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM)","route":"/pairings/prrt-plus-captem/","field":"links","label":"AGITG CONTROL NET midgut NET first results (ASCO 2020, J Clin Oncol 38:604)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2022.40.16_suppl.4122","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"prrt-plus-captem","kind":"pairing","name":"PRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM)","route":"/pairings/prrt-plus-captem/","field":"links","label":"AGITG CONTROL NET final results (Pavlakis et al., ASCO 2022, J Clin Oncol 40:4122)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2022.40.6_suppl.TPS211","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"docetaxel-then-lu177-psma","kind":"pairing","name":"Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617","route":"/pairings/docetaxel-then-lu177-psma/","field":"links","label":"PSMAfore design (taxane-naive, ARPI-progressed population), ASCO 2022"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5005","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"idea-rlt-plus-parp-inhibitor","kind":"idea","name":"Adding a PARP inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-parp-inhibitor/","field":"links","label":"LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in mCRPC (JCO, 2023)"},{"id":"pluvicto-plus-olaparib","kind":"pairing","name":"177Lu-PSMA-617 (Pluvicto) with olaparib","route":"/pairings/pluvicto-plus-olaparib/","field":"links","label":"LuPARP phase 1 abstract (Sandhu et al., ASCO 2023, J Clin Oncol 41:5005)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2023.41.16_suppl.5039","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"cu-64-sar-bispsma","kind":"drug","name":"Copper-64 SAR-bisPSMA","route":"/drugs/cu-64-sar-bispsma/","field":"links","label":"Lengyelova, Wong, Lenzo, Parker, Emmett; JCO 2023: 64Cu-SAR-bisPSMA (PROPELLER) PET imaging in confirmed prostate cancer"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.2025.43.5_suppl.TPS282","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"idea-alpha-for-oligometastatic-disease","kind":"idea","name":"Alpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer","route":"/ideas/idea-alpha-for-oligometastatic-disease/","field":"links","label":"ACCEL: Ac-225-PSMA-62 phase Ia/Ib/II trial in oligometastatic and castration-resistant prostate cancer (ASCO abstract, 2025)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.21.00714","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","field":"links","label":"JCO 2022"},{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","field":"outcomes.source (Complete remission at 18 months)"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.00573","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"paper-tagawa-ac225-j591-jco-2024","kind":"paper","name":"Phase I dose-escalation study of 225Ac-J591, a PSMA-targeting alpha-emitting antibody, in mCRPC","route":"/key-papers/paper-tagawa-ac225-j591-jco-2024/","field":"links","label":"ASCO Publications: full text"}]},{"url":"https://ascopubs.org/doi/10.1200/JCO.23.01177","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"fdg-pet-response-adapted-therapy","kind":"pairing","name":"FDG PET then response-adapted chemotherapy","route":"/pairings/fdg-pet-response-adapted-therapy/","field":"links","label":"Long-term follow-up of RATHL (Luminari et al., J Clin Oncol 2024)"}]},{"url":"https://ascopubs.org/journal/jco","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","field":"url"}]},{"url":"https://cdn.ymaws.com/www.bnms.org.uk/resource/resmgr/ukrg/resources/2021_information_resources_r.pdf","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"radiolabelling-quality-control","kind":"technology","name":"Radiolabelling quality control","route":"/technologies/radiolabelling-quality-control/","field":"links","label":"BNMS/UKRG information resource: radiochemical purity systems of radiopharmaceuticals"}]},{"url":"https://dmd.aspetjournals.org/content/50/9/1218","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"norepinephrine-transporter","kind":"target","name":"Norepinephrine transporter (NET)","route":"/targets/norepinephrine-transporter/","field":"links","label":"DMD: clinical applications and roles of transporters in disposition, tumour targeting and tissue toxicity of MIBG"}]},{"url":"https://doaj.org/toc/1470-7330","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","field":"links","label":"DOAJ record"}]},{"url":"https://doi.org/10.1001/jamaoncol.2018.0977","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2018.0977","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"idea-reg-ac225-accelerator-pharmacopoeia","kind":"idea","name":"Regional cyclotron hubs for actinium-225 with an agreed actinium-227 impurity limit","route":"/ideas/idea-reg-ac225-accelerator-pharmacopoeia/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-alpha-emitter-portfolio","kind":"idea","name":"Fund alpha emitters beyond actinium-225: lead-212, terbium-149 and astatine-211","route":"/ideas/idea-reg-alpha-emitter-portfolio/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-isotope-supply-observatory","kind":"idea","name":"A global medical isotope supply observatory with forecasts and shortage alerts","route":"/ideas/idea-reg-isotope-supply-observatory/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-regional-radiopharmacy-hubs","kind":"idea","name":"Regional radiopharmacy hubs and harmonised transport rules for short-lived isotopes","route":"/ideas/idea-reg-regional-radiopharmacy-hubs/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"idea-reg-yb176-enrichment-capacity","kind":"idea","name":"Build Western ytterbium-176 enrichment so lutetium-177 has more than one supplier","route":"/ideas/idea-reg-yb176-enrichment-capacity/","field":"links","label":"Bottleneck evidence (Manufacturing cost and time for living and radioactive medicines): Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"links","label":"Hernandez, Prasad & Gellad, Total costs of chimeric antigen receptor T-cell immunotherapy (JAMA Oncology 2018)"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"metrics (Estimated total cost of CAR-T therapy including list price and management of adverse events (2018 US analysis))"}]},{"url":"https://doi.org/10.1001/jamaoncol.2019.0096","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2019.0096","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"papers","label":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial"},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"papers","label":"Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial"}]},{"url":"https://doi.org/10.1001/jamaoncol.2020.0147","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2763312","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"idea-psma-pet-guided-mdt","kind":"idea","name":"PSMA-PET-guided metastasis-directed therapy as a curative strategy in oligorecurrent prostate cancer","route":"/ideas/idea-psma-pet-guided-mdt/","field":"links","label":"ORIOLE: observation versus stereotactic ablative radiation for oligometastatic prostate cancer (JAMA Oncology 2020)"}]},{"url":"https://doi.org/10.1001/jamaoncol.2021.3771","status":403,"ok":false,"finalUrl":"https://jamanetwork.com/journals/jamaoncology/fullarticle/2783766","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"papers","label":"Diagnostic Accuracy of 68Ga-PSMA-11 PET for Pelvic Nodal Metastasis Detection Prior to Radical Prostatectomy and Pelvic Lymph Node Dissection: A Multicenter Prospective Phase 3 Imaging Trial"}]},{"url":"https://doi.org/10.1039/C3CS60304K","status":403,"ok":false,"finalUrl":"https://pubs.rsc.org/cs/article/43/1/260-290/398610","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"dota-chelation","kind":"technology","name":"DOTA chelation","route":"/technologies/dota-chelation/","field":"links","label":"Price & Orvig, Chem Soc Rev 2014: Matching chelators to radiometals for radiopharmaceuticals"}]},{"url":"https://doi.org/10.1039/D0CS00556H","status":403,"ok":false,"finalUrl":"https://pubs.rsc.org/cs/article/50/3/1480-1494/681982","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"peptide-drug-conjugate","kind":"technology","name":"Peptide-drug & small-molecule-drug conjugates","route":"/technologies/peptide-drug-conjugate/","field":"links","label":"Cooper et al., Peptides as a platform for targeted therapeutics for cancer: peptide-drug conjugates (Chemical Society Reviews 2021)"}]},{"url":"https://doi.org/10.1056/NEJM199910143411601","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJM199910143411601","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"papers","label":"Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group"}]},{"url":"https://doi.org/10.1056/NEJMoa1003825","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1003825","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"links","label":"Sunitinib in pancreatic NET (NEJM 2011)"}]},{"url":"https://doi.org/10.1056/NEJMoa1009290","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/abs/10.1056/NEJMoa1009290","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"links","label":"RADIANT-3 (NEJM 2011)"},{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","field":"outcomes.source (Progression-free survival (RADIANT-3))"}]},{"url":"https://doi.org/10.1056/NEJMoa1213755","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1213755","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","field":"papers","label":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases"},{"id":"paper-alsympca-radium-223-nejm-2013","kind":"paper","name":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases","route":"/key-papers/paper-alsympca-radium-223-nejm-2013/","field":"links","label":"N Engl J Med 2013"}]},{"url":"https://doi.org/10.1056/NEJMoa1316158","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1316158","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"paper-clarinet-lanreotide-nejm-2014","kind":"paper","name":"CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours","route":"/key-papers/paper-clarinet-lanreotide-nejm-2014/","field":"links","label":"N Engl J Med 2014"}]},{"url":"https://doi.org/10.1056/NEJMoa1510093","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1510093","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016","kind":"paper","name":"RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma","route":"/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/","field":"links","label":"N Engl J Med 2016"}]},{"url":"https://doi.org/10.1056/NEJMoa1607427","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1607427","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"links","label":"NETTER-1 (NEJM 2017)"},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","field":"links","label":"Strosberg et al., Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumours (NEJM 2017)"},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","field":"outcomes.source (Progression-free survival at 20 months)"},{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","field":"outcomes.source (Objective response rate)"},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"papers","label":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors"},{"id":"paper-netter-1-nejm-2017","kind":"paper","name":"NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide","route":"/key-papers/paper-netter-1-nejm-2017/","field":"links","label":"N Engl J Med 2017"}]},{"url":"https://doi.org/10.1056/NEJMoa1702900","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1702900","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"James et al., NEJM 2017: abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE)"}]},{"url":"https://doi.org/10.1056/NEJMoa1709866","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1709866","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"links","label":"Maude et al., Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia (ELIANA, NEJM 2018)"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"metrics (Patients in ELIANA for whom tisagenlecleucel could not be manufactured)"}]},{"url":"https://doi.org/10.1056/NEJMoa1800536","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1800536","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"outcomes.source (Metastasis-free survival)"},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"outcomes.source (Time to PSA progression)"},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"outcomes.source (Time to first subsequent antineoplastic therapy)"},{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"outcomes.source (Grade 3 or higher adverse events)"}]},{"url":"https://doi.org/10.1056/NEJMoa1815671","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa1815671","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","field":"papers","label":"ARAMIS: darolutamide in non-metastatic castration-resistant prostate cancer"}]},{"url":"https://doi.org/10.1056/NEJMoa2028485","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2028485","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"idea-trop2-pet-selection","kind":"idea","name":"TROP2 PET to choose and sequence TROP2 ADCs","route":"/ideas/idea-trop2-pet-selection/","field":"links","label":"ASCENT: sacituzumab govitecan doubles survival in heavily pretreated metastatic triple-negative breast cancer (New England Journal of Medicine 2021)"}]},{"url":"https://doi.org/10.1056/NEJMoa2103425","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2103425","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","field":"links","label":"Belzutifan in VHL (NEJM 2021)"}]},{"url":"https://doi.org/10.1056/NEJMoa2107322","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2107322","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/","field":"links","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer (New England Journal of Medicine 2021)"},{"id":"psma-pet-to-rlt","kind":"pairing","name":"PSMA PET → PSMA radioligand therapy","route":"/pairings/psma-pet-to-rlt/","field":"links","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer (New England Journal of Medicine 2021)"},{"id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/","field":"links","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer (New England Journal of Medicine 2021)"},{"id":"radiopharma-roadmap","kind":"roadmap","name":"Radiopharmaceutical roadmap: iodine → lutetium → actinium","route":"/roadmaps/radiopharma-roadmap/","field":"links","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer (New England Journal of Medicine 2021)"},{"id":"idea-total-body-pet-dosimetry","kind":"idea","name":"Total-body PET for personalised radioligand dosing","route":"/ideas/idea-total-body-pet-dosimetry/","field":"links","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer (New England Journal of Medicine 2021)"},{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","field":"papers","label":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer"},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"papers","label":"Lutetium-177–PSMA-617 for metastatic castration-resistant prostate cancer"},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/","field":"links","label":"NEJM 2021"}]},{"url":"https://doi.org/10.1056/NEJMoa2309719","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2309719","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"multiple-endocrine-neoplasia","kind":"indication","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/indications/multiple-endocrine-neoplasia/","field":"links","label":"LIBRETTO-531 (NEJM 2023)"}]},{"url":"https://doi.org/10.1056/NEJMoa2403991","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMoa2403991","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/","field":"links","label":"CABINET (NEJM 2024)"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"links","label":"CABINET (NEJM 2024)"},{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","field":"outcomes.source (Progression-free survival (pancreatic NET))"},{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","field":"outcomes.source (Progression-free survival (extra-pancreatic NET))"},{"id":"paper-cabinet-cabozantinib-nejm-2024","kind":"paper","name":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours","route":"/key-papers/paper-cabinet-cabozantinib-nejm-2024/","field":"links","label":"N Engl J Med 2025"}]},{"url":"https://doi.org/10.1056/NEJMp2109826","status":403,"ok":false,"finalUrl":"https://www.nejm.org/doi/10.1056/NEJMp2109826","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","field":"links","label":"Shah, Rahman, Theoret & Pazdur, The drug-dosing conundrum in oncology: when less is more (NEJM 2021)"}]},{"url":"https://doi.org/10.1089/thy.2014.0335","status":403,"ok":false,"finalUrl":"https://journals.sagepub.com/doi/10.1089/thy.2014.0335","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"multiple-endocrine-neoplasia","kind":"indication","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/indications/multiple-endocrine-neoplasia/","field":"links","label":"ATA medullary thyroid carcinoma guideline (2015)"},{"id":"multiple-endocrine-neoplasia","kind":"indication","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/indications/multiple-endocrine-neoplasia/","field":"standardOfCare.guideline (MEN2 carriers (RET-positive))"}]},{"url":"https://doi.org/10.1093/neuonc/noab150","status":403,"ok":false,"finalUrl":"https://academic.oup.com/neuro-oncology/article/23/11/1821/6310843","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"meningioma","kind":"indication","name":"Meningioma","route":"/indications/meningioma/","field":"links","label":"EANO guideline on meningiomas (Neuro-Oncology 2021)"}]},{"url":"https://doi.org/10.1097/RLU.0000000000005798","status":403,"ok":false,"finalUrl":"https://journals.lww.com/10.1097/RLU.0000000000005798","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/","field":"links","label":"Diagnostic accuracy of 18F-florastamin PET/CT in intermediate-risk suspected prostate cancer (Clin Nucl Med, 2025)"}]},{"url":"https://doi.org/10.1126/science.aah4199","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.aah4199","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/","field":"links","label":"Ku et al., Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance (Science 2017)"}]},{"url":"https://doi.org/10.1126/science.abb9601","status":403,"ok":false,"finalUrl":"https://www.science.org/doi/10.1126/science.abb9601","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"molecular-imaging-roadmap","kind":"roadmap","name":"Molecular imaging roadmap: FDG → PSMA → FAP → antigen and immune PET","route":"/roadmaps/molecular-imaging-roadmap/","field":"links","label":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms (Science 2020)"},{"id":"paper-detect-a-science-2020","kind":"paper","name":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","route":"/key-papers/paper-detect-a-science-2020/","field":"links","label":"DOI"}]},{"url":"https://doi.org/10.1146/annurev.med.57.080904.190431","status":403,"ok":false,"finalUrl":"https://www.annualreviews.org/doi/10.1146/annurev.med.57.080904.190431","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"papers","label":"Molecular imaging in the development of cancer therapeutics"}]},{"url":"https://doi.org/10.1158/1078-0432.CCR-19-1026","status":403,"ok":false,"finalUrl":"https://aacrjournals.org/clincancerres/article/25/23/6939/82129/Phase-I-Trial-of-Well-Differentiated","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"idea-net-antagonist-ligands","kind":"idea","name":"SSTR antagonist radioligands to increase tumour dose","route":"/ideas/idea-net-antagonist-ligands/","field":"links","label":"Reidy-Lagunes et al., Phase 1 trial of the SSTR antagonist radioligand 177Lu-satoreotide tetraxetan in neuroendocrine tumours (Clinical Cancer Research 2019)"}]},{"url":"https://doi.org/10.1182/blood-2014-01-550905","status":403,"ok":false,"finalUrl":"https://ashpublications.org/blood/article/123/18/2791/32505/Somatic-mutations-in-MYD88-and-CXCR4-are","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/","field":"links","label":"CXCR4 in WM (Blood 2014)"}]},{"url":"https://doi.org/10.1200/JCO.20.02672","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.02672","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","field":"links","label":"ZGDH3 (J Clin Oncol 2021)"}]},{"url":"https://doi.org/10.1200/JCO.20.03282","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.20.03282","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"pop-rt","kind":"trial","name":"POP-RT","route":"/trials/pop-rt/","field":"links","label":"JCO 2021"}]},{"url":"https://doi.org/10.1200/JCO.2004.07.188","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2004.07.188","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"paper-sempet-de-santis-jco-2004","kind":"paper","name":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals","route":"/key-papers/paper-sempet-de-santis-jco-2004/","field":"links","label":"J Clin Oncol 2004"}]},{"url":"https://doi.org/10.1200/JCO.2007.13.8925","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2007.13.8925","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"papers","label":"Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study"}]},{"url":"https://doi.org/10.1200/JCO.2009.22.8510","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2009.22.8510","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"links","label":"PROMID (JCO 2009)"}]},{"url":"https://doi.org/10.1200/JCO.2015.64.2702","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2015.64.2702","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","field":"links","label":"PCWG3 trial design recommendations incl. PSA response reporting (Scher et al., J Clin Oncol 2016)"}]},{"url":"https://doi.org/10.1200/JCO.2017.75.6155","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.75.6155","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","field":"metrics (Patients requiring dose reduction of abemaciclib for adverse events in first-line MONARCH 3)"}]},{"url":"https://doi.org/10.1200/JCO.2017.77.6880","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2017.77.6880","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"papers","label":"Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study"}]},{"url":"https://doi.org/10.1200/JCO.2019.37.15_suppl.4005","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.2019.37.15_suppl.4005","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"papers","label":"Prospective randomized phase II trial of pazopanib versus placebo in patients with progressive carcinoid tumors (Alliance A021202)"}]},{"url":"https://doi.org/10.1200/JCO.21.00714","status":403,"ok":false,"finalUrl":"https://ascopubs.org/doi/10.1200/JCO.21.00714","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","field":"links","label":"Ho et al., J Clin Oncol 2022: selumetinib plus adjuvant radioactive iodine (ASTRA)"}]},{"url":"https://doi.org/10.1210/jc.2012-1230","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jcem/article/97/9/2990/2536740","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"multiple-endocrine-neoplasia","kind":"indication","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/indications/multiple-endocrine-neoplasia/","field":"links","label":"MEN1 clinical practice guidelines (JCEM 2012)"},{"id":"multiple-endocrine-neoplasia","kind":"indication","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/indications/multiple-endocrine-neoplasia/","field":"standardOfCare.guideline (MEN1 carriers)"}]},{"url":"https://doi.org/10.1210/jc.2014-1498","status":403,"ok":false,"finalUrl":"https://academic.oup.com/jcem/article/99/6/1915/2537399","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","field":"links","label":"Endocrine Society PPGL guideline 2014"},{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","field":"standardOfCare.guideline (Genetic diagnosis)"},{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","field":"standardOfCare.guideline (Biochemical and imaging work-up)"},{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","field":"standardOfCare.guideline (Adrenal tumours in VHL and MEN2)"},{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","field":"standardOfCare.guideline (Head and neck paragangliomas)"},{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","field":"standardOfCare.guideline (Surveillance of carriers)"},{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","field":"standardOfCare.guideline (Advanced disease in carriers)"},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","field":"links","label":"Endocrine Society PPGL guideline 2014"},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","field":"standardOfCare.guideline (All patients)"},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","field":"standardOfCare.guideline (Staging)"},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","field":"standardOfCare.guideline (Indolent disease)"},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","field":"standardOfCare.guideline (Progressive disease, radionuclide therapy)"},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","field":"standardOfCare.guideline (Progressive disease, systemic drugs)"},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","field":"standardOfCare.guideline (Trials)"},{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/","field":"links","label":"Endocrine Society guideline 2014"},{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/","field":"standardOfCare.guideline (Localised, secreting)"},{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/","field":"standardOfCare.guideline (All patients)"}]},{"url":"https://doi.org/10.1530/ERC-15-0119","status":403,"ok":false,"finalUrl":"https://journals.bioscientifica.com/erc/article/22/4/657-664/33952","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","field":"links","label":"Heetfeld et al. (Endocrine-Related Cancer 2015)"}]},{"url":"https://doi.org/10.2174/1874471011666180416161908","status":403,"ok":false,"finalUrl":"https://www.eurekaselect.com/161324/article","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"metrics (Historic global actinium-225 supply from thorium-229 stockpiles)"}]},{"url":"https://doi.org/10.6004/jnccn.2025.5012","status":403,"ok":false,"finalUrl":"https://jnccn.org/view/journals/jnccn/23/Supplement/article-e255012.xml","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"papers","label":"Management of Advanced Gastroenteropancreatic Neuroendocrine Tumors"}]},{"url":"https://inis.iaea.org/records/06vmc-y0w54","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"f-isotope-supply","kind":"section","name":"Isotope supply","route":"/fronts/f-isotope-supply/","field":"links","label":"IAEA/OECD-NEA: Towards a robust supply chain for medical radioisotopes"}]},{"url":"https://investor.lilly.com/news-releases/news-release-details/fda-approves-updated-label-lillys-amyvid-florbetapir-f-18","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"alzheimers-disease","kind":"indication","name":"Alzheimer's disease","route":"/indications/alzheimers-disease/","field":"links","label":"FDA: Amyvid label update supporting amyloid-targeting therapy selection (June 2025)"},{"id":"f-18-florbetapir","kind":"drug","name":"Florbetapir F-18","route":"/drugs/f-18-florbetapir/","field":"links","label":"Eli Lilly: FDA approves updated Amyvid label for treatment selection (25 June 2025)"},{"id":"amyloid-beta","kind":"target","name":"Amyloid beta plaques","route":"/targets/amyloid-beta/","field":"links","label":"Eli Lilly: FDA approves updated Amyvid label for amyloid-targeting therapy selection (25 June 2025)"}]},{"url":"https://investor.lilly.com/node/43256/pdf","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"tau-protein","kind":"target","name":"Tau protein (neurofibrillary tangles)","route":"/targets/tau-protein/","field":"links","label":"Eli Lilly: FDA approval of Tauvid (28 May 2020)"}]},{"url":"https://jamanetwork.com/collections/5644/oncology","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","field":"links","label":"JAMA Network oncology"}]},{"url":"https://jamanetwork.com/journals/jama","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","field":"url"}]},{"url":"https://jamanetwork.com/journals/jama/fullarticle/2729371","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"ideas-amyloid","kind":"trial","name":"IDEAS (Imaging Dementia-Evidence for Amyloid Scanning)","route":"/trials/ideas-amyloid/","field":"links","label":"JAMA 2019: IDEAS primary results (Rabinovici et al.)"},{"id":"ideas-amyloid","kind":"trial","name":"IDEAS (Imaging Dementia-Evidence for Amyloid Scanning)","route":"/trials/ideas-amyloid/","field":"outcomes.source (Change in composite patient management plan within 90 days, mild cognitive impairment group)"},{"id":"ideas-amyloid","kind":"trial","name":"IDEAS (Imaging Dementia-Evidence for Amyloid Scanning)","route":"/trials/ideas-amyloid/","field":"outcomes.source (Change in composite patient management plan within 90 days, dementia of uncertain cause group)"}]},{"url":"https://jamanetwork.com/journals/jamacardiology/fullarticle/2546034","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"cardiac-amyloidosis-attr","kind":"indication","name":"Cardiac amyloidosis (transthyretin, ATTR-CM)","route":"/indications/cardiac-amyloidosis-attr/","field":"links","label":"Gillmore et al. 2016, JAMA Cardiology: Tc-99m PYP scintigraphy for ATTR cardiac amyloidosis"},{"id":"tc-99m-pyrophosphate","kind":"drug","name":"Technetium Tc-99m pyrophosphate","route":"/drugs/tc-99m-pyrophosphate/","field":"links","label":"Gillmore et al. 2016, JAMA Cardiology: multicentre study of Tc-99m PYP for ATTR cardiac amyloidosis"}]},{"url":"https://journals.lww.com/hep/fulltext/2021/11000/yttrium_90_radioembolization_for_the_treatment_of.9.aspx","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"y-90-glass-microspheres","kind":"drug","name":"Yttrium-90 glass microspheres","route":"/drugs/y-90-glass-microspheres/","field":"links","label":"LEGACY study, Hepatology 2021"}]},{"url":"https://journals.lww.com/nuclearmed/pages/default.aspx","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"clinical-nuclear-medicine","kind":"journal","name":"Clinical Nuclear Medicine","route":"/journals/clinical-nuclear-medicine/","field":"links","label":"Clinical Nuclear Medicine (LWW journal home)"},{"id":"clinical-nuclear-medicine","kind":"journal","name":"Clinical Nuclear Medicine","route":"/journals/clinical-nuclear-medicine/","field":"url"}]},{"url":"https://journals.sagepub.com/home/cbr","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","route":"/journals/cancer-biotherapy-and-radiopharmaceuticals/","field":"links","label":"Homepage"},{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","route":"/journals/cancer-biotherapy-and-radiopharmaceuticals/","field":"url"}]},{"url":"https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-acquire-life-molecular-imaging-upfront-payment-350","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"life-molecular-imaging","kind":"company","name":"Life Molecular Imaging","route":"/companies/life-molecular-imaging/","field":"links","label":"Lantheus: Lantheus to Acquire Life Molecular Imaging (Jan 2025)"}]},{"url":"https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-and-point-biopharma-announce-positive-topline-results","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"lu-177-pnt2002","kind":"drug","name":"Lutetium-177 PNT2002","route":"/drugs/lu-177-pnt2002/","field":"links","label":"Lantheus/POINT: positive topline SPLASH results, 18 December 2023"}]},{"url":"https://lantheusholdings.gcs-web.com/news-releases/news-release-details/lantheus-presents-results-primary-analysis-phase-3-pivotal","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"lu177-psma-it","kind":"drug","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/","field":"links","label":"SPLASH primary analysis (Lantheus, ESMO 2024)"}]},{"url":"https://onlinelibrary.wiley.com/doi/am-pdf/10.1002/anie.201709532","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"macropa-chelation","kind":"technology","name":"Macropa chelation","route":"/technologies/macropa-chelation/","field":"links","label":"Thiele et al., Angew. Chem. Int. Ed. 2017: An eighteen-membered macrocyclic ligand for actinium-225 targeted alpha therapy"}]},{"url":"https://onlinelibrary.wiley.com/doi/full/10.1002/jmrs.836","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"theranostic-pair-term","kind":"term","name":"Theranostic pair","route":"/terms/theranostic-pair-term/","field":"links","label":"Molecular theranostics: principles, challenges and controversies, J Med Radiat Sci 2025"}]},{"url":"https://onlinelibrary.wiley.com/journal/17549485","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","route":"/journals/journal-of-medical-imaging-and-radiation-oncology/","field":"links","label":"Homepage"},{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","route":"/journals/journal-of-medical-imaging-and-radiation-oncology/","field":"url"}]},{"url":"https://publications.ersnet.org/content/breathe/7/3/221","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"split-function-lung-perfusion","kind":"technology","name":"Split-function perfusion scintigraphy before lung resection","route":"/technologies/split-function-lung-perfusion/","field":"links","label":"Fitness for radical treatment of lung cancer patients (Breathe 2011): why segment counting suffices before lobectomy"}]},{"url":"https://pubs.acs.org/doi/10.1021/acs.inorgchem.3c01983","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"macropa-chelation","kind":"technology","name":"Macropa chelation","route":"/technologies/macropa-chelation/","field":"links","label":"Equilibrium thermodynamics of macropa complexes with radiopharmaceutical metals (Inorg. Chem. 2023)"}]},{"url":"https://pubs.acs.org/doi/10.1021/bc034109i","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"radiolysis","kind":"term","name":"Radiolysis (self-radiolysis of radiopharmaceuticals)","route":"/terms/radiolysis/","field":"links","label":"Bioconjugate Chemistry: ascorbic acid as a buffer agent and radiolytic stabilizer for metalloradiopharmaceuticals"}]},{"url":"https://pubs.acs.org/doi/10.1021/ja983706q","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"dota-chelation","kind":"technology","name":"DOTA chelation","route":"/technologies/dota-chelation/","field":"links","label":"Mechanism and energetics of 90Y-DOTA complexation (J. Am. Chem. Soc. 1999)"}]},{"url":"https://pubs.acs.org/doi/abs/10.1021/acs.bioconjchem.8b00556","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"albumin-binder-ligands","kind":"technology","name":"Albumin-binder ligands","route":"/technologies/albumin-binder-ligands/","field":"links","label":"Wang et al.: Single low-dose injection of Evans blue modified PSMA-617 radioligand therapy (Bioconjugate Chem 2018)"}]},{"url":"https://pubs.rsc.org/en/content/articlehtml/2014/cs/c3cs60304k","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"chelator-term","kind":"term","name":"Chelator (bifunctional chelating agent)","route":"/terms/chelator-term/","field":"links","label":"Chemical Society Reviews: matching chelators to radiometals for radiopharmaceuticals"}]},{"url":"https://pubs.rsc.org/en/content/articlehtml/2025/sc/d4sc06969b","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"sarcophagine-chelation","kind":"technology","name":"Sarcophagine chelation","route":"/technologies/sarcophagine-chelation/","field":"links","label":"Potential theranostics of breast cancer with copper-64/67-sarcophagine-trastuzumab (Chem. Sci. 2025)"}]},{"url":"https://pubs.rsna.org/doi/10.1148/radiol.2018172232","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"andrei-iagaru","kind":"person","name":"Andrei Iagaru","route":"/people/andrei-iagaru/","field":"papers","label":"Gallium 68 PSMA-11 PET/MR imaging in patients with intermediate- or high-risk prostate cancer"}]},{"url":"https://pubs.rsna.org/doi/full/10.1148/radiol.222801","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"opp-gpc3-hcc-china","kind":"opportunity","name":"GPC3 imaging of the indeterminate liver nodule, led from China","route":"/opportunities/opp-gpc3-hcc-china/","field":"links","label":"LI-RADS: pooled proportion of hepatocellular carcinoma by category, Radiology 2023"}]},{"url":"https://pubs.rsna.org/journal/radiology","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"radiology","kind":"journal","name":"Radiology","route":"/journals/radiology/","field":"url"}]},{"url":"https://rad.uw.edu/people/airavani","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"amir-iravani","kind":"person","name":"Amir Iravani","route":"/people/amir-iravani/","field":"profiles","label":"UW Radiology profile (2022-2026)"}]},{"url":"https://scholar.google.com.au/citations?user=0Mq8GUMAAAAJ&hl=en","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"dale-bailey","kind":"person","name":"Dale L. Bailey","route":"/people/dale-bailey/","field":"profiles","label":"Google Scholar"}],"archive":"https://web.archive.org/web/20220120070258/https://scholar.google.com.au/citations?user=0Mq8GUMAAAAJ&hl=en"},{"url":"https://scholar.google.com/citations?user=8RwEbvgAAAAJ&hl=en","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"andrei-iagaru","kind":"person","name":"Andrei Iagaru","route":"/people/andrei-iagaru/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/citations?user=ZB07UFEAAAAJ&hl=en","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"stefano-fanti","kind":"person","name":"Stefano Fanti","route":"/people/stefano-fanti/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Emily%20K.%20Bergsland","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"links","label":"Google Scholar"},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Jeremie%20Calais","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"links","label":"Google Scholar"},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Johannes%20Czernin","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"links","label":"Google Scholar"},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Katherine%20K.%20Matthay","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"links","label":"Google Scholar"},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Rahul%20Aggarwal","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"links","label":"Google Scholar"},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"profiles","label":"Google Scholar"}]},{"url":"https://scholar.google.com/scholar?q=Thomas%20A.%20Hope","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"links","label":"Google Scholar"},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"profiles","label":"Google Scholar"}]},{"url":"https://www.ahajournals.org/doi/10.1161/circimaging.109.854893","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"tc-99m-tetrofosmin","kind":"drug","name":"Technetium Tc-99m tetrofosmin","route":"/drugs/tc-99m-tetrofosmin/","field":"links","label":"First-pass extraction fractions of Tl-201, Tc-99m sestamibi and tetrofosmin (Circ Cardiovasc Imaging)"}]},{"url":"https://www.ahajournals.org/doi/10.1161/JAHA.122.028342","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"opp-cardiac-sarcoidosis-specific-tracer","kind":"opportunity","name":"An inflammation tracer that does not need a diet","route":"/opportunities/opp-cardiac-sarcoidosis-specific-tracer/","field":"links","label":"Clinically manifest against autopsy prevalence, JAHA 2023"}]},{"url":"https://www.annalsofoncology.org","status":403,"ok":false,"finalUrl":"https://www.annalsofoncology.org/","checked":"2026-10-21","refs":[{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/","field":"url"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(24)01516-3/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/","field":"links","label":"CheckMate 214 8-year follow-up"}]},{"url":"https://www.annalsofoncology.org/article/S0923-7534(25)04871-9/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","field":"links","label":"Annals of Oncology LBA6 (ESMO 2025)"}]},{"url":"https://www.astrazeneca.com","status":403,"ok":false,"finalUrl":"https://www.astrazeneca.com/","checked":"2026-10-21","refs":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","field":"links","label":"Official website"},{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","field":"website"},{"id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","field":"links","label":"Official website"},{"id":"fusion-pharma","kind":"company","name":"Fusion Pharmaceuticals (AstraZeneca)","route":"/companies/fusion-pharma/","field":"website"}]},{"url":"https://www.astrazeneca.com/media-centre/press-releases/2022/lynparza-approved-in-the-us-as-adjuvant-treatment-for-patients-with-germline-brca-mutated-her2-negative-high-risk-early-breast-cancer.html","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"standardOfCare.guideline (Early-stage, germline BRCA-mutated, HER2-negative, high-risk disease)"}]},{"url":"https://www.bayer.com","status":403,"ok":false,"finalUrl":"https://www.bayer.com/","checked":"2026-10-21","refs":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/","field":"links","label":"Official website"},{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/","field":"website"}]},{"url":"https://www.beckershospitalreview.com/radiology/ucla-health-taps-fred-hutch-theranostics-leader/","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"amir-iravani","kind":"person","name":"Amir Iravani","route":"/people/amir-iravani/","field":"links","label":"Becker's Hospital Review coverage"}]},{"url":"https://www.cityofhope.org/phillip-kuo","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"phillip-kuo","kind":"person","name":"Phillip H. Kuo","route":"/people/phillip-kuo/","field":"links","label":"City of Hope profile"},{"id":"phillip-kuo","kind":"person","name":"Phillip H. Kuo","route":"/people/phillip-kuo/","field":"profiles","label":"City of Hope profile"}]},{"url":"https://www.drugs.com/pro/quadramet.html","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"sm-153","kind":"isotope","name":"Samarium-153","route":"/isotopes/sm-153/","field":"links","label":"FDA/manufacturer label: Quadramet (samarium Sm-153 lexidronam) prescribing information"}]},{"url":"https://www.europeanurology.com","status":403,"ok":false,"finalUrl":"https://www.europeanurology.com/","checked":"2026-10-21","refs":[{"id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/","field":"url"}]},{"url":"https://www.gehealthcare.com","status":403,"ok":false,"finalUrl":"https://www.gehealthcare.com/","checked":"2026-10-21","refs":[{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/","field":"links","label":"Official website"},{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/","field":"website"}]},{"url":"https://www.gehealthcare.com/en-us/about/newsroom/press-releases/ge-healthcare-completes-acquisition-of-nihon-medi-physics-nmp-a-leading-radiopharmaceutical-company-in-japan","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"nihon-medi-physics","kind":"company","name":"Nihon Medi-Physics","route":"/companies/nihon-medi-physics/","field":"links","label":"GE HealthCare completes acquisition of Nihon Medi-Physics"}]},{"url":"https://www.gehealthcare.com/en-us/products/molecular-imaging/pet-radiochemistry","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"automated-synthesis-modules","kind":"technology","name":"Automated synthesis modules","route":"/technologies/automated-synthesis-modules/","field":"links","label":"GE HealthCare: PET radiochemistry (FASTlab 2, TRACERlab product overview)"}]},{"url":"https://www.gehealthcare.com/products/molecular-imaging/spect-ct","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/","field":"links","label":"GE HealthCare: SPECT/CT systems"}]},{"url":"https://www.globenewswire.com/news-release/2025/10/21/3170190/0/en/alpha-tau-announces-receipt-of-radioactive-material-license-for-its-new-hampshire-manufacturing-facility-advancing-towards-commercial-readiness.html","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","field":"links","label":"Alpha Tau: receipt of radioactive material license for New Hampshire manufacturing facility (2025)"}]},{"url":"https://www.globenewswire.com/news-release/2026/04/20/3276793/0/en/perspective-therapeutics-presents-updated-interim-data-of-212pb-vmt-%CE%B1-net-in-its-ongoing-phase-1-2a-clinical-trial-at-the-2026-aacr-annual-meeting.html","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"pb-212-vmt-alpha-net","kind":"drug","name":"Lead-212 VMT-alpha-NET","route":"/drugs/pb-212-vmt-alpha-net/","field":"links","label":"Perspective Therapeutics: updated interim data at AACR 2026"},{"id":"pb-212-vmt-alpha-net","kind":"drug","name":"Lead-212 VMT-alpha-NET","route":"/drugs/pb-212-vmt-alpha-net/","field":"dosing.source"}]},{"url":"https://www.globenewswire.com/news-release/2026/08/10/3342260/0/en/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-results.html","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/","field":"links","label":"Q2 2026 highlights"}],"archive":"https://web.archive.org/web/20260823021448/https://www.globenewswire.com/news-release/2026/08/10/3342260/0/en/perspective-therapeutics-provides-recent-business-highlights-and-reports-2q-2026-results.html"},{"url":"https://www.hopkinsmedicine.org/kimmel-cancer-center","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/","field":"links","label":"Official website"},{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/","field":"website"}]},{"url":"https://www.iaea.org/newscenter/news/actinium-225-production-and-supply","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"idea-reg-legacy-radium-recovery-ac225","kind":"idea","name":"Recover legacy radium-226 sources worldwide as the feedstock for actinium-225","route":"/ideas/idea-reg-legacy-radium-recovery-ac225/","field":"links","label":"IAEA on actinium-225 supply"}]},{"url":"https://www.iaea.org/newscenter/news/alternatives-for-accessing-lifesaving-diagnostic-radioisotopes-cyclotron-based-gallium-68-for-cancer-detection","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/","field":"links","label":"IAEA: cyclotron-based gallium-68 for cancer detection (2024)"}]},{"url":"https://www.iaea.org/newscenter/news/new-crp-production-of-cyclotron-based-gallium-68-radioisotope-and-related-radiopharmaceuticals-f22073","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"ge-68","kind":"isotope","name":"Germanium-68","route":"/isotopes/ge-68/","field":"links","label":"IAEA: new CRP on cyclotron-based gallium-68 (2020)"}]},{"url":"https://www.iaea.org/publications/7451/quality-assurance-for-radioactivity-measurement-in-nuclear-medicine","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"gamma-probes-dose-calibrators","kind":"technology","name":"Gamma probes, handheld gamma cameras and dose calibrators","route":"/technologies/gamma-probes-dose-calibrators/","field":"links","label":"IAEA: quality assurance for radioactivity measurement in nuclear medicine (Technical Reports Series 454)"}]},{"url":"https://www.iaea.org/publications/7892/cyclotron-produced-radionuclides-principles-and-practice","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/","field":"links","label":"IAEA: cyclotron produced radionuclides"}]},{"url":"https://www.iaea.org/services/rays-of-hope","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency: Rays of Hope","route":"/institutions/iaea/","field":"links","label":"Rays of Hope"},{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency: Rays of Hope","route":"/institutions/iaea/","field":"website"},{"id":"rafael-mariano-grossi","kind":"person","name":"Rafael Mariano Grossi","route":"/people/rafael-mariano-grossi/","field":"links","label":"Institution profile"},{"id":"rafael-mariano-grossi","kind":"person","name":"Rafael Mariano Grossi","route":"/people/rafael-mariano-grossi/","field":"profiles","label":"Institution profile"}]},{"url":"https://www.iaea.org/topics/cancer","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"iaea","kind":"institution","name":"International Atomic Energy Agency: Rays of Hope","route":"/institutions/iaea/","field":"links","label":"IAEA cancer"}]},{"url":"https://www.ingentaconnect.com/content/ben/crp/2012/00000005/00000003/art00006","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"bi-213","kind":"isotope","name":"Bismuth-213","route":"/isotopes/bi-213/","field":"links","label":"Bismuth-213 and Actinium-225 - Generator Performance (Current Radiopharmaceuticals, 2012)"}]},{"url":"https://www.isotopes.gov/information/actinium-225","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"idea-accelerator-ac225-at-scale","kind":"idea","name":"Scaling actinium-225 supply with proton accelerators instead of the thorium-229 cow","route":"/ideas/idea-accelerator-ac225-at-scale/","field":"links","label":"Production Methods for Ac-225 (DOE Isotope Program)"},{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/","field":"links","label":"DOE Isotope Program: Production Methods for Ac-225"}]},{"url":"https://www.jacc.org/doi/10.1016/j.jacc.2020.08.042","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"opp-cardiac-sarcoidosis-specific-tracer","kind":"opportunity","name":"An inflammation tracer that does not need a diet","route":"/opportunities/opp-cardiac-sarcoidosis-specific-tracer/","field":"links","label":"No reliable serum biomarker in sarcoidosis, JACC state-of-the-art review"}]},{"url":"https://www.jacc.org/doi/10.1016/S0735-1097(00)01148-7","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"tc-99m-tetrofosmin","kind":"drug","name":"Technetium Tc-99m tetrofosmin","route":"/drugs/tc-99m-tetrofosmin/","field":"links","label":"Sestamibi vs tetrofosmin defect detection in mild-to-moderate CAD (JACC 2001)"}]},{"url":"https://www.lilly.com","status":403,"ok":false,"finalUrl":"https://www.lilly.com/","checked":"2026-10-21","refs":[{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/","field":"links","label":"Official website"},{"id":"eli-lilly","kind":"company","name":"Eli Lilly (incl. Loxo)","route":"/companies/eli-lilly/","field":"website"}]},{"url":"https://www.lilly.com/","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","field":"links","label":"Official website"},{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","field":"website"}]},{"url":"https://www.mayoclinic.org","status":403,"ok":false,"finalUrl":"https://www.mayoclinic.org/","checked":"2026-10-21","refs":[{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","field":"links","label":"Official website"},{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","field":"website"}]},{"url":"https://www.mdpi.com/1420-3049/26/2/414","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"i-124","kind":"isotope","name":"Iodine-124","route":"/isotopes/i-124/","field":"links","label":"MDPI: radiochemistry, production and immunoPET imaging of iodine-124"}]},{"url":"https://www.mdpi.com/1422-0067/25/1/462","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"bone-hydroxyapatite","kind":"target","name":"Bone mineral (hydroxyapatite)","route":"/targets/bone-hydroxyapatite/","field":"links","label":"MDPI: bisphosphonates as radiopharmaceuticals - DOTAZOL review of bone-targeting chemistry"}]},{"url":"https://www.mdpi.com/1424-8247/13/8/173","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"idea-bispecific-radioligands","kind":"idea","name":"Bispecific PSMA/GRPR radioligands for discordant prostate cancer lesions","route":"/ideas/idea-bispecific-radioligands/","field":"links","label":"Current State of Radiolabeled Heterobivalent Peptidic Ligands in Tumor Imaging and Therapy (MDPI review, 2020)"}]},{"url":"https://www.mdpi.com/1424-8247/14/7/701","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"radiohybrid-chemistry","kind":"technology","name":"Radiohybrid (rh) chemistry","route":"/technologies/radiohybrid-chemistry/","field":"links","label":"Recent advances in the clinical translation of silicon fluoride acceptor (SiFA) chemistry (Pharmaceuticals 2021)"}]},{"url":"https://www.mdpi.com/1424-8247/16/4/606","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","field":"links","label":"PET imaging in bladder cancer: an update and future direction, MDPI"}]},{"url":"https://www.mdpi.com/1424-8247/17/6/680","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"hot-cells-and-shielding","kind":"technology","name":"Hot cells and radiation shielding","route":"/technologies/hot-cells-and-shielding/","field":"links","label":"Design and construction of a radiochemistry laboratory: hot cell and shielded-trench case study (Pharmaceuticals 2024)"}]},{"url":"https://www.mdpi.com/1424-8247/18/10/1578","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"alpha-daughter-redistribution","kind":"technology","name":"Alpha-emitter daughter redistribution ('free daughter' problem)","route":"/technologies/alpha-daughter-redistribution/","field":"links","label":"SECURE project review: clinical application and future potential of alpha-particle therapy, recoil section (Pharmaceuticals 2025)"}]},{"url":"https://www.mdpi.com/2072-6694/14/11/2668","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"links","label":"Review of PET/CT in colorectal cancer, including the rising-CEA indication"}]},{"url":"https://www.mdpi.com/2072-6694/14/6/1550","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"mesothelin","kind":"target","name":"Mesothelin (MSLN)","route":"/targets/mesothelin/","field":"links","label":"MDPI Cancers: mesothelin as an immunotherapeutic target, including BAY2287411 thorium-227 conjugate"}]},{"url":"https://www.mdpi.com/2072-6694/17/18/3055","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"f-alpha-therapy","kind":"section","name":"Targeted alpha therapy","route":"/fronts/f-alpha-therapy/","field":"links","label":"Actinium-225/Bismuth-213 supply and application barriers (Cancers, 2025)"},{"id":"alpha-daughter-redistribution","kind":"technology","name":"Alpha-emitter daughter redistribution ('free daughter' problem)","route":"/technologies/alpha-daughter-redistribution/","field":"links","label":"Actinium-225/bismuth-213 as potential leaders for targeted alpha therapy: recoil and mitigation strategies (Cancers 2025)"}]},{"url":"https://www.mdpi.com/2072-6694/17/9/1494","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"f-radioembolisation","kind":"section","name":"Radioembolisation","route":"/fronts/f-radioembolisation/","field":"links","label":"Advances and emerging techniques in Y-90 radioembolisation for HCC (Cancers, 2025)"}]},{"url":"https://www.nejm.org","status":403,"ok":false,"finalUrl":"https://www.nejm.org/","checked":"2026-10-21","refs":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","field":"url"}]},{"url":"https://www.nejm.org/browse/specialty/hematology-oncology","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","field":"links","label":"Hematology/Oncology specialty page"}]},{"url":"https://www.nejm.org/doi/10.1056/NEJMoa1213755","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"f-alpha-therapy","kind":"section","name":"Targeted alpha therapy","route":"/fronts/f-alpha-therapy/","field":"links","label":"ALSYMPCA trial (Parker et al., NEJM 2013)"},{"id":"f-bone-targeted","kind":"section","name":"Bone-targeted radiopharmaceuticals","route":"/fronts/f-bone-targeted/","field":"links","label":"ALSYMPCA trial (Parker et al., NEJM 2013)"}]},{"url":"https://www.nejm.org/doi/10.1056/NEJMoa1510093","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"deauville-for-pet","kind":"term","name":"Deauville five-point scale for PET","route":"/terms/deauville-for-pet/","field":"links","label":"RATHL trial: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma, NEJM 2016"}]},{"url":"https://www.nejm.org/doi/10.1056/NEJMoa2107322","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"f-radioligand-therapy","kind":"section","name":"Radioligand therapy","route":"/fronts/f-radioligand-therapy/","field":"links","label":"VISION trial (Sartor et al., NEJM 2021)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1109589","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"hilo","kind":"trial","name":"HiLo","route":"/trials/hilo/","field":"links","label":"NEJM 2012"},{"id":"hilo","kind":"trial","name":"HiLo","route":"/trials/hilo/","field":"outcomes.source (Successful ablation)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1112088","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","field":"links","label":"CROSS trial, van Hagen et al., NEJM 2012"},{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","field":"standardOfCare.guideline (Resectable oesophageal/junctional (Siewert I-II) adenocarcinoma)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1213755","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1406470","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","field":"links","label":"NEJM 2015"},{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","field":"outcomes.source (Progression-free survival)"},{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","field":"outcomes.source (Objective response rate)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1503747","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa1510093","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"rathl","kind":"trial","name":"RATHL","route":"/trials/rathl/","field":"outcomes.source (Progression-free survival at 3 years (PET2-negative))"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2107322","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","field":"outcomes.source (Overall survival)"},{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","field":"outcomes.source (Radiographic progression-free survival)"},{"id":"docetaxel-then-lu177-psma","kind":"pairing","name":"Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617","route":"/pairings/docetaxel-then-lu177-psma/","field":"links","label":"Sartor et al., VISION primary results, N Engl J Med 2021 (full text)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2111953","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","field":"links","label":"NEJM 2022"},{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","field":"outcomes.source (Patients without events at 3 years)"}]},{"url":"https://www.nejm.org/doi/full/10.1056/NEJMoa2303974","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/","field":"outcomes.source (Metastasis-free survival, enzalutamide + leuprolide vs leuprolide)"}]},{"url":"https://www.nice.org.uk/guidance/published?ngt=Technology%20appraisal%20guidance","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"access.source (UK)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"access.source (UK)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"access.source (UK)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"access.source (UK)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"access.source (UK)"}]},{"url":"https://www.oecd-nea.org/jcms/pl_20168/medical-radioisotopes","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/","field":"links","label":"OECD Nuclear Energy Agency: supply of medical radioisotopes"}]},{"url":"https://www.oecd-nea.org/jcms/pl_26262/medical-radioisotopes","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"idea-reg-medical-isotope-reactor-reserve","kind":"idea","name":"A coordinated reserve and shared schedule for the world's medical isotope reactors","route":"/ideas/idea-reg-medical-isotope-reactor-reserve/","field":"links","label":"OECD NEA medical radioisotopes"}]},{"url":"https://www.pfizer.com","status":403,"ok":false,"finalUrl":"https://www.pfizer.com/","checked":"2026-10-21","refs":[{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/","field":"links","label":"Official website"},{"id":"pfizer","kind":"company","name":"Pfizer (incl. Seagen)","route":"/companies/pfizer/","field":"website"}]},{"url":"https://www.science.org","status":403,"ok":false,"finalUrl":"https://www.science.org/","checked":"2026-10-21","refs":[{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/","field":"links","label":"Science journals"}]},{"url":"https://www.science.org/journal/stm","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"science-translational-medicine","kind":"journal","name":"Science Translational Medicine","route":"/journals/science-translational-medicine/","field":"url"}]},{"url":"https://www.sciencedirect.com/journal/nuclear-medicine-and-biology","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"nuclear-medicine-and-biology","kind":"journal","name":"Nuclear Medicine and Biology","route":"/journals/nuclear-medicine-and-biology/","field":"links","label":"Nuclear Medicine and Biology (ScienceDirect journal home)"},{"id":"nuclear-medicine-and-biology","kind":"journal","name":"Nuclear Medicine and Biology","route":"/journals/nuclear-medicine-and-biology/","field":"url"}]},{"url":"https://www.sciencedirect.com/science/article/pii/S0302283824000206","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"scott-tagawa","kind":"person","name":"Scott T. Tagawa","route":"/people/scott-tagawa/","field":"links","label":"VISION safety analysis, European Urology 2024"},{"id":"scott-tagawa","kind":"person","name":"Scott T. Tagawa","route":"/people/scott-tagawa/","field":"papers","label":"Safety Analyses of the Phase 3 VISION Trial of [177Lu]Lu-PSMA-617 in Patients with Metastatic Castration-resistant Prostate Cancer"}]},{"url":"https://www.sciencedirect.com/topics/immunology-and-microbiology/linear-energy-transfer","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"linear-energy-transfer","kind":"term","name":"Linear energy transfer (LET)","route":"/terms/linear-energy-transfer/","field":"links","label":"ScienceDirect Topics: linear energy transfer, representative values"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_8k.htm","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","field":"links","label":"Form 8-K: merger agreement with Eli Lilly"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1811764/000110465923106146/tm2327397d1_ex99-4.htm","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","field":"links","label":"Lilly press release (8-K exhibit 99.4)"}]},{"url":"https://www.sec.gov/Archives/edgar/data/1811764/000119312523303512/d594310d8k.htm","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"point-biopharma","kind":"company","name":"POINT Biopharma","route":"/companies/point-biopharma/","field":"links","label":"Form 8-K: completion of merger"}]},{"url":"https://www.sec.gov/Archives/edgar/data/2007191/000200719125000003/frelease.htm","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","field":"links","label":"Telix asset purchase from ImaginAb, including a discovery-stage DLL3 programme for small-cell lung cancer (13 January 2025)"}]},{"url":"https://www.skandionkliniken.se","status":403,"ok":false,"finalUrl":"https://skandionkliniken.se/","checked":"2026-10-21","refs":[{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","route":"/institutions/uppsala-akademiska/","field":"links","label":"Skandion Clinic"}]},{"url":"https://www.terumo.com/newsrelease/detail/20180412/274","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"quirem-medical","kind":"company","name":"Quirem Medical","route":"/companies/quirem-medical/","field":"links","label":"Terumo: Terumo and Quirem welcome positive reimbursement decision for QuiremSpheres in the Netherlands (2018)"}]},{"url":"https://www.terumo.com/newsrelease/detail/20190107/234","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"ho-166-microspheres","kind":"drug","name":"Holmium-166 microspheres","route":"/drugs/ho-166-microspheres/","field":"links","label":"Terumo: QuiremScout CE mark announcement, 2019"}]},{"url":"https://www.terumo.com/newsrelease/detail/20200715/543","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"quirem-medical","kind":"company","name":"Quirem Medical","route":"/companies/quirem-medical/","field":"links","label":"Terumo: Terumo Acquires Quirem Medical to Enhance its Interventional Oncology Portfolio (2020)"}]},{"url":"https://www.terumo.com/newsrelease/detail/20220614/5296","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"quirem-medical","kind":"company","name":"Quirem Medical","route":"/companies/quirem-medical/","field":"links","label":"Terumo: Holmium-166 SIRT demonstrates safety and efficacy in HEPAR Primary study (JNM 2022) (2022)"}]},{"url":"https://www.terumo.com/newsrelease/detail/20240703/6221","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"quirem-medical","kind":"company","name":"Quirem Medical","route":"/companies/quirem-medical/","field":"links","label":"Terumo: NICE publishes new guidance supporting QuiremSpheres for HCC (2024)"}]},{"url":"https://www.thelancet.com/clinical/diseases/cancer","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","field":"links","label":"Oncology collection"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(14)60421-9/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/","field":"links","label":"Lancet 2014"},{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/","field":"outcomes.source (Progression-free survival)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(15)01037-5/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"outcomes.source (Overall survival, docetaxel arm (M1))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(20)30314-7/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/","field":"links","label":"Lancet 2020"},{"id":"propsma","kind":"trial","name":"proPSMA","route":"/trials/propsma/","field":"outcomes.source (Accuracy for pelvic nodal or distant metastases (AUC))"},{"id":"rodney-hicks","kind":"person","name":"Rodney J. Hicks","route":"/people/rodney-hicks/","field":"links","label":"proPSMA trial, The Lancet 2020"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(21)00237-3/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/","field":"outcomes.source (PSA response ≥50%)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(22)00367-1/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"outcomes.source (Overall survival, abiraterone arm (M1 subgroup))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)00054-0/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/","field":"outcomes.source (3-year invasive disease-free survival (PET-adapted arm))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01315-1/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","field":"outcomes.source (Progression-free survival at 4 years)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)01653-2/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","field":"outcomes.source (Radiographic progression-free survival)"},{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","field":"outcomes.source (Overall survival (crossover-adjusted))"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02551-0/abstract","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"hcc-intermediate","kind":"indication","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/indications/hcc-intermediate/","field":"links","label":"EMERALD-1 (Lancet 2025)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(24)02575-3/abstract","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"hcc-intermediate","kind":"indication","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/indications/hcc-intermediate/","field":"links","label":"LEAP-012 (Lancet 2025)"}]},{"url":"https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(25)00629-4/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"ion-trial","kind":"trial","name":"IoN","route":"/trials/ion-trial/","field":"links","label":"Lancet 2025"},{"id":"ion-trial","kind":"trial","name":"IoN","route":"/trials/ion-trial/","field":"outcomes.source (Recurrence-free at 5 years)"}]},{"url":"https://www.thelancet.com/journals/lancet/home","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","field":"url"}]},{"url":"https://www.thelancet.com/journals/landia/article/PIIS2213-8587(24)00276-6/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","field":"links","label":"5-year follow-up"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(19)30821-6/abstract","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"paper-herrmann-radiotheranostics-lancet-oncol-2020","kind":"paper","name":"Radiotheranostics: a roadmap for future development","route":"/key-papers/paper-herrmann-radiotheranostics-lancet-oncol-2020/","field":"links","label":"The Lancet Oncology: article"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(23)00529-6/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/","field":"outcomes.source (Overall survival)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(24)00135-9/abstract","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"enza-p","kind":"trial","name":"ENZA-p","route":"/trials/enza-p/","field":"links","label":"Lancet Oncology 2024: ENZA-p interim results"},{"id":"enza-p","kind":"trial","name":"ENZA-p","route":"/trials/enza-p/","field":"outcomes.source (PSA progression-free survival)"}]},{"url":"https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(25)00193-7/fulltext","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"neuro-imaging-roadmap","kind":"roadmap","name":"Neuro-oncology imaging roadmap: FDG PET → amino acid PET → SSTR2 theranostics in meningioma","route":"/roadmaps/neuro-imaging-roadmap/","field":"links","label":"Update to the RANO working group and EANO recommendations for PET imaging in gliomas (Lancet Oncology 2025)"}]},{"url":"https://www.thelancet.com/journals/lanonc/commissions","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","field":"links","label":"Lancet Oncology Commissions"}]},{"url":"https://www.thelancet.com/journals/lanonc/home","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","field":"url"}]},{"url":"https://www.umcg.nl","status":403,"ok":false,"finalUrl":"https://www.umcg.nl/","checked":"2026-10-21","refs":[{"id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","route":"/institutions/umcg-groningen/","field":"links","label":"Official website"},{"id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","route":"/institutions/umcg-groningen/","field":"website"}]},{"url":"https://www.urotoday.com/","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"src-urotoday","kind":"collection","name":"UroToday","route":"/collections/src-urotoday/","field":"links","label":"UroToday"},{"id":"src-urotoday","kind":"collection","name":"UroToday","route":"/collections/src-urotoday/","field":"url"}]},{"url":"https://www.urotoday.com/conference-highlights/asco-2023/asco-2023-prostate-cancer/144916-asco-2023-luparp-phase-1-trial-of-177lu-psma-617-and-olaparib-in-patients-with-metastatic-castration-resistant-prostate-cancer-mcrpc.html","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"pluvicto-plus-olaparib","kind":"pairing","name":"177Lu-PSMA-617 (Pluvicto) with olaparib","route":"/pairings/pluvicto-plus-olaparib/","field":"links","label":"UroToday conference summary of LuPARP results and comparison with TheraP/VISION"}]},{"url":"https://www.urotoday.com/video-lectures/2025-ucsf-ucla-psma-conference/video/4752-beyond-lutetium-psma-exploring-terbium-161-for-treatment-resistant-prostate-cancer-presentation-michael-hofman.html","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"idea-tb161-instead-of-lu177","kind":"idea","name":"Terbium-161 instead of lutetium-177 in the same ligands","route":"/ideas/idea-tb161-instead-of-lu177/","field":"links","label":"Peter Mac / UCSF-UCLA PSMA Conference 2025: Michael Hofman on terbium-161 (VIOLET)"}]},{"url":"https://www.urotoday.com/video-lectures/practical-aspects-of-operationalizing-lutetium-177-177lu-psma-617-in-the-urology-clinic/video/3623-how-one-urology-clinic-successfully-sets-up-a-hot-lab-for-radioligand-therapy-program-william-oresick.html","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"b-hot-lab-capacity","kind":"bottleneck","name":"Hot lab and shielded treatment room capacity","route":"/bottlenecks/b-hot-lab-capacity/","field":"links","label":"How one urology clinic set up a hot lab for a radioligand therapy programme (UroToday)"}]},{"url":"https://www.wolterskluwer.com/en/solutions/ovid/clinical-nuclear-medicine-235","status":403,"ok":false,"checked":"2026-10-21","refs":[{"id":"clinical-nuclear-medicine","kind":"journal","name":"Clinical Nuclear Medicine","route":"/journals/clinical-nuclear-medicine/","field":"links","label":"Wolters Kluwer/Ovid: Clinical Nuclear Medicine journal page"}]},{"url":"https://doi.org/10.1200/JCO.24.01373","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"ielsg37","kind":"trial","name":"IELSG37","route":"/trials/ielsg37/","field":"links","label":"Journal of Clinical Oncology 2024"},{"id":"ielsg37","kind":"trial","name":"IELSG37","route":"/trials/ielsg37/","field":"outcomes.source (Progression-free survival at 30 months)"}],"archiveRequested":false},{"url":"https://eanm.org/news/eanms-new-own-journals-feb-2025/","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"ejnmmi","kind":"journal","name":"European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)","route":"/journals/ejnmmi/","field":"links","label":"EANM: EANM's new own journals (Feb 2025)"}],"archive":"https://web.archive.org/web/20260417222404/https://eanm.org/news/eanms-new-own-journals-feb-2025/"},{"url":"https://en.wikipedia.org/wiki/Navidea_Biopharmaceuticals","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","field":"links","label":"Wikipedia"},{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Radiation_necrosis","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"radiation-necrosis","kind":"term","name":"Radiation necrosis (brain)","route":"/terms/radiation-necrosis/","field":"links","label":"Wikipedia"},{"id":"radiation-necrosis","kind":"term","name":"Radiation necrosis (brain)","route":"/terms/radiation-necrosis/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://en.wikipedia.org/wiki/Technetium_(99mTc)_sulfur_colloid","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"technetium-sulfur-colloid","kind":"drug","name":"Technetium Tc-99m sulfur colloid","route":"/drugs/technetium-sulfur-colloid/","field":"links","label":"Wikipedia"},{"id":"technetium-sulfur-colloid","kind":"drug","name":"Technetium Tc-99m sulfur colloid","route":"/drugs/technetium-sulfur-colloid/","field":"wikipedia"}],"archiveRequested":false},{"url":"https://nuklearmedizin.mri.tum.de/de/lebenslauf-prof-dr-med-matthias-eiber","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"matthias-eiber","kind":"person","name":"Matthias Eiber","route":"/people/matthias-eiber/","field":"links","label":"TUM CV page"},{"id":"matthias-eiber","kind":"person","name":"Matthias Eiber","route":"/people/matthias-eiber/","field":"profiles","label":"TUM Klinik für Nuklearmedizin CV (German)"}],"archive":"https://web.archive.org/web/20251014173334/https://nuklearmedizin.mri.tum.de/de/lebenslauf-prof-dr-med-matthias-eiber"},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"f-molecular-imaging","kind":"section","name":"Molecular imaging","route":"/fronts/f-molecular-imaging/","field":"links","label":"proPSMA trial (Hofman et al., Lancet 2020)"}],"archive":"https://web.archive.org/web/20260919083406/https://pmc.ncbi.nlm.nih.gov/articles/"},{"url":"https://www.163.com/dy/article/K0V13Q6H05118K9D.html","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"pexiretide-tc99m","kind":"drug","name":"Technetium (99mTc) pexiretide","route":"/drugs/pexiretide-tc99m/","field":"regulatoryEvents.source (2025-02)"}],"archiveRequested":true},{"url":"https://www.accessdata.fda.gov/cdrh_docs/pdf/p990065b.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"y-90-resin-microspheres","kind":"drug","name":"Yttrium-90 resin microspheres","route":"/drugs/y-90-resin-microspheres/","field":"links","label":"FDA: original SSED for colorectal indication (2002)"}],"archive":"https://web.archive.org/web/20260306142909/https://www.accessdata.fda.gov/cdrh_docs/pdf/p990065b.pdf"},{"url":"https://www.accessdata.fda.gov/cdrh_docs/pdf/P990065S014B.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"y-90-resin-microspheres","kind":"drug","name":"Yttrium-90 resin microspheres","route":"/drugs/y-90-resin-microspheres/","field":"links","label":"FDA: Summary of safety and effectiveness data (HCC supplement)"},{"id":"y-90-resin-microspheres","kind":"drug","name":"Yttrium-90 resin microspheres","route":"/drugs/y-90-resin-microspheres/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260923092906/https://www.accessdata.fda.gov/cdrh_docs/pdf/P990065S014B.pdf"},{"url":"https://www.accessdata.fda.gov/cdrh_docs/pdf2/k023242.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"i-125-seeds","kind":"drug","name":"Iodine-125 brachytherapy seeds","route":"/drugs/i-125-seeds/","field":"links","label":"FDA 510(k) clearance letter: I-Plant Model 3500 iodine-125 brachytherapy seeds"}],"archive":"https://web.archive.org/web/20260922084008/https://www.accessdata.fda.gov/cdrh_docs/pdf2/k023242.pdf"},{"url":"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200029B.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"y-90-glass-microspheres","kind":"drug","name":"Yttrium-90 glass microspheres","route":"/drugs/y-90-glass-microspheres/","field":"links","label":"FDA: Summary of safety and effectiveness data (P200029)"},{"id":"y-90-glass-microspheres","kind":"drug","name":"Yttrium-90 glass microspheres","route":"/drugs/y-90-glass-microspheres/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20251214213031/https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200029B.pdf"},{"url":"https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200029C.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/","field":"links","label":"FDA PMA summary: TheraSphere Yttrium-90 Glass Microspheres"}],"archive":"https://web.archive.org/web/20250624203653/https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200029C.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022290orig1s001ltr.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"i-123-mibg-cardiac","kind":"drug","name":"Iobenguane I-123 (cardiac use)","route":"/drugs/i-123-mibg-cardiac/","field":"links","label":"FDA approval letter: supplemental NDA 22-290/S-001 (cardiac heart failure indication, 2013)"},{"id":"i-123-mibg","kind":"drug","name":"Iobenguane I-123","route":"/drugs/i-123-mibg/","field":"links","label":"FDA supplemental approval letter, NDA 22-290 (2013 cardiac indication)"}],"archive":"https://web.archive.org/web/20250403031753/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2013/022290Orig1s001ltr.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/203415Orig1s026;213674Orig1s016ltr.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","field":"links","label":"FDA supplement approval letter: Xtandi NDA 203415/S-026 and NDA 213674/S-016 (EMBARK overall survival), 24 July 2026"},{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","field":"regulatoryEvents.source (2026-07-24)"}],"archive":"https://web.archive.org/web/20261007111331/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/203415Orig1s026;213674Orig1s016ltr.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217060Orig1s000TAltr.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"links","label":"FDA tentative approval letter, ANDA 217060 (21 Sep 2026)"}],"archive":"https://web.archive.org/web/20261007143519/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/217060Orig1s000TAltr.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220496Orig1s000ltr.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-florquinitau","kind":"drug","name":"Florquinitau F-18","route":"/drugs/f-18-florquinitau/","field":"links","label":"FDA approval letter: NDA 220496, 13 August 2026"}],"archive":"https://web.archive.org/web/20261007112054/https://www.accessdata.fda.gov/drugsatfda_docs/appletter/2026/220496Orig1s000ltr.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018124s013lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"tc-99m-mdp","kind":"drug","name":"Technetium Tc-99m medronate (MDP)","route":"/drugs/tc-99m-mdp/","field":"links","label":"FDA label: CIS-MDP (Kit for the Preparation of Technetium Tc 99m Medronate)"}],"archive":"https://web.archive.org/web/20250421055735/https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/018124s013lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021870lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/","field":"links","label":"FDA label: Fludeoxyglucose F 18 Injection (initial approval 2005)"}],"archive":"https://web.archive.org/web/20260302204806/https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021870lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022119s001lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"n-13-ammonia","kind":"drug","name":"Ammonia N-13","route":"/drugs/n-13-ammonia/","field":"links","label":"FDA label: Ammonia N 13 Injection, 2011 revision"},{"id":"n-13-ammonia","kind":"drug","name":"Ammonia N-13","route":"/drugs/n-13-ammonia/","field":"dosing.source"},{"id":"n-13","kind":"isotope","name":"Nitrogen-13","route":"/isotopes/n-13/","field":"links","label":"FDA label: Ammonia N 13 Injection (initial approval 2007)"}],"archive":"https://web.archive.org/web/20250411213042/https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022119s001lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202008s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"amyloid-beta","kind":"target","name":"Amyloid beta plaques","route":"/targets/amyloid-beta/","field":"links","label":"FDA label: Amyvid (florbetapir F 18 injection)"}],"archive":"https://web.archive.org/web/20260922084255/https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/202008s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020134s012lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"sr-89-chloride","kind":"drug","name":"Strontium-89 chloride","route":"/drugs/sr-89-chloride/","field":"links","label":"FDA label: Metastron (strontium-89 chloride injection)"},{"id":"sr-89-chloride","kind":"drug","name":"Strontium-89 chloride","route":"/drugs/sr-89-chloride/","field":"dosing.source"},{"id":"sr-89","kind":"isotope","name":"Strontium-89","route":"/isotopes/sr-89/","field":"links","label":"FDA label: Metastron (strontium-89 chloride injection)"}],"archive":"https://web.archive.org/web/20250413084939/https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/020134s012lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"ra-223","kind":"isotope","name":"Radium-223","route":"/isotopes/ra-223/","field":"links","label":"FDA label: Xofigo (radium Ra 223 dichloride)"}],"archive":"https://web.archive.org/web/20251204000347/https://www.accessdata.fda.gov/drugsatfda_docs/label/2013/203971lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021305s041lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"i-131","kind":"isotope","name":"Iodine-131","route":"/isotopes/i-131/","field":"links","label":"FDA label: Sodium Iodide I 131 Capsules (diagnostic)"}],"archive":"https://web.archive.org/web/20250505185536/https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/021305s041lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016517s016lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"i-131","kind":"isotope","name":"Iodine-131","route":"/isotopes/i-131/","field":"links","label":"FDA label: Sodium Iodide I-131 Solution (therapeutic)"}],"archive":"https://web.archive.org/web/20250325173147/https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/016517s016lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019829s034lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"tc-99m-hmpao-brain","kind":"drug","name":"Technetium-99m exametazime (brain perfusion)","route":"/drugs/tc-99m-hmpao-brain/","field":"links","label":"FDA label: Ceretec (technetium Tc99m exametazime kit)"},{"id":"tc-99m-hmpao-brain","kind":"drug","name":"Technetium-99m exametazime (brain perfusion)","route":"/drugs/tc-99m-hmpao-brain/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20250803054049/https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/019829s034lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125019s227lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"rituximab-then-ibritumomab-tiuxetan","kind":"pairing","name":"Rituximab pretreatment before ibritumomab tiuxetan (Zevalin)","route":"/pairings/rituximab-then-ibritumomab-tiuxetan/","field":"links","label":"FDA label: Zevalin (ibritumomab tiuxetan), 2018 revision"}],"archive":"https://web.archive.org/web/20250224052037/https://www.accessdata.fda.gov/drugsatfda_docs/label/2018/125019s227lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019785s022lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"tc-99m-sestamibi","kind":"drug","name":"Technetium Tc-99m sestamibi","route":"/drugs/tc-99m-sestamibi/","field":"links","label":"FDA label: Cardiolite (technetium Tc-99m sestamibi), revised December 2019"},{"id":"tc-99m-sestamibi","kind":"drug","name":"Technetium Tc-99m sestamibi","route":"/drugs/tc-99m-sestamibi/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20250324081226/https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/019785s022lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200655s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-fdopa","kind":"drug","name":"Fluorodopa F-18","route":"/drugs/f-18-fdopa/","field":"links","label":"FDA label: Fluorodopa F 18 Injection"},{"id":"f-18-fdopa","kind":"drug","name":"Fluorodopa F-18","route":"/drugs/f-18-fdopa/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20250612090609/https://www.accessdata.fda.gov/drugsatfda_docs/label/2019/200655s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022290s005lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"i-123-mibg-cardiac","kind":"drug","name":"Iobenguane I-123 (cardiac use)","route":"/drugs/i-123-mibg-cardiac/","field":"links","label":"FDA label: AdreView (iobenguane I 123 injection), 2020 revision"},{"id":"i-123-mibg-cardiac","kind":"drug","name":"Iobenguane I-123 (cardiac use)","route":"/drugs/i-123-mibg-cardiac/","field":"dosing.source"},{"id":"i-123-mibg","kind":"drug","name":"Iobenguane I-123","route":"/drugs/i-123-mibg/","field":"links","label":"FDA label: AdreView (Iobenguane I 123 Injection)"},{"id":"i-123-mibg","kind":"drug","name":"Iobenguane I-123","route":"/drugs/i-123-mibg/","field":"dosing.source"},{"id":"i-123-mibg","kind":"drug","name":"Iobenguane I-123","route":"/drugs/i-123-mibg/","field":"toxicity.source (Dizziness, rash, pruritus, flushing, headache or injection-site haemorrhage (combined))"}],"archive":"https://web.archive.org/web/20250502062909/https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/022290s005lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"opp-her3-imaging-crossover","kind":"opportunity","name":"HER3 imaging, and why three tracers stalled","route":"/opportunities/opp-her3-imaging-crossover/","field":"links","label":"Fluoroestradiol F-18 label, the receptor-imaging precedent"}],"archive":"https://web.archive.org/web/20250629165722/https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/212155s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/Drugsatfda_Docs/Label/2020/213227s000lbl.Pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/","field":"links","label":"FDA label: Detectnet (copper Cu 64 dotatate injection)"},{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/","field":"dosing.source"},{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/","field":"toxicity.source (Nausea)"},{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/","field":"toxicity.source (Vomiting)"},{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/","field":"toxicity.source (Flushing)"}],"archive":"https://web.archive.org/web/20250324012208/https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/213227s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020314Orig1s000Lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"in-111-pentetreotide","kind":"drug","name":"Indium-111 pentetreotide","route":"/drugs/in-111-pentetreotide/","field":"links","label":"FDA label: Octreoscan (kit for the preparation of Indium In 111 Pentetreotide Injection)"},{"id":"in-111-pentetreotide","kind":"drug","name":"Indium-111 pentetreotide","route":"/drugs/in-111-pentetreotide/","field":"dosing.source"}],"archiveRequested":false},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020372Orig1s033lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"tc-99m-tetrofosmin","kind":"drug","name":"Technetium Tc-99m tetrofosmin","route":"/drugs/tc-99m-tetrofosmin/","field":"links","label":"FDA label: Myoview (technetium Tc-99m tetrofosmin), 2022 revision"},{"id":"tc-99m-tetrofosmin","kind":"drug","name":"Technetium Tc-99m tetrofosmin","route":"/drugs/tc-99m-tetrofosmin/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20250330215711/https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/020372Orig1s033lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022454s010lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"parkinsonian-syndromes","kind":"indication","name":"Parkinsonian syndromes","route":"/indications/parkinsonian-syndromes/","field":"links","label":"FDA label: DaTscan (ioflupane I 123 injection)"},{"id":"i-123-ioflupane","kind":"drug","name":"Ioflupane I-123","route":"/drugs/i-123-ioflupane/","field":"links","label":"FDA label: DaTscan (ioflupane I 123 injection)"},{"id":"i-123-ioflupane","kind":"drug","name":"Ioflupane I-123","route":"/drugs/i-123-ioflupane/","field":"dosing.source"},{"id":"dopamine-transporter","kind":"target","name":"Dopamine transporter (DAT)","route":"/targets/dopamine-transporter/","field":"links","label":"FDA label: DATSCAN (ioflupane I 123 injection)"}],"archive":"https://web.archive.org/web/20250323163929/https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/022454s010lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-radioligand-therapy","kind":"section","name":"Radioligand therapy","route":"/fronts/f-radioligand-therapy/","field":"links","label":"FDA label: Pluvicto (accessdata.fda.gov)"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/","field":"links","label":"FDA label: Pluvicto (lutetium Lu 177 vipivotide tetraxetan)"}],"archive":"https://web.archive.org/web/20260922084030/https://www.accessdata.fda.gov/drugsatfda_docs/label/2022/215833s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017881s030lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"tc-99m-maa","kind":"drug","name":"Technetium Tc-99m albumin aggregated (MAA)","route":"/drugs/tc-99m-maa/","field":"links","label":"FDA label: DRAXIMAGE MAA (BLA 017881), revised December 2023"}],"archive":"https://web.archive.org/web/20251018041303/https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/017881s030lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210089s002lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"tc-99m-maa","kind":"drug","name":"Technetium Tc-99m albumin aggregated (MAA)","route":"/drugs/tc-99m-maa/","field":"links","label":"FDA label: PULMOTECH MAA (BLA 210089), revised August 2023"},{"id":"tc-99m-maa","kind":"drug","name":"Technetium Tc-99m albumin aggregated (MAA)","route":"/drugs/tc-99m-maa/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20250320213642/https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/210089s002lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019414s034lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"rb-82-chloride","kind":"drug","name":"Rubidium Rb-82 chloride","route":"/drugs/rb-82-chloride/","field":"links","label":"FDA label: CardioGen-82 (rubidium Rb 82 generator), 2024 revision"},{"id":"rb-82-chloride","kind":"drug","name":"Rubidium Rb-82 chloride","route":"/drugs/rb-82-chloride/","field":"dosing.source"},{"id":"sr82-rb82-generators","kind":"technology","name":"Strontium-82/rubidium-82 generators","route":"/technologies/sr82-rb82-generators/","field":"links","label":"FDA label: CardioGen-82 (rubidium Rb 82 generator), 2024 revision"}],"archive":"https://web.archive.org/web/20250405210638/https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/019414s034lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022335Orig1s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"technegas","kind":"drug","name":"Technegas (technetium Tc-99m labelled carbon inhalation aerosol)","route":"/drugs/technegas/","field":"links","label":"FDA label: TECHNEGAS, kit for the preparation of technetium Tc 99m labeled carbon inhalation aerosol (NDA 022335)"},{"id":"technegas","kind":"drug","name":"Technegas (technetium Tc-99m labelled carbon inhalation aerosol)","route":"/drugs/technegas/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20240928233133/https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/022335Orig1s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208700Orig1s032lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"ga68-dotatate-then-lutathera","kind":"pairing","name":"68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)","route":"/pairings/ga68-dotatate-then-lutathera/","field":"links","label":"FDA label: Lutathera (lutetium Lu 177 dotatate), 2024 revision, eligibility criteria"}],"archive":"https://web.archive.org/web/20251113130302/https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208700Orig1s032lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212123s031lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-flortaucipir","kind":"drug","name":"Flortaucipir F-18","route":"/drugs/f-18-flortaucipir/","field":"links","label":"FDA label: Tauvid (flortaucipir F 18 injection)"},{"id":"f-18-flortaucipir","kind":"drug","name":"Flortaucipir F-18","route":"/drugs/f-18-flortaucipir/","field":"dosing.source"},{"id":"tau-protein","kind":"target","name":"Tau protein (neurofibrillary tangles)","route":"/targets/tau-protein/","field":"links","label":"FDA label: Tauvid (flortaucipir F 18 injection)"}],"archive":"https://web.archive.org/web/20250221180936/https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/212123s031lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215168s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-flurpiridaz","kind":"drug","name":"Flurpiridaz F-18","route":"/drugs/f-18-flurpiridaz/","field":"links","label":"FDA label: Flyrcado (flurpiridaz F 18) injection, September 2024"},{"id":"f-18-flurpiridaz","kind":"drug","name":"Flurpiridaz F-18","route":"/drugs/f-18-flurpiridaz/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260208193313/https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215168s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/017538s023,018321s026lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"tc-99m-pyrophosphate","kind":"drug","name":"Technetium Tc-99m pyrophosphate","route":"/drugs/tc-99m-pyrophosphate/","field":"links","label":"FDA label: Technescan PYP (Tc-99m pyrophosphate), 2025 revision"},{"id":"tc-99m-pyrophosphate","kind":"drug","name":"Technetium Tc-99m pyrophosphate","route":"/drugs/tc-99m-pyrophosphate/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260923092738/https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/017538s023,018321s026lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/018035s043lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"tc-99m-mdp","kind":"drug","name":"Technetium Tc-99m medronate (MDP)","route":"/drugs/tc-99m-mdp/","field":"links","label":"FDA label: Draximage MDP-25 (Kit for the Preparation of Technetium Tc 99m Medronate Injection)"},{"id":"tc-99m-mdp","kind":"drug","name":"Technetium Tc-99m medronate (MDP)","route":"/drugs/tc-99m-mdp/","field":"dosing.source"}],"archiveRequested":false},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/018150s029lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"tl-201-chloride","kind":"drug","name":"Thallous chloride Tl-201","route":"/drugs/tl-201-chloride/","field":"links","label":"FDA label: Thallous Chloride Tl 201 Injection, 2025 revision"},{"id":"tl-201-chloride","kind":"drug","name":"Thallous chloride Tl-201","route":"/drugs/tl-201-chloride/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260923092716/https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/018150s029lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202008s046lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-florbetapir","kind":"drug","name":"Florbetapir F-18","route":"/drugs/f-18-florbetapir/","field":"links","label":"FDA label: Amyvid (florbetapir F 18 injection), 2025 revision"},{"id":"f-18-florbetapir","kind":"drug","name":"Florbetapir F-18","route":"/drugs/f-18-florbetapir/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20260314020433/https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/202008s046lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215833s021s024lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"salivary-gland-toxicity","kind":"term","name":"Salivary gland toxicity (xerostomia) from PSMA radioligand therapy","route":"/terms/salivary-gland-toxicity/","field":"links","label":"FDA label: Pluvicto (lutetium Lu 177 vipivotide tetraxetan), accessdata.fda.gov"},{"id":"myelosuppression-after-rlt","kind":"term","name":"Myelosuppression after radioligand therapy","route":"/terms/myelosuppression-after-rlt/","field":"links","label":"FDA label: Pluvicto, dosage modifications and adverse reactions"}],"archive":"https://web.archive.org/web/20250725181431/https://www.accessdata.fda.gov/drugsatfda_docs/label/2025/215833s021s024lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/204677s041lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-florbetaben","kind":"drug","name":"Florbetaben F-18","route":"/drugs/f-18-florbetaben/","field":"links","label":"FDA label: Neuraceq (florbetaben F 18 injection)"},{"id":"f-18-florbetaben","kind":"drug","name":"Florbetaben F-18","route":"/drugs/f-18-florbetaben/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20261007112019/https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/204677s041lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220496Orig1s000lbl.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-florquinitau","kind":"drug","name":"Florquinitau F-18","route":"/drugs/f-18-florquinitau/","field":"links","label":"FDA label: Tauklarify (florquinitau F 18 injection), August 2026"},{"id":"f-18-florquinitau","kind":"drug","name":"Florquinitau F-18","route":"/drugs/f-18-florquinitau/","field":"dosing.source"},{"id":"f-18-florquinitau","kind":"drug","name":"Florquinitau F-18","route":"/drugs/f-18-florquinitau/","field":"toxicity.source (Headache)"}],"archive":"https://web.archive.org/web/20260927084815/https://www.accessdata.fda.gov/drugsatfda_docs/label/2026/220496Orig1s000lbl.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022119orig1s001.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"n-13-ammonia","kind":"drug","name":"Ammonia N-13","route":"/drugs/n-13-ammonia/","field":"links","label":"FDA approval package, NDA 22-119/S-001"}],"archive":"https://web.archive.org/web/20250401105903/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022119Orig1s001.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000MedR.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"dopamine-transporter","kind":"target","name":"Dopamine transporter (DAT)","route":"/targets/dopamine-transporter/","field":"links","label":"FDA medical review, NDA 022454 (mechanism of action)"}],"archive":"https://web.archive.org/web/20250401111248/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022454sOrig1s000MedR.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022494Orig1s000Approv.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-naf","kind":"drug","name":"Sodium fluoride F-18","route":"/drugs/f-18-naf/","field":"links","label":"FDA approval letter, NDA 22-494 (2011)"}],"archive":"https://web.archive.org/web/20250413084805/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2011/022494Orig1s000Approv.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021660Orig1s037.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","field":"links","label":"FDA approval letter, nab-paclitaxel plus gemcitabine for metastatic pancreatic adenocarcinoma"}],"archive":"https://web.archive.org/web/20260210115704/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/021660Orig1s037.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000MedR.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"bone-pain-palliation","kind":"indication","name":"Bone pain palliation from osteoblastic metastases","route":"/indications/bone-pain-palliation/","field":"links","label":"FDA medical review: radium Ra 223 dichloride (Xofigo), NDA 203971"}],"archive":"https://web.archive.org/web/20241009231144/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000MedR.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000RiskR.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"sm-153","kind":"isotope","name":"Samarium-153","route":"/isotopes/sm-153/","field":"links","label":"FDA: comparative physical properties of bone-palliation radiopharmaceuticals (Xofigo NDA review)"},{"id":"sr-89","kind":"isotope","name":"Strontium-89","route":"/isotopes/sr-89/","field":"links","label":"FDA: comparative physical properties of bone-palliation radiopharmaceuticals (Xofigo NDA review)"}],"archive":"https://web.archive.org/web/20260922084213/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000RiskR.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000TOC.cfm","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"alpha-therapy-roadmap","kind":"roadmap","name":"Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline","route":"/roadmaps/alpha-therapy-roadmap/","field":"links","label":"FDA: Alsympca (radium-223 dichloride) approval, May 2013"}],"archive":"https://web.archive.org/web/20250303065853/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/203971Orig1s000TOC.cfm"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208547Orig1s000Approv.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"sstr-theranostics-roadmap","kind":"roadmap","name":"SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha","route":"/roadmaps/sstr-theranostics-roadmap/","field":"links","label":"FDA: Netspot (gallium Ga 68 dotatate) approval, June 2016"}],"archive":"https://web.archive.org/web/20250331223432/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2016/208547Orig1s000Approv.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210828Orig1s000Approv.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"ga-68-dotatoc","kind":"drug","name":"Gallium-68 edotreotide (DOTATOC)","route":"/drugs/ga-68-dotatoc/","field":"links","label":"FDA approval letter, NDA 210828, Ga-68-DOTATOC (2019)"}],"archive":"https://web.archive.org/web/20260909190244/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210828Orig1s000Approv.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210828Orig1s000MultidisciplineR.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"ga-68-dotatoc","kind":"drug","name":"Gallium-68 edotreotide (DOTATOC)","route":"/drugs/ga-68-dotatoc/","field":"links","label":"FDA multi-discipline review, NDA 210828"},{"id":"ga-68-dotatoc","kind":"drug","name":"Gallium-68 edotreotide (DOTATOC)","route":"/drugs/ga-68-dotatoc/","field":"dosing.source"}],"archive":"https://web.archive.org/web/20250304092835/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/210828Orig1s000MultidisciplineR.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212123Orig1s000IntegratedR.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"tau-protein","kind":"target","name":"Tau protein (neurofibrillary tangles)","route":"/targets/tau-protein/","field":"links","label":"FDA integrated review, NDA 212123 (mechanism of action, pivotal trial data)"}],"archive":"https://web.archive.org/web/20260922084309/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212123Orig1s000IntegratedR.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212643Orig1s000Approv.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"psma-theranostics-roadmap","kind":"roadmap","name":"PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha","route":"/roadmaps/psma-theranostics-roadmap/","field":"links","label":"FDA: Ga 68 PSMA-11 injection approval (UCSF/UCLA), December 2020"}],"archive":"https://web.archive.org/web/20250315203417/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/212643Orig1s000Approv.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213227Orig1s000Approv.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/","field":"links","label":"FDA approval letter, NDA 213227 (2020)"}],"archive":"https://web.archive.org/web/20250401183539/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2020/213227Orig1s000Approv.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/022335Orig1s000Approv.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"technegas","kind":"drug","name":"Technegas (technetium Tc-99m labelled carbon inhalation aerosol)","route":"/drugs/technegas/","field":"links","label":"FDA approval package, NDA 022335, approval date 29 September 2023"},{"id":"technegas","kind":"drug","name":"Technegas (technetium Tc-99m labelled carbon inhalation aerosol)","route":"/drugs/technegas/","field":"regulatoryEvents.source (2023-09-29)"}],"archive":"https://web.archive.org/web/20250404012659/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/022335Orig1s000Approv.pdf"},{"url":"https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215168Orig1s000Approv.pdf","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-flurpiridaz","kind":"drug","name":"Flurpiridaz F-18","route":"/drugs/f-18-flurpiridaz/","field":"links","label":"FDA approval letter and package, NDA 215168 (Flyrcado)"},{"id":"f-18-flurpiridaz","kind":"drug","name":"Flurpiridaz F-18","route":"/drugs/f-18-flurpiridaz/","field":"regulatoryEvents.source (2024-09-27)"}],"archive":"https://web.archive.org/web/20250427090555/https://www.accessdata.fda.gov/drugsatfda_docs/nda/2024/215168Orig1s000Approv.pdf"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216410","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","field":"links","label":"Drugs@FDA: ANDA 216410, gallium Ga 68 gozetotide (RadioMedix)"},{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","field":"regulatoryEvents.source (2026-06-08)"}],"archive":"https://web.archive.org/web/20261014094000/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216410"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217060","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"links","label":"Drugs@FDA: ANDA 217060, Bravnetsa (Lantheus), tentative approval"}],"archive":"https://web.archive.org/web/20261007111359/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=217060"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218525","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"lu-177-dotatate-generic","kind":"drug","name":"Lutetium-177 dotatate (radioligand equivalent)","route":"/drugs/lu-177-dotatate-generic/","field":"links","label":"Drugs@FDA: NDA 218525, Bexlutry (lutetium Lu 177 dotatate)"},{"id":"lu-177-dotatate-generic","kind":"drug","name":"Lutetium-177 dotatate (radioligand equivalent)","route":"/drugs/lu-177-dotatate-generic/","field":"regulatoryEvents.source (2026-09-14)"}],"archive":"https://web.archive.org/web/20261002131335/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218525"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218592","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-fet","kind":"drug","name":"Floretyrosine F-18 (FET)","route":"/drugs/f-18-fet/","field":"links","label":"Drugs@FDA: NDA 218592, Pixclara (floretyrosine F 18)"},{"id":"f-18-fet","kind":"drug","name":"Floretyrosine F-18 (FET)","route":"/drugs/f-18-fet/","field":"regulatoryEvents.source (2026-09-11)"}],"archive":"https://web.archive.org/web/20261008125303/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218592"},{"url":"https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220496","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"f-18-florquinitau","kind":"drug","name":"Florquinitau F-18","route":"/drugs/f-18-florquinitau/","field":"links","label":"Drugs@FDA: NDA 220496, Tauklarify"},{"id":"f-18-florquinitau","kind":"drug","name":"Florquinitau F-18","route":"/drugs/f-18-florquinitau/","field":"regulatoryEvents.source (2026-08-13)"}],"archive":"https://web.archive.org/web/20261007023322/https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=220496"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P990065S014","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"y-90-resin-microspheres","kind":"drug","name":"Yttrium-90 resin microspheres","route":"/drugs/y-90-resin-microspheres/","field":"links","label":"FDA PMA P990065/S014 approval order"}],"archive":"https://web.archive.org/web/20260922084047/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpma/pma.cfm?ID=P990065S014"},{"url":"https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm","status":404,"ok":false,"finalUrl":"https://www.accessdata.fda.gov/apology_objects/abuse-detection-apology.html","checked":"2026-10-21","refs":[{"id":"medical-imaging-scanner-manufacturing","kind":"technology","name":"CT, MRI and PET scanner manufacturing","route":"/technologies/medical-imaging-scanner-manufacturing/","field":"links","label":"FDA medical device recalls database"}],"archive":"https://web.archive.org/web/20260830062434/https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfres/res.cfm"},{"url":"https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cardiogen-82-information","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"rb-82","kind":"isotope","name":"Rubidium-82","route":"/isotopes/rb-82/","field":"links","label":"FDA: CardioGen-82 information"}],"archive":"https://web.archive.org/web/20260322175555/https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/cardiogen-82-information"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-treatment-gep-nets","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"sstr-theranostics-roadmap","kind":"roadmap","name":"SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha","route":"/roadmaps/sstr-theranostics-roadmap/","field":"links","label":"FDA: Lutathera (lutetium Lu 177 dotatate) approval for GEP-NETs, January 2018"}],"archive":"https://web.archive.org/web/20260418064937/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-dotatate-treatment-gep-nets"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-grants-accelerated-approval-tarlatamab-extensive-stage-small-cell-lung-cancer","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"opp-dll3-imaging-sclc","kind":"opportunity","name":"DLL3 imaging for small-cell lung cancer","route":"/opportunities/opp-dll3-imaging-sclc/","field":"links","label":"FDA: accelerated approval of tarlatamab, May 2024"}],"archiveRequested":false},{"url":"https://www.fda.gov/media/152280/download","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"neeta-pandit-taskar","kind":"person","name":"Neeta Pandit-Taskar","route":"/people/neeta-pandit-taskar/","field":"links","label":"FDA-NRC Workshop presenter biography (actinium-225)"}],"archive":"https://web.archive.org/web/20251214122908/https://www.fda.gov/media/152280/download"},{"url":"https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-and-dcb-sign-exclusive-licensing-development-agreement-for-solucin-in-south-korea","status":404,"ok":false,"checked":"2026-10-21","refs":[{"id":"duchembio","kind":"company","name":"DuChemBio","route":"/companies/duchembio/","field":"links","label":"ITM and DCB exclusive licensing and development agreement (n.c.a. 177Lu-edotreotide in South Korea)"}],"archiveRequested":false},{"url":"https://www.mskcc.org/cancer-care/doctors/neeta-pandit-taskar","status":404,"ok":false,"finalUrl":"https://www.mskcc.org/archived/cancer-care/doctors/neeta-pandit-taskar","checked":"2026-10-21","refs":[{"id":"neeta-pandit-taskar","kind":"person","name":"Neeta Pandit-Taskar","route":"/people/neeta-pandit-taskar/","field":"profiles","label":"Former MSK profile (2000-2025)"}],"archive":"https://web.archive.org/web/20250518013952/https://www.mskcc.org/cancer-care/doctors/neeta-pandit-taskar"},{"url":"https://www.hmpgloballearningnetwork.com/site/rpei/conference-coverage/personalized-dosimetry-guides-177lu-psma-617-therapy-prostate-cancer","status":406,"ok":false,"checked":"2026-10-21","refs":[{"id":"idea-dosimetry-guided-dosing-standard","kind":"idea","name":"Kidney-dosimetry-guided dosing as the default for PSMA radioligand therapy","route":"/ideas/idea-dosimetry-guided-dosing-standard/","field":"links","label":"Personalized Dosimetry Guides 177Lu-PSMA-617 Therapy (conference coverage, University of Wisconsin series)"}]},{"url":"https://www.atom-hitech.com/","status":412,"ok":false,"checked":"2026-10-21","refs":[{"id":"hta-atom-hi-tech","kind":"company","name":"HTA (Atom Hi-Tech)","route":"/companies/hta-atom-hi-tech/","field":"website"}],"archive":"https://web.archive.org/web/20241204102012/https://www.atom-hitech.com/"},{"url":"https://www.circ.com.cn/","status":412,"ok":false,"checked":"2026-10-21","refs":[{"id":"china-isotope-radiation","kind":"company","name":"China Isotope & Radiation Corporation","route":"/companies/china-isotope-radiation/","field":"website"}],"archive":"https://web.archive.org/web/20241204120608/https://circ.com.cn/"},{"url":"https://www.nmpa.gov.cn","status":412,"ok":false,"finalUrl":"https://www.nmpa.gov.cn/","checked":"2026-10-21","refs":[{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","field":"links","label":"NMPA (National Medical Products Administration)"}],"archive":"https://web.archive.org/web/20260304224604/https://www.nmpa.gov.cn/"},{"url":"https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.cd009323.pub3/full","status":419,"ok":false,"checked":"2026-10-21","refs":[{"id":"opp-fap-pancreatic-staging","kind":"opportunity","name":"FAP imaging to stop futile pancreatic surgery","route":"/opportunities/opp-fap-pancreatic-staging/","field":"links","label":"Cochrane review: unresectable disease found at laparotomy after CT"}]},{"url":"http://www.zhhyx.com.cn/about.jhtml","status":500,"ok":false,"finalUrl":"https://www.zhhyx.com.cn/about.jhtml","checked":"2026-10-21","refs":[{"id":"chinese-journal-of-nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","route":"/journals/chinese-journal-of-nuclear-medicine-and-molecular-imaging/","field":"links","label":"Journal home and masthead (ISSN 2095-2848, CN 32-1828/R)"}]},{"url":"https://www.usz.ch/en/","status":500,"ok":false,"checked":"2026-10-21","refs":[{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/","field":"links","label":"Homepage"},{"id":"usz-zurich","kind":"institution","name":"University Hospital Zurich / Comprehensive Cancer Center Zurich","route":"/institutions/usz-zurich/","field":"website"}]},{"url":"https://scp.nrc.gov/asletters/tech/sp22074.pdf","status":503,"ok":false,"finalUrl":"https://www.nrc.gov/documents-reports/state-communications-portal","checked":"2026-10-21","refs":[{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/","field":"links","label":"NRC STC-22-074: Medical use, radiation safety and waste guidance for Lu-177 (Lutathera/Pluvicto)"},{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/","field":"metrics (Lutetium-177m contaminant activity in Lutathera/Pluvicto (161-day half-life, requires formal LLW disposal if detected))"}]},{"url":"https://www.alzforum.org/news/conference-coverage/first-field-synuclein-pet-only-multiple-system-atrophy","status":503,"ok":false,"checked":"2026-10-21","refs":[{"id":"opp-alpha-synuclein-pet-parkinsons","kind":"opportunity","name":"Alpha-synuclein PET: works for MSA, not for Parkinson's","route":"/opportunities/opp-alpha-synuclein-pet-parkinsons/","field":"links","label":"Conference report: signal only in multiple system atrophy"},{"id":"alpha-synuclein","kind":"target","name":"Alpha-synuclein","route":"/targets/alpha-synuclein/","field":"links","label":"Conference report: PET signal only in multiple system atrophy"}]},{"url":"https://www.cms.gov/medicare-coverage-database/","status":503,"ok":false,"checked":"2026-10-21","refs":[{"id":"medicare-ced","kind":"term","name":"Medicare coverage with evidence development","route":"/terms/medicare-ced/","field":"links","label":"CMS: Medicare Coverage Database"}]},{"url":"https://www.cms.gov/medicare-coverage-database/view/article.aspx?articleId=53134","status":503,"ok":false,"checked":"2026-10-21","refs":[{"id":"f-18-fdg-brain","kind":"drug","name":"Fludeoxyglucose F-18 (brain metabolism)","route":"/drugs/f-18-fdg-brain/","field":"links","label":"CMS coding article: PET scan coverage reference table including FDG dementia indication (A53134)"}]},{"url":"https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&NCAId=265","status":503,"ok":false,"checked":"2026-10-21","refs":[{"id":"amyloid-beta","kind":"target","name":"Amyloid beta plaques","route":"/targets/amyloid-beta/","field":"links","label":"CMS national coverage determination memo: beta-amyloid PET in dementia"}]},{"url":"https://www.cms.gov/medicare-coverage-database/view/ncacal-decision-memo.aspx?proposed=N&ncaid=308","status":503,"ok":false,"checked":"2026-10-21","refs":[{"id":"f-18-florbetapir","kind":"drug","name":"Florbetapir F-18","route":"/drugs/f-18-florbetapir/","field":"links","label":"CMS: decision memo removing the amyloid PET national coverage determination (NCA-CAL 308)"},{"id":"f-18-flutemetamol","kind":"drug","name":"Flutemetamol F-18","route":"/drugs/f-18-flutemetamol/","field":"links","label":"CMS: decision memo removing the amyloid PET national coverage determination (NCA-CAL 308)"},{"id":"f-18-florbetaben","kind":"drug","name":"Florbetaben F-18","route":"/drugs/f-18-florbetaben/","field":"links","label":"CMS: decision memo removing the amyloid PET national coverage determination (NCA-CAL 308)"},{"id":"ideas-amyloid","kind":"trial","name":"IDEAS (Imaging Dementia-Evidence for Amyloid Scanning)","route":"/trials/ideas-amyloid/","field":"links","label":"CMS: amyloid PET national coverage determination removal decision memo"}]},{"url":"https://www.ptcog.site/index.php/facilities-in-operation-public","status":503,"ok":false,"checked":"2026-10-21","refs":[{"id":"charite","kind":"institution","name":"Charité Universitätsmedizin Berlin","route":"/institutions/charite/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"johns-hopkins","kind":"institution","name":"Johns Hopkins Hospital / Sidney Kimmel Comprehensive Cancer Center","route":"/institutions/johns-hopkins/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","field":"links","label":"PTCOG: particle therapy facilities in operation"},{"id":"umcg-groningen","kind":"institution","name":"University Medical Center Groningen Comprehensive Cancer Center","route":"/institutions/umcg-groningen/","field":"links","label":"PTCOG: particle therapy facilities in operation"}]},{"url":"https://www.sydney.edu.au/AcademicProfiles/profile/resource?urlid=dale.bailey&type=cv","status":503,"ok":false,"checked":"2026-10-21","refs":[{"id":"dale-bailey","kind":"person","name":"Dale L. Bailey","route":"/people/dale-bailey/","field":"links","label":"University of Sydney CV"},{"id":"dale-bailey","kind":"person","name":"Dale L. Bailey","route":"/people/dale-bailey/","field":"profiles","label":"University of Sydney academic profile / CV"}]},{"url":"http://arxiv.org/pdf/2006.03125","status":200,"ok":true,"finalUrl":"https://arxiv.org/pdf/2006.03125","checked":"2026-10-21","refs":[{"id":"kr-81m","kind":"isotope","name":"Krypton-81m","route":"/isotopes/kr-81m/","field":"links","label":"IAEA evaluated nuclear data for 81Rb production, 82Kr(p,2n)81Rb, parent half-life 4.572 h"}]},{"url":"http://cellbion.co.kr/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cellbion","kind":"company","name":"CellBion","route":"/companies/cellbion/","field":"website"}]},{"url":"http://cellbion.co.kr/?r=reen&c=98/105","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cellbion","kind":"company","name":"CellBion","route":"/companies/cellbion/","field":"links","label":"CellBion company profile (founded July 2010, Seoul)"}]},{"url":"http://cellbion.co.kr/?r=reen&c=99/108","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cellbion","kind":"company","name":"CellBion","route":"/companies/cellbion/","field":"links","label":"CellBion pipeline (177Lu-DGUL, 68Ga-NGUL, 225Ac programmes)"}]},{"url":"http://convergentrx.com/","status":200,"ok":true,"finalUrl":"https://convergentrx.com/","checked":"2026-10-21","refs":[{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","route":"/companies/convergent-therapeutics/","field":"links","label":"Official website"},{"id":"convergent-therapeutics","kind":"company","name":"Convergent Therapeutics","route":"/companies/convergent-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20260612201909/https://convergentrx.com/"},{"url":"http://www.lnhb.fr/nuclides/Tc-99m_tables.pdf","status":200,"ok":true,"finalUrl":"https://www.lnhb.fr/nuclides/Tc-99m_tables.pdf","checked":"2026-10-21","refs":[{"id":"tc-99m","kind":"isotope","name":"Technetium-99m","route":"/isotopes/tc-99m/","field":"links","label":"NNDC/LNHB: Tc-99m decay data tables"}]},{"url":"https://acsearch.acr.org/docs/3102386/narrative/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"thyroid-nodule-assessment","kind":"indication","name":"Functional assessment of thyroid nodules","route":"/indications/thyroid-nodule-assessment/","field":"links","label":"ACR Appropriateness Criteria: thyroid disease"}]},{"url":"https://alphatau.com","status":200,"ok":true,"finalUrl":"https://alphatau.com/","checked":"2026-10-21","refs":[{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","field":"website"}]},{"url":"https://alphatau.com/alpha-dart-technology/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","field":"links","label":"Alpha Tau: Alpha DaRT technology overview"}]},{"url":"https://alphatau.com/alpha-tau-announces-100-local-disease-control-rate-and-favorable-safety-profile-observed-in-alpha-dart-pancreatic-cancer-trials-presented-at-ddw-2026/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","field":"links","label":"Alpha Tau: 100% local disease control rate in Alpha DaRT pancreatic cancer trials, presented at DDW 2026"}]},{"url":"https://alphatau.com/alpha-tau-announces-second-quarter-2026-financial-results-and-provides-corporate-update/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","field":"links","label":"Alpha Tau: Q2 2026 financial results and corporate update"}]},{"url":"https://ame.nd.edu/research-legacy/faculty-research-labs/rroeder/publications/publication-pdf/2016%20ADDR%20Cole.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bone-hydroxyapatite","kind":"target","name":"Bone mineral (hydroxyapatite)","route":"/targets/bone-hydroxyapatite/","field":"links","label":"Applied Radiation and Isotopes review: targeted delivery to bone using bisphosphonate ligands"}]},{"url":"https://anzup.org.au","status":200,"ok":true,"finalUrl":"https://anzup.org.au/","checked":"2026-10-21","refs":[{"id":"anzup","kind":"institution","name":"ANZUP Cancer Trials Group","route":"/institutions/anzup/","field":"links","label":"ANZUP"},{"id":"anzup","kind":"institution","name":"ANZUP Cancer Trials Group","route":"/institutions/anzup/","field":"website"}],"archive":"https://web.archive.org/web/20260619022629/https://anzup.org.au/"},{"url":"https://anzup.org.au/clinical-trial/upfrontpsma-trial/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"upfront-psma","kind":"trial","name":"UpFrontPSMA","route":"/trials/upfront-psma/","field":"links","label":"ANZUP: UpFrontPSMA trial page"}]},{"url":"https://anzup.org.au/trials/","status":200,"ok":true,"finalUrl":"https://anzup.org.au/presentation/trials-in-progress-p3bep-anzup-1302-an-international-randomized-phase-3-trial-of-accelerated-versus-standard-bep-chemotherapy-for-individuals-aged-11-45-years-with-intermediate-and-poor-risk-metas/","checked":"2026-10-21","refs":[{"id":"anzup","kind":"institution","name":"ANZUP Cancer Trials Group","route":"/institutions/anzup/","field":"links","label":"Trials"}]},{"url":"https://artbio.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","field":"links","label":"Official website"},{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","field":"website"}],"archive":"https://web.archive.org/web/20260606081545/https://artbio.com/"},{"url":"https://arxiv.org/abs/2603.22666","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-ai-lesion-segmentation-dosimetry","kind":"idea","name":"AI segmentation to make voxel-level radioligand dosimetry practical at scale","route":"/ideas/idea-ai-lesion-segmentation-dosimetry/","field":"links","label":"Towards Routine AI-Based PET/CT and SPECT/CT Lesion Segmentation and Tracking in PSMA Theranostics (arXiv, 2026)"}]},{"url":"https://ascopost.com/issues/january-25-2020/fda-approves-olaparib-for-patients-with-germline-brca-mutated-metastatic-pancreatic-cancer/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","field":"links","label":"ASCO Post: FDA approves olaparib for germline BRCA-mutated metastatic pancreatic cancer"}]},{"url":"https://ascopost.com/issues/november-25-2018/treatment-with-radium-223-plus-abiraterone-not-advisable-in-metastatic-prostate-cancer/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radium223-abiraterone-caution","kind":"pairing","name":"Radium-223 with abiraterone: a caution, not a combination","route":"/pairings/radium223-abiraterone-caution/","field":"links","label":"ASCO Post summary of ERA-223 (fracture rate, OS)"}]},{"url":"https://atomicalchemy.us","status":200,"ok":true,"finalUrl":"https://oklo.com/","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"atomic-alchemy","kind":"company","name":"Atomic Alchemy","route":"/companies/atomic-alchemy/","field":"links","label":"Official website"},{"id":"atomic-alchemy","kind":"company","name":"Atomic Alchemy","route":"/companies/atomic-alchemy/","field":"website"}],"archive":"https://web.archive.org/web/20260401143757/https://www.atomicalchemy.us/"},{"url":"https://axisimagingnews.com/radiology-products/imaging-equipment/nuclear-medicine/snmmi-issues-new-guidelines-for-diagnosing-fever-of-unknown-origin","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fever-of-unknown-origin","kind":"indication","name":"Fever of unknown origin","route":"/indications/fever-of-unknown-origin/","field":"links","label":"SNMMI: new appropriate use criteria for FUO (news summary)"}]},{"url":"https://biomarker.onclive.com/breast-cancer/triple-negative-tnbc/biomarkers/trop2","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-trop2-imaging-heterogeneity","kind":"opportunity","name":"TROP2 imaging where no tissue test is required","route":"/opportunities/opp-trop2-imaging-heterogeneity/","field":"links","label":"TROP2 biomarker review: no companion diagnostic, no validated plasma assay"}]},{"url":"https://boa.unimib.it/retrieve/2b572834-6cd0-4a4d-af21-27e8aa4987a1/Van%20den%20Wyngaert%20et%20al-2026-The%20EANM%20Journal-VoR.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"links","label":"EANM nuclear medicine workforce survey (European Journal of Nuclear Medicine, 2024 data)"},{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"metrics (European nuclear medicine departments reporting an open vacancy (EANM 2024 survey))"},{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"metrics (Technologist/radiographer vacancy rate in Europe (EANM 2024 survey))"},{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"metrics (European vacancies unfilled for 6 months or longer)"}]},{"url":"https://brandoncapital.vc/portfolio/advancell/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"advancell","kind":"company","name":"AdvanCell","route":"/companies/advancell/","field":"links","label":"Brandon Capital: Advancell portfolio page"}]},{"url":"https://britatom.gov.in/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"brit","kind":"institution","name":"Board of Radiation and Isotope Technology","route":"/institutions/brit/","field":"links","label":"BRIT (Department of Atomic Energy)"},{"id":"brit","kind":"institution","name":"Board of Radiation and Isotope Technology","route":"/institutions/brit/","field":"website"}],"archive":"https://web.archive.org/web/20260612200426/https://britatom.gov.in/"},{"url":"https://britatom.gov.in/en/product/radiopharmaceuticals/therapeutic","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"brit","kind":"institution","name":"Board of Radiation and Isotope Technology","route":"/institutions/brit/","field":"links","label":"BRIT therapeutic radiopharmaceuticals product list"}],"archive":"https://web.archive.org/web/20251211142815/https://britatom.gov.in/en/product/radiopharmaceuticals/therapeutic"},{"url":"https://bwxtmedical.com/wp-content/uploads/2024/05/tc-99m-product-sheet.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","route":"/companies/bwxt-medical/","field":"links","label":"BWXT Medical: Tc-99m generators product sheet (PDF)"}]},{"url":"https://cancer.ucsf.edu","status":200,"ok":true,"finalUrl":"https://cancer.ucsf.edu/","checked":"2026-10-21","refs":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/","field":"links","label":"Official website"},{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/","field":"website"}],"archive":"https://web.archive.org/web/20260905022036/https://cancer.ucsf.edu/"},{"url":"https://cancerimagingjournal.biomedcentral.com/","status":200,"ok":true,"finalUrl":"https://link.springer.com/journal/40644","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","field":"links","label":"Homepage"},{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","field":"url"}]},{"url":"https://cap.stanford.edu/profiles/frdActionServlet?choiceId=printerprofile&profileversion=full&profileId=8156","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"andrei-iagaru","kind":"person","name":"Andrei Iagaru","route":"/people/andrei-iagaru/","field":"links","label":"Stanford Profiles"}]},{"url":"https://cap.stanford.edu/profiles/viewCV?facultyId=8156&name=Andrei_Iagaru","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"andrei-iagaru","kind":"person","name":"Andrei Iagaru","route":"/people/andrei-iagaru/","field":"profiles","label":"Stanford Profiles CV"}]},{"url":"https://captions.snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2025/Use%20of%20Radiopharm_FINAL.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"extravasation-radiopharmaceutical","kind":"term","name":"Radiopharmaceutical extravasation","route":"/terms/extravasation-radiopharmaceutical/","field":"links","label":"SNMMI: Use of Radiopharmaceuticals guideline (clinical use and administration, extravasation)"}]},{"url":"https://cdn.amegroups.cn/journals/amepc/files/journals/3/articles/18019/public/18019-PB1-3327-R2.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"i-125-seeds","kind":"drug","name":"Iodine-125 brachytherapy seeds","route":"/drugs/i-125-seeds/","field":"links","label":"Prostate brachytherapy review, Translational Andrology and Urology 2018"},{"id":"i-125-seeds","kind":"drug","name":"Iodine-125 brachytherapy seeds","route":"/drugs/i-125-seeds/","field":"dosing.source"}]},{"url":"https://cdn.clinicaltrials.gov/large-docs/70/NCT03054870/Prot_SAP_001.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct03054870","kind":"trial","name":"CYC-009: Technegas versus xenon-133 ventilation imaging","route":"/trials/nct03054870/","field":"links","label":"CYC-009 protocol and statistical analysis plan (ClinicalTrials.gov document)"}]},{"url":"https://chinanm.cma.org.cn/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"csnm","kind":"institution","name":"Chinese Society of Nuclear Medicine","route":"/institutions/csnm/","field":"links","label":"Chinese Society of Nuclear Medicine (Chinese Medical Association)"},{"id":"csnm","kind":"institution","name":"Chinese Society of Nuclear Medicine","route":"/institutions/csnm/","field":"website"}]},{"url":"https://chinanm.cma.org.cn/art/2026/4/22/art_1509_60533.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"csnm","kind":"institution","name":"Chinese Society of Nuclear Medicine","route":"/institutions/csnm/","field":"links","label":"Chinese Journal of Nuclear Medicine and Molecular Imaging, 2026 issue 3 contents"},{"id":"chinese-journal-of-nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Chinese Journal of Nuclear Medicine and Molecular Imaging","route":"/journals/chinese-journal-of-nuclear-medicine-and-molecular-imaging/","field":"links","label":"Chinese Society of Nuclear Medicine: journal contents"}]},{"url":"https://clinicaltrials.gov","status":200,"ok":true,"finalUrl":"https://clinicaltrials.gov/","checked":"2026-10-21","refs":[{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","field":"dosing.source"},{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/","field":"links","label":"ClinicalTrials.gov"},{"id":"clinicaltrials-gov","kind":"collection","name":"ClinicalTrials.gov","route":"/collections/clinicaltrials-gov/","field":"url"}],"archive":"https://web.archive.org/web/20260921045819/https://clinicaltrials.gov/"},{"url":"https://clinicaltrials.gov/search?intr=225Ac-PSMA-617","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","field":"links","label":"ClinicalTrials.gov: trials of Actinium-225 PSMA agents"}]},{"url":"https://clinicaltrials.gov/search?intr=AAA817","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"aaa817","kind":"drug","name":"AAA817","route":"/drugs/aaa817/","field":"links","label":"ClinicalTrials.gov: trials of AAA817"}]},{"url":"https://clinicaltrials.gov/search?intr=AL2846","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"al2846","kind":"drug","name":"AL2846","route":"/drugs/al2846/","field":"links","label":"ClinicalTrials.gov: trials of AL2846"}]},{"url":"https://clinicaltrials.gov/search?intr=FAP-2286","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","field":"links","label":"ClinicalTrials.gov: trials of FAP-2286 (177Lu / 68Ga)"}]},{"url":"https://clinicaltrials.gov/search?intr=FC303","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/","field":"links","label":"ClinicalTrials.gov: trials of Florastamin F-18"}]},{"url":"https://clinicaltrials.gov/search?intr=FPI-2265","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fpi-2265","kind":"drug","name":"FPI-2265","route":"/drugs/fpi-2265/","field":"links","label":"ClinicalTrials.gov: trials of FPI-2265"}]},{"url":"https://clinicaltrials.gov/search?intr=HRS-4357","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hrs-4357","kind":"drug","name":"HRS-4357","route":"/drugs/hrs-4357/","field":"links","label":"ClinicalTrials.gov: trials of HRS-4357"}]},{"url":"https://clinicaltrials.gov/search?intr=Iomab-B","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"iomab-b","kind":"drug","name":"Iomab-B","route":"/drugs/iomab-b/","field":"links","label":"ClinicalTrials.gov: trials of Iomab-B"}]},{"url":"https://clinicaltrials.gov/search?intr=JNJ-87189401","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jnj-87189401","kind":"drug","name":"JNJ-87189401","route":"/drugs/jnj-87189401/","field":"links","label":"ClinicalTrials.gov: trials of JNJ-87189401"}]},{"url":"https://clinicaltrials.gov/search?intr=PSMA-1007%20F-18","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma-1007-f18","kind":"drug","name":"PSMA-1007 F-18","route":"/drugs/psma-1007-f18/","field":"links","label":"ClinicalTrials.gov: trials of PSMA-1007 F-18"}]},{"url":"https://clinicaltrials.gov/search?intr=RYZ101","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","field":"links","label":"ClinicalTrials.gov: trials of Actinium-225 DOTATATE"}]},{"url":"https://clinicaltrials.gov/search?intr=TLX250-CDx","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"girentuximab-zr89","kind":"drug","name":"Zirconium-89 girentuximab","route":"/drugs/girentuximab-zr89/","field":"links","label":"ClinicalTrials.gov: trials of Zirconium-89 girentuximab"}]},{"url":"https://clinicaltrials.gov/search?lead=ABX%20advanced%20biochemical%20compounds","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","route":"/companies/abx-advanced-biochemical-compounds/","field":"links","label":"ClinicalTrials.gov: trials led by ABX advanced biochemical compounds"}]},{"url":"https://clinicaltrials.gov/search?lead=Cellectar%20Biosciences","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","route":"/companies/cellectar/","field":"links","label":"ClinicalTrials.gov: trials led by Cellectar Biosciences"}]},{"url":"https://clinicaltrials.gov/search?lead=FutureChem","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"futurechem","kind":"company","name":"FutureChem","route":"/companies/futurechem/","field":"links","label":"ClinicalTrials.gov: trials led by FutureChem"}]},{"url":"https://clinicaltrials.gov/search?lead=Monopar%20Therapeutics%20Inc.","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"monopar","kind":"company","name":"Monopar Therapeutics","route":"/companies/monopar/","field":"links","label":"ClinicalTrials.gov: trials led by Monopar Therapeutics Inc."}]},{"url":"https://clinicaltrials.gov/search?lead=Navidea%20Biopharmaceuticals","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"navidea","kind":"company","name":"Navidea Biopharmaceuticals","route":"/companies/navidea/","field":"links","label":"ClinicalTrials.gov: trials led by Navidea Biopharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?lead=Radiopharm%20Theranostics%2C%20Ltd","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/","field":"links","label":"ClinicalTrials.gov: trials led by Radiopharm Theranostics"}]},{"url":"https://clinicaltrials.gov/search?lead=Sinotau%20Pharmaceutical%20Group","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","route":"/companies/sinotau-pharmaceutical/","field":"links","label":"ClinicalTrials.gov: trials led by Sinotau Pharmaceutical"}]},{"url":"https://clinicaltrials.gov/search?lead=Spectrum%20Pharmaceuticals","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","field":"links","label":"ClinicalTrials.gov: trials led by Spectrum Pharmaceuticals"}]},{"url":"https://clinicaltrials.gov/search?term=actinium-225","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-nanogenerators","kind":"technology","name":"Alpha-emitter nanogenerators and daughter trapping","route":"/technologies/alpha-nanogenerators/","field":"links","label":"ClinicalTrials.gov: actinium-225"}],"archive":"https://web.archive.org/web/20250418141848/https://clinicaltrials.gov/search?term=actinium-225"},{"url":"https://clinicaltrials.gov/search?term=lutetium%20PSMA%20olaparib","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radionuclide-parp-combination","kind":"technology","name":"Radioligand plus DNA-repair inhibitor combinations","route":"/technologies/radionuclide-parp-combination/","field":"links","label":"ClinicalTrials.gov: Lu-177 PSMA plus olaparib"}]},{"url":"https://clinicaltrials.gov/search?term=terbium-161","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"auger-electron-therapy","kind":"technology","name":"Auger-electron therapy","route":"/technologies/auger-electron-therapy/","field":"links","label":"ClinicalTrials.gov: terbium-161"}]},{"url":"https://clinicaltrials.gov/search?term=total-body%20PET","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"total-body-pet-screening","kind":"technology","name":"Total-body PET for screening and ultra-low-dose imaging","route":"/technologies/total-body-pet-screening/","field":"links","label":"ClinicalTrials.gov: total-body PET"}]},{"url":"https://clinicaltrials.gov/study/NCT00268476","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"ClinicalTrials.gov NCT00268476"}]},{"url":"https://clinicaltrials.gov/study/NCT00309985","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/","field":"links","label":"ClinicalTrials.gov NCT00309985"}],"archive":"https://web.archive.org/web/20260207133939/https://clinicaltrials.gov/study/NCT00309985"},{"url":"https://clinicaltrials.gov/study/NCT00415233","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hilo","kind":"trial","name":"HiLo","route":"/trials/hilo/","field":"links","label":"ClinicalTrials.gov NCT00415233"}],"archive":"https://web.archive.org/web/20251028072024/https://clinicaltrials.gov/study/NCT00415233"},{"url":"https://clinicaltrials.gov/study/NCT00510068","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","field":"links","label":"ClinicalTrials.gov NCT00510068"}]},{"url":"https://clinicaltrials.gov/study/NCT00678327","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rathl","kind":"trial","name":"RATHL","route":"/trials/rathl/","field":"links","label":"ClinicalTrials.gov NCT00678327"}]},{"url":"https://clinicaltrials.gov/study/NCT00699751","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alsympca","kind":"trial","name":"ALSYMPCA","route":"/trials/alsympca/","field":"links","label":"ClinicalTrials.gov NCT00699751"}],"archive":"https://web.archive.org/web/20260907201215/https://clinicaltrials.gov/study/NCT00699751"},{"url":"https://clinicaltrials.gov/study/NCT00984282","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"decision-sorafenib","kind":"trial","name":"DECISION","route":"/trials/decision-sorafenib/","field":"links","label":"ClinicalTrials.gov NCT00984282"}],"archive":"https://web.archive.org/web/20260615115143/https://clinicaltrials.gov/study/NCT00984282"},{"url":"https://clinicaltrials.gov/study/NCT01321554","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"select-lenvatinib","kind":"trial","name":"SELECT","route":"/trials/select-lenvatinib/","field":"links","label":"ClinicalTrials.gov NCT01321554"}]},{"url":"https://clinicaltrials.gov/study/NCT01398085","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ion-trial","kind":"trial","name":"IoN","route":"/trials/ion-trial/","field":"links","label":"ClinicalTrials.gov NCT01398085"}],"archive":"https://web.archive.org/web/20260926072642/https://clinicaltrials.gov/study/NCT01398085"},{"url":"https://clinicaltrials.gov/study/NCT01482442","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sarah-sirvenib","kind":"trial","name":"SARAH and SIRveNIB","route":"/trials/sarah-sirvenib/","field":"links","label":"ClinicalTrials.gov NCT01482442"}]},{"url":"https://clinicaltrials.gov/study/NCT01578239","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"netter-1","kind":"trial","name":"NETTER-1","route":"/trials/netter-1/","field":"links","label":"ClinicalTrials.gov NCT01578239"}],"archive":"https://web.archive.org/web/20260308034957/https://clinicaltrials.gov/study/NCT01578239"},{"url":"https://clinicaltrials.gov/study/NCT01599559","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ielsg37","kind":"trial","name":"IELSG37","route":"/trials/ielsg37/","field":"links","label":"ClinicalTrials.gov NCT01599559"}],"archive":"https://web.archive.org/web/20260515141146/https://clinicaltrials.gov/study/NCT01599559"},{"url":"https://clinicaltrials.gov/study/NCT01837745","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"estimabl2","kind":"trial","name":"ESTIMABL2","route":"/trials/estimabl2/","field":"links","label":"ClinicalTrials.gov NCT01837745"}],"archive":"https://web.archive.org/web/20260410231005/https://clinicaltrials.gov/study/NCT01837745"},{"url":"https://clinicaltrials.gov/study/NCT01843062","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"astra","kind":"trial","name":"ASTRA","route":"/trials/astra/","field":"links","label":"ClinicalTrials.gov NCT01843062"}],"archive":"https://web.archive.org/web/20260712153951/https://clinicaltrials.gov/study/NCT01843062"},{"url":"https://clinicaltrials.gov/study/NCT02003924","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prosper","kind":"trial","name":"PROSPER","route":"/trials/prosper/","field":"links","label":"ClinicalTrials.gov NCT02003924"}],"archive":"https://web.archive.org/web/20260929074608/https://clinicaltrials.gov/study/NCT02003924"},{"url":"https://clinicaltrials.gov/study/NCT02302105","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pop-rt","kind":"trial","name":"POP-RT","route":"/trials/pop-rt/","field":"links","label":"ClinicalTrials.gov NCT02302105 (POP-RT, Tata Memorial Centre)"}],"archive":"https://web.archive.org/web/20250326062913/https://clinicaltrials.gov/study/NCT02302105"},{"url":"https://clinicaltrials.gov/study/NCT02319837","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"embark","kind":"trial","name":"EMBARK","route":"/trials/embark/","field":"links","label":"ClinicalTrials.gov NCT02319837"}],"archive":"https://web.archive.org/web/20260611201231/https://clinicaltrials.gov/study/NCT02319837"},{"url":"https://clinicaltrials.gov/study/NCT02420756","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ideas-amyloid","kind":"trial","name":"IDEAS (Imaging Dementia-Evidence for Amyloid Scanning)","route":"/trials/ideas-amyloid/","field":"links","label":"ClinicalTrials.gov: NCT02420756"}]},{"url":"https://clinicaltrials.gov/study/NCT02578940","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"falcon","kind":"trial","name":"FALCON","route":"/trials/falcon/","field":"links","label":"ClinicalTrials.gov: NCT02578940"}]},{"url":"https://clinicaltrials.gov/study/NCT02661503","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/","field":"links","label":"ClinicalTrials.gov NCT02661503: GHSG HD21"},{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","field":"links","label":"ClinicalTrials.gov NCT02661503"}],"archive":"https://web.archive.org/web/20260212083444/https://clinicaltrials.gov/study/NCT02661503"},{"url":"https://clinicaltrials.gov/study/NCT02665065","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct02665065","kind":"trial","name":"Study of Iomab-B vs. Conventional Care in Older Subjects With Active, Relapsed or Refractory Acute Myeloid Leukemia","route":"/trials/nct02665065/","field":"links","label":"ClinicalTrials.gov NCT02665065"}],"archive":"https://web.archive.org/web/20251115082402/https://clinicaltrials.gov/study/NCT02665065"},{"url":"https://clinicaltrials.gov/study/NCT02952508","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct02952508","kind":"trial","name":"Study of Iopofosine I-131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) With Expansion in Waldenstrom","route":"/trials/nct02952508/","field":"links","label":"ClinicalTrials.gov NCT02952508"}],"archive":"https://web.archive.org/web/20260601100035/https://clinicaltrials.gov/study/NCT02952508"},{"url":"https://clinicaltrials.gov/study/NCT02981368","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"osprey","kind":"trial","name":"OSPREY","route":"/trials/osprey/","field":"links","label":"ClinicalTrials.gov: NCT02981368"}]},{"url":"https://clinicaltrials.gov/study/NCT03049189","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","field":"links","label":"ClinicalTrials.gov NCT03049189 (COMPETE)"},{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","field":"links","label":"ClinicalTrials.gov NCT03049189"},{"id":"sstr-pet-to-prrt","kind":"pairing","name":"SSTR PET → PRRT","route":"/pairings/sstr-pet-to-prrt/","field":"links","label":"ClinicalTrials.gov NCT03049189: COMPETE"},{"id":"idea-net-dosimetry-prrt","kind":"idea","name":"Dosimetry-personalised PRRT instead of four fixed cycles","route":"/ideas/idea-net-dosimetry-prrt/","field":"links","label":"ClinicalTrials.gov NCT03049189: COMPETE"}],"archive":"https://web.archive.org/web/20260216225854/https://clinicaltrials.gov/study/NCT03049189"},{"url":"https://clinicaltrials.gov/study/NCT03054870","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct03054870","kind":"trial","name":"CYC-009: Technegas versus xenon-133 ventilation imaging","route":"/trials/nct03054870/","field":"links","label":"ClinicalTrials.gov NCT03054870"}]},{"url":"https://clinicaltrials.gov/study/NCT03126916","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"anbl1531","kind":"trial","name":"COG ANBL1531","route":"/trials/anbl1531/","field":"links","label":"ClinicalTrials.gov NCT03126916"}],"archive":"https://web.archive.org/web/20261008234435/https://clinicaltrials.gov/study/NCT03126916"},{"url":"https://clinicaltrials.gov/study/NCT03161353","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"phergain","kind":"trial","name":"PHERGain","route":"/trials/phergain/","field":"links","label":"ClinicalTrials.gov NCT03161353"}],"archive":"https://web.archive.org/web/20251028114158/https://clinicaltrials.gov/study/NCT03161353"},{"url":"https://clinicaltrials.gov/study/NCT03354273","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"aurora-flurpiridaz","kind":"trial","name":"AURORA","route":"/trials/aurora-flurpiridaz/","field":"links","label":"ClinicalTrials.gov: NCT03354273"}]},{"url":"https://clinicaltrials.gov/study/NCT03375320","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cabinet","kind":"trial","name":"CABINET (Alliance A021602)","route":"/trials/cabinet/","field":"links","label":"ClinicalTrials.gov NCT03375320"}],"archive":"https://web.archive.org/web/20260606183153/https://clinicaltrials.gov/study/NCT03375320"},{"url":"https://clinicaltrials.gov/study/NCT03392428","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma-pet","kind":"technology","name":"PSMA PET","route":"/technologies/psma-pet/","field":"links","label":"ClinicalTrials.gov NCT03392428: TheraP (ANZUP 1603)"},{"id":"therap","kind":"trial","name":"TheraP (ANZUP 1603)","route":"/trials/therap/","field":"links","label":"ClinicalTrials.gov NCT03392428"},{"id":"psma-pet-to-rlt","kind":"pairing","name":"PSMA PET → PSMA radioligand therapy","route":"/pairings/psma-pet-to-rlt/","field":"links","label":"ClinicalTrials.gov NCT03392428: TheraP (ANZUP 1603)"}],"archive":"https://web.archive.org/web/20251028091831/https://clinicaltrials.gov/study/NCT03392428"},{"url":"https://clinicaltrials.gov/study/NCT03444844","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct03444844","kind":"trial","name":"Biodistribution and Dosimetry of Ga-68 P16-093 in Prostate Cancer","route":"/trials/nct03444844/","field":"links","label":"ClinicalTrials.gov NCT03444844"}],"archive":"https://web.archive.org/web/20250811171215/https://clinicaltrials.gov/study/NCT03444844"},{"url":"https://clinicaltrials.gov/study/NCT03511664","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"vision","kind":"trial","name":"VISION","route":"/trials/vision/","field":"links","label":"ClinicalTrials.gov NCT03511664"},{"id":"paper-vision-nejm-2021","kind":"paper","name":"VISION: lutetium-177 PSMA-617 radioligand therapy extends survival in advanced prostate cancer","route":"/key-papers/paper-vision-nejm-2021/","field":"links","label":"ClinicalTrials.gov NCT03511664"},{"id":"idea-dosimetry-guided-dosing-standard","kind":"idea","name":"Kidney-dosimetry-guided dosing as the default for PSMA radioligand therapy","route":"/ideas/idea-dosimetry-guided-dosing-standard/","field":"links","label":"VISION: 177Lu-PSMA-617 (ClinicalTrials.gov, NCT03511664)"}]},{"url":"https://clinicaltrials.gov/study/NCT03533283","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct03533283","kind":"trial","name":"An Open-Label Phase lB/II Study of Glofitamab and Atezolizumab or Polatuzumab Vedotin in Adult Patients With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma","route":"/trials/nct03533283/","field":"links","label":"ClinicalTrials.gov NCT03533283"}],"archive":"https://web.archive.org/web/20260517023900/https://clinicaltrials.gov/study/NCT03533283"},{"url":"https://clinicaltrials.gov/study/NCT03658447","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-rlt-plus-checkpoint-inhibitor","kind":"idea","name":"Adding a checkpoint inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-checkpoint-inhibitor/","field":"links","label":"PRINCE study (ClinicalTrials.gov, NCT03658447)"},{"id":"prince-trial","kind":"trial","name":"PRINCE","route":"/trials/prince-trial/","field":"links","label":"ClinicalTrials.gov: NCT03658447"}]},{"url":"https://clinicaltrials.gov/study/NCT03659448","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-ceacam5-imaging-colorectal","kind":"opportunity","name":"CEACAM5 imaging for occult colorectal recurrence","route":"/opportunities/opp-ceacam5-imaging-colorectal/","field":"links","label":"NCT03659448: SGM-101 phase 3 in colorectal cancer"}]},{"url":"https://clinicaltrials.gov/study/NCT03690388","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct03690388","kind":"trial","name":"A Study of Cabozantinib Compared With Placebo in Subjects With Radioiodine-refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Va","route":"/trials/nct03690388/","field":"links","label":"ClinicalTrials.gov NCT03690388"}],"archive":"https://web.archive.org/web/20260712151357/https://clinicaltrials.gov/study/NCT03690388"},{"url":"https://clinicaltrials.gov/study/NCT03739684","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"condor","kind":"trial","name":"CONDOR","route":"/trials/condor/","field":"links","label":"ClinicalTrials.gov: NCT03739684"}]},{"url":"https://clinicaltrials.gov/study/NCT03849118","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-caix-indeterminate-renal-mass","kind":"opportunity","name":"CAIX imaging of the indeterminate renal mass","route":"/opportunities/opp-caix-indeterminate-renal-mass/","field":"links","label":"NCT03849118: ZIRCON"},{"id":"zircon","kind":"trial","name":"ZIRCON","route":"/trials/zircon/","field":"links","label":"ClinicalTrials.gov: NCT03849118"}]},{"url":"https://clinicaltrials.gov/study/NCT03872778","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-grpr-psma-negative-prostate","kind":"opportunity","name":"GRPR imaging when the PSMA scan is negative","route":"/opportunities/opp-grpr-psma-negative-prostate/","field":"links","label":"NCT03872778: NeoRay, 177Lu-NeoB"}]},{"url":"https://clinicaltrials.gov/study/NCT03874884","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-rlt-plus-parp-inhibitor","kind":"idea","name":"Adding a PARP inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-parp-inhibitor/","field":"links","label":"177Lu-PSMA-617 Therapy and Olaparib in Patients With mCRPC (LuPARP) (ClinicalTrials.gov, NCT03874884)"},{"id":"pluvicto-plus-olaparib","kind":"pairing","name":"177Lu-PSMA-617 (Pluvicto) with olaparib","route":"/pairings/pluvicto-plus-olaparib/","field":"links","label":"ClinicalTrials.gov: NCT03874884 (LuPARP)"}]},{"url":"https://clinicaltrials.gov/study/NCT03934866","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-detect-a-science-2020","kind":"paper","name":"DETECT-A: a blood test plus PET-CT found treatable cancers in 10,000 women with no symptoms","route":"/key-papers/paper-detect-a-science-2020/","field":"links","label":"ClinicalTrials.gov NCT03934866"}]},{"url":"https://clinicaltrials.gov/study/NCT03972488","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct03972488","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","route":"/trials/nct03972488/","field":"links","label":"ClinicalTrials.gov NCT03972488"},{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/","field":"links","label":"ClinicalTrials.gov NCT03972488"}],"archive":"https://web.archive.org/web/20260520163554/https://clinicaltrials.gov/study/NCT03972488"},{"url":"https://clinicaltrials.gov/study/NCT03972657","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct03972657","kind":"trial","name":"A Trial to Find Out if REGN5678 (Nezastomig) is Safe and How Well it Works Alone or in Combination With Cemiplimab for Adult Participants With Metasta","route":"/trials/nct03972657/","field":"links","label":"ClinicalTrials.gov NCT03972657"}],"archive":"https://web.archive.org/web/20260929235203/https://clinicaltrials.gov/study/NCT03972657"},{"url":"https://clinicaltrials.gov/study/NCT04186819","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lighthouse","kind":"trial","name":"LIGHTHOUSE","route":"/trials/lighthouse/","field":"links","label":"ClinicalTrials.gov: NCT04186819"}]},{"url":"https://clinicaltrials.gov/study/NCT04186845","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"spotlight","kind":"trial","name":"SPOTLIGHT","route":"/trials/spotlight/","field":"links","label":"ClinicalTrials.gov: NCT04186845"}]},{"url":"https://clinicaltrials.gov/study/NCT04199741","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-dll3-imaging-sclc","kind":"opportunity","name":"DLL3 imaging for small-cell lung cancer","route":"/opportunities/opp-dll3-imaging-sclc/","field":"links","label":"NCT04199741: 89Zr-DFO-SC16.56 immuno-PET of neuroendocrine tumours"}]},{"url":"https://clinicaltrials.gov/study/NCT04206163","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cardiac-sarcoidosis-specific-tracer","kind":"opportunity","name":"An inflammation tracer that does not need a diet","route":"/opportunities/opp-cardiac-sarcoidosis-specific-tracer/","field":"links","label":"NCT04206163: somatostatin receptor imaging in inflammatory heart disease, 78 patients"}]},{"url":"https://clinicaltrials.gov/study/NCT04343885","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"upfront-psma","kind":"trial","name":"UpFrontPSMA","route":"/trials/upfront-psma/","field":"links","label":"ClinicalTrials.gov: NCT04343885"}]},{"url":"https://clinicaltrials.gov/study/NCT04419402","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"enza-p","kind":"trial","name":"ENZA-p","route":"/trials/enza-p/","field":"links","label":"ClinicalTrials.gov: NCT04419402"}]},{"url":"https://clinicaltrials.gov/study/NCT04430192","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lutectomy","kind":"trial","name":"LuTectomy","route":"/trials/lutectomy/","field":"links","label":"ClinicalTrials.gov: NCT04430192"}]},{"url":"https://clinicaltrials.gov/study/NCT04557059","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct04557059","kind":"trial","name":"A Study of Adding Apalutamide to Radiotherapy and LHRH Agonist in High-Risk Patients With Hormone-Sensitive Prostate Cancer","route":"/trials/nct04557059/","field":"links","label":"ClinicalTrials.gov NCT04557059"}],"archive":"https://web.archive.org/web/20260510173525/https://clinicaltrials.gov/study/NCT04557059"},{"url":"https://clinicaltrials.gov/study/NCT04647526","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/","field":"links","label":"ClinicalTrials.gov NCT04647526"},{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/","field":"outcomes.source (Radiographic progression-free survival)"},{"id":"splash","kind":"trial","name":"SPLASH","route":"/trials/splash/","field":"outcomes.source (Overall survival (interim))"},{"id":"lu-177-pnt2002","kind":"drug","name":"Lutetium-177 PNT2002","route":"/drugs/lu-177-pnt2002/","field":"links","label":"ClinicalTrials.gov: SPLASH (NCT04647526)"}]},{"url":"https://clinicaltrials.gov/study/NCT04689828","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psmafore","kind":"trial","name":"PSMAfore","route":"/trials/psmafore/","field":"links","label":"ClinicalTrials.gov NCT04689828"}]},{"url":"https://clinicaltrials.gov/study/NCT04706962","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sortilin","kind":"target","name":"Sortilin (SORT1)","route":"/targets/sortilin/","field":"links","label":"ClinicalTrials.gov NCT04706962: TH1902 in patients with advanced solid tumours"}]},{"url":"https://clinicaltrials.gov/study/NCT04711135","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct04711135","kind":"trial","name":"Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs","route":"/trials/nct04711135/","field":"links","label":"ClinicalTrials.gov NCT04711135"}],"archive":"https://web.archive.org/web/20260727132046/https://clinicaltrials.gov/study/NCT04711135"},{"url":"https://clinicaltrials.gov/study/NCT04720157","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","field":"links","label":"ClinicalTrials.gov NCT04720157"},{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","field":"outcomes.source (Radiographic progression-free survival)"},{"id":"idea-alpha-first-mhspc","kind":"idea","name":"Alpha-emitting PSMA therapy at first metastatic diagnosis","route":"/ideas/idea-alpha-first-mhspc/","field":"links","label":"ClinicalTrials.gov NCT04720157: PSMAddition"}],"archive":"https://web.archive.org/web/20260810043244/https://clinicaltrials.gov/study/NCT04720157"},{"url":"https://clinicaltrials.gov/study/NCT04724369","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct04724369","kind":"trial","name":"Open-Label Study of 18F-mFBG for Imaging Neuroblastoma","route":"/trials/nct04724369/","field":"links","label":"ClinicalTrials.gov NCT04724369"}],"archive":"https://web.archive.org/web/20260515144602/https://clinicaltrials.gov/study/NCT04724369"},{"url":"https://clinicaltrials.gov/study/NCT04807257","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct04807257","kind":"trial","name":"Auger Molecular Therapy (AMT) for Malignant Cutaneous Lesions Treatment","route":"/trials/nct04807257/","field":"links","label":"ClinicalTrials.gov NCT04807257"}],"archive":"https://web.archive.org/web/20250201194242/https://clinicaltrials.gov/study/NCT04807257"},{"url":"https://clinicaltrials.gov/study/NCT04868604","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct04868604","kind":"trial","name":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE)","route":"/trials/nct04868604/","field":"links","label":"ClinicalTrials.gov NCT04868604"},{"id":"cu-64-sar-bispsma","kind":"drug","name":"Copper-64 SAR-bisPSMA","route":"/drugs/cu-64-sar-bispsma/","field":"links","label":"ClinicalTrials.gov NCT04868604 (SECuRE)"},{"id":"idea-copper-theranostic-pair-standard","kind":"idea","name":"A single-molecule copper-64/copper-67 pair instead of switching ligands between scan and treatment","route":"/ideas/idea-copper-theranostic-pair-standard/","field":"links","label":"64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA (SECuRE) (ClinicalTrials.gov, NCT04868604)"}],"archive":"https://web.archive.org/web/20260718082727/https://clinicaltrials.gov/study/NCT04868604"},{"url":"https://clinicaltrials.gov/study/NCT04919226","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct04919226","kind":"trial","name":"Lutetium 177Lu-Edotreotide Versus Best Standard of Care in Well-differentiated Aggressive Grade-2 and Grade-3 GastroEnteroPancreatic NeuroEndocrine Tumors (GEP-NETs) - COMPOSE","route":"/trials/nct04919226/","field":"links","label":"ClinicalTrials.gov NCT04919226"}],"archive":"https://web.archive.org/web/20260924104643/https://clinicaltrials.gov/study/NCT04919226"},{"url":"https://clinicaltrials.gov/study/NCT04939610","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","field":"dosing.source"},{"id":"nct04939610","kind":"trial","name":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors","route":"/trials/nct04939610/","field":"links","label":"ClinicalTrials.gov NCT04939610"},{"id":"idea-fap-theranostics-sarcoma","kind":"idea","name":"FAP-targeted radioligand therapy for sarcoma","route":"/ideas/idea-fap-theranostics-sarcoma/","field":"links","label":"A Study of 177Lu-FAP-2286 in Advanced Solid Tumors (LuMIERE) (ClinicalTrials.gov, NCT04939610)"}],"archive":"https://web.archive.org/web/20260826004611/https://clinicaltrials.gov/study/NCT04939610"},{"url":"https://clinicaltrials.gov/study/NCT05004285","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05004285","kind":"trial","name":"Evaluate the Clinical Usefulness of [F-18]Florastamin PET/CT Imaging Diagnosis Compared to MRI Diagnosis","route":"/trials/nct05004285/","field":"links","label":"ClinicalTrials.gov NCT05004285"}],"archive":"https://web.archive.org/web/20250617141916/https://clinicaltrials.gov/study/NCT05004285"},{"url":"https://clinicaltrials.gov/study/NCT05063565","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05063565","kind":"trial","name":"TheraSphere With Durvalumab and Tremelimumab for HCC","route":"/trials/nct05063565/","field":"links","label":"ClinicalTrials.gov NCT05063565"}],"archive":"https://web.archive.org/web/20260325234958/https://clinicaltrials.gov/study/NCT05063565"},{"url":"https://clinicaltrials.gov/study/NCT05142696","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05142696","kind":"trial","name":"A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab","route":"/trials/nct05142696/","field":"links","label":"ClinicalTrials.gov NCT05142696"}],"archive":"https://web.archive.org/web/20260421125814/https://clinicaltrials.gov/study/NCT05142696"},{"url":"https://clinicaltrials.gov/study/NCT05153772","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/","field":"links","label":"ClinicalTrials.gov NCT05153772"},{"id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/","field":"links","label":"ClinicalTrials.gov NCT05153772: ALPHAMEDIX-02"}],"archive":"https://web.archive.org/web/20250416185812/https://clinicaltrials.gov/study/NCT05153772"},{"url":"https://clinicaltrials.gov/study/NCT05160051","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-68-fapi-46","kind":"drug","name":"Gallium-68 FAPI-46","route":"/drugs/ga-68-fapi-46/","field":"links","label":"ClinicalTrials.gov NCT05160051 (68Ga-FAPI-46 PET for imaging of FAP-expressing cancer)"}]},{"url":"https://clinicaltrials.gov/study/NCT05204927","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","field":"links","label":"ClinicalTrials.gov NCT05204927"},{"id":"eclipse-psma","kind":"trial","name":"ECLIPSE","route":"/trials/eclipse-psma/","field":"outcomes.source (Radiographic progression-free survival)"}],"archive":"https://web.archive.org/web/20260623190237/https://clinicaltrials.gov/study/NCT05204927"},{"url":"https://clinicaltrials.gov/study/NCT05219500","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05219500","kind":"trial","name":"Targeted Alpha Therapy With 225Actinium-Prostate Specific Membrane Antigen (PSMA)-I&T of Castration-resISTant Prostate Cancer (TATCIST).","route":"/trials/nct05219500/","field":"links","label":"ClinicalTrials.gov NCT05219500"}],"archive":"https://web.archive.org/web/20250515063746/https://clinicaltrials.gov/study/NCT05219500"},{"url":"https://clinicaltrials.gov/study/NCT05262855","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-fap-pancreatic-staging","kind":"opportunity","name":"FAP imaging to stop futile pancreatic surgery","route":"/opportunities/opp-fap-pancreatic-staging/","field":"links","label":"NCT05262855: [68Ga]FAPI-46 phase 2 in pancreatic cancer"}]},{"url":"https://clinicaltrials.gov/study/NCT05381103","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05381103","kind":"trial","name":"PSMA-PET to Guide Prostatectomy","route":"/trials/nct05381103/","field":"links","label":"ClinicalTrials.gov NCT05381103"}],"archive":"https://web.archive.org/web/20260411170224/https://clinicaltrials.gov/study/NCT05381103"},{"url":"https://clinicaltrials.gov/study/NCT05413850","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05413850","kind":"trial","name":"Anti-tumour Activity of (177Lu) rhPSMA-10.1 Injection","route":"/trials/nct05413850/","field":"links","label":"ClinicalTrials.gov NCT05413850"}],"archive":"https://web.archive.org/web/20260519185725/https://clinicaltrials.gov/study/NCT05413850"},{"url":"https://clinicaltrials.gov/study/NCT05459844","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05459844","kind":"trial","name":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","route":"/trials/nct05459844/","field":"links","label":"ClinicalTrials.gov NCT05459844"}],"archive":"https://web.archive.org/web/20250203001313/https://clinicaltrials.gov/study/NCT05459844"},{"url":"https://clinicaltrials.gov/study/NCT05477576","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","field":"dosing.source"},{"id":"action-1","kind":"trial","name":"ACTION-1","route":"/trials/action-1/","field":"links","label":"ClinicalTrials.gov NCT05477576"},{"id":"prrt-then-alpha-net","kind":"pairing","name":"Beta PRRT → alpha PRRT","route":"/pairings/prrt-then-alpha-net/","field":"links","label":"ClinicalTrials.gov NCT05477576: ACTION-1"},{"id":"alpha-therapy-roadmap","kind":"roadmap","name":"Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline","route":"/roadmaps/alpha-therapy-roadmap/","field":"links","label":"RayzeBio/ClinicalTrials.gov: ACTION-1 (NCT05477576)"}],"archive":"https://web.archive.org/web/20260121195415/https://clinicaltrials.gov/study/NCT05477576"},{"url":"https://clinicaltrials.gov/study/NCT05518903","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-68-fapi-46","kind":"drug","name":"Gallium-68 FAPI-46","route":"/drugs/ga-68-fapi-46/","field":"links","label":"ClinicalTrials.gov NCT05518903 (68Ga-FAPI-46 PET/CT for localised pancreatic ductal adenocarcinoma)"}]},{"url":"https://clinicaltrials.gov/study/NCT05547061","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05547061","kind":"trial","name":"A Phase 1/2 Clinical Trial to Evaluate the Safety, Tolerability, Dosimetry, and Anti-tumor Activity of Ga-68-NGUL / Lu-177-DGUL in Patients With Metastatic Castration-resistant Prostate Cancer (mCRPC) Refractory to Standard Therapy","route":"/trials/nct05547061/","field":"links","label":"ClinicalTrials.gov NCT05547061"}],"archive":"https://web.archive.org/web/20260604031745/https://clinicaltrials.gov/study/NCT05547061"},{"url":"https://clinicaltrials.gov/study/NCT05636618","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05636618","kind":"trial","name":"Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors","route":"/trials/nct05636618/","field":"links","label":"ClinicalTrials.gov NCT05636618"},{"id":"pb-212-vmt-alpha-net","kind":"drug","name":"Lead-212 VMT-alpha-NET","route":"/drugs/pb-212-vmt-alpha-net/","field":"links","label":"ClinicalTrials.gov: NCT05636618"}],"archive":"https://web.archive.org/web/20261007124949/https://clinicaltrials.gov/study/NCT05636618"},{"url":"https://clinicaltrials.gov/study/NCT05655312","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05655312","kind":"trial","name":"MC1R-targeted Alpha-particle Monotherapy and Combination Therapy Trial With Nivolumab in Adults With Advanced Melanoma","route":"/trials/nct05655312/","field":"links","label":"ClinicalTrials.gov NCT05655312"}],"archive":"https://web.archive.org/web/20261002182053/https://clinicaltrials.gov/study/NCT05655312"},{"url":"https://clinicaltrials.gov/study/NCT05658003","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05658003","kind":"trial","name":"A Study Evaluating [177Lu]Lu-PSMA-617 vs. a Change of Androgen Receptor-directed Therapy in Taxane Treatment Naive Chinese Male Patients With Progressive Metastatic Castrate Resistant Prostate Cancer","route":"/trials/nct05658003/","field":"links","label":"ClinicalTrials.gov NCT05658003"}],"archive":"https://web.archive.org/web/20250201050950/https://clinicaltrials.gov/study/NCT05658003"},{"url":"https://clinicaltrials.gov/study/NCT05675410","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pet-adapted-therapy","kind":"technology","name":"PET-adapted (response-adapted) therapy","route":"/technologies/pet-adapted-therapy/","field":"links","label":"ClinicalTrials.gov NCT05675410: AHOD2131 (COG / NCTN)"},{"id":"ahod2131","kind":"trial","name":"AHOD2131 (COG / NCTN)","route":"/trials/ahod2131/","field":"links","label":"ClinicalTrials.gov NCT05675410"}],"archive":"https://web.archive.org/web/20260916073334/https://clinicaltrials.gov/study/NCT05675410"},{"url":"https://clinicaltrials.gov/study/NCT05682443","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05682443","kind":"trial","name":"ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC","route":"/trials/nct05682443/","field":"links","label":"ClinicalTrials.gov NCT05682443"}],"archive":"https://web.archive.org/web/20260711080650/https://clinicaltrials.gov/study/NCT05682443"},{"url":"https://clinicaltrials.gov/study/NCT05706129","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05706129","kind":"trial","name":"A Study to Assess Safety, Tolerability and Imaging Characteristics of [68Ga]Ga-DPI-4452 and to Assess Safety, Tolerability, and Efficacy of [177Lu]Lu-DPI-4452 in Participants With Unresectable Locally Advanced or Metastatic Solid Tumors","route":"/trials/nct05706129/","field":"links","label":"ClinicalTrials.gov NCT05706129"}],"archive":"https://web.archive.org/web/20250325173426/https://clinicaltrials.gov/study/NCT05706129"},{"url":"https://clinicaltrials.gov/study/NCT05849298","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05849298","kind":"trial","name":"A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC","route":"/trials/nct05849298/","field":"links","label":"ClinicalTrials.gov NCT05849298"}],"archive":"https://web.archive.org/web/20260510181435/https://clinicaltrials.gov/study/NCT05849298"},{"url":"https://clinicaltrials.gov/study/NCT05884255","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05884255","kind":"trial","name":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","route":"/trials/nct05884255/","field":"links","label":"ClinicalTrials.gov NCT05884255"}],"archive":"https://web.archive.org/web/20251117121251/https://clinicaltrials.gov/study/NCT05884255"},{"url":"https://clinicaltrials.gov/study/NCT05936658","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05936658","kind":"trial","name":"[18F]Florastamin PET/CT Imaging Examination in Patients With Suspected Recurrent or Metastatic Prostate Cancer","route":"/trials/nct05936658/","field":"links","label":"ClinicalTrials.gov NCT05936658"}],"archive":"https://web.archive.org/web/20260515135848/https://clinicaltrials.gov/study/NCT05936658"},{"url":"https://clinicaltrials.gov/study/NCT05939414","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct05939414","kind":"trial","name":"An Open-label Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan Versus Observation in PSMA Positive OMPC.","route":"/trials/nct05939414/","field":"links","label":"ClinicalTrials.gov NCT05939414"}],"archive":"https://web.archive.org/web/20260825223727/https://clinicaltrials.gov/study/NCT05939414"},{"url":"https://clinicaltrials.gov/study/NCT06004661","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06004661","kind":"trial","name":"Study of Lutetium (177Lu) Vipivotide Tetraxetan in mCRPC Participants With Moderately and Severely Impaired and With Normal Renal Function","route":"/trials/nct06004661/","field":"links","label":"ClinicalTrials.gov NCT06004661"}],"archive":"https://web.archive.org/web/20260202092650/https://clinicaltrials.gov/study/NCT06004661"},{"url":"https://clinicaltrials.gov/study/NCT06040099","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06040099","kind":"trial","name":"A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat","route":"/trials/nct06040099/","field":"links","label":"ClinicalTrials.gov NCT06040099"},{"id":"tare-plus-durvalumab-hcc","kind":"pairing","name":"Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma","route":"/pairings/tare-plus-durvalumab-hcc/","field":"links","label":"ClinicalTrials.gov: NCT06040099 (EMERALD-Y90, TARE + durvalumab + bevacizumab)"}],"archive":"https://web.archive.org/web/20260118163225/https://www.clinicaltrials.gov/study/NCT06040099"},{"url":"https://clinicaltrials.gov/study/NCT06084806","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06084806","kind":"trial","name":"Test-retest Evaluation of [18F]F-AraG PET","route":"/trials/nct06084806/","field":"links","label":"ClinicalTrials.gov NCT06084806"}],"archive":"https://web.archive.org/web/20250202033347/https://clinicaltrials.gov/study/NCT06084806"},{"url":"https://clinicaltrials.gov/study/NCT06107374","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06107374","kind":"trial","name":"Imaging Advanced NSCLC Patients Undergoing PD-1/PD-L1 Directed Therapy Using [18F]-FARAG","route":"/trials/nct06107374/","field":"links","label":"ClinicalTrials.gov NCT06107374"}],"archive":"https://web.archive.org/web/20250203052347/https://clinicaltrials.gov/study/NCT06107374"},{"url":"https://clinicaltrials.gov/study/NCT06122584","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06122584","kind":"trial","name":"Diagnostic Performance of [18F]PSMA-1007 PET/CT Imaging in Patients With Newly-Diagnosed Prostate Cancer","route":"/trials/nct06122584/","field":"links","label":"ClinicalTrials.gov NCT06122584"}],"archive":"https://web.archive.org/web/20260214102643/https://clinicaltrials.gov/study/NCT06122584"},{"url":"https://clinicaltrials.gov/study/NCT06139575","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06139575","kind":"trial","name":"Phase 1/2 Clinical Study of Lutetium Lu 177 JH020002 Injection in Patients With Advanced Prostate Cancer","route":"/trials/nct06139575/","field":"links","label":"ClinicalTrials.gov NCT06139575"}],"archive":"https://web.archive.org/web/20250203155017/https://clinicaltrials.gov/study/NCT06139575"},{"url":"https://clinicaltrials.gov/study/NCT06147037","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ac-225-fpi-2068","kind":"drug","name":"Actinium-225 FPI-2068","route":"/drugs/ac-225-fpi-2068/","field":"links","label":"ClinicalTrials.gov: NCT06147037"}]},{"url":"https://clinicaltrials.gov/study/NCT06162988","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tpbg-5t4","kind":"target","name":"5T4 (trophoblast glycoprotein)","route":"/targets/tpbg-5t4/","field":"links","label":"ClinicalTrials.gov NCT06162988: PET imaging of 68Ga-NOTA-H006 in malignancy"}]},{"url":"https://clinicaltrials.gov/study/NCT06184035","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06184035","kind":"trial","name":"A Dose Escalation and Expansion Study of [177Lu]Lu-SN201 in Participants With Advanced Cancer","route":"/trials/nct06184035/","field":"links","label":"ClinicalTrials.gov NCT06184035"}],"archive":"https://web.archive.org/web/20260616222625/https://clinicaltrials.gov/study/NCT06184035"},{"url":"https://clinicaltrials.gov/study/NCT06216249","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-dosimetry-guided-dosing-standard","kind":"idea","name":"Kidney-dosimetry-guided dosing as the default for PSMA radioligand therapy","route":"/ideas/idea-dosimetry-guided-dosing-standard/","field":"links","label":"FLEX-MRT: Phase 2 Randomized Trial of Flexible Dosing Schedule of 177Lu-PSMA-617 (ClinicalTrials.gov, NCT06216249)"}]},{"url":"https://clinicaltrials.gov/study/NCT06222489","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-her3-imaging-crossover","kind":"opportunity","name":"HER3 imaging, and why three tracers stalled","route":"/opportunities/opp-her3-imaging-crossover/","field":"links","label":"NCT06222489: 89Zr-patritumab deruxtecan PET/CT"},{"id":"her3","kind":"target","name":"HER3 (ERBB3)","route":"/targets/her3/","field":"links","label":"NCT06222489: 89Zr-patritumab deruxtecan PET/CT"}]},{"url":"https://clinicaltrials.gov/study/NCT06235151","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06235151","kind":"trial","name":"Copper Cu 64 PSMA I&T PET Imaging in Men With Newly Diagnosed Prostate Cancer","route":"/trials/nct06235151/","field":"links","label":"ClinicalTrials.gov NCT06235151"}],"archive":"https://web.archive.org/web/20260519042146/https://clinicaltrials.gov/study/NCT06235151"},{"url":"https://clinicaltrials.gov/study/NCT06247995","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06247995","kind":"trial","name":"A Phase I/II, Dose Finding and Optimization Study of [177Lu]Lu-NeoB in Combination With Capecitabine in Patients With GRPR+, ER+, HER2- Metastatic Breast Cancer After Progression on Previous Endocrine Therapy in Combination With a CDK4/6 Inhibitor.","route":"/trials/nct06247995/","field":"links","label":"ClinicalTrials.gov NCT06247995"}],"archive":"https://web.archive.org/web/20250813013215/https://www.clinicaltrials.gov/study/NCT06247995"},{"url":"https://clinicaltrials.gov/study/NCT06298916","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06298916","kind":"trial","name":"64Cu-LNTH-1363S in Patients With Sarcoma or Gastrointestinal Tract Cancer","route":"/trials/nct06298916/","field":"links","label":"ClinicalTrials.gov NCT06298916"}],"archive":"https://web.archive.org/web/20260515144209/https://clinicaltrials.gov/study/NCT06298916"},{"url":"https://clinicaltrials.gov/study/NCT06359847","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06359847","kind":"trial","name":"Study of ST-1898 in Locally Advanced or Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer","route":"/trials/nct06359847/","field":"links","label":"ClinicalTrials.gov NCT06359847"}],"archive":"https://web.archive.org/web/20250204005742/https://clinicaltrials.gov/study/NCT06359847"},{"url":"https://clinicaltrials.gov/study/NCT06369831","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06369831","kind":"trial","name":"HER2 Targeted Molecular Imaging in mBC and Other Metastatic Solid Carcinomas Using 68Ga-ABS011","route":"/trials/nct06369831/","field":"links","label":"ClinicalTrials.gov NCT06369831"}],"archive":"https://web.archive.org/web/20251211162645/https://clinicaltrials.gov/study/NCT06369831"},{"url":"https://clinicaltrials.gov/study/NCT06383052","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06383052","kind":"trial","name":"A Phase 1/2 Study of 177Lu-NYM032 Injection in mCRPC","route":"/trials/nct06383052/","field":"links","label":"ClinicalTrials.gov NCT06383052"}],"archive":"https://web.archive.org/web/20250202055434/https://clinicaltrials.gov/study/NCT06383052"},{"url":"https://clinicaltrials.gov/study/NCT06383520","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-gpc3-hcc-china","kind":"opportunity","name":"GPC3 imaging of the indeterminate liver nodule, led from China","route":"/opportunities/opp-gpc3-hcc-china/","field":"links","label":"NCT06383520: GPC3-targeted PET imaging in hepatocellular carcinoma, Wuhan"}]},{"url":"https://clinicaltrials.gov/study/NCT06398444","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06398444","kind":"trial","name":"A Clinical Study of Lutetium[177Lu] Oxodotreotide Injection in Patients With Advanced Neuroendocrine Neoplasms","route":"/trials/nct06398444/","field":"links","label":"ClinicalTrials.gov NCT06398444"}],"archive":"https://web.archive.org/web/20250201123650/https://clinicaltrials.gov/study/NCT06398444"},{"url":"https://clinicaltrials.gov/study/NCT06402331","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alphabreak","kind":"trial","name":"AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)","route":"/trials/alphabreak/","field":"links","label":"ClinicalTrials.gov NCT06402331"},{"id":"beta-then-alpha","kind":"pairing","name":"Beta radioligand → alpha radioligand","route":"/pairings/beta-then-alpha/","field":"links","label":"ClinicalTrials.gov NCT06402331: AlphaBreak (FPI-2265) & AcTION (225Ac-PSMA-617)"}],"archive":"https://web.archive.org/web/20260508222214/https://clinicaltrials.gov/study/NCT06402331"},{"url":"https://clinicaltrials.gov/study/NCT06474806","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06474806","kind":"trial","name":"Safety and Diagnostic Performance of uPAR PET Imaging in Localised, Untreated Prostate Cancer","route":"/trials/nct06474806/","field":"links","label":"ClinicalTrials.gov NCT06474806"}],"archive":"https://web.archive.org/web/20250203141139/https://clinicaltrials.gov/study/NCT06474806"},{"url":"https://clinicaltrials.gov/study/NCT06504147","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06504147","kind":"trial","name":"A Study of Radspherin® in Patients With Primary Advanced Epithelial Cancer, With Peritoneal Metastasis That Are Homologous Recombination Proficient Scheduled to Undergo Neoadjuvant Chemotherapy and Interval Debulking Surgery","route":"/trials/nct06504147/","field":"links","label":"ClinicalTrials.gov NCT06504147"}],"archive":"https://web.archive.org/web/20250619071156/https://clinicaltrials.gov/study/NCT06504147"},{"url":"https://clinicaltrials.gov/study/NCT06505395","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06505395","kind":"trial","name":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","route":"/trials/nct06505395/","field":"links","label":"ClinicalTrials.gov NCT06505395"}],"archive":"https://web.archive.org/web/20251012151059/https://clinicaltrials.gov/study/NCT06505395"},{"url":"https://clinicaltrials.gov/study/NCT06520345","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06520345","kind":"trial","name":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","route":"/trials/nct06520345/","field":"links","label":"ClinicalTrials.gov NCT06520345"},{"id":"tlx-591","kind":"drug","name":"Lutetium-177 rosopatamab tetraxetan","route":"/drugs/tlx-591/","field":"links","label":"ClinicalTrials.gov: ProstACT Global (NCT06520345)"}],"archive":"https://web.archive.org/web/20260815070846/https://clinicaltrials.gov/study/NCT06520345"},{"url":"https://clinicaltrials.gov/study/NCT06549465","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06549465","kind":"trial","name":"Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)","route":"/trials/nct06549465/","field":"links","label":"ClinicalTrials.gov NCT06549465"}],"archive":"https://web.archive.org/web/20251118065505/https://clinicaltrials.gov/study/NCT06549465"},{"url":"https://clinicaltrials.gov/study/NCT06569420","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06569420","kind":"trial","name":"Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC","route":"/trials/nct06569420/","field":"links","label":"ClinicalTrials.gov NCT06569420"}],"archive":"https://web.archive.org/web/20250201173616/https://clinicaltrials.gov/study/NCT06569420"},{"url":"https://clinicaltrials.gov/study/NCT06590857","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06590857","kind":"trial","name":"Trial of 225Ac-DOTATATE (RYZ101) in Subjects With ER+, HER2-negative Unresectable or Metastatic Breast Cancer Expressing SSTRs.","route":"/trials/nct06590857/","field":"links","label":"ClinicalTrials.gov NCT06590857"}],"archive":"https://web.archive.org/web/20251110093658/https://www.clinicaltrials.gov/study/NCT06590857"},{"url":"https://clinicaltrials.gov/study/NCT06710756","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06710756","kind":"trial","name":"Lead-212 PSV359 Therapy for Patients With Solid Tumors","route":"/trials/nct06710756/","field":"links","label":"ClinicalTrials.gov NCT06710756"},{"id":"pb-212-psv359","kind":"drug","name":"Lead-212 PSV359","route":"/drugs/pb-212-psv359/","field":"links","label":"ClinicalTrials.gov NCT06710756: lead-212 PSV359 therapy for patients with solid tumours"}],"archive":"https://web.archive.org/web/20261008111047/https://clinicaltrials.gov/study/NCT06710756"},{"url":"https://clinicaltrials.gov/study/NCT06726161","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06726161","kind":"trial","name":"Study of the Theranostic Pair RYZ811 (Diagnostic) and RYZ801 (Therapeutic) to Identify and Treat Subjects With GPC3+ (Glypican-3) Unresectable HCC","route":"/trials/nct06726161/","field":"links","label":"ClinicalTrials.gov NCT06726161"}],"archive":"https://web.archive.org/web/20260209152105/https://clinicaltrials.gov/study/NCT06726161"},{"url":"https://clinicaltrials.gov/study/NCT06750419","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06750419","kind":"trial","name":"89Zr-TLX250 for PET/CT Imaging of ccRCC - ZIRCON-CP Study","route":"/trials/nct06750419/","field":"links","label":"ClinicalTrials.gov NCT06750419"}],"archive":"https://web.archive.org/web/20250710051623/https://clinicaltrials.gov/study/NCT06750419"},{"url":"https://clinicaltrials.gov/study/NCT06754085","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06754085","kind":"trial","name":"Study of 18F-Florastamin PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer","route":"/trials/nct06754085/","field":"links","label":"ClinicalTrials.gov NCT06754085"}],"archive":"https://web.archive.org/web/20260213130257/https://clinicaltrials.gov/study/NCT06754085"},{"url":"https://clinicaltrials.gov/study/NCT06777433","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06777433","kind":"trial","name":"Phase 2b Imaging Study of RAD101 in Participants With Suspected Recurrent Brain Metastases","route":"/trials/nct06777433/","field":"links","label":"ClinicalTrials.gov NCT06777433"}],"archive":"https://web.archive.org/web/20260707082813/https://clinicaltrials.gov/study/NCT06777433"},{"url":"https://clinicaltrials.gov/study/NCT06780670","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06780670","kind":"trial","name":"Open-label Study Comparing AAA817 Versus Standard of Care in the Treatment of Previously Treated PSMA-positive mCRPC Adults Who Have Disease Progressed on or After [177Lu]Lu-PSMA Targeted Therapy","route":"/trials/nct06780670/","field":"links","label":"ClinicalTrials.gov NCT06780670"}],"archive":"https://web.archive.org/web/20260429015600/https://clinicaltrials.gov/study/NCT06780670"},{"url":"https://clinicaltrials.gov/study/NCT06784752","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06784752","kind":"trial","name":"Study to Evaluate the Efficacy and Safety of [177Lu]Lu-DOTA-TATE in Patients With Grade 1 and Grade 2 Advanced GEP-NET","route":"/trials/nct06784752/","field":"links","label":"ClinicalTrials.gov NCT06784752"}],"archive":"https://web.archive.org/web/20260418011545/https://clinicaltrials.gov/study/NCT06784752"},{"url":"https://clinicaltrials.gov/study/NCT06855277","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06855277","kind":"trial","name":"Study Comparing AAA817+ARPI Versus Standard of Care in Adult Participants With PSMA-positive mCRPC","route":"/trials/nct06855277/","field":"links","label":"ClinicalTrials.gov NCT06855277"}],"archive":"https://web.archive.org/web/20260418070034/https://clinicaltrials.gov/study/NCT06855277"},{"url":"https://clinicaltrials.gov/study/NCT06860971","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06860971","kind":"trial","name":"A Study of AL2846 Capsule Versus Placebo in the Treatment of Advanced Radioiodine-Refractory Differentiated Thyroid Carcinoma","route":"/trials/nct06860971/","field":"links","label":"ClinicalTrials.gov NCT06860971"}],"archive":"https://web.archive.org/web/20260328044215/https://clinicaltrials.gov/study/NCT06860971"},{"url":"https://clinicaltrials.gov/study/NCT06894511","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06894511","kind":"trial","name":"An Open-label Study of Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI Versus AAA617 in PSMA Positive First-line mCRPC","route":"/trials/nct06894511/","field":"links","label":"ClinicalTrials.gov NCT06894511"}],"archive":"https://web.archive.org/web/20260617222740/https://clinicaltrials.gov/study/NCT06894511"},{"url":"https://clinicaltrials.gov/study/NCT06906471","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06906471","kind":"trial","name":"A Single-Arm, Blinded, Fluorescent PSMA Histopathology Trial of AS1986NS","route":"/trials/nct06906471/","field":"links","label":"ClinicalTrials.gov NCT06906471"}],"archive":"https://web.archive.org/web/20260929215203/https://clinicaltrials.gov/study/NCT06906471"},{"url":"https://clinicaltrials.gov/study/NCT06909825","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06909825","kind":"trial","name":"FPI-2265 (225Ac-PSMA-I&T) and Olaparib for Patients With Metastatic Castration-Resistant Prostate Cancer (mCRPC)","route":"/trials/nct06909825/","field":"links","label":"ClinicalTrials.gov NCT06909825"},{"id":"idea-rlt-plus-parp-inhibitor","kind":"idea","name":"Adding a PARP inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-parp-inhibitor/","field":"links","label":"FPI-2265 and Olaparib for Patients With mCRPC (ClinicalTrials.gov, NCT06909825)"}],"archive":"https://web.archive.org/web/20250612191529/https://clinicaltrials.gov/study/NCT06909825"},{"url":"https://clinicaltrials.gov/study/NCT06925581","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06925581","kind":"trial","name":"A Trial of HRS-6768 in Patients With Advanced Solid Tumors","route":"/trials/nct06925581/","field":"links","label":"ClinicalTrials.gov NCT06925581"}],"archive":"https://web.archive.org/web/20250619041614/https://clinicaltrials.gov/study/NCT06925581"},{"url":"https://clinicaltrials.gov/study/NCT06943495","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-dosimetry-guided-dosing-standard","kind":"idea","name":"Kidney-dosimetry-guided dosing as the default for PSMA radioligand therapy","route":"/ideas/idea-dosimetry-guided-dosing-standard/","field":"links","label":"PRODIGY-2: Personalized vs. Fixed-Activity 177Lu-PSMA-617 (ClinicalTrials.gov, NCT06943495)"}]},{"url":"https://clinicaltrials.gov/study/NCT06990880","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct06990880","kind":"trial","name":"A Study of GSK5458514 Administered Alone or In Combination With Other Anti-Cancer Agents in Participants With Prostate Cancer","route":"/trials/nct06990880/","field":"links","label":"ClinicalTrials.gov NCT06990880"}]},{"url":"https://clinicaltrials.gov/study/NCT07047118","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07047118","kind":"trial","name":"A Study of JSB462 (Luxdegalutamide) Plus Lutetium (177Lu) Vipivotide Tetraxetan in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)","route":"/trials/nct07047118/","field":"links","label":"ClinicalTrials.gov NCT07047118"}],"archive":"https://web.archive.org/web/20251207005732/https://clinicaltrials.gov/study/NCT07047118"},{"url":"https://clinicaltrials.gov/study/NCT07052214","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07052214","kind":"trial","name":"PSMA PET Combined With MRI for the Detection of PCa","route":"/trials/nct07052214/","field":"links","label":"ClinicalTrials.gov NCT07052214"}],"archive":"https://web.archive.org/web/20260616205803/https://clinicaltrials.gov/study/NCT07052214"},{"url":"https://clinicaltrials.gov/study/NCT07070349","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07070349","kind":"trial","name":"A Trial of HRS-6213 in Healthy Subjects and Patients With Solid Tumors","route":"/trials/nct07070349/","field":"links","label":"ClinicalTrials.gov NCT07070349"}]},{"url":"https://clinicaltrials.gov/study/NCT07129252","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07129252","kind":"trial","name":"A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors","route":"/trials/nct07129252/","field":"links","label":"ClinicalTrials.gov NCT07129252"}],"archive":"https://web.archive.org/web/20260611042703/https://clinicaltrials.gov/study/NCT07129252"},{"url":"https://clinicaltrials.gov/study/NCT07150715","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-alpha-for-oligometastatic-disease","kind":"idea","name":"Alpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer","route":"/ideas/idea-alpha-for-oligometastatic-disease/","field":"links","label":"ANDROMEDA: Alpha- or Beta-Emitting Radionuclide With Metastasis-Directed SBRT for Recurrent Oligometastatic Prostate Cancer (ClinicalTrials.gov, NCT07150715)"}]},{"url":"https://clinicaltrials.gov/study/NCT07150806","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"neuro-imaging-roadmap","kind":"roadmap","name":"Neuro-oncology imaging roadmap: FDG PET → amino acid PET → SSTR2 theranostics in meningioma","route":"/roadmaps/neuro-imaging-roadmap/","field":"links","label":"ClinicalTrials.gov: RYZ101 for progressive/recurrent intracranial meningioma (NCT07150806)"}]},{"url":"https://clinicaltrials.gov/study/NCT07164443","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mcrpc","kind":"trial","name":"A Study of Pasritamig With or Without JNJ-87189401 Versus Placebo for Late Line Metastatic Castration-resistant Prostate Cancer (mCRPC)","route":"/trials/mcrpc/","field":"links","label":"ClinicalTrials.gov NCT07164443"}],"archive":"https://web.archive.org/web/20260517210323/https://clinicaltrials.gov/study/NCT07164443"},{"url":"https://clinicaltrials.gov/study/NCT07189871","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07189871","kind":"trial","name":"177Lu-BetaBart in Patients With Relapsed/Refractory, Locally Advanced Inoperable, or Metastatic Solid Tumors","route":"/trials/nct07189871/","field":"links","label":"ClinicalTrials.gov NCT07189871"}],"archive":"https://web.archive.org/web/20260408141535/https://clinicaltrials.gov/study/NCT07189871"},{"url":"https://clinicaltrials.gov/study/NCT07197580","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07197580","kind":"trial","name":"Phase 3 Study to Assess Safety and Efficacy of 177Lu-TLX250 in Advanced Relapsed or Recurrent ccRCC","route":"/trials/nct07197580/","field":"links","label":"ClinicalTrials.gov NCT07197580"}]},{"url":"https://clinicaltrials.gov/study/NCT07217704","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07217704","kind":"trial","name":"Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Gastric or Esophageal Cancer.","route":"/trials/nct07217704/","field":"links","label":"ClinicalTrials.gov NCT07217704"}],"archive":"https://web.archive.org/web/20260929183312/https://clinicaltrials.gov/study/NCT07217704"},{"url":"https://clinicaltrials.gov/study/NCT07219238","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07219238","kind":"trial","name":"Study to Evaluate the Diagnostic Performance of GEH300079 (68Ga) Injection PET/CT for Detection of PC in Patients With Colorectal, Gastric, Ovarian, o","route":"/trials/nct07219238/","field":"links","label":"ClinicalTrials.gov NCT07219238"}],"archive":"https://web.archive.org/web/20260906070828/https://clinicaltrials.gov/study/NCT07219238"},{"url":"https://clinicaltrials.gov/study/NCT07226986","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07226986","kind":"trial","name":"A Phase Ib/II Open-label Study of AMO959 With Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) in Combination With ARPI in Adult Participants With PSMA","route":"/trials/nct07226986/","field":"links","label":"ClinicalTrials.gov NCT07226986"}],"archive":"https://web.archive.org/web/20260520045808/https://clinicaltrials.gov/study/NCT07226986"},{"url":"https://clinicaltrials.gov/study/NCT07258407","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07258407","kind":"trial","name":"A Clinical Trial Evaluating the Safety of TD001 In Patients With PSMA-Expressing Metastatic Prostate Cancer","route":"/trials/nct07258407/","field":"links","label":"ClinicalTrials.gov NCT07258407"}],"archive":"https://web.archive.org/web/20260114231132/https://clinicaltrials.gov/study/NCT07258407"},{"url":"https://clinicaltrials.gov/study/NCT07259213","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07259213","kind":"trial","name":"A Study of Terbium 161 (161Tb)-RAD402 in Participants With CRPC","route":"/trials/nct07259213/","field":"links","label":"ClinicalTrials.gov NCT07259213"}],"archive":"https://web.archive.org/web/20260414174845/https://clinicaltrials.gov/study/NCT07259213"},{"url":"https://clinicaltrials.gov/study/NCT07276789","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07276789","kind":"trial","name":"Efficacy and Safety of a Single Dose of LS301-IT for Fluorescence Intraoperative Molecular Imaging (IMI) for Patients Undergoing Lung Cancer Resection for Non Small Cell Lung Cancer","route":"/trials/nct07276789/","field":"links","label":"ClinicalTrials.gov NCT07276789"}],"archive":"https://web.archive.org/web/20260121071719/https://clinicaltrials.gov/study/NCT07276789"},{"url":"https://clinicaltrials.gov/study/NCT07278479","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07278479","kind":"trial","name":"Study of [212Pb]Pb-DOTAM-MAM279 ([212Pb]Pb-MP0712) in Patients With Small Cell Lung Cancer and Other DLL3 Expressing Solid Tumors","route":"/trials/nct07278479/","field":"links","label":"ClinicalTrials.gov NCT07278479"}],"archive":"https://web.archive.org/web/20260430051629/https://clinicaltrials.gov/study/NCT07278479"},{"url":"https://clinicaltrials.gov/study/NCT07311694","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07311694","kind":"trial","name":"A Phase III Study Comparing HRS-4357 With Novel Androgen Receptor Pathway Inhibitors in Patients With Progressive, PSMA-Positive Metastatic Castration-Resistant Prostate Cancer","route":"/trials/nct07311694/","field":"links","label":"ClinicalTrials.gov NCT07311694"}],"archive":"https://web.archive.org/web/20260120064939/https://clinicaltrials.gov/study/NCT07311694"},{"url":"https://clinicaltrials.gov/study/NCT07352345","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-gpc3-hcc-china","kind":"opportunity","name":"GPC3 imaging of the indeterminate liver nodule, led from China","route":"/opportunities/opp-gpc3-hcc-china/","field":"links","label":"NCT07352345: GPC3 PET against enhanced MRI, 150 patients"}]},{"url":"https://clinicaltrials.gov/study/NCT07357519","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07357519","kind":"trial","name":"Lu-TARGO (177Lu-TARGeted Osteosarcoma Therapy)","route":"/trials/nct07357519/","field":"links","label":"ClinicalTrials.gov NCT07357519"}],"archive":"https://web.archive.org/web/20260518055932/https://clinicaltrials.gov/study/NCT07357519"},{"url":"https://clinicaltrials.gov/study/NCT07432633","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07432633","kind":"trial","name":"[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07432633/","field":"links","label":"ClinicalTrials.gov NCT07432633"}],"archive":"https://web.archive.org/web/20260609152652/https://clinicaltrials.gov/study/NCT07432633"},{"url":"https://clinicaltrials.gov/study/NCT07567521","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07567521","kind":"trial","name":"A Study of TRC003 in the Treatment of Patients With Progressive PSMA-positive mCRPC","route":"/trials/nct07567521/","field":"links","label":"ClinicalTrials.gov NCT07567521"}]},{"url":"https://clinicaltrials.gov/study/NCT07590934","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07590934","kind":"trial","name":"Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer","route":"/trials/nct07590934/","field":"links","label":"ClinicalTrials.gov NCT07590934"}],"archive":"https://web.archive.org/web/20261008000250/https://clinicaltrials.gov/study/NCT07590934"},{"url":"https://clinicaltrials.gov/study/NCT07611110","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07611110","kind":"trial","name":"AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)","route":"/trials/nct07611110/","field":"links","label":"ClinicalTrials.gov NCT07611110"}],"archive":"https://web.archive.org/web/20261008064244/https://clinicaltrials.gov/study/NCT07611110"},{"url":"https://clinicaltrials.gov/study/NCT07615101","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07615101","kind":"trial","name":"Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.","route":"/trials/nct07615101/","field":"links","label":"ClinicalTrials.gov NCT07615101"}]},{"url":"https://clinicaltrials.gov/study/NCT07649122","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07649122","kind":"trial","name":"This Study Evaluates the Diagnostic Performance and Safety of 68Ga-NYM032 PET/CT Imaging in Patients With Suspected Recurrence of Prostate Cancer.","route":"/trials/nct07649122/","field":"links","label":"ClinicalTrials.gov NCT07649122"}]},{"url":"https://clinicaltrials.gov/study/NCT07677787","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-dll3-imaging-sclc","kind":"opportunity","name":"DLL3 imaging for small-cell lung cancer","route":"/opportunities/opp-dll3-imaging-sclc/","field":"links","label":"NCT07677787: DLL3-targeted PET/CT in small-cell lung cancer (gallium-68)"}]},{"url":"https://clinicaltrials.gov/study/NCT07691775","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07691775","kind":"trial","name":"A Study to Evaluate the Safety and Diagnostic Performance of F18 FBPA PET/CT Imaging in Solid Tumors","route":"/trials/nct07691775/","field":"links","label":"ClinicalTrials.gov NCT07691775"}]},{"url":"https://clinicaltrials.gov/study/NCT07702292","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nct07702292","kind":"trial","name":"[68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications","route":"/trials/nct07702292/","field":"links","label":"ClinicalTrials.gov NCT07702292"}]},{"url":"https://content.govdelivery.com/attachments/WADOH/2025/01/25/file_attachments/3142978/2025%20USP%20825%20Radiopharmaceuticals%20Addendum.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiopharmacy-term","kind":"term","name":"Radiopharmacy (practice and discipline)","route":"/terms/radiopharmacy-term/","field":"links","label":"2025 USP <825> Radiopharmaceuticals Addendum"}]},{"url":"https://daiichisankyo.us/press-releases/-/article/patritumab-deruxtecan-bla-submission-receives-complete-response-letter-from-fda-due-to-inspection-findings-at-third-party-manufacturer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-her3-imaging-crossover","kind":"opportunity","name":"HER3 imaging, and why three tracers stalled","route":"/opportunities/opp-her3-imaging-crossover/","field":"links","label":"Complete response letter for patritumab deruxtecan, June 2024"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"dosing.source"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Lymphocytes decreased)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Haemoglobin decreased)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Fatigue)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Dry mouth)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Nausea)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Decreased appetite)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"toxicity.source (Platelets decreased)"}],"archive":"https://web.archive.org/web/20260802152014/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=5f670c12-cca5-4d73-8a88-241f753d1bc7","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-67-citrate","kind":"drug","name":"Gallium citrate Ga-67","route":"/drugs/ga-67-citrate/","field":"links","label":"FDA label: Gallium Citrate Ga-67 Injection (DailyMed, Curium US LLC)"},{"id":"ga-67-citrate","kind":"drug","name":"Gallium citrate Ga-67","route":"/drugs/ga-67-citrate/","field":"dosing.source"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=61f00cb4-ea53-4ba6-a890-78586095d2f6","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"c-11","kind":"isotope","name":"Carbon-11","route":"/isotopes/c-11/","field":"links","label":"FDA label: Choline C 11 Injection (NDA 203155, approved 12 Sep 2012)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"dosing.source"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Lymphopenia)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (GGT increased)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Vomiting)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Nausea)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (AST increased)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (ALT increased)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Hyperglycaemia)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Hypokalaemia)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Myelodysplastic syndrome)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"toxicity.source (Acute leukaemia)"}],"archive":"https://web.archive.org/web/20260723153603/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72d1a024-00b7-418a-b36e-b2cb48f2ab55"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"dosing.source"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Nausea)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Fatigue)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Anaemia)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Vomiting)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Diarrhoea)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Leukopenia)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Neutropenia)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (MDS/AML)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Pneumonitis)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"toxicity.source (Venous thromboembolism (prostate))"}],"archive":"https://web.archive.org/web/20260915160451/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=741ff3e3-dc1a-45a6-84e5-2481b27131aa"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"dosing.source"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Pneumonitis (any cause, PACIFIC))"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Cough)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Fatigue)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Radiation pneumonitis)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Upper respiratory infection)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Dyspnoea)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"toxicity.source (Rash)"}],"archive":"https://web.archive.org/web/20260730195349/https://www.dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"dosing.source"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Hypothyroidism (immune-mediated))"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Pneumonitis (immune-mediated))"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Colitis (immune-mediated))"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Hepatitis (immune-mediated))"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Fatigue)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Musculoskeletal pain)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Rash)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Diarrhoea)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"toxicity.source (Pyrexia)"}],"archive":"https://web.archive.org/web/20260909142251/https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=9333c79b-d487-4538-a9f0-71b91a02b287"},{"url":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d867a881-108e-41fa-91ab-dc4df00cbb55","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-naf","kind":"drug","name":"Sodium fluoride F-18","route":"/drugs/f-18-naf/","field":"links","label":"FDA label: Sodium Fluoride F 18 Injection (DailyMed)"},{"id":"f-18-naf","kind":"drug","name":"Sodium fluoride F-18","route":"/drugs/f-18-naf/","field":"dosing.source"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=3bb6caf8-ac98-46c7-a9f0-961e66032705&type=display","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-cardiac-imaging","kind":"section","name":"Cardiac imaging","route":"/fronts/f-cardiac-imaging/","field":"links","label":"FLYRCADO prescribing information (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=5f670c12-cca5-4d73-8a88-241f753d1bc7","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-67","kind":"isotope","name":"Gallium-67","route":"/isotopes/ga-67/","field":"links","label":"DailyMed/FDA label: Gallium Citrate Ga 67"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=93d8f3b2-1216-41dc-a63d-0e812b33891d","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"in-111","kind":"isotope","name":"Indium-111","route":"/isotopes/in-111/","field":"links","label":"FDA/DailyMed label: OctreoScan (indium In 111 pentetreotide)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/getFile.cfm?setid=b3558f16-8f9a-4e55-8d9c-836427ebaa57&type=pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-flutemetamol","kind":"drug","name":"Flutemetamol F-18","route":"/drugs/f-18-flutemetamol/","field":"links","label":"FDA label: Vizamyl (flutemetamol F 18 injection)"},{"id":"f-18-flutemetamol","kind":"drug","name":"Flutemetamol F-18","route":"/drugs/f-18-flutemetamol/","field":"dosing.source"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Axumin","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=389a502e-a7d5-43dd-b6bf-f022ff23f3b9","checked":"2026-10-21","refs":[{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=capecitabine","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","field":"links","label":"US label (DailyMed)"}],"archive":"https://web.archive.org/web/20260117003823/https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Capecitabine"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Cerianna","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2c2a2df-cf3e-4a29-a033-231ed5a94b58","checked":"2026-10-21","refs":[{"id":"fluoroestradiol-f18","kind":"drug","name":"Fluoroestradiol F-18 (FES PET)","route":"/drugs/fluoroestradiol-f18/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=choline%20c%2011","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Detectnet","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=f898c8a7-beb7-4318-a8ea-6f058d69342b","checked":"2026-10-21","refs":[{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/","field":"links","label":"Label: Detectnet (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=dexrazoxane","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dexrazoxane","kind":"drug","name":"Dexrazoxane","route":"/drugs/dexrazoxane/","field":"links","label":"US label (DailyMed)"}],"archive":"https://web.archive.org/web/20260117033605/https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=DEXRAZOXANE"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=ibritumomab%20tiuxetan","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=25d367dc-da65-44c9-a844-1bf15339c285","checked":"2026-10-21","refs":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=iobenguane","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"iobenguane-i-131","kind":"drug","name":"Iobenguane I-131 (therapeutic)","route":"/drugs/iobenguane-i-131/","field":"links","label":"US label (DailyMed)"}],"archive":"https://web.archive.org/web/20250125012839/https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Iobenguane"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Lymphoseek","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=72f31b09-4d7b-475c-b37a-9daf2ad80240","checked":"2026-10-21","refs":[{"id":"tilmanocept-tc99m","kind":"drug","name":"Technetium-99m tilmanocept","route":"/drugs/tilmanocept-tc99m/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Netspot","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b2b3be70-17d8-4093-896c-f1c54a2cf242","checked":"2026-10-21","refs":[{"id":"ga68-dotatate","kind":"drug","name":"Gallium-68 DOTATATE (and Cu-64 DOTATATE)","route":"/drugs/ga68-dotatate/","field":"links","label":"Label: Netspot (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=Rituxan","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","field":"dosing.source"},{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","field":"toxicity.source (Infusion-related reactions (first infusion))"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=samarium","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=technetium%20tc%2099m%20sulfur%20colloid","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"technetium-sulfur-colloid","kind":"drug","name":"Technetium Tc-99m sulfur colloid","route":"/drugs/technetium-sulfur-colloid/","field":"links","label":"Label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?labeltype=all&query=thyrotropin%20alfa","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"thyrotropin-alfa","kind":"drug","name":"Thyrotropin alfa","route":"/drugs/thyrotropin-alfa/","field":"links","label":"US label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Abiraterone%20acetate","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cabazitaxel","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cabozantinib","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20240610053322/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Cabozantinib"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Docetaxel","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20240615025115/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=docetaxel"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Durvalumab","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8baba4ea-2855-42fa-9bd9-5a7548d4cec3","checked":"2026-10-21","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Enzalutamide","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b129fdc9-1d8e-425c-a5a9-8a2ed36dfbdf","checked":"2026-10-21","refs":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20210510050236/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Enzalutamide"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Everolimus","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20240615023453/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=everolimus"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Flotufolastat%20F-18","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=907ac4a4-a088-4826-ab50-cfc31985c9d4","checked":"2026-10-21","refs":[{"id":"flotufolastat","kind":"drug","name":"Flotufolastat F-18","route":"/drugs/flotufolastat/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Fludeoxyglucose%20F%2018","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fludeoxyglucose-f18","kind":"drug","name":"Fludeoxyglucose F-18 (FDG)","route":"/drugs/fludeoxyglucose-f18/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20220704003706/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=FLUDEOXYGLUCOSE%20F%2018"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Gallium-68%20gozetotide","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga68-psma-11","kind":"drug","name":"Gallium-68 gozetotide (PSMA-11)","route":"/drugs/ga68-psma-11/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Illuccix","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=d4643b31-9b4f-673f-e053-2a95a90a559d","checked":"2026-10-21","refs":[{"id":"illuccix","kind":"drug","name":"Illuccix (kit for Ga-68 gozetotide)","route":"/drugs/illuccix/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Locametz","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=8683b06e-4901-4526-89ad-23a8fe2d1331","checked":"2026-10-21","refs":[{"id":"locametz","kind":"drug","name":"Locametz (kit for Ga-68 gozetotide)","route":"/drugs/locametz/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lutetium-177%20dotatate","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Lutetium-177%20vipivotide%20tetraxetan","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=14908037-2892-4d98-a053-253ce35afb1a","checked":"2026-10-21","refs":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Olaparib","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20220707020350/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Olaparib"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Pembrolizumab","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Piflufolastat%20F-18","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Radioactive%20iodine","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Radium-223%20dichloride","status":200,"ok":true,"finalUrl":"https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a398400e-bd31-41a9-9696-4f7c06569ede","checked":"2026-10-21","refs":[{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","field":"links","label":"FDA label (DailyMed)"}]},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Rituximab","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20240301221502/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=rituximab"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sorafenib","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20230129083154/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=sorafenib"},{"url":"https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sunitinib","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","field":"links","label":"FDA label (DailyMed)"}],"archive":"https://web.archive.org/web/20250120144413/https://dailymed.nlm.nih.gov/dailymed/search.cfm?query=Sunitinib"},{"url":"https://datacommons.cancer.gov/repository/imaging-data-commons","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","route":"/collections/imaging-data-commons/","field":"links","label":"NCI CRDC: Imaging Data Commons overview"},{"id":"idea-open-dosimetry-data-commons","kind":"idea","name":"An open data commons linking patient-level radiopharmaceutical dosimetry to outcomes","route":"/ideas/idea-open-dosimetry-data-commons/","field":"links","label":"Imaging Data Commons (NCI Cancer Research Data Commons)"}]},{"url":"https://dctd.cancer.gov/drug-discovery-development/reagents-materials/imaging-ind-resources/documentation/flt-ib.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-fluorothymidine","kind":"drug","name":"Fluorothymidine F-18 (FLT)","route":"/drugs/f-18-fluorothymidine/","field":"links","label":"NCI Investigator's Brochure: [F-18]FLT, an investigational PET radiopharmaceutical"}]},{"url":"https://digitalcommons.wustl.edu/oa_4/3816","status":200,"ok":true,"finalUrl":"https://digitalcommons.wustl.edu/oa_4/3816/","checked":"2026-10-21","refs":[{"id":"delphine-chen","kind":"person","name":"Delphine L. Chen","route":"/people/delphine-chen/","field":"papers","label":"Pilot study: PARP1 imaging in advanced prostate cancer"}]},{"url":"https://digitalhealth.tu-dresden.de","status":200,"ok":true,"finalUrl":"https://digitalhealth.tu-dresden.de/","checked":"2026-10-21","refs":[{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","field":"links","label":"EKFZ for Digital Health"}],"archive":"https://web.archive.org/web/20260710143340/https://digitalhealth.tu-dresden.de/"},{"url":"https://doi.org/10.1007/s00259-007-0449-7","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s00259-007-0449-7","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"links","label":"18F-FLT and 18F-FDG uptake versus Ki-67 in NSCLC (Eur J Nucl Med Mol Imaging, 2007)"}]},{"url":"https://doi.org/10.1007/s00259-009-1297-4","status":200,"ok":true,"finalUrl":"https://link.springer.com/10.1007/s00259-009-1297-4","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"papers","label":"FDG PET and PET/CT: EANM procedure guidelines for tumour PET imaging: version 1.0"}]},{"url":"https://doi.org/10.1016/j.ejca.2008.10.026","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0959804908008733","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","field":"links","label":"European Journal of Cancer 2009: New response evaluation criteria in solid tumours, revised RECIST guideline (version 1.1)"}]},{"url":"https://doi.org/10.1016/j.euo.2018.03.010","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2588931118300191","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"papers","label":"Heterogeneous Flare in Prostate-specific Membrane Antigen Positron Emission Tomography Tracer Uptake with Initiation of Androgen Pathway Blockade in Metastatic Prostate Cancer"}]},{"url":"https://doi.org/10.1016/j.hoc.2015.09.002","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0889858815001379","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"papers","label":"Systemic Therapies for Advanced Gastrointestinal Carcinoid Tumors"}]},{"url":"https://doi.org/10.1016/j.prnil.2025.07.001","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S2287888225000625","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/","field":"links","label":"18F-florastamin PET/CT in men with clinical suspicion of prostate cancer (Prostate International, 2025)"}]},{"url":"https://doi.org/10.1016/j.radonc.2020.04.003","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0167814020301845","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/","field":"links","label":"Lievens et al., Defining oligometastatic disease from a radiation oncology perspective: an ESTRO-ASTRO consensus (Radiotherapy and Oncology 2020)"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)00817-X","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S014067361500817X","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/","field":"links","label":"RADIANT-4 (Lancet 2016)"},{"id":"radiant-3-4","kind":"trial","name":"RADIANT-3 and RADIANT-4","route":"/trials/radiant-3-4/","field":"outcomes.source (Progression-free survival (RADIANT-4))"}]},{"url":"https://doi.org/10.1016/S0140-6736(15)01037-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673615010375","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"James et al., Lancet 2016: addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE)"}]},{"url":"https://doi.org/10.1016/S0140-6736(18)32486-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673618324863","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"Parker et al., Lancet 2018: radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE)"}]},{"url":"https://doi.org/10.1016/S0140-6736(19)30650-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673619306506","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","field":"links","label":"Earl et al., 6 versus 12 months of adjuvant trastuzumab (PERSEPHONE, Lancet 2019)"},{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","field":"metrics (Six vs twelve months of adjuvant trastuzumab in HER2-positive breast cancer (PERSEPHONE): 4-year disease-free survival)"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)30314-7","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620303147","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"paper-propsma-hofman-lancet-2020","kind":"paper","name":"proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer","route":"/key-papers/paper-propsma-hofman-lancet-2020/","field":"links","label":"Lancet 2020"}]},{"url":"https://doi.org/10.1016/S0140-6736(20)31553-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673620315531","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","field":"papers","label":"RADICALS-RT: timing of radiotherapy after radical prostatectomy"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)00100-8","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621001008","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"Langley et al., Lancet 2021: transdermal oestradiol for androgen suppression in prostate cancer, long-term cardiovascular outcomes from PATCH"}]},{"url":"https://doi.org/10.1016/S0140-6736(21)02437-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673621024375","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"Attard et al., Lancet 2022: abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer (STAMPEDE)"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)01700-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623017002","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"idea-mced-plus-fapi","kind":"idea","name":"FAPI PET as the workup for MCED positives","route":"/ideas/idea-mced-plus-fapi/","field":"links","label":"PATHFINDER: the first prospective test of a multi-cancer blood test in people without symptoms (The Lancet 2023)"}]},{"url":"https://doi.org/10.1016/S0140-6736(23)02554-0","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673623025540","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","field":"links","label":"FIRSTMAPPP (Lancet 2024)"},{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/","field":"links","label":"FIRSTMAPPP (Lancet 2024)"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)00701-3","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624007013","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","field":"links","label":"NETTER-2 (Lancet 2024)"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"links","label":"NETTER-2 (Lancet 2024)"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)01315-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624013151","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"hd21","kind":"trial","name":"GHSG HD21","route":"/trials/hd21/","field":"outcomes.source (Treatment-related morbidity)"}]},{"url":"https://doi.org/10.1016/S0140-6736(24)01653-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673624016532","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"papers","label":"177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore)"}]},{"url":"https://doi.org/10.1016/S0140-6736(26)00604-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0140673626006045","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","field":"outcomes.source (Progression-free survival)"},{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","field":"outcomes.source (Overall survival (interim))"}]},{"url":"https://doi.org/10.1016/S1470-2045(16)30214-5","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204516302145","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"osteosarcoma","kind":"indication","name":"Osteosarcoma","route":"/indications/osteosarcoma/","field":"links","label":"EURAMOS-1 (Lancet Oncol 2016)"}]},{"url":"https://doi.org/10.1016/S1470-2045(17)30683-6","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204517306836","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"sarah-sirvenib","kind":"trial","name":"SARAH and SIRveNIB","route":"/trials/sarah-sirvenib/","field":"outcomes.source (Overall survival (SARAH))"}]},{"url":"https://doi.org/10.1016/s1470-2045(19)30415-2","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204519304152","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"papers","label":"18F-fluciclovine PET-CT and 68Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial"}]},{"url":"https://doi.org/10.1016/S1470-2045(23)00148-1","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204523001481","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"Attard et al., Lancet Oncology 2023: abiraterone plus prednisolone with or without enzalutamide for metastatic prostate cancer starting ADT (STAMPEDE)"}]},{"url":"https://doi.org/10.1016/S1470-2045(24)00402-9","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S1470204524004029","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"caix-pet","kind":"technology","name":"CAIX PET (89Zr-girentuximab)","route":"/technologies/caix-pet/","field":"links","label":"Shuch et al., ZIRCON: 89Zr-girentuximab PET-CT imaging of clear-cell renal cell carcinoma (Lancet Oncology 2024)"},{"id":"idea-caix-theranostics","kind":"idea","name":"CAIX theranostics: 89Zr-girentuximab PET and 177Lu/225Ac-girentuximab therapy","route":"/ideas/idea-caix-theranostics/","field":"links","label":"Shuch et al., ZIRCON: 89Zr-girentuximab PET-CT imaging of clear-cell renal cell carcinoma (Lancet Oncology 2024)"}]},{"url":"https://doi.org/10.1038/453840a","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2F453840a&code=2a8f6fde-4113-4ef1-9dc5-3b771fec6696","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"idea-fund-academic-radiopharma-pipeline","kind":"idea","name":"A university cyclotron network with shared regulatory files for new tracers","route":"/ideas/idea-fund-academic-radiopharma-pipeline/","field":"links","label":"Bottleneck evidence (The valley of death between lab and product): Butler, Translational research: crossing the valley of death (Nature 2008)"}]},{"url":"https://doi.org/10.1038/nm.4045","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nm.4045","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/","field":"links","label":"Beltran et al., Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer (Nat Med 2016)"}]},{"url":"https://doi.org/10.1038/nrc3162","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fnrc3162&code=76511bd6-e941-480f-a2d9-00189282b9a9","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"choline-metabolism-in-cancer","kind":"pathway","name":"Choline metabolism in cancer","route":"/pathways/choline-metabolism-in-cancer/","field":"links","label":"Review: Choline metabolism in malignant transformation"}]},{"url":"https://doi.org/10.1038/nrc4016","status":200,"ok":true,"finalUrl":"https://www.nature.com/articles/nrc4016","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/","field":"links","label":"Review: Emerging mechanisms of resistance to AR inhibitors in prostate cancer"}]},{"url":"https://doi.org/10.1038/s41591-018-0255-8","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-018-0255-8&code=37758023-66dc-4e8b-b070-3ed006ed9407","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"immuno-pet","kind":"technology","name":"Immuno-PET","route":"/technologies/immuno-pet/","field":"links","label":"Bensch et al., 89Zr-atezolizumab imaging as a non-invasive approach to assess clinical response to PD-L1 blockade (Nature Medicine 2018)"}]},{"url":"https://doi.org/10.1093/annonc/mdv577","status":200,"ok":true,"finalUrl":"https://linkinghub.elsevier.com/retrieve/pii/S0923753419357424","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"her2-pet","kind":"technology","name":"HER2 PET","route":"/technologies/her2-pet/","field":"links","label":"Gebhart et al., ZEPHIR: molecular imaging of heterogeneity in advanced HER2-positive breast cancer with 89Zr-trastuzumab PET (Annals of Oncology 2016)"}]},{"url":"https://doi.org/10.1172/JCI97992","status":200,"ok":true,"finalUrl":"https://www.jci.org/articles/view/97992","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"parp-pet","kind":"technology","name":"PARP PET","route":"/technologies/parp-pet/","field":"links","label":"Makvandi et al., A PET imaging agent for evaluating PARP-1 expression in ovarian cancer (Journal of Clinical Investigation 2018)"}]},{"url":"https://doi.org/10.2967/jnumed.116.183194","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/58/1/85","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"papers","label":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients"}]},{"url":"https://doi.org/10.2967/jnumed.117.193169","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/59/1/147","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"idea-mfbg-pet-replaces-mibg","kind":"idea","name":"18F-MFBG PET replacing 123I-MIBG scintigraphy","route":"/ideas/idea-mfbg-pet-replaces-mibg/","field":"links","label":"Pandit-Taskar et al., Biodistribution and dosimetry of 18F-meta-fluorobenzylguanidine: a first-in-human PET study (Journal of Nuclear Medicine 2017)"}]},{"url":"https://doi.org/10.2967/jnumed.118.217463","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/60/5/623","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019","kind":"paper","name":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma","route":"/key-papers/paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019/","field":"links","label":"J Nucl Med 2019"}]},{"url":"https://doi.org/10.2967/jnumed.119.226498","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/60/3/299","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"nuclear-medicine-hardware","kind":"technology","name":"Nuclear medicine and total-body PET hardware","route":"/technologies/nuclear-medicine-hardware/","field":"links","label":"Badawi et al., First human imaging studies with the EXPLORER total-body PET scanner (Journal of Nuclear Medicine 2019)"}]},{"url":"https://doi.org/10.2967/jnumed.119.227967","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/60/6/801","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"idea-fap-theranostics-pancancer","kind":"idea","name":"FAP theranostics as a pan-cancer stromal strategy","route":"/ideas/idea-fap-theranostics-pancancer/","field":"links","label":"Kratochwil et al., 68Ga-FAPI PET/CT: tracer uptake in 28 different kinds of cancer (Journal of Nuclear Medicine 2019)"}]},{"url":"https://doi.org/10.2967/jnumed.121.261982","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/62/10/1440","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"papers","label":"Prospective phase 2 trial of PSMA-targeted molecular RadiothErapy with (177)Lu-PSMA-617 for metastatic castration-reSISTant Prostate Cancer (RESIST-PC): efficacy results of the UCLA cohort"}]},{"url":"https://doi.org/10.2967/jnumed.121.262485","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/63/5/720","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"idea-cd8-pet-io","kind":"idea","name":"CD8 PET to stop or switch immunotherapy early","route":"/ideas/idea-cd8-pet-io/","field":"links","label":"Farwell et al., CD8-targeted PET imaging of tumour-infiltrating T cells in patients with cancer: a phase 1 first-in-human study of 89Zr-Df-IAB22M2C (Journal of Nuclear Medicine 2021)"}]},{"url":"https://doi.org/10.2967/jnumed.123.266806","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/65/4/527","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"links","label":"68Ga-FAPI-04 PET/CT in NSCLC: nodal metastasis and FAP expression (J Nucl Med, 2024)"}]},{"url":"https://doi.org/10.3348/kjr.2023.0411","status":200,"ok":true,"finalUrl":"https://kjronline.org/DOIx.php?id=10.3348/kjr.2023.0411","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"pexiretide-tc99m","kind":"drug","name":"Technetium (99mTc) pexiretide","route":"/drugs/pexiretide-tc99m/","field":"links","label":"99mTc-3PRGD2 SPECT/CT for diagnosing lymph node metastasis of primary malignant lung tumours (Korean Journal of Radiology, 2023)"}]},{"url":"https://doi.org/10.3389/fonc.2022.898764","status":200,"ok":true,"finalUrl":"https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.898764/full","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"pexiretide-tc99m","kind":"drug","name":"Technetium (99mTc) pexiretide","route":"/drugs/pexiretide-tc99m/","field":"links","label":"Advances in clinical oncology research on 99mTc-3PRGD2 SPECT imaging (Frontiers in Oncology, 2022)"}]},{"url":"https://eanm.org/news/release-of-the-2026-european-nuclear-medicine-guide-jan-2026/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"eanm-guidelines","kind":"collection","name":"EANM Guidelines","route":"/collections/eanm-guidelines/","field":"links","label":"EANM: Release of the 2026 European Nuclear Medicine Guide"}]},{"url":"https://eanm.org/publications/guidelines/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"eanm-guidelines","kind":"collection","name":"EANM Guidelines","route":"/collections/eanm-guidelines/","field":"links","label":"EANM: Guidelines"},{"id":"eanm-guidelines","kind":"collection","name":"EANM Guidelines","route":"/collections/eanm-guidelines/","field":"url"}]},{"url":"https://eanm.org/publications/guidelines/overview/dosimetry/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-dosimetry","kind":"section","name":"Dosimetry","route":"/fronts/f-dosimetry/","field":"links","label":"EANM dosimetry committee recommendations for 177Lu-labelled SSTR- and PSMA-targeting ligands"},{"id":"paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022","kind":"paper","name":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","route":"/key-papers/paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022/","field":"links","label":"EANM: dosimetry guidelines overview"}]},{"url":"https://eanm.org/publications/guidelines/overview/inflammation-infection/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-infection-imaging","kind":"section","name":"Infection & inflammation imaging","route":"/fronts/f-infection-imaging/","field":"links","label":"EANM: Inflammation/Infection guideline overview page"}]},{"url":"https://eanm.org/publications/useful-resources/nuclear-medicine-guide/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"eanm-guidelines","kind":"collection","name":"EANM Guidelines","route":"/collections/eanm-guidelines/","field":"links","label":"EANM: European Nuclear Medicine Guide"}]},{"url":"https://eanm.org/the-eanm-community/organisation/board/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","field":"links","label":"Society page"},{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","field":"profiles","label":"Society page"}]},{"url":"https://eanm.org/wp-content/uploads/2024/06/EANM_2019_TechGuide.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiochemical-purity","kind":"term","name":"Radiochemical purity (RCP)","route":"/terms/radiochemical-purity/","field":"links","label":"EANM 2019 technologist guide: radiopharmacy, an update"}]},{"url":"https://eanm.org/wp-content/uploads/2024/06/EANM22_TechGuide.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"spect-dosimetry-workflow","kind":"technology","name":"SPECT dosimetry workflow for radionuclide therapy","route":"/technologies/spect-dosimetry-workflow/","field":"links","label":"EANM: Radionuclide therapy management technologist guide"}]},{"url":"https://eanm.org/wp-content/uploads/2025/02/EANM-Reply-to-the-public-consultation-on-the-European-Medicines-Agency-Concept-paper-on-clinical-evaluation-of-therapeutic-radiopharmaceuticals-in-oncology.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-dosimetry-standardisation","kind":"bottleneck","name":"Dosimetry standardisation for radioligand therapy","route":"/bottlenecks/b-dosimetry-standardisation/","field":"links","label":"EANM reply to EMA consultation on clinical evaluation of therapeutic radiopharmaceuticals (Jan 2025)"},{"id":"f-dosimetry","kind":"section","name":"Dosimetry","route":"/fronts/f-dosimetry/","field":"links","label":"EANM reply to EMA concept paper on clinical evaluation of therapeutic radiopharmaceuticals (Jan 2025)"}]},{"url":"https://ec.europa.eu/health/documents/community-register/2020/20200211147169/anx_147169_en.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rituximab-then-ibritumomab-tiuxetan","kind":"pairing","name":"Rituximab pretreatment before ibritumomab tiuxetan (Zevalin)","route":"/pairings/rituximab-then-ibritumomab-tiuxetan/","field":"links","label":"EMA product information: Zevalin (rituximab pretreatment rationale and dosing)"}]},{"url":"https://education.nccn.org/sites/default/files/course/2023-02/2_Neoadjuvant.Adjuvant%20Treatment_NCCNbc23_v2.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"standardOfCare.guideline (Residual disease after neoadjuvant chemotherapy (non-pCR))"}]},{"url":"https://ejnmmipharmchem.springeropen.com/articles/10.1186/s41181-024-00258-y","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s41181-024-00258-y","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"zr-89","kind":"isotope","name":"Zirconium-89","route":"/isotopes/zr-89/","field":"links","label":"EJNMMI Radiopharmacy & Chemistry: good practices for 89Zr production"}]},{"url":"https://ejnmmiphys.springeropen.com/articles/10.1186/s40658-021-00405-3","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s40658-021-00405-3","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"quantitative-spect","kind":"technology","name":"Quantitative SPECT","route":"/technologies/quantitative-spect/","field":"links","label":"Optimisation of SPECT/CT imaging protocols for quantitative accuracy (EJNMMI Physics 2021)"}]},{"url":"https://ejnmmires.springeropen.com/articles/10.1186/s13550-024-01164-9","status":200,"ok":true,"finalUrl":"https://link.springer.com/article/10.1186/s13550-024-01164-9","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"upar","kind":"target","name":"uPAR (urokinase plasminogen activator receptor)","route":"/targets/upar/","field":"links","label":"EJNMMI Research: phase 2 trial of 68Ga-NOTA-AE105 uPAR PET in glioma, survival correlation"}]},{"url":"https://en.cnnc.com.cn/2026-02/13/c_1164555.htm","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hta-atom-hi-tech","kind":"company","name":"HTA (Atom Hi-Tech)","route":"/companies/hta-atom-hi-tech/","field":"links","label":"CNNC: China achieves large-scale production of Germanium-68 (HTA, February 2026)"}]},{"url":"https://en.edaily.co.kr/news/eda202608205175/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/","field":"links","label":"First sales, with the 30 April 2026 approval date (Edaily, English)"}]},{"url":"https://en.sedaily.com/finance/2026/05/04/futurechem-wins-approval-for-koreas-first-prostate-cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/","field":"links","label":"FutureChem wins approval for Korea's first prostate cancer diagnostic (Seoul Economic Daily, English)"},{"id":"florastamin-f18","kind":"drug","name":"Florastamin F-18","route":"/drugs/florastamin-f18/","field":"regulatoryEvents.source (2026-04-30)"}]},{"url":"https://en.wikipedia.org/wiki/Abiraterone_acetate","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"abiraterone","kind":"drug","name":"Abiraterone acetate","route":"/drugs/abiraterone/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260730232219/https://en.wikipedia.org/wiki/Abiraterone_acetate"},{"url":"https://en.wikipedia.org/wiki/Actinium-225","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/","field":"links","label":"Wikipedia"}],"archive":"https://web.archive.org/web/20260701130813/https://en.wikipedia.org/wiki/Actinium-225"},{"url":"https://en.wikipedia.org/wiki/All_India_Institute_of_Medical_Sciences,_Delhi","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260921085132/https://en.wikipedia.org/wiki/All_India_Institute_of_Medical_Sciences,_Delhi"},{"url":"https://en.wikipedia.org/wiki/Anemia","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","field":"links","label":"Wikipedia"},{"id":"anaemia","kind":"term","name":"Anaemia","route":"/terms/anaemia/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261003040657/https://en.wikipedia.org/wiki/Anemia"},{"url":"https://en.wikipedia.org/wiki/Antiandrogen","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"arpi","kind":"term","name":"Androgen receptor pathway inhibitor (ARPI)","route":"/terms/arpi/","field":"links","label":"Wikipedia"},{"id":"arpi","kind":"term","name":"Androgen receptor pathway inhibitor (ARPI)","route":"/terms/arpi/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261001040742/https://en.wikipedia.org/wiki/Antiandrogen"},{"url":"https://en.wikipedia.org/wiki/Antibody-drug_conjugate","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/","field":"links","label":"Wikipedia"},{"id":"payload","kind":"term","name":"Payload (ADC)","route":"/terms/payload/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261005055015/https://en.wikipedia.org/wiki/Antibody-drug_conjugate"},{"url":"https://en.wikipedia.org/wiki/Antigen","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/","field":"links","label":"Wikipedia"},{"id":"antigen","kind":"term","name":"Antigen","route":"/terms/antigen/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261004231943/https://en.wikipedia.org/wiki/Antigen"},{"url":"https://en.wikipedia.org/wiki/Astatine","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/","field":"links","label":"Wikipedia"},{"id":"astatine-211-alpha-therapy","kind":"technology","name":"Astatine-211 alpha therapy","route":"/technologies/astatine-211-alpha-therapy/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260921083419/https://en.wikipedia.org/wiki/Astatine"},{"url":"https://en.wikipedia.org/wiki/AstraZeneca","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"astrazeneca","kind":"company","name":"AstraZeneca","route":"/companies/astrazeneca/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260918184329/https://en.wikipedia.org/wiki/AstraZeneca"},{"url":"https://en.wikipedia.org/wiki/Bayer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bayer","kind":"company","name":"Bayer","route":"/companies/bayer/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260919122355/https://en.wikipedia.org/wiki/Bayer"},{"url":"https://en.wikipedia.org/wiki/Becquerel","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"becquerel-curie","kind":"term","name":"Becquerel and curie (units of radioactivity)","route":"/terms/becquerel-curie/","field":"links","label":"BIPM/Wikipedia: becquerel, SI unit of activity"}]},{"url":"https://en.wikipedia.org/wiki/Biochemical_recurrence","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prostate-bcr","kind":"indication","name":"Biochemical recurrence of prostate cancer","route":"/indications/prostate-bcr/","field":"links","label":"Wikipedia"},{"id":"prostate-bcr","kind":"indication","name":"Biochemical recurrence of prostate cancer","route":"/indications/prostate-bcr/","field":"wikipedia"},{"id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","field":"links","label":"Wikipedia"},{"id":"biochemical-recurrence","kind":"term","name":"Biochemical recurrence (BCR)","route":"/terms/biochemical-recurrence/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260207092109/https://en.wikipedia.org/wiki/Biochemical_recurrence"},{"url":"https://en.wikipedia.org/wiki/Bioconjugation","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/","field":"links","label":"Wikipedia"},{"id":"site-specific-conjugation","kind":"technology","name":"Site-specific conjugation & linker chemistry","route":"/technologies/site-specific-conjugation/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260901123900/https://en.wikipedia.org/wiki/Bioconjugation"},{"url":"https://en.wikipedia.org/wiki/Biological_half-life","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/","field":"links","label":"Wikipedia"},{"id":"half-life","kind":"term","name":"Half-life","route":"/terms/half-life/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261002211547/https://en.wikipedia.org/wiki/Biological_half-life"},{"url":"https://en.wikipedia.org/wiki/Bone_marrow","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bone-marrow","kind":"term","name":"Bone marrow","route":"/terms/bone-marrow/","field":"links","label":"Wikipedia"},{"id":"bone-marrow","kind":"term","name":"Bone marrow","route":"/terms/bone-marrow/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261001182225/https://en.wikipedia.org/wiki/Bone_marrow"},{"url":"https://en.wikipedia.org/wiki/Bone_metastasis","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","field":"links","label":"Wikipedia"},{"id":"bone-metastases","kind":"term","name":"Bone metastases and skeletal-related events","route":"/terms/bone-metastases/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260414005945/https://en.wikipedia.org/wiki/Bone_metastasis"},{"url":"https://en.wikipedia.org/wiki/Boston_Scientific","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260820033416/https://en.wikipedia.org/wiki/Boston_Scientific"},{"url":"https://en.wikipedia.org/wiki/Brachytherapy#Prostate_cancer","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Brachytherapy","checked":"2026-10-21","refs":[{"id":"ldr-seed-brachytherapy","kind":"technology","name":"Low-dose-rate seed brachytherapy","route":"/technologies/ldr-seed-brachytherapy/","field":"links","label":"Wikipedia"}],"archive":"https://web.archive.org/web/20260908114223/https://en.wikipedia.org/wiki/Brachytherapy"},{"url":"https://en.wikipedia.org/wiki/Bristol_Myers_Squibb","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260919233612/https://en.wikipedia.org/wiki/Bristol_Myers_Squibb"},{"url":"https://en.wikipedia.org/wiki/Cabazitaxel","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cabazitaxel","kind":"drug","name":"Cabazitaxel","route":"/drugs/cabazitaxel/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260806002559/https://en.wikipedia.org/wiki/Cabazitaxel"},{"url":"https://en.wikipedia.org/wiki/Cabozantinib","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260528231937/https://en.wikipedia.org/wiki/Cabozantinib"},{"url":"https://en.wikipedia.org/wiki/Canon_Medical_Systems_Corporation","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","route":"/companies/canon-medical/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260829034359/https://en.wikipedia.org/wiki/Canon_Medical_Systems_Corporation"},{"url":"https://en.wikipedia.org/wiki/Capecitabine","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260829030405/https://en.wikipedia.org/wiki/Capecitabine"},{"url":"https://en.wikipedia.org/wiki/Carcinoembryonic_antigen","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","field":"links","label":"Wikipedia"},{"id":"ceacam5","kind":"target","name":"CEACAM5","route":"/targets/ceacam5/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260803213316/https://en.wikipedia.org/wiki/Carcinoembryonic_antigen"},{"url":"https://en.wikipedia.org/wiki/Castration-resistant_prostate_cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/","field":"links","label":"Wikipedia"},{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/","field":"wikipedia"},{"id":"prostate-nmcrpc","kind":"indication","name":"Non-metastatic castration-resistant prostate cancer","route":"/indications/prostate-nmcrpc/","field":"links","label":"Wikipedia"},{"id":"prostate-nmcrpc","kind":"indication","name":"Non-metastatic castration-resistant prostate cancer","route":"/indications/prostate-nmcrpc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260501200928/https://en.wikipedia.org/wiki/Castration-resistant_prostate_cancer"},{"url":"https://en.wikipedia.org/wiki/CD20","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","field":"links","label":"Wikipedia"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","field":"wikipedia"},{"id":"cd20","kind":"target","name":"CD20","route":"/targets/cd20/","field":"prevalence.source"}],"archive":"https://web.archive.org/web/20260731200408/https://en.wikipedia.org/wiki/CD20"},{"url":"https://en.wikipedia.org/wiki/CD276","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","field":"links","label":"Wikipedia"},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","field":"wikipedia"},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","field":"prevalence.source"},{"id":"b7h3","kind":"target","name":"B7-H3","route":"/targets/b7h3/","field":"prevalence.source"}],"archive":"https://web.archive.org/web/20251224040940/https://en.wikipedia.org/wiki/CD276"},{"url":"https://en.wikipedia.org/wiki/Choline_C-11","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","field":"links","label":"Wikipedia"},{"id":"choline-c11","kind":"drug","name":"Choline C-11","route":"/drugs/choline-c11/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Colorectal_cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Crossover_study","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"crossover","kind":"term","name":"Crossover in trials","route":"/terms/crossover/","field":"links","label":"Wikipedia"},{"id":"crossover","kind":"term","name":"Crossover in trials","route":"/terms/crossover/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260930222209/https://en.wikipedia.org/wiki/Crossover_study"},{"url":"https://en.wikipedia.org/wiki/CT_scan","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/","field":"links","label":"Wikipedia"},{"id":"ct","kind":"technology","name":"CT (computed tomography)","route":"/technologies/ct/","field":"wikipedia"},{"id":"medical-imaging-scanner-manufacturing","kind":"technology","name":"CT, MRI and PET scanner manufacturing","route":"/technologies/medical-imaging-scanner-manufacturing/","field":"links","label":"Wikipedia"}],"archive":"https://web.archive.org/web/20260912235804/https://en.wikipedia.org/wiki/CT_scan"},{"url":"https://en.wikipedia.org/wiki/Curie_(unit)","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"becquerel-curie","kind":"term","name":"Becquerel and curie (units of radioactivity)","route":"/terms/becquerel-curie/","field":"links","label":"Wikipedia: curie, definition and conversion to becquerels"}]},{"url":"https://en.wikipedia.org/wiki/CXCR4","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cxcr4","kind":"target","name":"CXCR4","route":"/targets/cxcr4/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260902075857/https://en.wikipedia.org/wiki/CXCR4"},{"url":"https://en.wikipedia.org/wiki/Dexrazoxane","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dexrazoxane","kind":"drug","name":"Dexrazoxane","route":"/drugs/dexrazoxane/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260512161049/https://en.wikipedia.org/wiki/Dexrazoxane"},{"url":"https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/","field":"links","label":"Wikipedia"},{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260904150511/https://en.wikipedia.org/wiki/Diffuse_large_B-cell_lymphoma"},{"url":"https://en.wikipedia.org/wiki/DLL3","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","field":"links","label":"Wikipedia"},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","field":"wikipedia"},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","field":"prevalence.source"},{"id":"dll3","kind":"target","name":"DLL3","route":"/targets/dll3/","field":"prevalence.source"}],"archive":"https://web.archive.org/web/20251125183306/https://en.wikipedia.org/wiki/DLL3"},{"url":"https://en.wikipedia.org/wiki/Docetaxel","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"docetaxel","kind":"drug","name":"Docetaxel","route":"/drugs/docetaxel/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260902123220/https://en.wikipedia.org/wiki/Docetaxel"},{"url":"https://en.wikipedia.org/wiki/Donafenib","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260203080939/https://en.wikipedia.org/wiki/Donafenib"},{"url":"https://en.wikipedia.org/wiki/Dosimetry","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"in-vivo-dosimetry","kind":"technology","name":"In vivo dosimetry and patient-specific quality assurance","route":"/technologies/in-vivo-dosimetry/","field":"links","label":"Wikipedia"},{"id":"radioligand-dosimetry","kind":"technology","name":"Radioligand dosimetry","route":"/technologies/radioligand-dosimetry/","field":"links","label":"Wikipedia"},{"id":"radioligand-dosimetry","kind":"technology","name":"Radioligand dosimetry","route":"/technologies/radioligand-dosimetry/","field":"wikipedia"},{"id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/","field":"links","label":"Wikipedia"},{"id":"dosimetry","kind":"term","name":"Dosimetry","route":"/terms/dosimetry/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260829065956/https://en.wikipedia.org/wiki/Dosimetry"},{"url":"https://en.wikipedia.org/wiki/DOTA-TATE","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/","field":"links","label":"Wikipedia"},{"id":"sstr-pet","kind":"technology","name":"Somatostatin receptor PET (68Ga/64Cu-DOTATATE)","route":"/technologies/sstr-pet/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260802224410/https://en.wikipedia.org/wiki/DOTA-TATE"},{"url":"https://en.wikipedia.org/wiki/Durvalumab","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20251009035731/https://en.wikipedia.org/wiki/Durvalumab"},{"url":"https://en.wikipedia.org/wiki/Effective_half-life","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"effective-half-life","kind":"term","name":"Effective half-life","route":"/terms/effective-half-life/","field":"links","label":"Wikipedia: effective half-life, derivation and formula"}]},{"url":"https://en.wikipedia.org/wiki/Enzalutamide","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"enzalutamide","kind":"drug","name":"Enzalutamide","route":"/drugs/enzalutamide/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260731221112/https://en.wikipedia.org/wiki/Enzalutamide"},{"url":"https://en.wikipedia.org/wiki/Estimand","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"estimand","kind":"term","name":"Estimands and intercurrent events (ICH E9(R1))","route":"/terms/estimand/","field":"links","label":"Wikipedia"},{"id":"estimand","kind":"term","name":"Estimands and intercurrent events (ICH E9(R1))","route":"/terms/estimand/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20251026145445/https://en.wikipedia.org/wiki/Estimand"},{"url":"https://en.wikipedia.org/wiki/Everolimus","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"everolimus","kind":"drug","name":"Everolimus","route":"/drugs/everolimus/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260906150714/https://en.wikipedia.org/wiki/Everolimus"},{"url":"https://en.wikipedia.org/wiki/Fibroblast_activation_protein,_alpha","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/","field":"links","label":"Wikipedia"},{"id":"fapi-pet","kind":"technology","name":"FAPI PET","route":"/technologies/fapi-pet/","field":"wikipedia"},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","field":"links","label":"Wikipedia"},{"id":"fap","kind":"target","name":"FAP","route":"/targets/fap/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260311144306/https://en.wikipedia.org/wiki/Fibroblast_activation_protein,_alpha"},{"url":"https://en.wikipedia.org/wiki/Fluciclovine_(18F)","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fluciclovine-f18","kind":"drug","name":"Fluciclovine F-18","route":"/drugs/fluciclovine-f18/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260607221409/https://en.wikipedia.org/wiki/Fluciclovine_(18F)"},{"url":"https://en.wikipedia.org/wiki/Fludeoxyglucose_(18F)","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/","field":"links","label":"Wikipedia"},{"id":"fdg-pet","kind":"technology","name":"FDG PET","route":"/technologies/fdg-pet/","field":"wikipedia"},{"id":"fludeoxyglucose-f18","kind":"drug","name":"Fludeoxyglucose F-18 (FDG)","route":"/drugs/fludeoxyglucose-f18/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260902191619/https://en.wikipedia.org/wiki/Fludeoxyglucose_%2818F%29"},{"url":"https://en.wikipedia.org/wiki/Fluorine-18","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/","field":"links","label":"Wikipedia"}],"archive":"https://web.archive.org/web/20260902191619/https://en.wikipedia.org/wiki/Fluorine-18"},{"url":"https://en.wikipedia.org/wiki/Fluoroestradiol_F-18","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fes-pet","kind":"technology","name":"FES PET (oestrogen receptor imaging)","route":"/technologies/fes-pet/","field":"links","label":"Wikipedia: Fluoroestradiol F-18"},{"id":"fluoroestradiol-f18","kind":"drug","name":"Fluoroestradiol F-18 (FES PET)","route":"/drugs/fluoroestradiol-f18/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20250530004138/https://en.wikipedia.org/wiki/Fluoroestradiol_F-18"},{"url":"https://en.wikipedia.org/wiki/Folate_receptor_1","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","field":"links","label":"Wikipedia"},{"id":"folr1","kind":"target","name":"Folate receptor alpha","route":"/targets/folr1/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260109170430/https://en.wikipedia.org/wiki/Folate_receptor_1"},{"url":"https://en.wikipedia.org/wiki/Follicular_lymphoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"follicular-lymphoma","kind":"indication","name":"Follicular lymphoma","route":"/indications/follicular-lymphoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260907192533/https://en.wikipedia.org/wiki/Follicular_lymphoma"},{"url":"https://en.wikipedia.org/wiki/Gallium-68_generator","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ge-68","kind":"isotope","name":"Germanium-68","route":"/isotopes/ge-68/","field":"links","label":"Wikipedia: gallium-68 generator (68Ge production routes)"}]},{"url":"https://en.wikipedia.org/wiki/Gastrin-releasing_peptide_receptor","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","field":"links","label":"Wikipedia"},{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260718002043/https://en.wikipedia.org/wiki/Gastrin-releasing_peptide_receptor"},{"url":"https://en.wikipedia.org/wiki/GE_HealthCare","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ge-healthcare","kind":"company","name":"GE HealthCare","route":"/companies/ge-healthcare/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260917002348/https://en.wikipedia.org/wiki/GE_HealthCare"},{"url":"https://en.wikipedia.org/wiki/Glioblastoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"glioblastoma","kind":"indication","name":"Glioma & glioblastoma","route":"/indications/glioblastoma/","field":"links","label":"Wikipedia"},{"id":"glioblastoma","kind":"indication","name":"Glioma & glioblastoma","route":"/indications/glioblastoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260921124858/https://en.wikipedia.org/wiki/Glioblastoma"},{"url":"https://en.wikipedia.org/wiki/Glutamate_carboxypeptidase_II","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","field":"links","label":"Wikipedia"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260704161725/https://en.wikipedia.org/wiki/Glutamate_carboxypeptidase_II"},{"url":"https://en.wikipedia.org/wiki/Glypican_3","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/","field":"links","label":"Wikipedia"},{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/","field":"wikipedia"},{"id":"gpc3","kind":"target","name":"Glypican-3","route":"/targets/gpc3/","field":"prevalence.source"}],"archive":"https://web.archive.org/web/20260703182421/https://en.wikipedia.org/wiki/Glypican_3"},{"url":"https://en.wikipedia.org/wiki/Gray_(unit)","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gray-unit","kind":"term","name":"Gray unit (Gy)","route":"/terms/gray-unit/","field":"links","label":"Wikipedia"},{"id":"gray-unit","kind":"term","name":"Gray unit (Gy)","route":"/terms/gray-unit/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261007012952/https://en.wikipedia.org/wiki/Gray_%28unit%29"},{"url":"https://en.wikipedia.org/wiki/Hamamatsu_Photonics","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260829010324/https://en.wikipedia.org/wiki/Hamamatsu_Photonics"},{"url":"https://en.wikipedia.org/wiki/Hepatocellular_carcinoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hcc","kind":"indication","name":"Hepatocellular carcinoma","route":"/indications/hcc/","field":"links","label":"Wikipedia"},{"id":"hcc","kind":"indication","name":"Hepatocellular carcinoma","route":"/indications/hcc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260917122507/https://en.wikipedia.org/wiki/Hepatocellular_carcinoma"},{"url":"https://en.wikipedia.org/wiki/HER2-positive_breast_cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"links","label":"Wikipedia"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260814041608/https://en.wikipedia.org/wiki/HER2-positive_breast_cancer"},{"url":"https://en.wikipedia.org/wiki/HER2/neu","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"links","label":"Wikipedia"},{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260908043701/https://en.wikipedia.org/wiki/HER2/neu"},{"url":"https://en.wikipedia.org/wiki/Hot_cell","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hot-lab","kind":"term","name":"Hot lab (radiopharmacy dispensing area)","route":"/terms/hot-lab/","field":"links","label":"Wikipedia: Hot cell"}]},{"url":"https://en.wikipedia.org/wiki/Hypoxia-inducible_factor","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hif-vhl","kind":"pathway","name":"VHL / HIF oxygen sensing","route":"/pathways/hif-vhl/","field":"links","label":"Wikipedia"},{"id":"hif-vhl","kind":"pathway","name":"VHL / HIF oxygen sensing","route":"/pathways/hif-vhl/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260805142122/https://en.wikipedia.org/wiki/Hypoxia-inducible_factor"},{"url":"https://en.wikipedia.org/wiki/Ibritumomab_tiuxetan","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260602155246/https://en.wikipedia.org/wiki/Ibritumomab_tiuxetan"},{"url":"https://en.wikipedia.org/wiki/Indium-111","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"in-111","kind":"isotope","name":"Indium-111","route":"/isotopes/in-111/","field":"links","label":"Wikipedia: indium-111 (production routes)"}]},{"url":"https://en.wikipedia.org/wiki/Institut_Jules_Bordet","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20240108184546/https://en.wikipedia.org/wiki/Institut_Jules_Bordet"},{"url":"https://en.wikipedia.org/wiki/Iobenguane","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/","field":"links","label":"Wikipedia"},{"id":"mibg-theranostics","kind":"technology","name":"MIBG imaging and 131I-MIBG therapy","route":"/technologies/mibg-theranostics/","field":"wikipedia"},{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","field":"links","label":"Wikipedia"},{"id":"i131-mibg","kind":"drug","name":"131I-MIBG (iobenguane I-131) therapy","route":"/drugs/i131-mibg/","field":"wikipedia"},{"id":"iobenguane-i-131","kind":"drug","name":"Iobenguane I-131 (therapeutic)","route":"/drugs/iobenguane-i-131/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260626062316/https://en.wikipedia.org/wiki/Iobenguane"},{"url":"https://en.wikipedia.org/wiki/Iodine-131","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","field":"wikipedia"},{"id":"radioiodine-term","kind":"term","name":"Radioiodine therapy (I-131)","route":"/terms/radioiodine-term/","field":"links","label":"Wikipedia"},{"id":"radioiodine-term","kind":"term","name":"Radioiodine therapy (I-131)","route":"/terms/radioiodine-term/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260813122704/https://en.wikipedia.org/wiki/Iodine-131"},{"url":"https://en.wikipedia.org/wiki/Isotopes_of_iodine#Iodine-131","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Isotopes_of_iodine","checked":"2026-10-21","refs":[{"id":"radioiodine-therapy","kind":"technology","name":"Radioiodine therapy and whole-body iodine scanning","route":"/technologies/radioiodine-therapy/","field":"links","label":"Wikipedia"},{"id":"radioiodine-therapy","kind":"technology","name":"Radioiodine therapy and whole-body iodine scanning","route":"/technologies/radioiodine-therapy/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260904075216/https://en.wikipedia.org/wiki/Isotopes_of_iodine"},{"url":"https://en.wikipedia.org/wiki/JAMA","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jama","kind":"journal","name":"JAMA","route":"/journals/jama/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Johnson_%26_Johnson","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260925165947/https://en.wikipedia.org/wiki/Johnson_%26_Johnson"},{"url":"https://en.wikipedia.org/wiki/Journal_of_Clinical_Oncology","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Journal_of_Nuclear_Cardiology","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"journal-of-nuclear-cardiology","kind":"journal","name":"Journal of Nuclear Cardiology","route":"/journals/journal-of-nuclear-cardiology/","field":"links","label":"Journal of Nuclear Cardiology — Wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Karolinska_University_Hospital","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261001213620/https://en.wikipedia.org/wiki/Karolinska_University_Hospital"},{"url":"https://en.wikipedia.org/wiki/King_Faisal_Specialist_Hospital_and_Research_Centre","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","route":"/institutions/kfshrc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260911092538/https://en.wikipedia.org/wiki/King_Faisal_Specialist_Hospital_and_Research_Centre"},{"url":"https://en.wikipedia.org/wiki/KLK2","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/","field":"links","label":"Wikipedia"},{"id":"klk2","kind":"target","name":"KLK2 (kallikrein-2)","route":"/targets/klk2/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260730112942/https://en.wikipedia.org/wiki/KLK2"},{"url":"https://en.wikipedia.org/wiki/Ligand_(biochemistry)","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ligand","kind":"term","name":"Ligand","route":"/terms/ligand/","field":"links","label":"Wikipedia"},{"id":"ligand","kind":"term","name":"Ligand","route":"/terms/ligand/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261005220338/https://en.wikipedia.org/wiki/Ligand_(biochemistry)"},{"url":"https://en.wikipedia.org/wiki/Lutetium_(177Lu)_oxodotreotide","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260313053232/https://en.wikipedia.org/wiki/Lutetium_(177Lu)_oxodotreotide"},{"url":"https://en.wikipedia.org/wiki/Lutetium_(177Lu)_vipivotide_tetraxetan","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260328162146/https://en.wikipedia.org/wiki/Lutetium_(177Lu)_vipivotide_tetraxetan"},{"url":"https://en.wikipedia.org/wiki/Lutetium-177","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/","field":"links","label":"Wikipedia"},{"id":"lu177-radioligand-therapy","kind":"technology","name":"Lutetium-177 radioligand therapy","route":"/technologies/lu177-radioligand-therapy/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20251113024100/https://en.wikipedia.org/wiki/Lutetium-177"},{"url":"https://en.wikipedia.org/wiki/Mayo_Clinic","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mayo-clinic","kind":"institution","name":"Mayo Clinic","route":"/institutions/mayo-clinic/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261005001053/https://en.wikipedia.org/wiki/Mayo_Clinic"},{"url":"https://en.wikipedia.org/wiki/MD_Anderson_Cancer_Center","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261004140000/https://en.wikipedia.org/wiki/MD_Anderson_Cancer_Center"},{"url":"https://en.wikipedia.org/wiki/Mediso","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mediso","kind":"company","name":"Mediso","route":"/companies/mediso/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260208051058/https://en.wikipedia.org/wiki/Mediso"},{"url":"https://en.wikipedia.org/wiki/Memorial_Sloan_Kettering_Cancer_Center","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261002225819/https://en.wikipedia.org/wiki/Memorial_Sloan_Kettering_Cancer_Center"},{"url":"https://en.wikipedia.org/wiki/Meningioma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"meningioma","kind":"indication","name":"Meningioma","route":"/indications/meningioma/","field":"links","label":"Wikipedia"},{"id":"meningioma","kind":"indication","name":"Meningioma","route":"/indications/meningioma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260903190247/https://en.wikipedia.org/wiki/Meningioma"},{"url":"https://en.wikipedia.org/wiki/Multiple_endocrine_neoplasia","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"multiple-endocrine-neoplasia","kind":"indication","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/indications/multiple-endocrine-neoplasia/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260908053122/https://en.wikipedia.org/wiki/Multiple_endocrine_neoplasia"},{"url":"https://en.wikipedia.org/wiki/Myelosuppression","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cytopenias","kind":"term","name":"Cytopenias and myelosuppression","route":"/terms/cytopenias/","field":"links","label":"Wikipedia"},{"id":"cytopenias","kind":"term","name":"Cytopenias and myelosuppression","route":"/terms/cytopenias/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260518032822/https://en.wikipedia.org/wiki/Myelosuppression"},{"url":"https://en.wikipedia.org/wiki/Nectin-4","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/","field":"links","label":"Wikipedia"},{"id":"nectin4","kind":"target","name":"Nectin-4","route":"/targets/nectin4/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260708215756/https://en.wikipedia.org/wiki/Nectin-4"},{"url":"https://en.wikipedia.org/wiki/Neuroblastoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"neuroblastoma","kind":"indication","name":"Neuroblastoma (paediatric)","route":"/indications/neuroblastoma/","field":"links","label":"Wikipedia"},{"id":"neuroblastoma","kind":"indication","name":"Neuroblastoma (paediatric)","route":"/indications/neuroblastoma/","field":"wikipedia"},{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/","field":"links","label":"Wikipedia: Neuroblastoma"},{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260916224853/https://en.wikipedia.org/wiki/Neuroblastoma"},{"url":"https://en.wikipedia.org/wiki/Neuroendocrine_tumor","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","field":"links","label":"Wikipedia"},{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","field":"wikipedia"},{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/","field":"links","label":"Wikipedia"},{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/","field":"wikipedia"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/","field":"links","label":"Wikipedia"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/","field":"wikipedia"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"links","label":"Wikipedia"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"wikipedia"},{"id":"lineage-plasticity-neuroendocrine","kind":"pathway","name":"Lineage plasticity & neuroendocrine transformation","route":"/pathways/lineage-plasticity-neuroendocrine/","field":"wikipedia"},{"id":"net-grade-ki67","kind":"term","name":"Neuroendocrine tumour grade (Ki-67) and WHO classification","route":"/terms/net-grade-ki67/","field":"links","label":"Wikipedia"},{"id":"net-grade-ki67","kind":"term","name":"Neuroendocrine tumour grade (Ki-67) and WHO classification","route":"/terms/net-grade-ki67/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260822015219/https://en.wikipedia.org/wiki/Neuroendocrine_tumor"},{"url":"https://en.wikipedia.org/wiki/Non-small-cell_lung_cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Novartis","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260915234113/https://en.wikipedia.org/wiki/Novartis"},{"url":"https://en.wikipedia.org/wiki/Olaparib","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260719174524/https://en.wikipedia.org/wiki/Olaparib"},{"url":"https://en.wikipedia.org/wiki/Oliver_Sartor","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Osteosarcoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"osteosarcoma","kind":"indication","name":"Osteosarcoma","route":"/indications/osteosarcoma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260908034829/https://en.wikipedia.org/wiki/Osteosarcoma"},{"url":"https://en.wikipedia.org/wiki/Pancreatic_neuroendocrine_tumor","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"links","label":"Wikipedia"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260417234005/https://en.wikipedia.org/wiki/Pancreatic_neuroendocrine_tumor"},{"url":"https://en.wikipedia.org/wiki/Paraganglioma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","field":"links","label":"Wikipedia"},{"id":"hereditary-ppgl","kind":"indication","name":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","route":"/indications/hereditary-ppgl/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260419074056/https://en.wikipedia.org/wiki/Paraganglioma"},{"url":"https://en.wikipedia.org/wiki/PARP_inhibitor","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","field":"links","label":"Wikipedia"},{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260909223009/https://en.wikipedia.org/wiki/PARP_inhibitor"},{"url":"https://en.wikipedia.org/wiki/Pasireotide","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/","field":"links","label":"Wikipedia"},{"id":"pasireotide","kind":"drug","name":"Pasireotide","route":"/drugs/pasireotide/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260731151921/https://en.wikipedia.org/wiki/Pasireotide"},{"url":"https://en.wikipedia.org/wiki/Pembrolizumab","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260802113751/https://en.wikipedia.org/wiki/Pembrolizumab"},{"url":"https://en.wikipedia.org/wiki/People's_Liberation_Army_General_Hospital_and_Medical_School","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pla-general-hospital","kind":"institution","name":"Chinese PLA General Hospital","route":"/institutions/pla-general-hospital/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260817192250/https://en.wikipedia.org/wiki/People%27s_Liberation_Army_General_Hospital_and_Medical_School"},{"url":"https://en.wikipedia.org/wiki/Peptide_receptor_radionuclide_therapy","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/","field":"links","label":"Wikipedia"},{"id":"prrt","kind":"technology","name":"Peptide receptor radionuclide therapy (PRRT)","route":"/technologies/prrt/","field":"wikipedia"},{"id":"prrt-term","kind":"term","name":"PRRT (peptide receptor radionuclide therapy)","route":"/terms/prrt-term/","field":"links","label":"Wikipedia"},{"id":"prrt-term","kind":"term","name":"PRRT (peptide receptor radionuclide therapy)","route":"/terms/prrt-term/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20251114131412/https://en.wikipedia.org/wiki/Peptide_receptor_radionuclide_therapy"},{"url":"https://en.wikipedia.org/wiki/PET-CT","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/","field":"links","label":"Wikipedia"},{"id":"pet-ct","kind":"technology","name":"PET/CT","route":"/technologies/pet-ct/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260908130655/https://en.wikipedia.org/wiki/PET-CT"},{"url":"https://en.wikipedia.org/wiki/PET-MRI","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pet-mri","kind":"technology","name":"PET/MRI","route":"/technologies/pet-mri/","field":"links","label":"Wikipedia"},{"id":"pet-mri","kind":"technology","name":"PET/MRI","route":"/technologies/pet-mri/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260106074608/https://en.wikipedia.org/wiki/PET-MRI"},{"url":"https://en.wikipedia.org/wiki/Peter_MacCallum_Cancer_Centre","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260205034119/https://en.wikipedia.org/wiki/Peter_MacCallum_Cancer_Centre"},{"url":"https://en.wikipedia.org/wiki/Pharmacokinetics","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/","field":"links","label":"Wikipedia"},{"id":"pharmacokinetics","kind":"term","name":"Pharmacokinetics (PK), half-life and exposure","route":"/terms/pharmacokinetics/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261004113825/https://en.wikipedia.org/wiki/Pharmacokinetics"},{"url":"https://en.wikipedia.org/wiki/Pheochromocytoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","field":"links","label":"Wikipedia"},{"id":"metastatic-ppgl","kind":"indication","name":"Metastatic pheochromocytoma and paraganglioma","route":"/indications/metastatic-ppgl/","field":"wikipedia"},{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260919232917/https://en.wikipedia.org/wiki/Pheochromocytoma"},{"url":"https://en.wikipedia.org/wiki/Phosphorus-32","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"phosphorus-32","kind":"drug","name":"Phosphorus-32 (radiophosphorus)","route":"/drugs/phosphorus-32/","field":"links","label":"Wikipedia"},{"id":"phosphorus-32","kind":"drug","name":"Phosphorus-32 (radiophosphorus)","route":"/drugs/phosphorus-32/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260604062119/https://en.wikipedia.org/wiki/Phosphorus-32"},{"url":"https://en.wikipedia.org/wiki/Physics_of_magnetic_resonance_imaging","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"medical-imaging-scanner-manufacturing","kind":"technology","name":"CT, MRI and PET scanner manufacturing","route":"/technologies/medical-imaging-scanner-manufacturing/","field":"links","label":"Wikipedia"}],"archive":"https://web.archive.org/web/20260802030300/https://en.wikipedia.org/wiki/Physics_of_magnetic_resonance_imaging"},{"url":"https://en.wikipedia.org/wiki/Piflufolastat_F-18","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20250623022908/https://en.wikipedia.org/wiki/Piflufolastat_F-18"},{"url":"https://en.wikipedia.org/wiki/Positron_emission_tomography","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/","field":"links","label":"Wikipedia"},{"id":"pet","kind":"technology","name":"PET (positron emission tomography)","route":"/technologies/pet/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260916113739/https://en.wikipedia.org/wiki/Positron_emission_tomography"},{"url":"https://en.wikipedia.org/wiki/Prostate_cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/","field":"links","label":"Wikipedia"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/","field":"wikipedia"},{"id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/","field":"links","label":"Wikipedia"},{"id":"prostate-nepc","kind":"indication","name":"Neuroendocrine and small-cell prostate cancer","route":"/indications/prostate-nepc/","field":"links","label":"Wikipedia"},{"id":"prostate-nepc","kind":"indication","name":"Neuroendocrine and small-cell prostate cancer","route":"/indications/prostate-nepc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260914115732/https://en.wikipedia.org/wiki/Prostate_cancer"},{"url":"https://en.wikipedia.org/wiki/Prostate_cancer_staging","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prostate-high-risk","kind":"indication","name":"Localised prostate cancer, high and very high risk","route":"/indications/prostate-high-risk/","field":"links","label":"Wikipedia"},{"id":"prostate-high-risk","kind":"indication","name":"Localised prostate cancer, high and very high risk","route":"/indications/prostate-high-risk/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260716114528/https://en.wikipedia.org/wiki/Prostate_cancer_staging"},{"url":"https://en.wikipedia.org/wiki/Prostate_cancer#Castration-resistant_prostate_cancer","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Prostate_cancer","checked":"2026-10-21","refs":[{"id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","field":"links","label":"Wikipedia"},{"id":"mcrpc-mhspc","kind":"term","name":"mCRPC and mHSPC (castration-resistant vs hormone-sensitive prostate cancer)","route":"/terms/mcrpc-mhspc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261005110550/https://en.wikipedia.org/wiki/Prostate_Cancer"},{"url":"https://en.wikipedia.org/wiki/Prostate_cancer#Metastatic_disease","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Prostate_cancer","checked":"2026-10-21","refs":[{"id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260914115732/https://en.wikipedia.org/wiki/Prostate_cancer"},{"url":"https://en.wikipedia.org/wiki/Prostate-specific_antigen","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psa50","kind":"term","name":"PSA50 / PSA90 response","route":"/terms/psa50/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261005213450/https://en.wikipedia.org/wiki/Prostate-specific_antigen"},{"url":"https://en.wikipedia.org/wiki/Prostatectomy","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prostatectomy","kind":"term","name":"Radical prostatectomy","route":"/terms/prostatectomy/","field":"links","label":"Wikipedia"},{"id":"prostatectomy","kind":"term","name":"Radical prostatectomy","route":"/terms/prostatectomy/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261012035535/https://en.wikipedia.org/wiki/Prostatectomy"},{"url":"https://en.wikipedia.org/wiki/Radiation_therapy","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","field":"links","label":"Wikipedia"},{"id":"radiotherapy","kind":"term","name":"Radiotherapy","route":"/terms/radiotherapy/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261004014249/https://en.wikipedia.org/wiki/Radiation_therapy"},{"url":"https://en.wikipedia.org/wiki/Radioimmunotherapy","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/","field":"links","label":"Wikipedia"},{"id":"radioimmunotherapy","kind":"technology","name":"Radio-antibody & radio-ADC","route":"/technologies/radioimmunotherapy/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260716064907/https://en.wikipedia.org/wiki/Radioimmunotherapy"},{"url":"https://en.wikipedia.org/wiki/Radioligand_therapy","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/","field":"links","label":"Wikipedia"},{"id":"radioligand-therapy","kind":"technology","name":"Radioligand therapy (beta emitters)","route":"/technologies/radioligand-therapy/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20251120005751/https://en.wikipedia.org/wiki/Radioligand_therapy"},{"url":"https://en.wikipedia.org/wiki/Radiomics","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiomics","kind":"technology","name":"Radiomics","route":"/technologies/radiomics/","field":"links","label":"Wikipedia"},{"id":"radiomics","kind":"technology","name":"Radiomics","route":"/technologies/radiomics/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260904125234/https://en.wikipedia.org/wiki/Radiomics"},{"url":"https://en.wikipedia.org/wiki/Radiopharmaceutical","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/","field":"links","label":"Wikipedia"}],"archive":"https://web.archive.org/web/20260908231819/https://en.wikipedia.org/wiki/Radiopharmaceutical"},{"url":"https://en.wikipedia.org/wiki/Radium-223","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radium-223","kind":"drug","name":"Radium-223 dichloride","route":"/drugs/radium-223/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260630033656/https://en.wikipedia.org/wiki/Radium-223"},{"url":"https://en.wikipedia.org/wiki/Renal_cell_carcinoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260908030938/https://en.wikipedia.org/wiki/Renal_cell_carcinoma"},{"url":"https://en.wikipedia.org/wiki/Response_Evaluation_Criteria_in_Solid_Tumors","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/","field":"links","label":"Wikipedia"},{"id":"complete-response-term","kind":"term","name":"Complete response (CR) and partial response (PR)","route":"/terms/complete-response-term/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260112191303/https://en.wikipedia.org/wiki/Response_evaluation_criteria_in_solid_tumors"},{"url":"https://en.wikipedia.org/wiki/Rituximab","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rituximab","kind":"drug","name":"Rituximab","route":"/drugs/rituximab/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260828042341/https://en.wikipedia.org/wiki/Rituximab"},{"url":"https://en.wikipedia.org/wiki/Samarium_(153Sm)_lexidronam","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260826182837/https://en.wikipedia.org/wiki/Samarium_(153Sm)_lexidronam"},{"url":"https://en.wikipedia.org/wiki/Selective_internal_radiation_therapy","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","field":"links","label":"Wikipedia"},{"id":"radioembolisation-tare","kind":"technology","name":"Radioembolisation (TARE / SIRT, yttrium-90)","route":"/technologies/radioembolisation-tare/","field":"wikipedia"},{"id":"tare","kind":"term","name":"TARE / SIRT (radioembolisation with yttrium-90)","route":"/terms/tare/","field":"links","label":"Wikipedia"},{"id":"tare","kind":"term","name":"TARE / SIRT (radioembolisation with yttrium-90)","route":"/terms/tare/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260311033402/https://en.wikipedia.org/wiki/Selective_internal_radiation_therapy"},{"url":"https://en.wikipedia.org/wiki/Sentinel_lymph_node","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gamma-probes-dose-calibrators","kind":"technology","name":"Gamma probes, handheld gamma cameras and dose calibrators","route":"/technologies/gamma-probes-dose-calibrators/","field":"links","label":"Wikipedia: sentinel lymph node"},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","field":"links","label":"Wikipedia"},{"id":"sentinel-lymph-node-biopsy","kind":"term","name":"Sentinel node biopsy","route":"/terms/sentinel-lymph-node-biopsy/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260927070532/https://en.wikipedia.org/wiki/Sentinel_lymph_node"},{"url":"https://en.wikipedia.org/wiki/Shanghai_Cancer_Center","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260920071026/https://en.wikipedia.org/wiki/Shanghai_Cancer_Center"},{"url":"https://en.wikipedia.org/wiki/Single-photon_emission_computed_tomography","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/","field":"links","label":"Wikipedia"},{"id":"spect","kind":"technology","name":"SPECT & bone scan","route":"/technologies/spect/","field":"wikipedia"},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/","field":"links","label":"Wikipedia: SPECT"},{"id":"spect-ct","kind":"technology","name":"SPECT/CT","route":"/technologies/spect-ct/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260918063902/https://en.wikipedia.org/wiki/Single-photon_emission_computed_tomography"},{"url":"https://en.wikipedia.org/wiki/Small-cell_carcinoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sclc","kind":"indication","name":"Small-cell lung cancer","route":"/indications/sclc/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260920233850/https://en.wikipedia.org/wiki/Small-cell_carcinoma"},{"url":"https://en.wikipedia.org/wiki/Somatostatin_receptor_2","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","field":"links","label":"Wikipedia"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","field":"wikipedia"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","field":"prevalence.source"},{"id":"sstr2","kind":"target","name":"Somatostatin receptor 2","route":"/targets/sstr2/","field":"prevalence.source"}],"archive":"https://web.archive.org/web/20260310172727/https://en.wikipedia.org/wiki/Somatostatin_receptor_2"},{"url":"https://en.wikipedia.org/wiki/Sorafenib","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sorafenib","kind":"drug","name":"Sorafenib","route":"/drugs/sorafenib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260805233854/https://en.wikipedia.org/wiki/Sorafenib"},{"url":"https://en.wikipedia.org/wiki/Spectrum_Pharmaceuticals","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","field":"links","label":"Wikipedia"},{"id":"spectrum-pharmaceuticals","kind":"company","name":"Spectrum Pharmaceuticals","route":"/companies/spectrum-pharmaceuticals/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260811185822/https://en.wikipedia.org/wiki/Spectrum_Pharmaceuticals"},{"url":"https://en.wikipedia.org/wiki/Standardized_uptake_value","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","field":"links","label":"Wikipedia"},{"id":"suv","kind":"term","name":"Standardised uptake value (SUV)","route":"/terms/suv/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260515002520/https://en.wikipedia.org/wiki/Standardized_uptake_value"},{"url":"https://en.wikipedia.org/wiki/STEAP1","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"steap1","kind":"target","name":"STEAP1","route":"/targets/steap1/","field":"links","label":"Wikipedia"},{"id":"steap1","kind":"target","name":"STEAP1","route":"/targets/steap1/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20250801005040/https://en.wikipedia.org/wiki/STEAP1"},{"url":"https://en.wikipedia.org/wiki/Sunitinib","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sunitinib","kind":"drug","name":"Sunitinib","route":"/drugs/sunitinib/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260902233928/https://en.wikipedia.org/wiki/Sunitinib"},{"url":"https://en.wikipedia.org/wiki/Targeted_alpha-particle_therapy","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/","field":"links","label":"Wikipedia"},{"id":"targeted-alpha-therapy","kind":"technology","name":"Targeted alpha therapy","route":"/technologies/targeted-alpha-therapy/","field":"wikipedia"},{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/","field":"links","label":"Wikipedia"},{"id":"alpha-vs-beta","kind":"term","name":"Alpha vs beta emitters","route":"/terms/alpha-vs-beta/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260826221040/https://en.wikipedia.org/wiki/Targeted_alpha-particle_therapy"},{"url":"https://en.wikipedia.org/wiki/Technetium-99m#Shortages","status":200,"ok":true,"finalUrl":"https://en.wikipedia.org/wiki/Technetium-99m","checked":"2026-10-21","refs":[{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/","field":"links","label":"Wikipedia: technetium-99m and the Mo-99 supply crisis"}],"archive":"https://web.archive.org/web/20260724174300/https://en.wikipedia.org/wiki/Technetium-99m"},{"url":"https://en.wikipedia.org/wiki/Temozolomide","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/","field":"links","label":"Wikipedia"},{"id":"temozolomide","kind":"drug","name":"Temozolomide","route":"/drugs/temozolomide/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260809074047/https://en.wikipedia.org/wiki/Temozolomide"},{"url":"https://en.wikipedia.org/wiki/The_Lancet","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lancet","kind":"journal","name":"The Lancet","route":"/journals/lancet/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/The_Lancet_Oncology","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lancet-oncology","kind":"journal","name":"The Lancet Oncology","route":"/journals/lancet-oncology/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/The_New_England_Journal_of_Medicine","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Theranostics","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/","field":"links","label":"Wikipedia"},{"id":"theranostics","kind":"term","name":"Theranostics","route":"/terms/theranostics/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20261001114429/https://en.wikipedia.org/wiki/Theranostics"},{"url":"https://en.wikipedia.org/wiki/Thrombocytopenia","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"thrombocytopenia","kind":"term","name":"Thrombocytopenia","route":"/terms/thrombocytopenia/","field":"links","label":"Wikipedia"},{"id":"thrombocytopenia","kind":"term","name":"Thrombocytopenia","route":"/terms/thrombocytopenia/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260928071503/https://en.wikipedia.org/wiki/Thrombocytopenia"},{"url":"https://en.wikipedia.org/wiki/Thyroid_cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"thyroid","kind":"indication","name":"Thyroid cancer","route":"/indications/thyroid/","field":"links","label":"Wikipedia"},{"id":"thyroid","kind":"indication","name":"Thyroid cancer","route":"/indications/thyroid/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260918063902/https://en.wikipedia.org/wiki/Thyroid_cancer"},{"url":"https://en.wikipedia.org/wiki/Thyrotropin_alfa","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"thyrotropin-alfa","kind":"drug","name":"Thyrotropin alfa","route":"/drugs/thyrotropin-alfa/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20250424155232/https://en.wikipedia.org/wiki/Thyrotropin_alfa"},{"url":"https://en.wikipedia.org/wiki/Tilmanocept","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tilmanocept-tc99m","kind":"drug","name":"Technetium-99m tilmanocept","route":"/drugs/tilmanocept-tc99m/","field":"wikipedia"}]},{"url":"https://en.wikipedia.org/wiki/Transcatheter_arterial_chemoembolization","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hcc-intermediate","kind":"indication","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/indications/hcc-intermediate/","field":"links","label":"Wikipedia"},{"id":"hcc-intermediate","kind":"indication","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/indications/hcc-intermediate/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260509033359/https://en.wikipedia.org/wiki/Transcatheter_arterial_chemoembolization"},{"url":"https://en.wikipedia.org/wiki/Tumor_hypoxia","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tumour-hypoxia","kind":"term","name":"Tumour hypoxia","route":"/terms/tumour-hypoxia/","field":"links","label":"Wikipedia"},{"id":"tumour-hypoxia","kind":"term","name":"Tumour hypoxia","route":"/terms/tumour-hypoxia/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260516184120/https://en.wikipedia.org/wiki/Tumor_hypoxia"},{"url":"https://en.wikipedia.org/wiki/UCSF_Helen_Diller_Family_Comprehensive_Cancer_Center","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ucsf","kind":"institution","name":"UCSF Helen Diller Family Comprehensive Cancer Center","route":"/institutions/ucsf/","field":"wikipedia"}],"archive":"https://web.archive.org/web/20260823153050/https://en.wikipedia.org/wiki/UCSF_Helen_Diller_Family_Comprehensive_Cancer_Center"},{"url":"https://endpoints.news/abdera-raises-110m-to-push-targeted-radiotherapies-where-they-havent-gone-before/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/","field":"links","label":"Endpoints News: Abdera raises $110M Series B"}],"archive":"https://web.archive.org/web/20250708175224/https://endpoints.news/abdera-raises-110m-to-push-targeted-radiotherapies-where-they-havent-gone-before/"},{"url":"https://endpoints.news/artbio-attracts-132m-as-its-alpha-radioligand-program-moves-into-the-clinic/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","field":"links","label":"Endpoints News: Artbio attracts $132M"}],"archive":"https://web.archive.org/web/20250806153522/https://endpoints.news/artbio-attracts-132m-as-its-alpha-radioligand-program-moves-into-the-clinic/"},{"url":"https://endpoints.news/artbio-raises-90m-as-radiopharma-field-finds-its-footing/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","field":"links","label":"Endpoints News: Artbio raises $90M"}],"archive":"https://web.archive.org/web/20250723134007/https://endpoints.news/artbio-raises-90m-as-radiopharma-field-finds-its-footing/"},{"url":"https://escholarship.org/content/qt1wx8761n/qt1wx8761n_noSplash_6eb388d1960fed7f031a438777911ba9.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-total-body-pet-lower-dose-tracers","kind":"idea","name":"Using total-body PET's sensitivity to cut diagnostic tracer dose, not just scan time","route":"/ideas/idea-total-body-pet-lower-dose-tracers/","field":"links","label":"Total-body PET/CT — first clinical experiences and future perspectives (eScholarship, UCSF/UC Davis)"}]},{"url":"https://escholarship.org/content/qt7480171k/qt7480171k_noSplash_75492753629cf0018dd0db00b41434a0.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tumour-to-background-ratio","kind":"term","name":"Tumour-to-background ratio (TBR)","route":"/terms/tumour-to-background-ratio/","field":"links","label":"PET-based response assessment criteria for diffuse gliomas (PET RANO 1.0), Lancet Oncology group report"}]},{"url":"https://escholarship.org/content/qt8hr5w9j2/qt8hr5w9j2.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"macropa-chelation","kind":"technology","name":"Macropa chelation","route":"/technologies/macropa-chelation/","field":"links","label":"Advancing chelation strategies for large metal ions for nuclear medicine (UC eScholarship dissertation)"}]},{"url":"https://exceldiagnostics.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"excel-diagnostics-nuclear-oncology","kind":"institution","name":"Excel Diagnostics and Nuclear Oncology Center","route":"/institutions/excel-diagnostics-nuclear-oncology/","field":"links","label":"Official website"},{"id":"excel-diagnostics-nuclear-oncology","kind":"institution","name":"Excel Diagnostics and Nuclear Oncology Center","route":"/institutions/excel-diagnostics-nuclear-oncology/","field":"website"}],"archive":"https://web.archive.org/web/20260609092555/https://exceldiagnostics.com/"},{"url":"https://fusionpharma.com/wp-content/uploads/2023/10/2068_AACR-poster_2023_Final.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ac-225-fpi-2068","kind":"drug","name":"Actinium-225 FPI-2068","route":"/drugs/ac-225-fpi-2068/","field":"links","label":"Fusion Pharmaceuticals: AACR-NCI-EORTC 2023 preclinical poster on FPI-2068"}]},{"url":"https://gco.iarc.fr/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf","status":200,"ok":true,"finalUrl":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/15-trachea-bronchus-and-lung-fact-sheet.pdf","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"links","label":"IARC Global Cancer Observatory: trachea, bronchus and lung factsheet (GLOBOCAN 2024)"}]},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/13-pancreas-fact-sheet.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","field":"links","label":"IARC GLOBOCAN 2024 pancreas factsheet"}]},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/30-bladder-fact-sheet.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","field":"links","label":"IARC GLOBOCAN 2024 bladder factsheet"}]},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/41-colorectum-fact-sheet.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"links","label":"IARC GLOBOCAN 2024 colorectum factsheet"}]},{"url":"https://gco.iarc.who.int/media/globocan/factsheets/cancers/7-stomach-fact-sheet.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","field":"links","label":"IARC GLOBOCAN 2024 stomach factsheet"}]},{"url":"https://gepris.dfg.de/gepris/person/15130779","status":200,"ok":true,"finalUrl":"https://gepris.dfg.de/person/15130779","checked":"2026-10-21","refs":[{"id":"michael-lassmann","kind":"person","name":"Michael Lassmann","route":"/people/michael-lassmann/","field":"profiles","label":"DFG GEPRIS researcher profile"}]},{"url":"https://global.medical.canon","status":200,"ok":true,"finalUrl":"https://global.medical.canon/","checked":"2026-10-21","refs":[{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","route":"/companies/canon-medical/","field":"links","label":"Official website"},{"id":"canon-medical","kind":"company","name":"Canon Medical Systems","route":"/companies/canon-medical/","field":"website"}],"archive":"https://web.archive.org/web/20260823125443/https://global.medical.canon/"},{"url":"https://gravitas.acr.org/PPTS/DownloadPreviewDocument?DocId=171","status":200,"ok":true,"finalUrl":"https://gravitas.acr.org/User/Login?ReturnUrl=%2fHome%2fError","checked":"2026-10-21","refs":[{"id":"release-criteria","kind":"term","name":"Product release criteria (radiopharmaceutical quality control)","route":"/terms/release-criteria/","field":"links","label":"ACR-SPR-SNMMI practice parameter excerpt on assay and administration quality control"}]},{"url":"https://gravitas.acr.org/PPTS/GetDocumentView?docId=29","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"graves-hyperthyroidism","kind":"indication","name":"Graves' disease and hyperthyroidism","route":"/indications/graves-hyperthyroidism/","field":"links","label":"ACR-ACNM-ARS-SNMMI-SPR practice parameter for treatment of benign and malignant thyroid disease with I-131 sodium iodide"}]},{"url":"https://he01.tci-thaijo.org/index.php/bulletinAMS/article/view/279571","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-ai-lesion-segmentation-dosimetry","kind":"idea","name":"AI segmentation to make voxel-level radioligand dosimetry practical at scale","route":"/ideas/idea-ai-lesion-segmentation-dosimetry/","field":"links","label":"Single time-point kidney dosimetry in 177Lu-PSMA therapy: AI-based vs manual segmentation (2025)"}]},{"url":"https://health-products.canada.ca/dpd-bdpp/info?lang=eng&code=107378","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma-1007-f18","kind":"drug","name":"PSMA-1007 F-18","route":"/drugs/psma-1007-f18/","field":"links","label":"Health Canada Drug Product Database: PROSTALUMIN, DIN 02571757"}]},{"url":"https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/","field":"links","label":"EU GMP Annex 3: manufacture of radiopharmaceuticals"}],"archive":"https://web.archive.org/web/20260919080027/https://health.ec.europa.eu/medicinal-products/eudralex/eudralex-volume-4_en"},{"url":"https://icrp.org/page.asp?id=505","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"icrp-publications","kind":"collection","name":"ICRP publications and dose coefficient databases","route":"/collections/icrp-publications/","field":"links","label":"ICRP: Dose Assessment Resources (viewers, apps, datasets)"}]},{"url":"https://icrpaedia.org/Absorbed,_Equivalent,_and_Effective_Dose","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"equivalent-dose","kind":"term","name":"Equivalent dose and effective dose (sievert)","route":"/terms/equivalent-dose/","field":"links","label":"ICRPaedia: Absorbed, Equivalent, and Effective Dose"}]},{"url":"https://intuitionlabs.ai/articles/radioligand-therapy-manufacturing-capacity","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-rlt-trial-capacity","kind":"bottleneck","name":"Clinical trial capacity for radioligand therapy","route":"/bottlenecks/b-rlt-trial-capacity/","field":"links","label":"Radioligand therapy manufacturing capacity: the CDMO and isotope-supply constraint (industry analysis)"},{"id":"b-rlt-trial-capacity","kind":"bottleneck","name":"Clinical trial capacity for radioligand therapy","route":"/bottlenecks/b-rlt-trial-capacity/","field":"metrics (Lutetium-177 radiopharmaceutical therapy trials of all phases reported in progress (industry analysis))"}]},{"url":"https://investor.cyclopharm.com/site/pdf/60334760-9465-4ad1-9ff3-1d17eb39d00c/Platform/ListPage/Immediate-11Site-Technegas-Rollout-at-University-Hospitals.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cyclopharm","kind":"company","name":"Cyclopharm","route":"/companies/cyclopharm/","field":"links","label":"Cyclopharm ASX announcement: 11-site Technegas rollout at University Hospitals, Cleveland, 15 July 2026"}]},{"url":"https://investor.cyclopharm.com/site/pdf/ee402a7a-7ffe-4386-9541-9d22f3e60b42/Platform/ListPage/CYC-1H2026-Results-Summary.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cyclopharm","kind":"company","name":"Cyclopharm","route":"/companies/cyclopharm/","field":"links","label":"Cyclopharm first-half 2026 results summary (investor presentation: 67 countries, 83 US revenue-generating sites as at 12 August 2026)"}]},{"url":"https://investor.lantheus.com/news-releases/news-release-details/lantheus-receives-us-fda-approval-pylarifyr-piflufolastat-f-18","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma-theranostics-roadmap","kind":"roadmap","name":"PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha","route":"/roadmaps/psma-theranostics-roadmap/","field":"links","label":"Lantheus: FDA approval of Pylarify, May 2021"}]},{"url":"https://investor.lantheus.com/node/14596/pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lu-177-pnt2002","kind":"drug","name":"Lutetium-177 PNT2002","route":"/drugs/lu-177-pnt2002/","field":"links","label":"FDA Fast Track designation announcement, 24 April 2023"}]},{"url":"https://ionetix.com","status":200,"ok":true,"finalUrl":"https://ionetix.com/","checked":"2026-10-21","refs":[{"id":"ionetix","kind":"company","name":"IONETIX","route":"/companies/ionetix/","field":"website"}]},{"url":"https://ionetix.com/2024/06/07/ionetix-produces-first-batch-of-actinium-225/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ionetix","kind":"company","name":"IONETIX","route":"/companies/ionetix/","field":"links","label":"IONETIX: IONETIX Launches Commercial Actinium-225 Production (2024)"}]},{"url":"https://ionetix.com/2024/10/17/ionetix-announces-start-of-construction-to-add-second-cyclotron-for-ac-225-production-at-its-alpha-isotope-manufacturing-facility/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ionetix","kind":"company","name":"IONETIX","route":"/companies/ionetix/","field":"links","label":"IONETIX: second cyclotron construction for Ac-225 production (2024)"}]},{"url":"https://ionetix.com/2026/04/21/ionetix-completes-30-million-financing-in-a-go-public-transaction/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ionetix","kind":"company","name":"IONETIX","route":"/companies/ionetix/","field":"links","label":"IONETIX: Ionetix Completes $30 million+ Financing in a Go-Public Transaction (2026)"}]},{"url":"https://ionetix.com/2026/09/01/ionetix-begins-shipping-astatine-211-to-support-preclinical-and-clinical-trials/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ionetix","kind":"company","name":"IONETIX","route":"/companies/ionetix/","field":"links","label":"IONETIX: Ionetix Begins Shipping Astatine-211 (2026)"},{"id":"at-211","kind":"isotope","name":"Astatine-211","route":"/isotopes/at-211/","field":"links","label":"Ionetix: Ionetix Begins Shipping Astatine-211 to Support Preclinical and Clinical Trials (2026)"}]},{"url":"https://ionetix.com/about/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ionetix","kind":"company","name":"IONETIX","route":"/companies/ionetix/","field":"links","label":"IONETIX: about"}]},{"url":"https://ir.actiniumpharma.com/press-releases","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","field":"links","label":"Press releases"}],"archive":"https://web.archive.org/web/20260618001044/https://ir.actiniumpharma.com/press-releases/"},{"url":"https://ir.actiniumpharma.com/press-releases/detail/525/actinium-pharmaceuticals-announces-actimab-a-intellectual","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","field":"links","label":"August 2026 Actimab-A and listing update"}]},{"url":"https://isotopes.gov/BNL-AP-Hot-Cells","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-accelerator-ac225-at-scale","kind":"idea","name":"Scaling actinium-225 supply with proton accelerators instead of the thorium-229 cow","route":"/ideas/idea-accelerator-ac225-at-scale/","field":"links","label":"Streamlined Actinium-225 Processing through new All-Purpose Hot Cells (DOE Isotope Program, 2023)"}]},{"url":"https://isotopes.gov/NRC-roundtable","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-accelerator-ac225-at-scale","kind":"idea","name":"Scaling actinium-225 supply with proton accelerators instead of the thorium-229 cow","route":"/ideas/idea-accelerator-ac225-at-scale/","field":"links","label":"DOE Isotope Program virtual roundtable with NRC on accelerator-produced Ac-225"}]},{"url":"https://isotopes.gov/sites/default/files/2024-11/Radium-224-Lead-212-Bismuth-212%20Generator%20Product%20Information%20.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ra-224","kind":"isotope","name":"Radium-224","route":"/isotopes/ra-224/","field":"links","label":"DOE Isotope Program: Radium-224/Lead-212/Bismuth-212 Generator Product Information"}]},{"url":"https://itm-radiopharma.com","status":200,"ok":true,"finalUrl":"https://www.itm-radiopharma.com/home/","checked":"2026-10-21","refs":[{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/","field":"links","label":"Official website"},{"id":"itm","kind":"company","name":"ITM Isotope Technologies Munich","route":"/companies/itm/","field":"website"}]},{"url":"https://jnm.snmjournals.org","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/","checked":"2026-10-21","refs":[{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/","field":"url"}]},{"url":"https://jnm.snmjournals.org/content/48/6/932","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"partial-volume-effect","kind":"term","name":"Partial volume effect (PVE)","route":"/terms/partial-volume-effect/","field":"links","label":"Journal of Nuclear Medicine: partial-volume effect in PET tumor imaging"}]},{"url":"https://jnm.snmjournals.org/content/50/3/477","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mird-formalism","kind":"term","name":"MIRD formalism","route":"/terms/mird-formalism/","field":"links","label":"Journal of Nuclear Medicine: MIRD Pamphlet No. 21, a generalized schema for radiopharmaceutical dosimetry"}]},{"url":"https://jnm.snmjournals.org/content/53/10/1633","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"graves-hyperthyroidism","kind":"indication","name":"Graves' disease and hyperthyroidism","route":"/indications/graves-hyperthyroidism/","field":"links","label":"SNMMI procedure standard: therapy of thyroid disease with I-131 (sodium iodide), version 3.0"}]},{"url":"https://jnm.snmjournals.org/content/56/3/410","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cxcr4-primary-aldosteronism","kind":"opportunity","name":"CXCR4 imaging instead of adrenal vein sampling","route":"/opportunities/opp-cxcr4-primary-aldosteronism/","field":"links","label":"68Ga-pentixafor dosimetry, J Nucl Med 2015"}]},{"url":"https://jnm.snmjournals.org/content/56/5/668","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"matthias-eiber","kind":"person","name":"Matthias Eiber","route":"/people/matthias-eiber/","field":"links","label":"68Ga-PSMA-11 PET/CT biochemical recurrence study, JNM 2015"}]},{"url":"https://jnm.snmjournals.org/content/58/10/1553","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pretargeted-radioimmunotherapy","kind":"technology","name":"Pretargeted radioimmunotherapy","route":"/technologies/pretargeted-radioimmunotherapy/","field":"links","label":"Pretargeted imaging and therapy (J Nucl Med 2017 mini-review)"}]},{"url":"https://jnm.snmjournals.org/content/58/2/235.full.pdf","status":200,"ok":true,"finalUrl":"https://jnm.snmjournals.org/content/jnumed/58/2/235.full.pdf","checked":"2026-10-21","refs":[{"id":"tc-99m-psma-imaging","kind":"drug","name":"Technetium Tc-99m PSMA agents (PSMA-I&S)","route":"/drugs/tc-99m-psma-imaging/","field":"links","label":"Robu et al., J Nucl Med 2017: preclinical evaluation and first patient application of 99mTc-PSMA-I&S for SPECT imaging and radioguided surgery in prostate cancer"}]},{"url":"https://jnm.snmjournals.org/content/58/3/379","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"upar","kind":"target","name":"uPAR (urokinase plasminogen activator receptor)","route":"/targets/upar/","field":"links","label":"JNM: first-in-human study of 68Ga-NOTA-AE105 for uPAR PET imaging"}]},{"url":"https://jnm.snmjournals.org/content/58/8/1341","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cardiac-sarcoidosis","kind":"indication","name":"Cardiac sarcoidosis","route":"/indications/cardiac-sarcoidosis/","field":"links","label":"Joint SNMMI-ASNC expert consensus document on 18F-FDG PET/CT in cardiac sarcoid detection and therapy monitoring (J Nucl Med 2017)"}]},{"url":"https://jnm.snmjournals.org/content/58/Supplement_2/39S","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"norepinephrine-transporter","kind":"target","name":"Norepinephrine transporter (NET)","route":"/targets/norepinephrine-transporter/","field":"links","label":"JNM (SNMMI supplement): norepinephrine transporter as a target for imaging and therapy"}]},{"url":"https://jnm.snmjournals.org/content/60/1/1","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-authorized-user-shortage","kind":"bottleneck","name":"Authorized user shortage for radionuclide therapy","route":"/bottlenecks/b-authorized-user-shortage/","field":"links","label":"JNM editorial: Delivering radionuclide therapies requires extensive training and competence"},{"id":"b-authorized-user-shortage","kind":"bottleneck","name":"Authorized user shortage for radionuclide therapy","route":"/bottlenecks/b-authorized-user-shortage/","field":"metrics (Training hours required for the 10 CFR 35.390 alternate Authorized User pathway)"},{"id":"b-authorized-user-shortage","kind":"bottleneck","name":"Authorized user shortage for radionuclide therapy","route":"/bottlenecks/b-authorized-user-shortage/","field":"metrics (Estimated US board-certified nuclear medicine physician workforce (2019))"},{"id":"b-authorized-user-shortage","kind":"bottleneck","name":"Authorized user shortage for radionuclide therapy","route":"/bottlenecks/b-authorized-user-shortage/","field":"metrics (Estimated dedicated theranostic centres needed for projected US radionuclide-therapy demand)"}]},{"url":"https://jnm.snmjournals.org/content/60/5/656","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"albumin-binder-ligands","kind":"technology","name":"Albumin-binder ligands","route":"/technologies/albumin-binder-ligands/","field":"links","label":"Albumin-binding PSMA ligands: implications for expanding the therapeutic window (J Nucl Med 2019)"}]},{"url":"https://jnm.snmjournals.org/content/61/4/520","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cck2-receptor","kind":"target","name":"CCK2 receptor (gastrin receptor)","route":"/targets/cck2-receptor/","field":"links","label":"JNM: CCK2 receptor agonist 177Lu-PP-F11N for medullary thyroid carcinoma therapy - dosimetry"}]},{"url":"https://jnm.snmjournals.org/content/61/5/735","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiohybrid-chemistry","kind":"technology","name":"Radiohybrid (rh) chemistry","route":"/technologies/radiohybrid-chemistry/","field":"links","label":"Wurzer et al.: Radiohybrid ligands, a novel tracer concept exemplified by 18F- or 68Ga-labeled rhPSMA inhibitors (J Nucl Med 2020)"}]},{"url":"https://jnm.snmjournals.org/content/61/6/792","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-grpr-psma-negative-prostate","kind":"opportunity","name":"GRPR imaging when the PSMA scan is negative","route":"/opportunities/opp-grpr-psma-negative-prostate/","field":"links","label":"GRPR distribution in cancer, J Nucl Med 2020"}]},{"url":"https://jnm.snmjournals.org/content/61/7/981","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"split-function-lung-perfusion","kind":"technology","name":"Split-function perfusion scintigraphy before lung resection","route":"/technologies/split-function-lung-perfusion/","field":"links","label":"Head-to-head comparison finding no significant difference between segment counting, planar perfusion and SPECT/CT (J Nucl Med 2020)"}]},{"url":"https://jnm.snmjournals.org/content/62/3/354","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"upar","kind":"target","name":"uPAR (urokinase plasminogen activator receptor)","route":"/targets/upar/","field":"links","label":"JNM: uPAR PET/MRI (68Ga-NOTA-AE105) and Gleason score correlation in prostate cancer"}]},{"url":"https://jnm.snmjournals.org/content/63/12/1836","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-regional-radiopharmacy-network","kind":"idea","name":"In-house hospital radiopharmacy compounding to cut dose waste","route":"/ideas/idea-regional-radiopharmacy-network/","field":"links","label":"Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center (Journal of Nuclear Medicine)"}]},{"url":"https://jnm.snmjournals.org/content/63/6/816","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"phillip-kuo","kind":"person","name":"Phillip H. Kuo","route":"/people/phillip-kuo/","field":"links","label":"Why we did what we did, JNM 2022"}]},{"url":"https://jnm.snmjournals.org/content/63/6/823","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"docetaxel-then-lu177-psma","kind":"pairing","name":"Docetaxel (taxane chemotherapy) then 177Lu-PSMA-617","route":"/pairings/docetaxel-then-lu177-psma/","field":"links","label":"JNM commentary on VISION eligibility criteria (prior taxane and ARPI requirements)"}]},{"url":"https://jnm.snmjournals.org/content/64/1/47","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","field":"links","label":"A 2022 international survey on the status of prostate cancer theranostics (JNM)"},{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","field":"metrics (Mean PSMA PET wait time, international 2022 survey)"}]},{"url":"https://jnm.snmjournals.org/content/64/10/1516","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/","field":"links","label":"Is Actinium Really Happening? (Journal of Nuclear Medicine, 2023)"}]},{"url":"https://jnm.snmjournals.org/content/64/10/1574","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"beta-psma-then-alpha-psma-rescue","kind":"pairing","name":"177Lu-PSMA-617 then 225Ac-PSMA rescue therapy","route":"/pairings/beta-psma-then-alpha-psma-rescue/","field":"links","label":"Zacherl et al., first clinical results for 225Ac-PSMA-I&T in advanced mCRPC, J Nucl Med 2021;62:669-674"}]},{"url":"https://jnm.snmjournals.org/content/64/supplement_1/TS19","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"links","label":"Future challenges and occupational prospects of nuclear medicine technologists (JNM abstract)"},{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"metrics (US nuclear medicine technologist workforce change, 2012–2022)"},{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"metrics (US NMTs surveyed who plan to retire or leave direct patient care within 5–10 years)"}]},{"url":"https://jnm.snmjournals.org/content/65/11/1740","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"myelosuppression-after-rlt","kind":"term","name":"Myelosuppression after radioligand therapy","route":"/terms/myelosuppression-after-rlt/","field":"links","label":"Efficacy and Toxicity of [177Lu]Lu-PSMA-617 for Metastatic CRPC (expanded access programme vs VISION), J Nucl Med 2024"}]},{"url":"https://jnm.snmjournals.org/content/65/5/744","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"caix","kind":"target","name":"CAIX (carbonic anhydrase IX)","route":"/targets/caix/","field":"links","label":"JNM editorial: kick-starting molecular theranostics in renal cell carcinoma (VHL/HIF, girentuximab, 68Ga-DPI-4452)"}]},{"url":"https://jnm.snmjournals.org/content/65/6/931","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"renal-protection-amino-acids","kind":"term","name":"Renal protection with amino acid co-infusion","route":"/terms/renal-protection-amino-acids/","field":"links","label":"Bergsma H, et al. Safety and Efficacy of Para-Aminohippurate Coinfusion for Nephroprotection, J Nucl Med 2024"}]},{"url":"https://jnm.snmjournals.org/content/67/8/1239","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"action-1","kind":"trial","name":"ACTION-1","route":"/trials/action-1/","field":"links","label":"ACTION-1 dosimetry (JNM 2026)"}],"archive":"https://web.archive.org/web/20260811122544/https://jnm.snmjournals.org/content/67/8/1239"},{"url":"https://jnm.snmjournals.org/content/early/2024/10/17/jnumed.124.268754","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"epilepsy-localisation","kind":"indication","name":"Presurgical localisation of drug-resistant focal epilepsy","route":"/indications/epilepsy-localisation/","field":"links","label":"SNMMI Procedure Standard/EANM Practice Guideline for Brain FDG PET Imaging, version 2.0 (2024)"}]},{"url":"https://jnm.snmjournals.org/content/early/2025/01/07/jnumed.124.268756","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alzheimers-disease","kind":"indication","name":"Alzheimer's disease","route":"/indications/alzheimers-disease/","field":"links","label":"SNMMI/Alzheimer's Association: updated appropriate use criteria for amyloid and tau PET (2025)"},{"id":"f-18-florbetapir","kind":"drug","name":"Florbetapir F-18","route":"/drugs/f-18-florbetapir/","field":"links","label":"SNMMI/Alzheimer's Association: updated appropriate use criteria for amyloid and tau PET (2025)"},{"id":"f-18-flortaucipir","kind":"drug","name":"Flortaucipir F-18","route":"/drugs/f-18-flortaucipir/","field":"links","label":"SNMMI/Alzheimer's Association: updated appropriate use criteria for amyloid and tau PET (2025)"},{"id":"f-neuro-imaging","kind":"section","name":"Neuro-imaging","route":"/fronts/f-neuro-imaging/","field":"links","label":"Updated Appropriate Use Criteria for Amyloid and Tau PET (J Nucl Med / Alzheimer's & Dementia, 2025)"}]},{"url":"https://jnm.snmjournals.org/content/early/2025/02/06/jnumed.125.269538","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-infection-imaging","kind":"section","name":"Infection & inflammation imaging","route":"/fronts/f-infection-imaging/","field":"links","label":"JNM summary: EANM/SNMMI FDG hybrid PET infection/inflammation guideline v2.0"}]},{"url":"https://jnm.snmjournals.org/content/early/2025/06/05/jnumed.125.269601","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-pretargeted-alpha-therapy","kind":"idea","name":"Pretargeted alpha radioimmunotherapy","route":"/ideas/idea-pretargeted-alpha-therapy/","field":"links","label":"225Ac alpha-pretargeted radioimmunotherapy of HER2-expressing breast cancer (J Nucl Med, 2025)"}]},{"url":"https://jnm.snmjournals.org/content/jnumed/50/2/25N.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dosimetry-roadmap","kind":"roadmap","name":"Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose","route":"/roadmaps/dosimetry-roadmap/","field":"links","label":"From the MIRD Committee: history and founding, 1965 (J Nucl Med)"}]},{"url":"https://jnm.snmjournals.org/content/jnumed/57/12/1941.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-kratochwil-ac225-psma-jnm-2016","kind":"paper","name":"225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer","route":"/key-papers/paper-kratochwil-ac225-psma-jnm-2016/","field":"links","label":"JNM: 225Ac-PSMA-617 first-in-human report (full text PDF)"}]},{"url":"https://jnm.snmjournals.org/content/jnumed/58/8/14N.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"michael-lassmann","kind":"person","name":"Michael Lassmann","route":"/people/michael-lassmann/","field":"links","label":"Lassmann receives 2017 Loevinger-Berman Award"}]},{"url":"https://jnm.snmjournals.org/content/jnumed/59/3/479.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma-rads","kind":"term","name":"PSMA-RADS (PSMA reporting and data system)","route":"/terms/psma-rads/","field":"links","label":"Rowe SP, Pienta KJ, Pomper MG, Gorin MA. Proposal for a Structured Reporting System for PSMA-Targeted PET Imaging: PSMA-RADS Version 1.0. J Nucl Med 2018;59:479-485"}]},{"url":"https://jnm.snmjournals.org/content/jnumed/65/2/206.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-fap-pancreatic-staging","kind":"opportunity","name":"FAP imaging to stop futile pancreatic surgery","route":"/opportunities/opp-fap-pancreatic-staging/","field":"links","label":"18F-FAPI-04 against FDG in 62 patients, J Nucl Med 2024"}]},{"url":"https://jnm.snmjournals.org/content/jnumed/early/2013/03/11/jnumed.112.114298.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bone-hydroxyapatite","kind":"target","name":"Bone mineral (hydroxyapatite)","route":"/targets/bone-hydroxyapatite/","field":"links","label":"JNM: kinetics of bone-seeking radiotracers (Tc-99m-diphosphonate vs 18F-fluoride)"}]},{"url":"https://jnm.snmjournals.org/content/jnumed/early/2018/09/06/jnumed.118.217588.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma-rads","kind":"term","name":"PSMA-RADS (PSMA reporting and data system)","route":"/terms/psma-rads/","field":"links","label":"Werner RA, et al. Interobserver Agreement for PSMA-RADS 1.0 on 18F-DCFPyL PET/CT. J Nucl Med (2018)"}]},{"url":"https://jnm.snmjournals.org/content/jnumed/early/2020/02/06/jnumed.119.238287.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-68-dotatoc","kind":"drug","name":"Gallium-68 edotreotide (DOTATOC)","route":"/drugs/ga-68-dotatoc/","field":"links","label":"Sunderland & Graham, J Nucl Med 2020: an academic medical centre's journey through the FDA NDA process for 68Ga-DOTATOC"}]},{"url":"https://jnm.snmjournals.org/content/jnumed/early/2021/07/22/jnumed.120.261016.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ra-223","kind":"isotope","name":"Radium-223","route":"/isotopes/ra-223/","field":"links","label":"Production and supply of alpha particle emitting radionuclides for TAT (JNM, 2021)"},{"id":"th-227","kind":"isotope","name":"Thorium-227","route":"/isotopes/th-227/","field":"links","label":"Production and supply of alpha particle emitting radionuclides for TAT (JNM, 2021)"}]},{"url":"https://jnm.snmjournals.org/content/jnumed/early/2022/05/19/jnumed.122.263823.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ho-166","kind":"isotope","name":"Holmium-166","route":"/isotopes/ho-166/","field":"links","label":"Safety and efficacy of holmium-166 radioembolization in HCC - the HEPAR Primary study (J Nucl Med, 2022)"}]},{"url":"https://journals.viamedica.pl/nuclear_medicine_review/article/download/NMR.2021.0020/63672","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"quantitative-spect","kind":"technology","name":"Quantitative SPECT","route":"/technologies/quantitative-spect/","field":"links","label":"Physical quantities useful for quality control of quantitative SPECT/CT (Nuclear Medicine Review 2021)"}]},{"url":"https://jsnm.org/english/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jsnm","kind":"institution","name":"Japanese Society of Nuclear Medicine","route":"/institutions/jsnm/","field":"website"}]},{"url":"https://jsnm.org/english/about_jsnm/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jsnm","kind":"institution","name":"Japanese Society of Nuclear Medicine","route":"/institutions/jsnm/","field":"links","label":"About the JSNM (established 1964, about 3,600 members)"}]},{"url":"https://jsnm.org/english/meetings_and_events/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jsnm","kind":"institution","name":"Japanese Society of Nuclear Medicine","route":"/institutions/jsnm/","field":"links","label":"JSNM meetings and events (66th 2026 Himeji, 67th 2027 Omiya)"}]},{"url":"https://jsnm.org/english/publications/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jsnm","kind":"institution","name":"Japanese Society of Nuclear Medicine","route":"/institutions/jsnm/","field":"links","label":"JSNM publications"},{"id":"annals-of-nuclear-medicine","kind":"journal","name":"Annals of Nuclear Medicine","route":"/journals/annals-of-nuclear-medicine/","field":"links","label":"JSNM publications"}]},{"url":"https://link.springer.com/article/10.1007/s00259-017-3675-7","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"extravasation-radiopharmaceutical","kind":"term","name":"Radiopharmaceutical extravasation","route":"/terms/extravasation-radiopharmaceutical/","field":"links","label":"van der Pol J, et al. Consequences of radiopharmaceutical extravasation and therapeutic interventions: a systematic review, Eur J Nucl Med Mol Imaging 2017"}]},{"url":"https://link.springer.com/article/10.1007/s00259-022-05727-7","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-dosimetry-standardisation","kind":"bottleneck","name":"Dosimetry standardisation for radioligand therapy","route":"/bottlenecks/b-dosimetry-standardisation/","field":"links","label":"EANM Dosimetry Committee recommendations for 177Lu-labelled SSTR/PSMA ligands (2022)"},{"id":"b-dosimetry-standardisation","kind":"bottleneck","name":"Dosimetry standardisation for radioligand therapy","route":"/bottlenecks/b-dosimetry-standardisation/","field":"metrics (Number of PRRT cycles needed to reach a preset kidney dose limit, across patients)"},{"id":"b-dosimetry-standardisation","kind":"bottleneck","name":"Dosimetry standardisation for radioligand therapy","route":"/bottlenecks/b-dosimetry-standardisation/","field":"metrics (Variation in total activity needed to reach a preset absorbed-dose limit)"},{"id":"spect-dosimetry-workflow","kind":"technology","name":"SPECT dosimetry workflow for radionuclide therapy","route":"/technologies/spect-dosimetry-workflow/","field":"links","label":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled SSTR- and PSMA-targeting ligands (Eur J Nucl Med Mol Imaging 2022)"}]},{"url":"https://link.springer.com/article/10.1007/s00259-022-05786-w","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fixed-versus-personalised-dosing","kind":"term","name":"Fixed versus personalised (dosimetry-guided) dosing","route":"/terms/fixed-versus-personalised-dosing/","field":"links","label":"Sandström M, et al. Phase II trial: efficacy and safety of individualized, dosimetry-based 177Lu-DOTATATE (ILUMINET), Eur J Nucl Med Mol Imaging 2022"}]},{"url":"https://link.springer.com/article/10.1007/s00259-023-06316-y","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-tb161-instead-of-lu177","kind":"idea","name":"Terbium-161 instead of lutetium-177 in the same ligands","route":"/ideas/idea-tb161-instead-of-lu177/","field":"links","label":"Opportunities and potential challenges of using terbium-161 for targeted radionuclide therapy in clinics (EJNMMI, 2023)"},{"id":"tb-161","kind":"isotope","name":"Terbium-161","route":"/isotopes/tb-161/","field":"links","label":"Opportunities and potential challenges of using terbium-161 (Eur J Nucl Med Mol Imaging, 2023)"}]},{"url":"https://link.springer.com/article/10.1007/s00259-023-06361-7","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ejnmmi","kind":"journal","name":"European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)","route":"/journals/ejnmmi/","field":"links","label":"50 years EJNM and EJNMMI (Eur J Nucl Med Mol Imaging, 2023)"}]},{"url":"https://link.springer.com/article/10.1007/s00259-024-06915-3","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fever-of-unknown-origin","kind":"indication","name":"Fever of unknown origin","route":"/indications/fever-of-unknown-origin/","field":"links","label":"EANM/SNMMI guideline/procedure standard for FDG hybrid PET use in infection and inflammation in adults v2.0"}]},{"url":"https://link.springer.com/article/10.1007/s10120-024-01518-1","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cldn18-2-imaging-gastric","kind":"opportunity","name":"Claudin-18.2 imaging when one biopsy says negative","route":"/opportunities/opp-cldn18-2-imaging-gastric/","field":"links","label":"CLDN18.2 positivity in pooled SPOTLIGHT and GLOW screening"},{"id":"cldn18-2","kind":"target","name":"Claudin-18.2","route":"/targets/cldn18-2/","field":"links","label":"CLDN18.2 positivity across pooled SPOTLIGHT and GLOW screening"},{"id":"cldn18-2","kind":"target","name":"Claudin-18.2","route":"/targets/cldn18-2/","field":"prevalence.source"}]},{"url":"https://link.springer.com/article/10.1007/s12149-024-01914-8","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"flare-phenomenon","kind":"term","name":"Flare phenomenon","route":"/terms/flare-phenomenon/","field":"links","label":"Flare phenomenon visualized by 99mTc-bone scintigraphy has favourable prognostic value in mCRPC, Ann Nucl Med 2024"}]},{"url":"https://link.springer.com/article/10.1007/s12350-022-03111-4","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cardiac-sarcoidosis-specific-tracer","kind":"opportunity","name":"An inflammation tracer that does not need a diet","route":"/opportunities/opp-cardiac-sarcoidosis-specific-tracer/","field":"links","label":"68Ga-DOTATATE against FDG in cardiac sarcoidosis, J Nucl Cardiol 2023"}]},{"url":"https://link.springer.com/article/10.1007/s40336-026-00769-5","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-dosimetry-guided-dosing-standard","kind":"idea","name":"Kidney-dosimetry-guided dosing as the default for PSMA radioligand therapy","route":"/ideas/idea-dosimetry-guided-dosing-standard/","field":"links","label":"Radioligand therapy and tumor dosimetry: where are we and where are we going? (2026 review)"}]},{"url":"https://link.springer.com/article/10.1186/s41181-021-00131-2","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sc-47","kind":"isotope","name":"Scandium-47","route":"/isotopes/sc-47/","field":"links","label":"Production of scandium radionuclides for theranostic applications (EJNMMI Radiopharm Chem, 2021)"}]},{"url":"https://link.springer.com/article/10.1186/s41181-022-00180-1","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ge68-ga68-generators","kind":"technology","name":"Germanium-68/gallium-68 generators","route":"/technologies/ge68-ga68-generators/","field":"links","label":"Good practices for 68Ga radiopharmaceutical production (EJNMMI Radiopharm. Chem. 2022)"}]},{"url":"https://link.springer.com/article/10.1186/s41181-025-00418-8","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"zr-89","kind":"isotope","name":"Zirconium-89","route":"/isotopes/zr-89/","field":"links","label":"Springer: clinical nuclear medicine applications of zirconium-89 immuno-PET"}]},{"url":"https://link.springer.com/content/pdf/10.1007/s00259-024-06640-x.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"time-activity-curve","kind":"term","name":"Time-activity curve (TAC)","route":"/terms/time-activity-curve/","field":"links","label":"EANM guidance document: dosimetry for first-in-human studies"}]},{"url":"https://link.springer.com/content/pdf/10.1007/s11864-026-01386-0.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-fap-theranostics-sarcoma","kind":"idea","name":"FAP-targeted radioligand therapy for sarcoma","route":"/ideas/idea-fap-theranostics-sarcoma/","field":"links","label":"Theranostics in Sarcoma: A Critical Review of Current Evidence and Future Directions (2026 review)"}]},{"url":"https://link.springer.com/journal/12149","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"annals-of-nuclear-medicine","kind":"journal","name":"Annals of Nuclear Medicine","route":"/journals/annals-of-nuclear-medicine/","field":"links","label":"Annals of Nuclear Medicine (Springer): ISSN 0914-7187 print, 1864-6433 electronic"},{"id":"annals-of-nuclear-medicine","kind":"journal","name":"Annals of Nuclear Medicine","route":"/journals/annals-of-nuclear-medicine/","field":"url"}]},{"url":"https://link.springer.com/journal/13139","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Nuclear Medicine and Molecular Imaging","route":"/journals/nuclear-medicine-and-molecular-imaging/","field":"links","label":"Nuclear Medicine and Molecular Imaging (Springer): ISSN 1869-3474 print, 1869-3482 electronic"},{"id":"nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Nuclear Medicine and Molecular Imaging","route":"/journals/nuclear-medicine-and-molecular-imaging/","field":"url"}]},{"url":"https://link.springer.com/journal/259","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ejnmmi","kind":"journal","name":"European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)","route":"/journals/ejnmmi/","field":"links","label":"EJNMMI home (Springer Nature)"},{"id":"ejnmmi","kind":"journal","name":"European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)","route":"/journals/ejnmmi/","field":"url"}]},{"url":"https://link.springer.com/journal/259/aims-and-scope","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ejnmmi","kind":"journal","name":"European Journal of Nuclear Medicine and Molecular Imaging (EJNMMI)","route":"/journals/ejnmmi/","field":"links","label":"EJNMMI aims and scope"}]},{"url":"https://link.springer.com/journal/41181","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ejnmmi-radiopharmacy-and-chemistry","kind":"journal","name":"EJNMMI Radiopharmacy and Chemistry","route":"/journals/ejnmmi-radiopharmacy-and-chemistry/","field":"links","label":"EJNMMI Radiopharmacy and Chemistry home (Springer)"},{"id":"ejnmmi-radiopharmacy-and-chemistry","kind":"journal","name":"EJNMMI Radiopharmacy and Chemistry","route":"/journals/ejnmmi-radiopharmacy-and-chemistry/","field":"url"}]},{"url":"https://link.springer.com/journal/41181/aims-and-scope","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ejnmmi-radiopharmacy-and-chemistry","kind":"journal","name":"EJNMMI Radiopharmacy and Chemistry","route":"/journals/ejnmmi-radiopharmacy-and-chemistry/","field":"links","label":"EJNMMI Radiopharmacy and Chemistry aims and scope"}]},{"url":"https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/fl/","status":200,"ok":true,"finalUrl":"https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/follicular-lymphoma/","checked":"2026-10-21","refs":[{"id":"follicular-lymphoma","kind":"indication","name":"Follicular lymphoma","route":"/indications/follicular-lymphoma/","field":"links","label":"Lymphoma Research Foundation: FL"}],"archive":"https://web.archive.org/web/20221014125031/https://lymphoma.org/understanding-lymphoma/aboutlymphoma/nhl/fl/"},{"url":"https://marianaoncology.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","field":"links","label":"Official website"},{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","field":"website"}],"archive":"https://web.archive.org/web/20260618074059/https://marianaoncology.com/"},{"url":"https://marianaoncology.com/news/mariana-oncology-announces-usd175-million-series-b-financing/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","field":"links","label":"Series B press release"}],"archive":"https://web.archive.org/web/20260618082401/https://marianaoncology.com/news/mariana-oncology-announces-usd175-million-series-b-financing/"},{"url":"https://marianaoncology.com/news/mariana-oncology-to-be-acquired-by-novartis-to-advance-precision-radiopharmaceuticals-to-treat-cancer/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mariana-oncology","kind":"company","name":"Mariana Oncology","route":"/companies/mariana-oncology/","field":"links","label":"Novartis acquisition announcement"}],"archive":"https://web.archive.org/web/20260510140429/https://marianaoncology.com/news/mariana-oncology-to-be-acquired-by-novartis-to-advance-precision-radiopharmaceuticals-to-treat-cancer/"},{"url":"https://med.stanford.edu/content/dam/sm/urology/JJimages/publications/Screening-rates-for-primary-aldosteronism-in-resistant-hypertension-A-cohort-study.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"links","label":"Screening rates for primary aldosteronism in resistant hypertension, a cohort study"}]},{"url":"https://med.stanford.edu/nuclearmedicine/people/faculty.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"andrei-iagaru","kind":"person","name":"Andrei Iagaru","route":"/people/andrei-iagaru/","field":"links","label":"Stanford Nuclear Medicine faculty page"},{"id":"andrei-iagaru","kind":"person","name":"Andrei Iagaru","route":"/people/andrei-iagaru/","field":"profiles","label":"Stanford Nuclear Medicine faculty page"}]},{"url":"https://mediso.com","status":200,"ok":true,"finalUrl":"https://mediso.com/","checked":"2026-10-21","refs":[{"id":"mediso","kind":"company","name":"Mediso","route":"/companies/mediso/","field":"links","label":"Official website"},{"id":"mediso","kind":"company","name":"Mediso","route":"/companies/mediso/","field":"website"}],"archive":"https://web.archive.org/web/20260826084327/https://mediso.com/"},{"url":"https://medlineplus.gov/genetics/gene/slc5a5/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nis-symporter","kind":"target","name":"NIS (sodium-iodide symporter)","route":"/targets/nis-symporter/","field":"links","label":"MedlinePlus Genetics: SLC5A5 gene"}]},{"url":"https://medraysintell.com/radiopharmaceutical-supply-chain-structure-7-7/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-cold-chain-logistics","kind":"bottleneck","name":"Cold chain and time-critical logistics","route":"/bottlenecks/b-cold-chain-logistics/","field":"links","label":"Radiopharmaceutical supply chain structure (MedRaySintell)"}]},{"url":"https://myscrs.org/preparing-clinical-sites-radiopharmaceutical-trials/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-rlt-trial-capacity","kind":"bottleneck","name":"Clinical trial capacity for radioligand therapy","route":"/bottlenecks/b-rlt-trial-capacity/","field":"links","label":"Preparing clinical sites for radiopharmaceutical trials (SCRS)"}]},{"url":"https://nds.iaea.org/indc/docs/presentations/INDC-2024-Global-overview.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"iaea-isotope-databases","kind":"collection","name":"IAEA nuclear data and isotope databases","route":"/collections/iaea-isotope-databases/","field":"links","label":"IAEA Nuclear Data Section: Global overview (databases and web applications)"}]},{"url":"https://nds.iaea.org/relnsd/vcharthtml/VChartHTML.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"iaea-isotope-databases","kind":"collection","name":"IAEA nuclear data and isotope databases","route":"/collections/iaea-isotope-databases/","field":"links","label":"IAEA Live Chart of Nuclides"},{"id":"iaea-isotope-databases","kind":"collection","name":"IAEA nuclear data and isotope databases","route":"/collections/iaea-isotope-databases/","field":"url"}]},{"url":"https://netrf.org/about-netrf/board-of-advisors/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lisa-bodei","kind":"person","name":"Lisa Bodei","route":"/people/lisa-bodei/","field":"profiles","label":"NETRF board of advisors biography"}]},{"url":"https://netrf.org/specialist/erik-mittra-md-phd/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"erik-mittra","kind":"person","name":"Erik S. Mittra","route":"/people/erik-mittra/","field":"links","label":"NETRF specialist profile"}]},{"url":"https://neuraceq.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"life-molecular-imaging","kind":"company","name":"Life Molecular Imaging","route":"/companies/life-molecular-imaging/","field":"links","label":"Neuraceq (florbetaben F18 injection) product site"}]},{"url":"https://news.bostonscientific.com/2021-03-18-Boston-Scientific-Receives-FDA-Approval-for-TheraSphere-TM-Y-90-Glass-Microspheres","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"y-90-glass-microspheres","kind":"drug","name":"Yttrium-90 glass microspheres","route":"/drugs/y-90-glass-microspheres/","field":"links","label":"Boston Scientific: FDA approval press release, 18 March 2021"}]},{"url":"https://niowaveinc.com","status":200,"ok":true,"finalUrl":"https://niowaveinc.com/","checked":"2026-10-21","refs":[{"id":"niowave","kind":"company","name":"Niowave","route":"/companies/niowave/","field":"website"}]},{"url":"https://nucleus.iaea.org/sites/accelerators/Modern%20AKP%20Site%20Assets/Educational%20Materials;%20Radioisotope%20and%20Radiopharmaceutical%20Production%20using%20a%20Medical%20Cyclotron/6-Quality%20Control%20and%20Batch%20Release/Radionuclidic%20Identity%20and%20Purity.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radionuclidic-purity","kind":"term","name":"Radionuclidic purity","route":"/terms/radionuclidic-purity/","field":"links","label":"IAEA: radionuclidic identity and purity (educational materials)"}]},{"url":"https://nucleusrad.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","field":"links","label":"Official website"},{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","field":"website"}],"archive":"https://web.archive.org/web/20260709222224/https://nucleusrad.com/"},{"url":"https://nucleusrad.com/news-events/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","field":"links","label":"News and events"}],"archive":"https://web.archive.org/web/20260511201030/https://nucleusrad.com/news-events/"},{"url":"https://nucleusrad.com/wp-content/uploads/Nucleus-RadioPharma-Secures-50-Million-Financing-from-OrbiMed-to-Expand-Radiopharmaceutical-Manufacturing-Capacity.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nucleus-radiopharma","kind":"company","name":"Nucleus RadioPharma","route":"/companies/nucleus-radiopharma/","field":"links","label":"OrbiMed financing release (PDF)"}],"archive":"https://web.archive.org/web/20260511183548/http://nucleusrad.com/wp-content/uploads/Nucleus-RadioPharma-Secures-50-Million-Financing-from-OrbiMed-to-Expand-Radiopharmaceutical-Manufacturing-Capacity.pdf"},{"url":"https://nuclidium.com","status":200,"ok":true,"finalUrl":"https://nuclidium.com/","checked":"2026-10-21","refs":[{"id":"nuclidium","kind":"company","name":"Nuclidium","route":"/companies/nuclidium/","field":"website"}]},{"url":"https://nuclidium.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nuclidium","kind":"company","name":"Nuclidium","route":"/companies/nuclidium/","field":"links","label":"Nuclidium: company site"}]},{"url":"https://nuclidium.com/nuclidium-announces-issuance-of-new-u-s-patent-covering-its-61cu-based-radiodiagnostic-program-for-psma-positive-prostate-cancer/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nuclidium","kind":"company","name":"Nuclidium","route":"/companies/nuclidium/","field":"links","label":"Nuclidium: issuance of new US patent covering its 61Cu-based radiodiagnostic programme for PSMA-positive prostate cancer (2026)"}]},{"url":"https://nuclidium.com/pipeline/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nuclidium","kind":"company","name":"Nuclidium","route":"/companies/nuclidium/","field":"links","label":"Nuclidium: pipeline (NU101)"}]},{"url":"https://nuklearmedizin.uk-essen.de/onkologie/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"wolfgang-fendler","kind":"person","name":"Wolfgang P. Fendler","route":"/people/wolfgang-fendler/","field":"links","label":"Essen Klinik für Nuklearmedizin, oncology team page"},{"id":"wolfgang-fendler","kind":"person","name":"Wolfgang P. Fendler","route":"/people/wolfgang-fendler/","field":"profiles","label":"Essen nuclear medicine department page"}]},{"url":"https://nvng.nl/wp-content/uploads/FAST-rapportage-medische-isotopen_def.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-hot-lab-capacity","kind":"bottleneck","name":"Hot lab and shielded treatment room capacity","route":"/bottlenecks/b-hot-lab-capacity/","field":"links","label":"The Dutch innovation ecosystem for nuclear medicine (hot lab cost and scarcity)"}],"archive":"https://web.archive.org/web/20240924082623/https://nvng.nl/wp-content/uploads/FAST-rapportage-medische-isotopen_def.pdf"},{"url":"https://oncodaily.com/genitourinary-oncology/radical-2","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-bone-targeted","kind":"section","name":"Bone-targeted radiopharmaceuticals","route":"/fronts/f-bone-targeted/","field":"links","label":"RADICAL trial (Alliance A031801): radium-223 + cabozantinib in mRCC (JCO, 27 Jul 2026)"}]},{"url":"https://oncodaily.com/oncolibrary/immune-oncology/rowan-study-enrol-complet","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tare-plus-durvalumab-hcc","kind":"pairing","name":"Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma","route":"/pairings/tare-plus-durvalumab-hcc/","field":"links","label":"ROWAN study (NCT05063565) enrolment-complete summary"}]},{"url":"https://open.library.ubc.ca/media/stream/pdf/24/1.0392203/4","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dota-chelation","kind":"technology","name":"DOTA chelation","route":"/technologies/dota-chelation/","field":"links","label":"Metal Chelating Agents for Medicinal Radionuclides (UBC open thesis, background on DOTA kinetics)"}]},{"url":"https://opendose.polsl.pl/project/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opendose","kind":"collection","name":"OpenDose","route":"/collections/opendose/","field":"links","label":"OpenDose project mirror"},{"id":"opendose","kind":"collection","name":"OpenDose","route":"/collections/opendose/","field":"url"}]},{"url":"https://opendose.polsl.pl/svalues/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opendose","kind":"collection","name":"OpenDose","route":"/collections/opendose/","field":"links","label":"OpenDose S values tool"}]},{"url":"https://openmedscience.com/the-rise-and-fall-of-iodine-131-tositumomab-bexxars-story/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"i-131-tositumomab","kind":"drug","name":"Iodine-131 tositumomab","route":"/drugs/i-131-tositumomab/","field":"links","label":"The rise and fall of iodine-131 tositumomab: Bexxar's story"},{"id":"i-131-tositumomab","kind":"drug","name":"Iodine-131 tositumomab","route":"/drugs/i-131-tositumomab/","field":"regulatoryEvents.source (2014-02-20)"}]},{"url":"https://orcid.org/0000-0002-2556-1977","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"michael-lassmann","kind":"person","name":"Michael Lassmann","route":"/people/michael-lassmann/","field":"profiles","label":"ORCID"}]},{"url":"https://orcid.org/0000-0003-1551-2036","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"neeta-pandit-taskar","kind":"person","name":"Neeta Pandit-Taskar","route":"/people/neeta-pandit-taskar/","field":"profiles","label":"ORCID"}]},{"url":"https://oslocancercluster.no","status":200,"ok":true,"finalUrl":"https://oslocancercluster.no/","checked":"2026-10-21","refs":[{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","field":"links","label":"Oslo Cancer Cluster"}],"archive":"https://web.archive.org/web/20261005052528/https://oslocancercluster.no/"},{"url":"https://pdf.hres.ca/dpd_pm/00050840.PDF","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tl-201","kind":"isotope","name":"Thallium-201","route":"/isotopes/tl-201/","field":"links","label":"Health Canada product monograph: Thallous Chloride Tl 201 Injection"}]},{"url":"https://perspectivetherapeutics.com","status":200,"ok":true,"finalUrl":"https://perspectivetherapeutics.com/","checked":"2026-10-21","refs":[{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20260925122654/https://www.perspectivetherapeutics.com/"},{"url":"https://perspectivetherapeutics.com/pipeline/vmt-alpha-net","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pb-212-vmt-alpha-net","kind":"drug","name":"Lead-212 VMT-alpha-NET","route":"/drugs/pb-212-vmt-alpha-net/","field":"links","label":"Perspective Therapeutics: VMT-alpha-NET pipeline page"}]},{"url":"https://perspectivetherapeutics.com/pr/perspective-therapeutics-announces-first-patient-dosed-in-a-phase-1-study-of-212pbvmtnet-to-treat-refractory-or-relapsedneuroendocrine-tumors","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pb-212-vmt-alpha-net","kind":"drug","name":"Lead-212 VMT-alpha-NET","route":"/drugs/pb-212-vmt-alpha-net/","field":"links","label":"Perspective Therapeutics: first patient dosed press release, 2023"}]},{"url":"https://perspectivetherapeutics.com/technology/manufacturing-logistics","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pb-212","kind":"isotope","name":"Lead-212","route":"/isotopes/pb-212/","field":"links","label":"Perspective Therapeutics: Manufacturing & Logistics (VMT-α-GEN Pb-212 generator)"}]},{"url":"https://pharmaphorum.com/rd/growth-radiotherapeutics-addressing-supply-chain-complexity","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-regional-radiopharmacy-network","kind":"idea","name":"In-house hospital radiopharmacy compounding to cut dose waste","route":"/ideas/idea-regional-radiopharmacy-network/","field":"links","label":"The growth of radiotherapeutics: Addressing supply chain complexity (pharmaphorum, 2026)"}]},{"url":"https://pharmasource.global/content/news/cdmo-news/duchembio-to-build-25-5m-radiopharmaceutical-cdmo-plant-in-south-korea/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"duchembio","kind":"company","name":"DuChemBio","route":"/companies/duchembio/","field":"links","label":"DuChemBio to build a KRW 34.3 billion radiopharmaceutical CDMO plant (September 2026)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10027805/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-molecular-imaging","kind":"section","name":"Molecular imaging","route":"/fronts/f-molecular-imaging/","field":"links","label":"EANM/SNMMI: PSMA PET/CT procedure guideline 2.0 (Eur J Nucl Med Mol Imaging, 2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10144982/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"technegas","kind":"drug","name":"Technegas (technetium Tc-99m labelled carbon inhalation aerosol)","route":"/drugs/technegas/","field":"links","label":"Technegas particle characterisation: nanoparticle agglomerates of 60-160 nm (review)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10159870/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma-theranostics-roadmap","kind":"roadmap","name":"PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha","route":"/roadmaps/psma-theranostics-roadmap/","field":"links","label":"FDA: Pluvicto (lutetium Lu 177 vipivotide tetraxetan) approval summary, March 2022 (PMC)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10254488/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"n-13","kind":"isotope","name":"Nitrogen-13","route":"/isotopes/n-13/","field":"links","label":"PMC: reliable production of large quantities of [13N]ammonia"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10288943/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cu-64","kind":"isotope","name":"Copper-64","route":"/isotopes/cu-64/","field":"links","label":"PMC: recent advances in 64Cu/67Cu-based radiopharmaceuticals (2023)"},{"id":"cu-67","kind":"isotope","name":"Copper-67","route":"/isotopes/cu-67/","field":"links","label":"Recent Advances in 64Cu/67Cu-Based Radiopharmaceuticals (Pharmaceutics, 2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10317889/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-dosimetry-standardisation","kind":"bottleneck","name":"Dosimetry standardisation for radioligand therapy","route":"/bottlenecks/b-dosimetry-standardisation/","field":"links","label":"Joint EANM/SNMMI procedure guideline for 177Lu-PSMA-RLT (2023)"},{"id":"b-dosimetry-standardisation","kind":"bottleneck","name":"Dosimetry standardisation for radioligand therapy","route":"/bottlenecks/b-dosimetry-standardisation/","field":"metrics (177Lu-PSMA-617 approved regimen: fixed activity per cycle)"},{"id":"dosimetry-roadmap","kind":"roadmap","name":"Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose","route":"/roadmaps/dosimetry-roadmap/","field":"links","label":"Joint EANM/SNMMI procedure guideline for 177Lu-PSMA-RLT (2023)"},{"id":"activity-prescription","kind":"term","name":"Activity prescription: fixed versus dosimetry-guided dosing","route":"/terms/activity-prescription/","field":"links","label":"PMC: joint EANM/SNMMI procedure guideline for 177Lu-labelled PSMA radioligand therapy"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10366059/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"automated-synthesis-modules","kind":"technology","name":"Automated synthesis modules","route":"/technologies/automated-synthesis-modules/","field":"links","label":"Simplified and highly-reliable automated production of [18F]FSPG for clinical studies, comparing TRACERlab and FASTlab (PMC 2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10368598/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ejnmmi-radiopharmacy-and-chemistry","kind":"journal","name":"EJNMMI Radiopharmacy and Chemistry","route":"/journals/ejnmmi-radiopharmacy-and-chemistry/","field":"links","label":"EJNMMI Radiopharmacy and Chemistry obtains its first impact factor (2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10375575/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sc-44","kind":"isotope","name":"Scandium-44","route":"/isotopes/sc-44/","field":"links","label":"PMC: current state of 44Ti/44Sc radionuclide generator systems"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10495309/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"relative-biological-effectiveness","kind":"term","name":"Relative biological effectiveness (RBE)","route":"/terms/relative-biological-effectiveness/","field":"links","label":"PMC: estimation of relative biological effectiveness of 225Ac compared to 177Lu"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10611796/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-alpha-synuclein-pet-parkinsons","kind":"opportunity","name":"Alpha-synuclein PET: works for MSA, not for Parkinson's","route":"/opportunities/opp-alpha-synuclein-pet-parkinsons/","field":"links","label":"[18F]ACI-12589 first-in-human, Nature Communications 2023"},{"id":"alpha-synuclein","kind":"target","name":"Alpha-synuclein","route":"/targets/alpha-synuclein/","field":"links","label":"[18F]ACI-12589 first-in-human, Nature Communications 2023"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10728412/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-fdopa","kind":"drug","name":"Fluorodopa F-18","route":"/drugs/f-18-fdopa/","field":"links","label":"Prospective comparison of 18F-FDOPA and 68Ga-DOTATOC PET/CT in pheochromocytoma/paraganglioma (2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10730517/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sc-47","kind":"isotope","name":"Scandium-47","route":"/isotopes/sc-47/","field":"links","label":"Production and purification of 43Sc and 47Sc from enriched titanium targets (Sci Rep, 2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10758070/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"renal-protection-amino-acids","kind":"term","name":"Renal protection with amino acid co-infusion","route":"/terms/renal-protection-amino-acids/","field":"links","label":"Long-term Nephrotoxicity after PRRT: Myth or Reality, PMC 2024"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10792730/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-68-pentixafor","kind":"drug","name":"Gallium-68 pentixafor","route":"/drugs/ga-68-pentixafor/","field":"links","label":"Advances in PET imaging of the CXCR4 receptor, Seminars in Nuclear Medicine 2023"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10798073/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tc-99m-psma-imaging","kind":"drug","name":"Technetium Tc-99m PSMA agents (PSMA-I&S)","route":"/drugs/tc-99m-psma-imaging/","field":"links","label":"Diagnostic value of 99mTc-PSMA-I&S SPECT/CT for prostate cancer detection and staging (2024)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10814892/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-ai-lesion-segmentation-dosimetry","kind":"idea","name":"AI segmentation to make voxel-level radioligand dosimetry practical at scale","route":"/ideas/idea-ai-lesion-segmentation-dosimetry/","field":"links","label":"Radiomics and Artificial Intelligence in Radiotheranostics (PMC review, 2024)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10905220/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/","field":"links","label":"Establishing a robust radioligand therapy programme (licensing and Agreement State detail)"},{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/","field":"metrics (US states with their own ('Agreement State') authority to license medical radioactive materials, as of 2024)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10957681/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-68-pentixafor","kind":"drug","name":"Gallium-68 pentixafor","route":"/drugs/ga-68-pentixafor/","field":"links","label":"CXCR4-directed PET/CT with 68Ga-pentixafor in solid tumours (142 patients), 2023"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC10957710/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"spect-dosimetry-workflow","kind":"technology","name":"SPECT dosimetry workflow for radionuclide therapy","route":"/technologies/spect-dosimetry-workflow/","field":"links","label":"EANM guidance document: dosimetry for first-in-human studies and phase 0/1 clinical trials (PMC 2024)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11083888/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"o-15","kind":"isotope","name":"Oxygen-15","route":"/isotopes/o-15/","field":"links","label":"PMC: frugal and translatable [15O]O2 production for human research"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11088613/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-radiochemistry","kind":"section","name":"Radiochemistry & manufacturing","route":"/fronts/f-radiochemistry/","field":"links","label":"Good practices for 89Zr radiopharmaceutical production and conjugation (EJNMMI Radiopharm Chem, 2024)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11139752/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"epilepsy-localisation","kind":"indication","name":"Presurgical localisation of drug-resistant focal epilepsy","route":"/indications/epilepsy-localisation/","field":"links","label":"EANM practice guidelines for an appropriate use of PET and SPECT for patients with epilepsy"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11149600/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cldn18-2-imaging-gastric","kind":"opportunity","name":"Claudin-18.2 imaging when one biopsy says negative","route":"/opportunities/opp-cldn18-2-imaging-gastric/","field":"links","label":"First-in-human CLDN18.2 PET imaging"},{"id":"cldn18-2","kind":"target","name":"Claudin-18.2","route":"/targets/cldn18-2/","field":"links","label":"First-in-human CLDN18.2 PET imaging"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11509096/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"split-function-lung-perfusion","kind":"technology","name":"Split-function perfusion scintigraphy before lung resection","route":"/technologies/split-function-lung-perfusion/","field":"links","label":"SPECT/CT quantification predicted postoperative FEV1 and DLCO better than planar or segment counting (2024)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11544963/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-bone-targeted","kind":"section","name":"Bone-targeted radiopharmaceuticals","route":"/fronts/f-bone-targeted/","field":"links","label":"Bone-targeting radionuclides in mCRPC: review of radium-223 combinations (Diagnostics, 2024)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11571012/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-bispecific-radioligands","kind":"idea","name":"Bispecific PSMA/GRPR radioligands for discordant prostate cancer lesions","route":"/ideas/idea-bispecific-radioligands/","field":"links","label":"Synthesis and Preclinical Evaluation of a Bispecific PSMA-617/RM2 Heterodimer (PMC, 2024)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11634952/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-fap-pancreatic-staging","kind":"opportunity","name":"FAP imaging to stop futile pancreatic surgery","route":"/opportunities/opp-fap-pancreatic-staging/","field":"links","label":"[18F]AlF-FAPI-74 in potentially resectable pancreatic cancer"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11732780/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-infection-imaging","kind":"section","name":"Infection & inflammation imaging","route":"/fronts/f-infection-imaging/","field":"links","label":"EANM/SNMMI guideline/procedure standard for FDG hybrid PET in infection and inflammation v2.0 (Eur J Nucl Med Mol Imaging, 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11745944/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lu-177-pnt2002","kind":"drug","name":"Lutetium-177 PNT2002","route":"/drugs/lu-177-pnt2002/","field":"links","label":"Initial clinical experience with 177Lu-PNT2002 (SPLASH lead-in), PMC 2025"},{"id":"lu-177-pnt2002","kind":"drug","name":"Lutetium-177 PNT2002","route":"/drugs/lu-177-pnt2002/","field":"dosing.source"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11816130/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"beta-psma-then-alpha-psma-rescue","kind":"pairing","name":"177Lu-PSMA-617 then 225Ac-PSMA rescue therapy","route":"/pairings/beta-psma-then-alpha-psma-rescue/","field":"links","label":"Long-term safety and survival outcomes of 225Ac-PSMA (PMC11816130, 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11876735/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lisa-bodei","kind":"person","name":"Lisa Bodei","route":"/people/lisa-bodei/","field":"links","label":"NETTER-1 dosimetry substudy, JNM 2025"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC11981304/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma-rads","kind":"term","name":"PSMA-RADS (PSMA reporting and data system)","route":"/terms/psma-rads/","field":"links","label":"PSMA-RADS: updated version 2.0 discussion (PMC, 2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12079709/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"activity-prescription","kind":"term","name":"Activity prescription: fixed versus dosimetry-guided dosing","route":"/terms/activity-prescription/","field":"links","label":"PMC: dosimetry in radiopharmaceutical therapy"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12079710/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-pretargeted-alpha-therapy","kind":"idea","name":"Pretargeted alpha radioimmunotherapy","route":"/ideas/idea-pretargeted-alpha-therapy/","field":"links","label":"Pretargeting: A Path Forward for Radioimmunotherapy (PMC review)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12121839/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"i-123","kind":"isotope","name":"Iodine-123","route":"/isotopes/i-123/","field":"links","label":"PMC: perspective on production and quality control of iodine-123"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12165876/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"links","label":"Implementation of the 9th TNM for lung cancer: practical points (2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12175995/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-cardiac-imaging","kind":"section","name":"Cardiac imaging","route":"/fronts/f-cardiac-imaging/","field":"links","label":"FDA approval of 18F-flurpiridaz for PET: stepping into a new era of MPI (J Nucl Med, 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12192484/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-alpha-synuclein-pet-parkinsons","kind":"opportunity","name":"Alpha-synuclein PET: works for MSA, not for Parkinson's","route":"/opportunities/opp-alpha-synuclein-pet-parkinsons/","field":"links","label":"Pooled meta-analysis of alpha-synuclein seed amplification assays"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12197855/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"re-188-sct","kind":"drug","name":"Rhenium-188 skin cancer therapy","route":"/drugs/re-188-sct/","field":"links","label":"EPIC-Skin phase 4 study, 12-month results (PMC, 2025)"},{"id":"re-188-sct","kind":"drug","name":"Rhenium-188 skin cancer therapy","route":"/drugs/re-188-sct/","field":"dosing.source"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12227459/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-nectin4-imaging-urothelial","kind":"opportunity","name":"A liver-cleared Nectin-4 tracer for urothelial cancer","route":"/opportunities/opp-nectin4-imaging-urothelial/","field":"links","label":"Review noting urinary excretion as a barrier to in-situ bladder detection, 2025"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12386959/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-bispecific-radioligands","kind":"idea","name":"Bispecific PSMA/GRPR radioligands for discordant prostate cancer lesions","route":"/ideas/idea-bispecific-radioligands/","field":"links","label":"Bispecific Radioligands (BRLs): Two Is Better Than One (PMC review, 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12393064/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"her3","kind":"target","name":"HER3 (ERBB3)","route":"/targets/her3/","field":"links","label":"HER3 expression in non-small cell lung cancer"},{"id":"her3","kind":"target","name":"HER3 (ERBB3)","route":"/targets/her3/","field":"prevalence.source"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12459304/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"links","label":"Universal screening for primary aldosteronism in hypertensive patients"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12464796/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"time-activity-curve","kind":"term","name":"Time-activity curve (TAC)","route":"/terms/time-activity-curve/","field":"links","label":"PMC: understanding time-activity curve and time-integrated activity coefficient calculation in radiopharmaceutical therapy"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12468084/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/","field":"links","label":"Actinium-225/Bismuth-213 as potential leaders for targeted alpha therapy (2025 review)"},{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/","field":"metrics (Legacy thorium-229 generator supply, worldwide)"},{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/","field":"metrics (Patients that legacy supply can treat per year)"},{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/","field":"metrics (Estimated annual demand from research and clinical trials alone)"},{"id":"bi-213","kind":"isotope","name":"Bismuth-213","route":"/isotopes/bi-213/","field":"links","label":"Actinium-225/Bismuth-213 as Potential Leaders for Targeted Alpha Therapy (Pharmaceutics, 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12494511/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tb-161","kind":"isotope","name":"Terbium-161","route":"/isotopes/tb-161/","field":"links","label":"Potentials and practical challenges of terbium-161 labeled radiopharmaceuticals (PMC, 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12563130/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-neoadjuvant-psma-therapy","kind":"idea","name":"Neoadjuvant PSMA radioligand therapy before prostatectomy","route":"/ideas/idea-neoadjuvant-psma-therapy/","field":"links","label":"Neoadjuvant 177Lutetium-PSMA-617 Radioligand Therapy for High-Risk Prostate Cancer (review, PMC 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12593530/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"epilepsy-localisation","kind":"indication","name":"Presurgical localisation of drug-resistant focal epilepsy","route":"/indications/epilepsy-localisation/","field":"links","label":"Review: drug-resistant epilepsy definition, pathophysiology and management (burden figures)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12607575/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-fap-pancreatic-staging","kind":"opportunity","name":"FAP imaging to stop futile pancreatic surgery","route":"/opportunities/opp-fap-pancreatic-staging/","field":"links","label":"FRONTIER terminated early for rapid clearance"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12623512/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-regional-radiopharmacy-network","kind":"idea","name":"In-house hospital radiopharmacy compounding to cut dose waste","route":"/ideas/idea-regional-radiopharmacy-network/","field":"links","label":"Optimization of the radiosynthesis of PSMA-targeting drugs using a cassette-based platform (MiniLu) (PMC, 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12629902/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-tb161-instead-of-lu177","kind":"idea","name":"Terbium-161 instead of lutetium-177 in the same ligands","route":"/ideas/idea-tb161-instead-of-lu177/","field":"links","label":"From lutetium to terbium: a new era in PSMA-targeted radioligand therapy (PMC, 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12647276/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cldn18-2-imaging-gastric","kind":"opportunity","name":"Claudin-18.2 imaging when one biopsy says negative","route":"/opportunities/opp-cldn18-2-imaging-gastric/","field":"links","label":"Multi-laboratory ring trial of CLDN18.2 immunohistochemistry"},{"id":"cldn18-2","kind":"target","name":"Claudin-18.2","route":"/targets/cldn18-2/","field":"links","label":"Multi-laboratory ring trial of CLDN18.2 immunohistochemistry"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12655809/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"monte-carlo-dosimetry","kind":"technology","name":"Monte Carlo dosimetry","route":"/technologies/monte-carlo-dosimetry/","field":"links","label":"Advancing internal dosimetry in personalised nuclear medicine: MCNP6/GATE/GAMOS comparison (PMC 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12660422/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-daughter-redistribution","kind":"technology","name":"Alpha-emitter daughter redistribution ('free daughter' problem)","route":"/technologies/alpha-daughter-redistribution/","field":"links","label":"Biodistribution of free francium-221 and bismuth-213 in tumour-bearing mice (PMC 2025)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12758208/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-her3-imaging-crossover","kind":"opportunity","name":"HER3 imaging, and why three tracers stalled","route":"/opportunities/opp-her3-imaging-crossover/","field":"links","label":"No validated HER3 immunohistochemistry assays or thresholds (review)"},{"id":"her3","kind":"target","name":"HER3 (ERBB3)","route":"/targets/her3/","field":"links","label":"No validated HER3 assays or scoring thresholds (review)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12775822/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pb-212","kind":"isotope","name":"Lead-212","route":"/isotopes/pb-212/","field":"links","label":"Lead radionuclides for theranostic applications in nuclear medicine (PMC, 2026)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12796145/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","field":"prevalence.source"},{"id":"psma","kind":"target","name":"PSMA","route":"/targets/psma/","field":"prevalence.source"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12929731/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"at-211","kind":"isotope","name":"Astatine-211","route":"/isotopes/at-211/","field":"links","label":"Solving the limited availability of Astatine-211 from a European perspective (PMC, 2026)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC12976585/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"caix","kind":"target","name":"CAIX (carbonic anhydrase IX)","route":"/targets/caix/","field":"links","label":"PMC: application of CAIX-targeted radiotracers in ccRCC"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13002445/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-cold-chain-logistics","kind":"bottleneck","name":"Cold chain and time-critical logistics","route":"/bottlenecks/b-cold-chain-logistics/","field":"links","label":"Challenges in radiopharmaceutical importation across six SADC countries (2026)"},{"id":"b-cold-chain-logistics","kind":"bottleneck","name":"Cold chain and time-critical logistics","route":"/bottlenecks/b-cold-chain-logistics/","field":"metrics (Reported radiopharmaceutical order-to-delivery lead times across surveyed SADC countries)"},{"id":"b-cold-chain-logistics","kind":"bottleneck","name":"Cold chain and time-critical logistics","route":"/bottlenecks/b-cold-chain-logistics/","field":"metrics (Customs clearance delays reported for radiopharmaceutical imports)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13096388/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ge68-ga68-generators","kind":"technology","name":"Germanium-68/gallium-68 generators","route":"/technologies/ge68-ga68-generators/","field":"links","label":"The 68Ge/68Ga generator for enhancing productivity: multi-year performance data (PMC 2026)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13114725/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Early stage)"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Metastatic)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13121216/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-alpha-synuclein-pet-parkinsons","kind":"opportunity","name":"Alpha-synuclein PET: works for MSA, not for Parkinson's","route":"/opportunities/opp-alpha-synuclein-pet-parkinsons/","field":"links","label":"No approved small-molecule alpha-synuclein PET agent"},{"id":"alpha-synuclein","kind":"target","name":"Alpha-synuclein","route":"/targets/alpha-synuclein/","field":"links","label":"No approved small-molecule alpha-synuclein PET agent"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13141699/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-molecular-imaging","kind":"section","name":"Molecular imaging","route":"/fronts/f-molecular-imaging/","field":"links","label":"PMC: Future opportunities and nuances with PSMA PET (2026 review, incl. 2026 NCCN guidance)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13379550/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-trop2-imaging-heterogeneity","kind":"opportunity","name":"TROP2 imaging where no tissue test is required","route":"/opportunities/opp-trop2-imaging-heterogeneity/","field":"links","label":"Longitudinal fall in TROP2 expression during treatment"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13394594/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-ceacam5-imaging-colorectal","kind":"opportunity","name":"CEACAM5 imaging for occult colorectal recurrence","route":"/opportunities/opp-ceacam5-imaging-colorectal/","field":"links","label":"CT nodal staging accuracy meta-analysis"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13458634/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-radioligand-therapy","kind":"section","name":"Radioligand therapy","route":"/fronts/f-radioligand-therapy/","field":"links","label":"Guideline of guidelines: 177Lu-PSMA RLT (BJU Int, 2026)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13530974/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"graves-hyperthyroidism","kind":"indication","name":"Graves' disease and hyperthyroidism","route":"/indications/graves-hyperthyroidism/","field":"links","label":"Graves' disease: review of disease characteristics, burden and treatments (2026)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2265108/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mesothelin","kind":"target","name":"Mesothelin (MSLN)","route":"/targets/mesothelin/","field":"links","label":"PMC: mesothelin-targeted cancer immunotherapy (expression table across tumour types)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC2797464/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-caix-indeterminate-renal-mass","kind":"opportunity","name":"CAIX imaging of the indeterminate renal mass","route":"/opportunities/opp-caix-indeterminate-renal-mass/","field":"links","label":"Benign proportion of resected small renal masses"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3086612/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"integrin-avb3","kind":"target","name":"Integrin αvβ3","route":"/targets/integrin-avb3/","field":"links","label":"PMC: PET imaging of integrin αvβ3 expression"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3184346/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"y-86","kind":"isotope","name":"Yttrium-86","route":"/isotopes/y-86/","field":"links","label":"PMC: 86Y-based PET radiopharmaceuticals, radiochemistry and applications"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3205271/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cck2-receptor","kind":"target","name":"CCK2 receptor (gastrin receptor)","route":"/targets/cck2-receptor/","field":"links","label":"PMC: radiolabeled CCK/gastrin peptides for imaging and therapy"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3408573/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nis-symporter","kind":"target","name":"NIS (sodium-iodide symporter)","route":"/targets/nis-symporter/","field":"links","label":"PMC: the sodium iodide symporter (NIS) - regulation and approaches to therapy"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3478111/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/","field":"links","label":"PMC: PET imaging with 18F-based radiopharmaceuticals"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3503149/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"at-211","kind":"isotope","name":"Astatine-211","route":"/isotopes/at-211/","field":"links","label":"Astatine-211: Production and Availability (Curr Radiopharm, PMC)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3622744/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"renal-protection-amino-acids","kind":"term","name":"Renal protection with amino acid co-infusion","route":"/terms/renal-protection-amino-acids/","field":"links","label":"IAEA, EANM, SNMMI practical guidance on peptide receptor radionuclide therapy (PRRNT) in neuroendocrine tumours, PMC"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3638650/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"re-188","kind":"isotope","name":"Rhenium-188","route":"/isotopes/re-188/","field":"links","label":"Rhenium-188 Production in Hospitals, by W-188/Re-188 Generator (PMC, 2013)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3752512/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nis-symporter","kind":"target","name":"NIS (sodium-iodide symporter)","route":"/targets/nis-symporter/","field":"links","label":"PMC: modulation of NIS expression in salivary gland tissue and I-131 uptake"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3778101/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"scott-tagawa","kind":"person","name":"Scott T. Tagawa","route":"/people/scott-tagawa/","field":"papers","label":"Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3812862/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dopamine-transporter","kind":"target","name":"Dopamine transporter (DAT)","route":"/targets/dopamine-transporter/","field":"links","label":"PMC: clinical utility of dopamine transporter SPECT imaging"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC3984880/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"relative-biological-effectiveness","kind":"term","name":"Relative biological effectiveness (RBE)","route":"/terms/relative-biological-effectiveness/","field":"links","label":"PMC: redefining relative biological effectiveness in the context of alpha-particle therapy"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4072020/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"integrin-avb3","kind":"target","name":"Integrin αvβ3","route":"/targets/integrin-avb3/","field":"links","label":"PMC: PET radiopharmaceuticals for imaging integrin expression"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4237663/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"norepinephrine-transporter","kind":"target","name":"Norepinephrine transporter (NET)","route":"/targets/norepinephrine-transporter/","field":"links","label":"PMC: 'Nothing but NET' - NET expression and efficacy of 131I-MIBG therapy"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4287223/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"time-of-flight-pet","kind":"term","name":"Time-of-flight (TOF) PET","route":"/terms/time-of-flight-pet/","field":"links","label":"PMC: update on time-of-flight PET imaging"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4415691/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-fluorothymidine","kind":"drug","name":"Fluorothymidine F-18 (FLT)","route":"/drugs/f-18-fluorothymidine/","field":"links","label":"Applications of PET imaging with the proliferation marker 18F-FLT (review, 2015)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4566054/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sr82-rb82-generators","kind":"technology","name":"Strontium-82/rubidium-82 generators","route":"/technologies/sr82-rb82-generators/","field":"links","label":"Story of rubidium-82 and advantages for myocardial perfusion PET imaging (PMC 2015)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4679356/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"integrin-avb3","kind":"target","name":"Integrin αvβ3","route":"/targets/integrin-avb3/","field":"links","label":"PMC: clinical application of radiolabeled RGD peptides for PET imaging of angiogenesis"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4715007/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"attenuation-correction","kind":"term","name":"Attenuation correction","route":"/terms/attenuation-correction/","field":"links","label":"PMC: attenuation correction in emission tomography using synergistic PET/MR data"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4747834/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"time-of-flight-pet","kind":"term","name":"Time-of-flight (TOF) PET","route":"/terms/time-of-flight-pet/","field":"links","label":"PMC: advances in time-of-flight PET"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4756438/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sarcophagine-chelation","kind":"technology","name":"Sarcophagine chelation","route":"/technologies/sarcophagine-chelation/","field":"links","label":"Comparison of bifunctional chelators including sarcophagine for 64Cu-rituximab labelling (PMC)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5013686/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"c-11","kind":"isotope","name":"Carbon-11","route":"/isotopes/c-11/","field":"links","label":"PMC: synthesis, isolation and purification of [11C]-choline"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5118403/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"upar","kind":"target","name":"uPAR (urokinase plasminogen activator receptor)","route":"/targets/upar/","field":"links","label":"PMC: PET imaging of uPAR in prostate cancer (review)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5120247/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"glut-hexokinase","kind":"target","name":"GLUT1 / hexokinase (glucose metabolism)","route":"/targets/glut-hexokinase/","field":"links","label":"PMC: mechanisms underlying FDG uptake in cancer"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5153343/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-ceacam5-imaging-colorectal","kind":"opportunity","name":"CEACAM5 imaging for occult colorectal recurrence","route":"/opportunities/opp-ceacam5-imaging-colorectal/","field":"links","label":"FDG PET/CT for occult colorectal recurrence with raised CEA"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5283715/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"i-124","kind":"isotope","name":"Iodine-124","route":"/isotopes/i-124/","field":"links","label":"PMC: I-124 imaging and dosimetry"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5363622/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cardiac-sarcoidosis-specific-tracer","kind":"opportunity","name":"An inflammation tracer that does not need a diet","route":"/opportunities/opp-cardiac-sarcoidosis-specific-tracer/","field":"links","label":"68Ga-DOTATOC compared with cardiac MRI, Oncotarget 2016"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5506097/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dosimetry-roadmap","kind":"roadmap","name":"Dosimetry roadmap: MIRD schema → fixed dosing → personalised, image-based dose","route":"/roadmaps/dosimetry-roadmap/","field":"links","label":"Sundlöv et al., individualised 177Lu-DOTATATE treatment based on kidney dosimetry (Eur J Nucl Med Mol Imaging 2017)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5514171/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/","field":"links","label":"The development, commercialization, and clinical context of yttrium-90 (PMC, 2016)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5565267/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/","field":"links","label":"Actinium-225 in targeted alpha-particle therapeutic applications (PMC)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5739519/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nis-symporter","kind":"target","name":"NIS (sodium-iodide symporter)","route":"/targets/nis-symporter/","field":"links","label":"PMC: sodium/iodide symporter - molecular physiology and preclinical applications (tissue distribution table)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5824696/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-pretargeted-alpha-therapy","kind":"idea","name":"Pretargeted alpha radioimmunotherapy","route":"/ideas/idea-pretargeted-alpha-therapy/","field":"links","label":"Pretargeting for imaging and therapy in oncological nuclear medicine (PMC, 2017)"},{"id":"pretargeted-radioimmunotherapy","kind":"technology","name":"Pretargeted radioimmunotherapy","route":"/technologies/pretargeted-radioimmunotherapy/","field":"links","label":"Pretargeting for imaging and therapy in oncological nuclear medicine (EJNMMI review 2017)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5824697/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sc-47","kind":"isotope","name":"Scandium-47","route":"/isotopes/sc-47/","field":"links","label":"47Sc as useful beta-minus-emitter for the radiotheragnostic paradigm (PMC, 2017)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5843801/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ejnmmi-radiopharmacy-and-chemistry","kind":"journal","name":"EJNMMI Radiopharmacy and Chemistry","route":"/journals/ejnmmi-radiopharmacy-and-chemistry/","field":"links","label":"Editorial launching EJNMMI Radiopharmacy and Chemistry (2016)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5843816/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"automated-synthesis-modules","kind":"technology","name":"Automated synthesis modules","route":"/technologies/automated-synthesis-modules/","field":"links","label":"Automation of the radiosynthesis of six different 18F-labelled radiopharmaceuticals on the AllinOne module (PMC 2016)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5852186/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"specific-activity","kind":"term","name":"Specific activity and molar activity","route":"/terms/specific-activity/","field":"links","label":"International consensus nomenclature for radiopharmaceutical chemistry (PMC)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5908296/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-baum-prrt-1048-patients-oncotarget-2018","kind":"paper","name":"Results and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms","route":"/key-papers/paper-baum-prrt-1048-patients-oncotarget-2018/","field":"links","label":"PMC: full text"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5963670/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"monte-carlo-dosimetry","kind":"technology","name":"Monte Carlo dosimetry","route":"/technologies/monte-carlo-dosimetry/","field":"links","label":"Development and validation of RAPID, a Geant4-based patient-specific voxel dosimetry tool (PMC 2018)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5978928/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bone-pain-palliation","kind":"indication","name":"Bone pain palliation from osteoblastic metastases","route":"/indications/bone-pain-palliation/","field":"links","label":"EANM guidelines for radionuclide therapy of bone metastases with beta-emitting radionuclides"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6020824/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"renal-obstruction","kind":"indication","name":"Suspected upper urinary tract obstruction","route":"/indications/renal-obstruction/","field":"links","label":"SNMMI Procedure Standard/EANM Practice Guideline for diuretic renal scintigraphy in adults with suspected upper urinary tract obstruction 1.0"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6126440/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"glut-hexokinase","kind":"target","name":"GLUT1 / hexokinase (glucose metabolism)","route":"/targets/glut-hexokinase/","field":"links","label":"PMC: imaging cancer metabolism, underlying biology and pitfalls of FDG-PET"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6270798/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sarcophagine-chelation","kind":"technology","name":"Sarcophagine chelation","route":"/technologies/sarcophagine-chelation/","field":"links","label":"Development of multi-functional chelators based on sarcophagine for 64Cu chelation (PMC)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6281542/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-flutemetamol","kind":"drug","name":"Flutemetamol F-18","route":"/drugs/f-18-flutemetamol/","field":"links","label":"Zhang et al.: Centiloid scaling for quantification of brain amyloid with [18F]flutemetamol"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6295389/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tare-vs-sorafenib-caution","kind":"pairing","name":"Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma","route":"/pairings/tare-vs-sorafenib-caution/","field":"links","label":"PMC review comparing SARAH and SIRveNIB outcomes"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6351513/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-fet","kind":"drug","name":"Floretyrosine F-18 (FET)","route":"/drugs/f-18-fet/","field":"links","label":"Joint EANM/EANO/RANO/SNMMI practice guidelines for PET imaging of gliomas with radiolabelled amino acids and FDG (2018)"},{"id":"neuro-imaging-roadmap","kind":"roadmap","name":"Neuro-oncology imaging roadmap: FDG PET → amino acid PET → SSTR2 theranostics in meningioma","route":"/roadmaps/neuro-imaging-roadmap/","field":"links","label":"Joint EANM/EANO/RANO practice guidelines/SNMMI procedure standards for glioma PET, version 1.0 (2019)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6450843/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"infection-prosthetic-joint","kind":"indication","name":"Prosthetic joint infection","route":"/indications/infection-prosthetic-joint/","field":"links","label":"EANM procedural guideline: white blood cell and anti-granulocyte monoclonal antibody scintigraphy"},{"id":"infection-prosthetic-joint","kind":"indication","name":"Prosthetic joint infection","route":"/indications/infection-prosthetic-joint/","field":"links","label":"Consensus document for the diagnosis of prosthetic joint infections (EANM, EBJIS, ESR, 2019)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6508962/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"glut-hexokinase","kind":"target","name":"GLUT1 / hexokinase (glucose metabolism)","route":"/targets/glut-hexokinase/","field":"links","label":"PMC: roles of GLUT-1 and HK-II expression in tumour biology and FDG uptake"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6587137/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"re-188","kind":"isotope","name":"Rhenium-188","route":"/isotopes/re-188/","field":"links","label":"Rhenium-188 Labeled Radiopharmaceuticals: Current Clinical Applications (Front Chem, 2019)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6642951/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radium223-abiraterone-caution","kind":"pairing","name":"Radium-223 with abiraterone: a caution, not a combination","route":"/pairings/radium223-abiraterone-caution/","field":"links","label":"PMC review discussing ERA-223 unblinding and fracture subtypes"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6690960/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-daughter-redistribution","kind":"technology","name":"Alpha-emitter daughter redistribution ('free daughter' problem)","route":"/technologies/alpha-daughter-redistribution/","field":"links","label":"The in vivo fate of 225Ac daughter nuclides using polymersomes as a model carrier (PMC 2019)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6708176/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mesothelin","kind":"target","name":"Mesothelin (MSLN)","route":"/targets/mesothelin/","field":"links","label":"PMC: mesothelin as a biomarker for targeted therapy"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC6813289/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"kr-81m","kind":"isotope","name":"Krypton-81m","route":"/isotopes/kr-81m/","field":"links","label":"EANM 2019 guideline for ventilation/perfusion SPECT (krypton and Technegas preferred over DTPA in COPD; 13 s half-life, 190 keV, simultaneous acquisition with Tc-99m)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7016057/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiochemical-purity","kind":"term","name":"Radiochemical purity (RCP)","route":"/terms/radiochemical-purity/","field":"links","label":"EANM guideline on validation of analytical methods for radiopharmaceuticals (PMC)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7047588/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pretargeted-radioimmunotherapy","kind":"technology","name":"Pretargeted radioimmunotherapy","route":"/technologies/pretargeted-radioimmunotherapy/","field":"links","label":"Towards optimisation of click-mediated pretargeted radioimmunotherapy (Mol. Pharm. 2019)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7082773/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ac-225","kind":"isotope","name":"Actinium-225","route":"/isotopes/ac-225/","field":"links","label":"Supply and Clinical Application of Actinium-225 and Bismuth-213 (PMC, 2020)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7116483/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cck2-receptor","kind":"target","name":"CCK2 receptor (gastrin receptor)","route":"/targets/cck2-receptor/","field":"links","label":"PMC: cholecystokinin-2 receptor targeting with radiolabeled peptides (review)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7158965/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fixed-versus-personalised-dosing","kind":"term","name":"Fixed versus personalised (dosimetry-guided) dosing","route":"/terms/fixed-versus-personalised-dosing/","field":"links","label":"Haug AR. PRRT of neuroendocrine tumors: individualized dosimetry or fixed dose scheme? EJNMMI Res 2020"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7198388/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiohybrid-chemistry","kind":"technology","name":"Radiohybrid (rh) chemistry","route":"/technologies/radiohybrid-chemistry/","field":"links","label":"PMC full text of the rhPSMA radiohybrid ligand paper"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7198676/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"monte-carlo-dosimetry","kind":"technology","name":"Monte Carlo dosimetry","route":"/technologies/monte-carlo-dosimetry/","field":"links","label":"Preclinical voxel-based dosimetry in theranostics: a review (PMC 2020)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7268111/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fdg-pet-response-adapted-therapy","kind":"pairing","name":"FDG PET then response-adapted chemotherapy","route":"/pairings/fdg-pet-response-adapted-therapy/","field":"links","label":"PMC review of PET-adapted approaches to primary therapy for advanced Hodgkin lymphoma"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7316220/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"heiko-schoder","kind":"person","name":"Heiko Schöder","route":"/people/heiko-schoder/","field":"links","label":"CALGB 50303 interim-PET analysis, Blood 2020"},{"id":"heiko-schoder","kind":"person","name":"Heiko Schöder","route":"/people/heiko-schoder/","field":"papers","label":"Prognostic value of interim FDG-PET in diffuse large cell lymphoma: results from the CALGB 50303 Clinical Trial"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7490874/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-alpha-for-oligometastatic-disease","kind":"idea","name":"Alpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer","route":"/ideas/idea-alpha-for-oligometastatic-disease/","field":"links","label":"Lutetium-177-PSMA-I&T as metastases-directed therapy in oligometastatic hormone-sensitive prostate cancer (BULLSEYE, BMC Cancer, 2020)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7515774/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ra-223","kind":"isotope","name":"Radium-223","route":"/isotopes/ra-223/","field":"links","label":"Radium-223 mechanism of action (Nature Reviews Urology, 2019)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7539649/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opendose","kind":"collection","name":"OpenDose","route":"/collections/opendose/","field":"links","label":"Chauvin et al., J Nucl Med 2020: OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry"},{"id":"idea-open-dosimetry-data-commons","kind":"idea","name":"An open data commons linking patient-level radiopharmaceutical dosimetry to outcomes","route":"/ideas/idea-open-dosimetry-data-commons/","field":"links","label":"OpenDose: Open-Access Resource for Nuclear Medicine Dosimetry (Journal of Nuclear Medicine, PMC)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7582814/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"caix","kind":"target","name":"CAIX (carbonic anhydrase IX)","route":"/targets/caix/","field":"links","label":"PMC review: CAIX in renal cell carcinoma, implications for imaging and therapy"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7599151/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rb-82","kind":"isotope","name":"Rubidium-82","route":"/isotopes/rb-82/","field":"links","label":"PMC: rubidium-82 generator yield and efficiency for PET perfusion imaging"},{"id":"sr82-rb82-generators","kind":"technology","name":"Strontium-82/rubidium-82 generators","route":"/technologies/sr82-rb82-generators/","field":"links","label":"Rubidium-82 generator yield and efficiency for PET perfusion imaging: comparative study (PMC 2020)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7603916/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"o-15","kind":"isotope","name":"Oxygen-15","route":"/isotopes/o-15/","field":"links","label":"PMC: EANM procedural guidelines for PET/CT quantitative myocardial perfusion (O-15/N-13/Rb-82/F-18-flurpiridaz comparison table)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7732571/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"y-90","kind":"isotope","name":"Yttrium-90","route":"/isotopes/y-90/","field":"links","label":"Yttrium-90 Radioembolization Dosimetry: What Trainees Need to Know (PMC, 2020)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7773938/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"albumin-binder-ligands","kind":"technology","name":"Albumin-binder ligands","route":"/technologies/albumin-binder-ligands/","field":"links","label":"Development of an albumin-based PSMA probe with prolonged circulation, PMC 2020"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7808361/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"kr-81m","kind":"isotope","name":"Krypton-81m","route":"/isotopes/kr-81m/","field":"links","label":"Comparative review: krypton-81m versus Technegas for ventilation imaging in COPD"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7835167/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"stefano-fanti","kind":"person","name":"Stefano Fanti","route":"/people/stefano-fanti/","field":"links","label":"Consensus statements on PSMA PET/CT response, EJNMMI 2021"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7907710/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"flare-phenomenon","kind":"term","name":"Flare phenomenon","route":"/terms/flare-phenomenon/","field":"links","label":"Conteduca V, et al. Flare phenomenon in prostate cancer: recent evidence on new drugs and next generation imaging, Ther Adv Med Oncol 2021"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7911942/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-flortaucipir","kind":"drug","name":"Flortaucipir F-18","route":"/drugs/f-18-flortaucipir/","field":"links","label":"PMC review: Tauvid, the first FDA-approved PET tracer for imaging tau pathology"},{"id":"tau-protein","kind":"target","name":"Tau protein (neurofibrillary tangles)","route":"/targets/tau-protein/","field":"links","label":"PMC: Tauvid, the first FDA-approved PET tracer for imaging tau pathology in Alzheimer's disease"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8038522/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"integrin-avb3","kind":"target","name":"Integrin αvβ3","route":"/targets/integrin-avb3/","field":"links","label":"PMC: RGD-binding integrins revisited - review of imaging targets including αvβ3"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8057355/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","field":"links","label":"Guideline of guidelines: muscle-invasive bladder cancer, PMC"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8143329/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bi-213","kind":"isotope","name":"Bismuth-213","route":"/isotopes/bi-213/","field":"links","label":"Bismuth-213 for Targeted Radionuclide Therapy (Pharmaceutics, 2021)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8149571/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sc-44","kind":"isotope","name":"Scandium-44","route":"/isotopes/sc-44/","field":"links","label":"PMC: production of scandium radionuclides for theranostic applications"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8241800/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","route":"/bottlenecks/b-enriched-target-material/","field":"links","label":"Challenges and future options for the production of lutetium-177 (EJNMMI, 2021)"},{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","route":"/bottlenecks/b-enriched-target-material/","field":"metrics (Fraction of irradiated ytterbium-176 target atoms converted to lutetium-177)"},{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","route":"/bottlenecks/b-enriched-target-material/","field":"metrics (Extra enriched target material needed for the no-carrier-added (Yb-176) route vs the carrier-added (Lu-176) route, for equivalent activity)"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/","field":"links","label":"Challenges and future options for the production of lutetium-177 (EJNMMI Radiopharm Chem, 2021)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8373794/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","route":"/collections/imaging-data-commons/","field":"links","label":"Fedorov et al., Cancer Res 2021: NCI Imaging Data Commons"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8394552/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","field":"links","label":"Ferrari C et al., review of PET/CT guideline positions in pancreatic cancer"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8426244/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-caix-indeterminate-renal-mass","kind":"opportunity","name":"CAIX imaging of the indeterminate renal mass","route":"/opportunities/opp-caix-indeterminate-renal-mass/","field":"links","label":"Girentuximab dosimetry"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8466155/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-synuclein","kind":"target","name":"Alpha-synuclein","route":"/targets/alpha-synuclein/","field":"links","label":"Alpha-synuclein cannot currently be assessed accurately in vivo"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8479035/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tc-99m-maa","kind":"drug","name":"Technetium Tc-99m albumin aggregated (MAA)","route":"/drugs/tc-99m-maa/","field":"links","label":"Kappadath et al.: lung shunt fraction from 99mTc-MAA SPECT/CT for Y-90 treatment planning, with the 30 Gy single and 50 Gy cumulative lung dose constraints"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8612333/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-grpr-psma-negative-prostate","kind":"opportunity","name":"GRPR imaging when the PSMA scan is negative","route":"/opportunities/opp-grpr-psma-negative-prostate/","field":"links","label":"68Ga-RM2 against PSMA tracers head to head, J Nucl Med 2021"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8671014/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"thyroid-nodule-assessment","kind":"indication","name":"Functional assessment of thyroid nodules","route":"/indications/thyroid-nodule-assessment/","field":"links","label":"Investigating thyroid nodules (review, ACR TI-RADS and functional imaging)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8777968/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pb-212","kind":"isotope","name":"Lead-212","route":"/isotopes/pb-212/","field":"links","label":"212Pb: Production Approaches and Targeted Therapy Applications (Pharmaceuticals, 2022)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8780589/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"theranostic-pair-term","kind":"term","name":"Theranostic pair","route":"/terms/theranostic-pair-term/","field":"links","label":"Expanding Theranostic Radiopharmaceuticals for Tumor Diagnosis and Therapy, PMC 2021 (theranostic pair table)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8830434/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"delphine-chen","kind":"person","name":"Delphine L. Chen","route":"/people/delphine-chen/","field":"papers","label":"A PET Radiotracer for Imaging Poly (ADP-Ribose) Polymerase-1"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8852230/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"beta-psma-then-alpha-psma-rescue","kind":"pairing","name":"177Lu-PSMA-617 then 225Ac-PSMA rescue therapy","route":"/pairings/beta-psma-then-alpha-psma-rescue/","field":"links","label":"Meta-analysis of efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy (PMC8852230)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8869247/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cold-kit-formulation","kind":"technology","name":"Cold kit formulation","route":"/technologies/cold-kit-formulation/","field":"links","label":"Cold kit labeling: the future of 68Ga radiopharmaceuticals? (PMC 2022)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8882889/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pretargeted-radioimmunotherapy","kind":"technology","name":"Pretargeted radioimmunotherapy","route":"/technologies/pretargeted-radioimmunotherapy/","field":"links","label":"Current landscape in clinical pretargeted radioimmunotherapy (PMC 2021)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC8912090/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cu-67","kind":"isotope","name":"Copper-67","route":"/isotopes/cu-67/","field":"links","label":"67Cu Production Capabilities: A Mini Review (Front Med, 2022)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9015994/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022","kind":"paper","name":"EANM dosimetry committee recommendations for dosimetry of 177Lu-labelled somatostatin-receptor- and PSMA-targeting ligands","route":"/key-papers/paper-eanm-lu177-dosimetry-recommendations-ejnmmi-2022/","field":"links","label":"PMC: full text"},{"id":"spect-dosimetry-workflow","kind":"technology","name":"SPECT dosimetry workflow for radionuclide therapy","route":"/technologies/spect-dosimetry-workflow/","field":"links","label":"PMC full text of the EANM 177Lu dosimetry recommendations"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9143622/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"chelator-term","kind":"term","name":"Chelator (bifunctional chelating agent)","route":"/terms/chelator-term/","field":"links","label":"PMC: the chemical scaffold of theranostic radiopharmaceuticals"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9165727/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"amyloid-beta","kind":"target","name":"Amyloid beta plaques","route":"/targets/amyloid-beta/","field":"links","label":"PMC: the role of amyloid PET in imaging neurodegenerative disorders"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9362842/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"macropa-chelation","kind":"technology","name":"Macropa chelation","route":"/technologies/macropa-chelation/","field":"links","label":"Kadassery et al., Bioconjugate Chem 2022: H2BZmacropa-NCS, a bifunctional chelator for 225Ac TAT"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9364764/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"krenning-score","kind":"term","name":"Krenning score","route":"/terms/krenning-score/","field":"links","label":"Somatostatin receptor imaging and theranostics: current practice and future prospects (JNM/PMC, 2021)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9588110/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ge-68","kind":"isotope","name":"Germanium-68","route":"/isotopes/ge-68/","field":"links","label":"PMC: good practices for 68Ga radiopharmaceutical production (68Ge production section)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9608311/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"salivary-gland-toxicity","kind":"term","name":"Salivary gland toxicity (xerostomia) from PSMA radioligand therapy","route":"/terms/salivary-gland-toxicity/","field":"links","label":"[177Lu]Lu-PSMA-617 (Pluvicto): The First FDA-Approved Radiotherapeutic for mCRPC, PMC 2022"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9626412/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ho-166-microspheres","kind":"drug","name":"Holmium-166 microspheres","route":"/drugs/ho-166-microspheres/","field":"links","label":"Holmium-166 radioembolisation: current status and future perspectives, PMC 2022"},{"id":"ho-166","kind":"isotope","name":"Holmium-166","route":"/isotopes/ho-166/","field":"links","label":"Holmium-166 Radioembolization: Current Status and Future Perspectives (Cancers, 2022)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9636342/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiolabelling-quality-control","kind":"technology","name":"Radiolabelling quality control","route":"/technologies/radiolabelling-quality-control/","field":"links","label":"Radiolabeling and quality control of therapeutic radiopharmaceuticals: cross-validation of RCY/RCP by radio-TLC and radio-HPLC (PMC 2022)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9701133/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-ceacam5-imaging-colorectal","kind":"opportunity","name":"CEACAM5 imaging for occult colorectal recurrence","route":"/opportunities/opp-ceacam5-imaging-colorectal/","field":"links","label":"DYNAMIC: ctDNA-guided adjuvant therapy in stage II colon cancer"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9737149/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga68-dotatate-then-lutathera","kind":"pairing","name":"68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)","route":"/pairings/ga68-dotatate-then-lutathera/","field":"links","label":"Clinical guide to PRRT with 177Lu-DOTATATE (PMC9737149)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9790144/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prrt-plus-captem","kind":"pairing","name":"PRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM)","route":"/pairings/prrt-plus-captem/","field":"links","label":"Systematic review of CAPTEM in advanced NENs (PMC9790144)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9803618/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"partial-volume-effect","kind":"term","name":"Partial volume effect (PVE)","route":"/terms/partial-volume-effect/","field":"links","label":"PMC: partial volume effect in SPECT and PET imaging and impact on dosimetry"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9812962/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"th-227","kind":"isotope","name":"Thorium-227","route":"/isotopes/th-227/","field":"links","label":"Development of radiopharmaceuticals for targeted alpha therapy (PMC, 2022)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9885765/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"th-227","kind":"isotope","name":"Thorium-227","route":"/isotopes/th-227/","field":"links","label":"Targeted thorium-227 conjugates as treatment options in oncology (Front Med, 2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9887039/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ra-224","kind":"isotope","name":"Radium-224","route":"/isotopes/ra-224/","field":"links","label":"Dual targeting with 224Ra/212Pb-conjugates for cancer therapy (PMC, 2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9921938/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"re-188","kind":"isotope","name":"Rhenium-188","route":"/isotopes/re-188/","field":"links","label":"Fundamentals of Rhenium-188 Radiopharmaceutical Chemistry (Pharmaceutics, 2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9931838/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"quantitative-spect","kind":"technology","name":"Quantitative SPECT","route":"/technologies/quantitative-spect/","field":"links","label":"EANM practice guideline for quantitative SPECT-CT (EJNMMI 2022)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9936343/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cxcr4-primary-aldosteronism","kind":"opportunity","name":"CXCR4 imaging instead of adrenal vein sampling","route":"/opportunities/opp-cxcr4-primary-aldosteronism/","field":"links","label":"68Ga-pentixafor against adrenal vein sampling in 100 patients, JAMA Network Open 2023"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9966725/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-daughter-redistribution","kind":"technology","name":"Alpha-emitter daughter redistribution ('free daughter' problem)","route":"/technologies/alpha-daughter-redistribution/","field":"links","label":"Preclinical evaluation of a lead-specific chelator (PSC) minimising 212Bi daughter redistribution (PMC 2023)"}]},{"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC9967390/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiolysis","kind":"term","name":"Radiolysis (self-radiolysis of radiopharmaceuticals)","route":"/terms/radiolysis/","field":"links","label":"PMC: radiolysis-associated decrease in radiochemical purity of 177Lu-radiopharmaceuticals and comparison of quenchers"}]},{"url":"https://portal.fis.tum.de/en/organisations/department-of-nuclear-medicine/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"matthias-eiber","kind":"person","name":"Matthias Eiber","route":"/people/matthias-eiber/","field":"papers","label":"[177Lu]Lu-PSMA-617 in patients with PSMA-positive metastatic androgen pathway modulator-naive/sensitive prostate cancer (PSMAddition): a phase 3 randomised, controlled trial"}]},{"url":"https://portal.fis.tum.de/en/persons/matthias-eiber/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"matthias-eiber","kind":"person","name":"Matthias Eiber","route":"/people/matthias-eiber/","field":"profiles","label":"TUM research portal (FIS)"}]},{"url":"https://portal.imaging.datacommons.cancer.gov/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","route":"/collections/imaging-data-commons/","field":"links","label":"NCI Imaging Data Commons portal"},{"id":"imaging-data-commons","kind":"collection","name":"NCI Imaging Data Commons (IDC)","route":"/collections/imaging-data-commons/","field":"url"}]},{"url":"https://proceedings.jacow.org/napac2019/talks/wezbb4_talk.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"niowave","kind":"company","name":"Niowave","route":"/companies/niowave/","field":"links","label":"JACoW/NAPAC 2019: High-power superconducting electron linacs for commercial applications (Niowave)"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Emily%20K.%20Bergsland","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","checked":"2026-10-21","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"links","label":"UCSF profile"},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Katherine%20K.%20Matthay","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","checked":"2026-10-21","refs":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"links","label":"UCSF profile"},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Rahul%20Aggarwal","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","checked":"2026-10-21","refs":[{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"links","label":"UCSF profile"},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"profiles","label":"UCSF profile"}]},{"url":"https://profiles.ucsf.edu/search/?searchtype=people&searchfor=Thomas%20A.%20Hope","status":200,"ok":true,"finalUrl":"https://profiles.ucsf.edu/Error/Default.aspx","checked":"2026-10-21","refs":[{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"links","label":"UCSF profile"},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"profiles","label":"UCSF profile"}]},{"url":"https://providers.upmc.com/provider/neeta-pandit-taskar/4210094","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"neeta-pandit-taskar","kind":"person","name":"Neeta Pandit-Taskar","route":"/people/neeta-pandit-taskar/","field":"links","label":"UPMC provider profile"},{"id":"neeta-pandit-taskar","kind":"person","name":"Neeta Pandit-Taskar","route":"/people/neeta-pandit-taskar/","field":"profiles","label":"UPMC provider profile"}]},{"url":"https://pubchem.ncbi.nlm.nih.gov/compound/Phosphorus-Radioisotopes","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"p-32","kind":"isotope","name":"Phosphorus-32","route":"/isotopes/p-32/","field":"links","label":"PubChem: Phosphorus, radioactive (phosphorus-32 compound summary)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=%28%22PSD-95%22%5Btiab%5D+OR+PSD95%5Btiab%5D+OR+DLG4%5Btiab%5D%29+AND+%28PET%5Btiab%5D+OR+radioligand%5Btiab%5D+OR+radiotracer%5Btiab%5D+OR+radiolabeled%5Btiab%5D+OR+radiolabelled%5Btiab%5D+OR+SPECT%5Btiab%5D%29","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dlg4-psd95","kind":"target","name":"DLG4 (PSD-95)","route":"/targets/dlg4-psd95/","field":"links","label":"PubMed search used for the absence statement: PSD-95/DLG4 with PET, SPECT, radioligand or radiotracer"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Aggarwal%20R%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"links","label":"PubMed"},{"id":"rahul-aggarwal","kind":"person","name":"Rahul Aggarwal","route":"/people/rahul-aggarwal/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bartenstein%20P%5BAuthor%5D%20PSMA","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","route":"/people/peter-bartenstein/","field":"links","label":"PubMed"},{"id":"peter-bartenstein","kind":"person","name":"Peter Bartenstein","route":"/people/peter-bartenstein/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Baum+RP%5BAuthor%5D+radionuclide","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"links","label":"PubMed"},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Bergsland%20EK%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"links","label":"PubMed"},{"id":"emily-bergsland","kind":"person","name":"Emily K. Bergsland","route":"/people/emily-bergsland/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Calais%20J%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"links","label":"PubMed"},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Czernin%20J%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"links","label":"PubMed"},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Delpassand+ES%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","field":"links","label":"PubMed"},{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Emmett%20L%5BAuthor%5D%20PSMA","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"louise-emmett","kind":"person","name":"Louise Emmett","route":"/people/louise-emmett/","field":"links","label":"PubMed"},{"id":"louise-emmett","kind":"person","name":"Louise Emmett","route":"/people/louise-emmett/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Erba+PA%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","field":"links","label":"PubMed"},{"id":"paola-anna-erba","kind":"person","name":"Paola Anna Erba","route":"/people/paola-anna-erba/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Fizazi%20K%5BAuthor%5D%20prostate%20abiraterone","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","field":"links","label":"PubMed"},{"id":"karim-fizazi","kind":"person","name":"Karim Fizazi","route":"/people/karim-fizazi/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Giesel%20FL%5BAuthor%5D%20FAPI","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/","field":"links","label":"PubMed"},{"id":"frederik-giesel","kind":"person","name":"Frederik Giesel","route":"/people/frederik-giesel/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Gillessen%20S%5BAuthor%5D%20prostate%20consensus","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","route":"/people/silke-gillessen/","field":"links","label":"PubMed"},{"id":"silke-gillessen","kind":"person","name":"Silke Gillessen","route":"/people/silke-gillessen/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Haberkorn%20U%5BAuthor%5D%20FAPI","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/","field":"links","label":"PubMed"},{"id":"uwe-haberkorn","kind":"person","name":"Uwe Haberkorn","route":"/people/uwe-haberkorn/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Herrmann%20K%5BAuthor%5D%20theranostics%20PSMA","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","route":"/people/ken-herrmann/","field":"links","label":"PubMed"},{"id":"ken-herrmann","kind":"person","name":"Ken Herrmann","route":"/people/ken-herrmann/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hofman%20MS%5BAuthor%5D%20PSMA","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","field":"links","label":"PubMed author search"},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Hope%20TA%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"links","label":"PubMed"},{"id":"thomas-hope","kind":"person","name":"Thomas A. Hope","route":"/people/thomas-hope/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Kratochwil%20C%5BAuthor%5D%20225Ac%20PSMA","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","route":"/people/clemens-kratochwil/","field":"links","label":"PubMed"},{"id":"clemens-kratochwil","kind":"person","name":"Clemens Kratochwil","route":"/people/clemens-kratochwil/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Lewis%20JS%5BAuthor%5D%20zirconium-89%20PET","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/","field":"links","label":"PubMed"},{"id":"jason-lewis","kind":"person","name":"Jason S. Lewis","route":"/people/jason-lewis/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Mach%20RH%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"robert-mach","kind":"person","name":"Robert H. Mach","route":"/people/robert-mach/","field":"links","label":"PubMed"},{"id":"robert-mach","kind":"person","name":"Robert H. Mach","route":"/people/robert-mach/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Matthay%20KK%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"links","label":"PubMed"},{"id":"katherine-matthay","kind":"person","name":"Katherine K. Matthay","route":"/people/katherine-matthay/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Morris%20MJ%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"links","label":"PubMed"},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Murphy%20DG%5BAuthor%5D%20PSMA%20prostate","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"declan-murphy","kind":"person","name":"Declan G. Murphy","route":"/people/declan-murphy/","field":"links","label":"PubMed"},{"id":"declan-murphy","kind":"person","name":"Declan G. Murphy","route":"/people/declan-murphy/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Parker%5BAuthor%5D","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"chris-parker","kind":"person","name":"Chris C. Parker","route":"/people/chris-parker/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sandhu%20S%5BAuthor%5D%20Peter%20MacCallum%20prostate%20PSMA","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","field":"links","label":"PubMed author search"},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Sartor%20O%5BAuthor%5D%20PSMA%20lutetium","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","field":"links","label":"PubMed"},{"id":"oliver-sartor","kind":"person","name":"A. Oliver Sartor","route":"/people/oliver-sartor/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Singh%20S%5BAuthor%5D%20neuroendocrine%20NETTER-2","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","field":"links","label":"PubMed"},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Song%20S%5BAuthor%5D%20Fudan%20TROP2%20PET","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","field":"links","label":"PubMed author search"},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","field":"profiles","label":"PubMed author search"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Strosberg%20J%5BAuthor%5D%20neuroendocrine%20lutetium","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","field":"links","label":"PubMed"},{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Vera+P%5BAuthor%5D+AND+Rouen","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/","field":"profiles","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=Weber%20WA%5BAuthor%5D%20PET","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"wolfgang-weber","kind":"person","name":"Wolfgang A. Weber","route":"/people/wolfgang-weber/","field":"links","label":"PubMed"},{"id":"wolfgang-weber","kind":"person","name":"Wolfgang A. Weber","route":"/people/wolfgang-weber/","field":"profiles","label":"PubMed"}]},{"url":"https://pure.eur.nl/ws/portalfiles/portal/150811942/1-s2.0-S1556859824000191-main.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-bispecific-radioligands","kind":"idea","name":"Bispecific PSMA/GRPR radioligands for discordant prostate cancer lesions","route":"/ideas/idea-bispecific-radioligands/","field":"links","label":"Gastrin Releasing Peptide Receptors-targeted PET imaging in prostate cancer (Erasmus MC review)"}]},{"url":"https://qims.amegroups.org/article/view/118297/html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-total-body-pet-lower-dose-tracers","kind":"idea","name":"Using total-body PET's sensitivity to cut diagnostic tracer dose, not just scan time","route":"/ideas/idea-total-body-pet-lower-dose-tracers/","field":"links","label":"One-tenth-activity total-body PET versus full-activity imaging in hepatic malignancies (QIMS, 2023)"}]},{"url":"https://rad.uw.edu/people/dlchen7","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"delphine-chen","kind":"person","name":"Delphine L. Chen","route":"/people/delphine-chen/","field":"links","label":"UW Radiology profile"},{"id":"delphine-chen","kind":"person","name":"Delphine L. Chen","route":"/people/delphine-chen/","field":"profiles","label":"UW Radiology profile"}]},{"url":"https://radionetics.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","field":"links","label":"Official website"},{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","field":"website"}],"archive":"https://web.archive.org/web/20260415192459/https://radionetics.com/"},{"url":"https://radionetics.com/news/radionetics-oncology-enters-into-strategic-agreement-with-lilly","status":200,"ok":true,"finalUrl":"https://radionetics.com/news/radionetics-oncology-enters-into-strategic-agreement-with-lilly/","checked":"2026-10-21","refs":[{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","field":"links","label":"Lilly strategic agreement release"}],"archive":"https://web.archive.org/web/20260606130104/https://radionetics.com/news/radionetics-oncology-enters-into-strategic-agreement-with-lilly/"},{"url":"https://radionetics.com/news/radionetics-oncology-raises-52-5m-series-a","status":200,"ok":true,"finalUrl":"https://radionetics.com/news/radionetics-oncology-raises-52-5m-series-a/","checked":"2026-10-21","refs":[{"id":"radionetics-oncology","kind":"company","name":"Radionetics Oncology","route":"/companies/radionetics-oncology/","field":"links","label":"Series A press release"}],"archive":"https://web.archive.org/web/20260121023719/https://radionetics.com/news/radionetics-oncology-raises-52-5m-series-a/"},{"url":"https://radiopaedia.org/articles/deauville-five-point-scale?lang=us","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"deauville-for-pet","kind":"term","name":"Deauville five-point scale for PET","route":"/terms/deauville-for-pet/","field":"links","label":"Radiopaedia: Deauville five-point scale"}]},{"url":"https://radiopaedia.org/articles/flare-phenomenon-bone-scintigraphy?lang=us","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"flare-phenomenon","kind":"term","name":"Flare phenomenon","route":"/terms/flare-phenomenon/","field":"links","label":"Radiopaedia: Flare phenomenon (bone scintigraphy)"}]},{"url":"https://radiopaedia.org/articles/iodine-123?lang=us","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"i-123","kind":"isotope","name":"Iodine-123","route":"/isotopes/i-123/","field":"links","label":"Radiopaedia: iodine-123"}]},{"url":"https://radiopaedia.org/articles/krenning-score-of-neuroendocrine-tumour-uptake?lang=us","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"krenning-score","kind":"term","name":"Krenning score","route":"/terms/krenning-score/","field":"links","label":"Radiopaedia: Krenning score of neuroendocrine tumour uptake"}]},{"url":"https://radiopaedia.org/articles/lugano-classification-pet-ct-treatment-response?lang=us","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"deauville-for-pet","kind":"term","name":"Deauville five-point scale for PET","route":"/terms/deauville-for-pet/","field":"links","label":"Radiopaedia: Lugano classification (PET-CT treatment response)"}]},{"url":"https://radiopaedia.org/articles/thallium-201-scintigraphy","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tl-201","kind":"isotope","name":"Thallium-201","route":"/isotopes/tl-201/","field":"links","label":"Radiopaedia: thallium-201 scintigraphy"}]},{"url":"https://radiopaedia.org/articles/tissue-to-background-ratio?lang=us","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tumour-to-background-ratio","kind":"term","name":"Tumour-to-background ratio (TBR)","route":"/terms/tumour-to-background-ratio/","field":"links","label":"Radiopaedia: tissue to background ratio"}]},{"url":"https://radiopharmtheranostics.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/","field":"links","label":"Official website"},{"id":"radiopharm-theranostics","kind":"company","name":"Radiopharm Theranostics","route":"/companies/radiopharm-theranostics/","field":"website"}],"archive":"https://web.archive.org/web/20260616214219/https://radiopharmtheranostics.com/"},{"url":"https://ratiotx.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","field":"links","label":"Official website"},{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20260915103507/https://ratiotx.com/"},{"url":"https://ratiotx.com/2026/07/31/ratio-therapeutics-closes-70-million-series-c-financing-to-advance-clinical-development-of-targeted-radiotherapeutics-pipeline-and-expand-manufacturing-infrastructure/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","field":"links","label":"Series C press release"}]},{"url":"https://ratiotx.com/news1/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ratio-therapeutics","kind":"company","name":"Ratio Therapeutics","route":"/companies/ratio-therapeutics/","field":"links","label":"News"}],"archive":"https://web.archive.org/web/20260710180515/https://ratiotx.com/news1/"},{"url":"https://recip-criteria.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"wolfgang-fendler","kind":"person","name":"Wolfgang P. Fendler","route":"/people/wolfgang-fendler/","field":"links","label":"RECIP 1.0, Radiology / RECIP criteria collaboration site"},{"id":"wolfgang-fendler","kind":"person","name":"Wolfgang P. Fendler","route":"/people/wolfgang-fendler/","field":"papers","label":"Novel framework for treatment response evaluation using PSMA PET/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study"}]},{"url":"https://resources.inmm.org/system/files/patram_proceedings/2010/233_Paper_TRANSPORT-OF-RADIOPHARMACEUTICALS,-CRADLE-TO-THE-P.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/","field":"links","label":"INMM PATRAM 2010: Transport of radiopharmaceuticals, cradle to the patient"},{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/","field":"metrics (Activity lost to a one-day transport delay of Mo-99 (66-hour half-life))"},{"id":"b-cold-chain-logistics","kind":"bottleneck","name":"Cold chain and time-critical logistics","route":"/bottlenecks/b-cold-chain-logistics/","field":"links","label":"INMM PATRAM 2010: Transport of radiopharmaceuticals, cradle to the patient"},{"id":"b-cold-chain-logistics","kind":"bottleneck","name":"Cold chain and time-critical logistics","route":"/bottlenecks/b-cold-chain-logistics/","field":"metrics (Activity lost to a one-day transport delay of molybdenum-99 (66-hour half-life))"}]},{"url":"https://robateltech.com/radiopharmaceutical-hot-cells-casks/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hot-cells-and-shielding","kind":"technology","name":"Hot cells and radiation shielding","route":"/technologies/hot-cells-and-shielding/","field":"links","label":"Robatel Technologies: radiopharmaceutical hot cells and casks, isotope-specific shielding overview"}]},{"url":"https://s45591.pcdn.co/wp-content/uploads/2025/12/2025-CNIC-Medical-Isotope-Ecosystem-Directory-DEC2025-AX.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","route":"/companies/bwxt-medical/","field":"links","label":"CNIC: Canadian Isotope Ecosystem Directory 2025 (BWXT Medical entry, PDF)"}]},{"url":"https://seer.cancer.gov/statfacts/html/breast.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"links","label":"SEER Cancer Stat Facts: female breast cancer"}]},{"url":"https://seer.cancer.gov/statfacts/html/colorect.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"links","label":"SEER Cancer Stat Facts: colorectal cancer"}]},{"url":"https://seer.cancer.gov/statfacts/html/lungb.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"links","label":"SEER Cancer Stat Facts: lung and bronchus cancer"}]},{"url":"https://seer.cancer.gov/statfacts/html/pancreas.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","field":"links","label":"SEER Cancer Stat Facts: pancreatic cancer"}]},{"url":"https://seer.cancer.gov/statfacts/html/stomach.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","field":"links","label":"SEER Cancer Stat Facts: stomach cancer"}]},{"url":"https://seer.cancer.gov/statfacts/html/urinb.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","field":"links","label":"SEER Cancer Stat Facts: bladder cancer"}]},{"url":"https://sijbrandijfoundation.org/fcct","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"},{"id":"excel-diagnostics-nuclear-oncology","kind":"institution","name":"Excel Diagnostics and Nuclear Oncology Center","route":"/institutions/excel-diagnostics-nuclear-oncology/","field":"links","label":"Listed on Future of Cancer Care Today (Sijbrandij Foundation)"}],"archive":"https://web.archive.org/web/20260708031928/https://sijbrandijfoundation.org/fcct"},{"url":"https://sites.snmmi.org/common/Uploaded%20files/Web/Advocacy%20and%20Initiatives/2023-09-07/NRC%20Comments%20on%20Extravasations%20Rulemaking%209-1-2023.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"extravasation-radiopharmaceutical","kind":"term","name":"Radiopharmaceutical extravasation","route":"/terms/extravasation-radiopharmaceutical/","field":"links","label":"SNMMI position statement and comments to NRC on extravasation rulemaking, 2023"}]},{"url":"https://snmmi.org/AM/Web/About/About-SNMMI/Advisory-Committees/Therapy-Advisory-Committee/Past-Presidents.aspx","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"neeta-pandit-taskar","kind":"person","name":"Neeta Pandit-Taskar","route":"/people/neeta-pandit-taskar/","field":"links","label":"SNMMI Therapy Advisory Committee past presidents"}]},{"url":"https://snmmi.org/common/Uploaded%20files/AUC%20Factsheets/Fever_of_Unknown_Origin_AUC_Factsheet.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fever-of-unknown-origin","kind":"indication","name":"Fever of unknown origin","route":"/indications/fever-of-unknown-origin/","field":"links","label":"SNMMI appropriate use criteria factsheet: fever of unknown origin"}]},{"url":"https://snmmi.org/common/Uploaded%20files/News/Theranostics_Stakeholders_Summit_White_Paper_FINAL_6-2025.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-authorized-user-shortage","kind":"bottleneck","name":"Authorized user shortage for radionuclide therapy","route":"/bottlenecks/b-authorized-user-shortage/","field":"links","label":"SNMMI Theranostics Stakeholders Summit white paper (2025)"},{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"links","label":"SNMMI Theranostics Stakeholders Summit white paper (2025), staffing survey"},{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"metrics (US institutions reporting current hiring vacancies in nuclear medicine/theranostics (SNMMI Summit survey))"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Centers/PET%20Center%20of%20Excellence/FLT_07-11-12%20Final.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-fluorothymidine","kind":"drug","name":"Fluorothymidine F-18 (FLT)","route":"/drugs/f-18-fluorothymidine/","field":"links","label":"SNMMI PET Center of Excellence FLT factsheet"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Appropriate%20Use%20Criteria/PSMA%20AUC%202022.03.15_final_BOD%20approved.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-jadvar-snmmi-psma-auc-jnm-2022","kind":"paper","name":"Appropriate use criteria for prostate-specific membrane antigen (PSMA) PET imaging","route":"/key-papers/paper-jadvar-snmmi-psma-auc-jnm-2022/","field":"links","label":"SNMMI: PSMA PET Appropriate Use Criteria (PDF)"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Appropriate%20Use%20Criteria/Updated%20AUC%20for%20PET%20Myocardial%20Perfusion%20Imaging-2.0%20FINAL.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"coronary-artery-disease","kind":"indication","name":"Coronary artery disease","route":"/indications/coronary-artery-disease/","field":"links","label":"SNMMI/ACC/ASNC updated appropriate use criteria for PET myocardial perfusion imaging 2.0"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2013/Final%20Breast%20Sentinel%20Node%20Guideline.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sentinel-node-mapping","kind":"indication","name":"Sentinel lymph node mapping in breast cancer and melanoma","route":"/indications/sentinel-node-mapping/","field":"links","label":"EANM and SNMMI practice guideline for lymphoscintigraphy and sentinel node localization in breast cancer"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2015/2015_EANM_PracticeGL_Lymphoscintigraphy.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sentinel-node-mapping","kind":"indication","name":"Sentinel lymph node mapping in breast cancer and melanoma","route":"/indications/sentinel-node-mapping/","field":"links","label":"EANM practice guidelines for lymphoscintigraphy and sentinel lymph node biopsy in melanoma"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2018/Pediatric%20Diuresis%20Renal_PSPG.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"renal-obstruction","kind":"indication","name":"Suspected upper urinary tract obstruction","route":"/indications/renal-obstruction/","field":"links","label":"SNMMI and EANM procedural guidelines for diuresis renography in infants and children"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2019/EANM%20SNMMI%20guideline%20on%20radionuclide%20imaging%20of%20phaeochromocytoma%20and%20paraganglioma.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-fdopa","kind":"drug","name":"Fluorodopa F-18","route":"/drugs/f-18-fdopa/","field":"links","label":"EANM/SNMMI 2019 practice guideline for radionuclide imaging of phaeochromocytoma and paraganglioma"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2019/EANM%20SNMMI%20Radio%20Iodine%20Uptake%20(RAIU)%20and%20Scintigraphy.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"thyroid-nodule-assessment","kind":"indication","name":"Functional assessment of thyroid nodules","route":"/indications/thyroid-nodule-assessment/","field":"links","label":"EANM practice guideline/SNMMI procedure standard for radioiodine uptake and scintigraphy (2019)"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2024/EANM%20SNMMI%20Guideline%20FDG%20Infection%20and%20Inflammation_SNMMI%20BOD%20FINAL.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"infection-prosthetic-joint","kind":"indication","name":"Prosthetic joint infection","route":"/indications/infection-prosthetic-joint/","field":"links","label":"EANM/SNMMI guideline/procedure standard for FDG hybrid PET use in infection and inflammation in adults v2.0 (2024/2025)"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Clinical%20Practice/Procedure%20Standards/2025/Flurpiridaz%20Procedure%20Standard-JNM.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-flurpiridaz","kind":"drug","name":"Flurpiridaz F-18","route":"/drugs/f-18-flurpiridaz/","field":"links","label":"SNMMI/JNM procedure standard: 18F-flurpiridaz PET myocardial perfusion imaging and blood flow quantification"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Education%20and%20Meetings/SNMMI%20Fact%20Sheet_Brain%20Death%20Fact%20Sheet%20Ceretec%20-Tc-99m%20HMPAO.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tc-99m-hmpao-brain","kind":"drug","name":"Technetium-99m exametazime (brain perfusion)","route":"/drugs/tc-99m-hmpao-brain/","field":"links","label":"SNMMI fact sheet: brain death assessment with Ceretec (Tc-99m HMPAO)"}]},{"url":"https://snmmi.org/common/Uploaded%20files/Web/Research-Publications/2026%20Salary%20and%20Workforce%20Study.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"links","label":"SNMMI-TS and NMTCB 2026 Salary and Workforce Study"},{"id":"b-nuclear-medicine-workforce","kind":"bottleneck","name":"Nuclear medicine technologist and physicist workforce","route":"/bottlenecks/b-nuclear-medicine-workforce/","field":"metrics (SNMMI 2026 median NMT hourly pay, and change since 2022)"}]},{"url":"https://snmmi.org/Web/Web/Clinical-Practice/Appropriate-Use-Criteria/Articles/Appropriate-Use-Criteria-for-Prostate-Specific-Membrane-Antigen--PSMA--PET-Imaging.aspx","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-jadvar-snmmi-psma-auc-jnm-2022","kind":"paper","name":"Appropriate use criteria for prostate-specific membrane antigen (PSMA) PET imaging","route":"/key-papers/paper-jadvar-snmmi-psma-auc-jnm-2022/","field":"links","label":"SNMMI: AUC overview page"}]},{"url":"https://snmmi.org/Web/Web/Clinical-Practice/Appropriate-Use-Criteria/Articles/Appropriate-Use-Criteria-for-Ventilation-Perfusion--V-Q--Imaging-in-Pulmonary-Embolism.aspx","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pulmonary-embolism-vq","kind":"indication","name":"Pulmonary embolism: ventilation/perfusion imaging","route":"/indications/pulmonary-embolism-vq/","field":"links","label":"SNMMI appropriate use criteria for ventilation/perfusion (V/Q) imaging in pulmonary embolism"}]},{"url":"https://snmmi.org/Web/Web/Clinical-Practice/Procedure-Standards/Procedure-Standards.aspx","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"snmmi-procedure-standards","kind":"collection","name":"SNMMI Procedure Standards","route":"/collections/snmmi-procedure-standards/","field":"links","label":"SNMMI: Procedure Standards"},{"id":"snmmi-procedure-standards","kind":"collection","name":"SNMMI Procedure Standards","route":"/collections/snmmi-procedure-standards/","field":"url"}]},{"url":"https://snmmi.org/Web/Web/Clinical-Practice/Procedure-Standards/Standards/General-Imaging-6-0.aspx","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"snmmi-procedure-standards","kind":"collection","name":"SNMMI Procedure Standards","route":"/collections/snmmi-procedure-standards/","field":"links","label":"SNMMI: General Imaging 6.0 procedure standard (example)"}]},{"url":"https://snmmi.org/Web/Web/News/Articles/FAQs-on-the-Centers-for-Medicare---Medicaid-Services--CMS--Major-Payment-Policy-Reform-for-Diagnosti.aspx","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-reimbursement-coding","kind":"bottleneck","name":"Reimbursement and coding for radiopharmaceuticals","route":"/bottlenecks/b-reimbursement-coding/","field":"links","label":"SNMMI FAQ on CMS CY2025 HOPPS diagnostic radiopharmaceutical payment reform"},{"id":"b-reimbursement-coding","kind":"bottleneck","name":"Reimbursement and coding for radiopharmaceuticals","route":"/bottlenecks/b-reimbursement-coding/","field":"metrics (CY2025 HOPPS separate-payment threshold for diagnostic radiopharmaceuticals)"}]},{"url":"https://snmmi.org/Web/Web/News/Articles/SNMMI-and-the-Alzheimer-s-Association-Release-Updated-Appropriate-Use-Criteria-for-Amyloid-and-Tau-P.Mobile.aspx","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-neuro-imaging","kind":"section","name":"Neuro-imaging","route":"/fronts/f-neuro-imaging/","field":"links","label":"SNMMI news release: updated AUC for amyloid and tau PET (Jan 2025)"}]},{"url":"https://sofie.com","status":200,"ok":true,"finalUrl":"https://sofie.com/","checked":"2026-10-21","refs":[{"id":"sofie-biosciences","kind":"company","name":"SOFIE Biosciences","route":"/companies/sofie-biosciences/","field":"website"}],"archive":"https://web.archive.org/web/20260421041854/https://sofie.com/"},{"url":"https://sofie.com/2026/02/11/sofie-biosciences-announces-first-patient-dosed-in-18ffapi-74-phase-3-study-for-pancreatic-cancer/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sofie-biosciences","kind":"company","name":"SOFIE Biosciences","route":"/companies/sofie-biosciences/","field":"links","label":"Phase 3 first patient"}],"archive":"https://web.archive.org/web/20260520095017/https://sofie.com/2026/02/11/sofie-biosciences-announces-first-patient-dosed-in-18ffapi-74-phase-3-study-for-pancreatic-cancer/"},{"url":"https://static1.squarespace.com/static/55550f38e4b0884d8d80118e/t/5565d1aae4b0660ba5b932e2/1432736170326/2014+-+Nov+-+JAMA+IM+-+Withdrawal+of+Drugs+for+Commercial+Reasons+-+Tositumomab.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"i-131-tositumomab","kind":"drug","name":"Iodine-131 tositumomab","route":"/drugs/i-131-tositumomab/","field":"links","label":"JAMA Internal Medicine: Withdrawal of drugs for commercial reasons - tositumomab, 2014"}]},{"url":"https://stcn.com/article/detail/3725436.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pexiretide-tc99m","kind":"drug","name":"Technetium (99mTc) pexiretide","route":"/drugs/pexiretide-tc99m/","field":"links","label":"Securities Times: approval, phase 3 comparison with FDG PET/CT and the SPECT installed base (Chinese)"}]},{"url":"https://synapse.patsnap.com/article/pantera-secures-E282AC134m-to-boost-actinium-225-production","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/","field":"links","label":"PanTera secures funding to scale actinium-225 production (company announcement, via Synapse)"}]},{"url":"https://tech.snmjournals.org/content/42/4/308","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gastrointestinal-bleeding","kind":"indication","name":"Gastrointestinal bleeding localisation","route":"/indications/gastrointestinal-bleeding/","field":"links","label":"The SNMMI Procedure Standard/EANM Practice Guideline for gastrointestinal bleeding scintigraphy 2.0"}]},{"url":"https://tech.snmjournals.org/content/48/4/315","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sentinel-node-mapping","kind":"indication","name":"Sentinel lymph node mapping in breast cancer and melanoma","route":"/indications/sentinel-node-mapping/","field":"links","label":"SNMMI technologist guideline: lymphoscintigraphy, breast and melanoma"}]},{"url":"https://tech.snmjournals.org/content/50/4/309","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"renal-obstruction","kind":"indication","name":"Suspected upper urinary tract obstruction","route":"/indications/renal-obstruction/","field":"links","label":"Diuretic renal scintigraphy protocol considerations (SNMMI Technologist)"}]},{"url":"https://tech.snmjournals.org/content/51/3/176","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sr-89-chloride","kind":"drug","name":"Strontium-89 chloride","route":"/drugs/sr-89-chloride/","field":"links","label":"SNMMI/EANM procedure guideline for palliative radionuclide bone therapies, 2023"},{"id":"bone-pain-palliation","kind":"indication","name":"Bone pain palliation from osteoblastic metastases","route":"/indications/bone-pain-palliation/","field":"links","label":"SNMMI Procedure Standard/EANM Practice Guideline for radionuclide therapy of painful bone metastases"}]},{"url":"https://tech.snmjournals.org/content/53/1/14","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gastrointestinal-bleeding","kind":"indication","name":"Gastrointestinal bleeding localisation","route":"/indications/gastrointestinal-bleeding/","field":"links","label":"The SNMMI Procedure Standard/ACNM Practice Guideline for Gastrointestinal Bleeding Scintigraphy 3.0 (2025)"}]},{"url":"https://tech.snmjournals.org/content/jnmt/35/1/3.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tc-99m-sestamibi","kind":"drug","name":"Technetium Tc-99m sestamibi","route":"/drugs/tc-99m-sestamibi/","field":"links","label":"First-pass myocardial extraction fractions of Tc-99m agents and Tl-201 (J Nucl Med Technol review)"},{"id":"tl-201-chloride","kind":"drug","name":"Thallous chloride Tl-201","route":"/drugs/tl-201-chloride/","field":"links","label":"First-pass extraction fraction comparison table (J Nucl Med Technol review)"}]},{"url":"https://tech.snmjournals.org/content/jnmt/48/2/106.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiopharmacy-term","kind":"term","name":"Radiopharmacy (practice and discipline)","route":"/terms/radiopharmacy-term/","field":"links","label":"USP General Chapter <825> Impact on Nuclear Medicine Technology Practice, J Nucl Med Technol 2020"},{"id":"release-criteria","kind":"term","name":"Product release criteria (radiopharmaceutical quality control)","route":"/terms/release-criteria/","field":"links","label":"USP General Chapter <825> Impact on Nuclear Medicine Technology Practice, J Nucl Med Technol 2020"}]},{"url":"https://tech.snmjournals.org/content/jnmt/52/2/74.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mird-formalism","kind":"term","name":"MIRD formalism","route":"/terms/mird-formalism/","field":"links","label":"Journal of Nuclear Medicine Technology: the MIRD schema for radiopharmaceutical dosimetry, a review"}]},{"url":"https://tech.snmjournals.org/content/jnmt/early/2021/09/27/jnmt.121.262320.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"decay-correction","kind":"term","name":"Decay correction","route":"/terms/decay-correction/","field":"links","label":"Journal of Nuclear Medicine Technology: decay correction for quantitative myocardial PET perfusion"}]},{"url":"https://tech.snmjournals.org/content/jnmt/early/2022/06/14/jnmt.122.263813.full.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga68-dotatate-then-lutathera","kind":"pairing","name":"68Ga-DOTATATE PET before Lutathera (177Lu-DOTATATE)","route":"/pairings/ga68-dotatate-then-lutathera/","field":"links","label":"SNMT practical considerations for 177Lu-DOTATATE programmes: SSTR imaging and patient selection"}]},{"url":"https://telixpharma.com","status":200,"ok":true,"finalUrl":"https://telixpharma.com/","checked":"2026-10-21","refs":[{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","field":"links","label":"Official website"},{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","field":"website"}],"archive":"https://web.archive.org/web/20260922030317/https://telixpharma.com/"},{"url":"https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-fet","kind":"drug","name":"Floretyrosine F-18 (FET)","route":"/drugs/f-18-fet/","field":"links","label":"Telix press release: FDA approves Pixclara, 14 September 2026"}]},{"url":"https://telixpharma.com/news-views/first-patient-dosed-in-phase-iii-prostact-global-study-of-antibody-based-prostate-cancer-therapy-candidate-tlx591/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tlx-591","kind":"drug","name":"Lutetium-177 rosopatamab tetraxetan","route":"/drugs/tlx-591/","field":"links","label":"Telix: first patient dosed in ProstACT GLOBAL Phase 3"}]},{"url":"https://telixpharma.com/news-views/highly-accurate-telixs-phase-iii-zircon-trial-for-kidney-cancer-imaging-published-in-the-lancet-oncology/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-zircon-lancet-oncol-2024","kind":"paper","name":"ZIRCON: [89Zr]Zr-girentuximab PET-CT for detecting clear-cell renal cell carcinoma","route":"/key-papers/paper-zircon-lancet-oncol-2024/","field":"links","label":"Telix Pharmaceuticals: ZIRCON results announcement"}]},{"url":"https://telixpharma.com/news-views/prostact-global-phase-3-study-part-1-achieves-primary-objectives/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tlx-591","kind":"drug","name":"Lutetium-177 rosopatamab tetraxetan","route":"/drugs/tlx-591/","field":"links","label":"Telix: ProstACT Global Part 1 achieves primary objectives, 9 March 2026"}]},{"url":"https://telixpharma.com/news-views/telix-and-regeneron-announce-strategic-radiopharma-collaboration/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","field":"links","label":"Telix and Regeneron announce strategic radiopharma collaboration (13 April 2026)"}],"archive":"https://web.archive.org/web/20260504180044/https://telixpharma.com/news-views/telix-and-regeneron-announce-strategic-radiopharma-collaboration/"},{"url":"https://telixpharma.com/news-views/telix-q2-2026-revenue-us247m-strong-momentum-and-pipeline-progress/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","field":"links","label":"Telix Q2 2026 results: the Regeneron collaboration is \"initially focused on lung cancer\" (21 July 2026)"}],"archive":"https://web.archive.org/web/20260828145814/https://telixpharma.com/news-views/telix-q2-2026-revenue-us247m-strong-momentum-and-pipeline-progress/"},{"url":"https://telixpharma.com/our-pipeline/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"telix","kind":"company","name":"Telix Pharmaceuticals","route":"/companies/telix/","field":"links","label":"Telix pipeline (no lung indication listed)"}],"archive":"https://web.archive.org/web/20261008183025/https://telixpharma.com/our-pipeline/"},{"url":"https://telixpharma.com/wp-content/uploads/2024/05/TLX_ProstACT_SELECT_Study_of_TLX591_rADC_Therapy_Positive_rPFS.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tlx-591","kind":"drug","name":"Lutetium-177 rosopatamab tetraxetan","route":"/drugs/tlx-591/","field":"links","label":"Telix: positive rPFS data from ProstACT SELECT trial"},{"id":"tlx-591","kind":"drug","name":"Lutetium-177 rosopatamab tetraxetan","route":"/drugs/tlx-591/","field":"dosing.source"}]},{"url":"https://telixpharma.com/wp-content/uploads/2026/09/USPI_PIXCLARA_Sep2026.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-fet","kind":"drug","name":"Floretyrosine F-18 (FET)","route":"/drugs/f-18-fet/","field":"links","label":"Pixclara (floretyrosine F 18) US Prescribing Information, Telix Pharmaceuticals"},{"id":"f-18-fet","kind":"drug","name":"Floretyrosine F-18 (FET)","route":"/drugs/f-18-fet/","field":"dosing.source"},{"id":"f-18-fet","kind":"drug","name":"Floretyrosine F-18 (FET)","route":"/drugs/f-18-fet/","field":"toxicity.source (Headache)"}]},{"url":"https://thd.org.tr/thdData/userfiles/file/RATHL_Adapted_Treatment_Guided_by_Interim_PET-CT_Scan-2016_NEJM.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fdg-pet-response-adapted-therapy","kind":"pairing","name":"FDG PET then response-adapted chemotherapy","route":"/pairings/fdg-pet-response-adapted-therapy/","field":"links","label":"Johnson P, et al. RATHL: adapted treatment guided by interim PET-CT, N Engl J Med 2016;374:2419-2429"}]},{"url":"https://trial.medpath.com/news/fda-approves-curium-s-bexlutry-first-generic-radioligand-challenging-lutathera-s-gep-net-monopoly","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lu-177-dotatate-generic","kind":"drug","name":"Lutetium-177 dotatate (radioligand equivalent)","route":"/drugs/lu-177-dotatate-generic/","field":"links","label":"MedPath: FDA approves Curium's Bexlutry, first generic radioligand"}]},{"url":"https://trial.medpath.com/news/lantheus-completes-789-million-acquisition-of-life-molecular-imaging-gains-fda-approved-alzheimer-s-diagnostic-agent","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"life-molecular-imaging","kind":"company","name":"Life Molecular Imaging","route":"/companies/life-molecular-imaging/","field":"links","label":"medpath: Lantheus completes $789 million acquisition of Life Molecular Imaging (2025)"}]},{"url":"https://tsapps.nist.gov/publication/get_pdf.cfm?pub_id=922075","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nuclear-medicine-and-biology","kind":"journal","name":"Nuclear Medicine and Biology","route":"/journals/nuclear-medicine-and-biology/","field":"links","label":"Nuclear Medicine and Biology — history note (60 years of Applied Radiation and Isotopes / Pergamon journals)"}]},{"url":"https://uroweb.org/guidelines","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"european-urology","kind":"journal","name":"European Urology","route":"/journals/european-urology/","field":"links","label":"EAU Guidelines"}]},{"url":"https://us.movember.com/","status":200,"ok":true,"finalUrl":"https://movember.com/","checked":"2026-10-21","refs":[{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","field":"links","label":"Movember"}]},{"url":"https://view.asiae.co.kr/en/article/2025060415574246814","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"kirams","kind":"institution","name":"Korea Institute of Radiological and Medical Sciences","route":"/institutions/kirams/","field":"links","label":"News report: KIRAMS approved to produce actinium-225 (Asia Business Daily English edition, June 2025)"}]},{"url":"https://vivo.weill.cornell.edu/display/cwid-stt2007","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"scott-tagawa","kind":"person","name":"Scott T. Tagawa","route":"/people/scott-tagawa/","field":"profiles","label":"Weill Cornell VIVO research profile"}]},{"url":"https://web.archive.org/web/20220115151814/http://duchembio.com/1-3history","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"duchembio","kind":"company","name":"DuChemBio","route":"/companies/duchembio/","field":"links","label":"DuChemBio company history (established 2002, renamed 2007; archived company site)"}]},{"url":"https://weillcornell.org/sttagawa","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"scott-tagawa","kind":"person","name":"Scott T. Tagawa","route":"/people/scott-tagawa/","field":"links","label":"Weill Cornell Medicine: Scott T. Tagawa"},{"id":"scott-tagawa","kind":"person","name":"Scott T. Tagawa","route":"/people/scott-tagawa/","field":"profiles","label":"Weill Cornell Medicine profile"}]},{"url":"https://wewillcure.com/insights/company-profiles/oncology/biotech-companies-advancing-radiopharmaceutical-treatments","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"full-life-technologies","kind":"company","name":"Full-Life Technologies","route":"/companies/full-life-technologies/","field":"links","label":"wewillcure.com: 10 biotech companies advancing radiopharmaceutical treatments (Full-Life financial/pipeline summary)"}]},{"url":"https://www-nds.iaea.org/relnsd/vcharthtml/api_v0_guide.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"iaea-isotope-databases","kind":"collection","name":"IAEA nuclear data and isotope databases","route":"/collections/iaea-isotope-databases/","field":"links","label":"IAEA Livechart Data Download API guide"}]},{"url":"https://www-pub.iaea.org/MTCD/Publications/PDF/Pub1515_Web.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radionuclidic-purity","kind":"term","name":"Radionuclidic purity","route":"/terms/radionuclidic-purity/","field":"links","label":"IAEA: cyclotron produced radionuclides, guidance on facility design and production (18F acceptance criteria)"}]},{"url":"https://www-pub.iaea.org/MTCD/Publications/PDF/Pub1589_web.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mo99-tc99m-generators","kind":"technology","name":"Molybdenum-99/technetium-99m generators","route":"/technologies/mo99-tc99m-generators/","field":"links","label":"IAEA: Non-HEU production technologies for molybdenum-99 and technetium-99m"}]},{"url":"https://www-pub.iaea.org/MTCD/Publications/PDF/Pub1605_web.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"decay-correction","kind":"term","name":"Decay correction","route":"/terms/decay-correction/","field":"links","label":"IAEA Human Health Reports No. 9: quantitative nuclear medicine imaging, decay correction"}]},{"url":"https://www-pub.iaea.org/MTCD/Publications/PDF/PUB1961_web.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cu-64","kind":"isotope","name":"Copper-64","route":"/isotopes/cu-64/","field":"links","label":"IAEA: copper-64 radiopharmaceuticals, production, quality control"},{"id":"sarcophagine-chelation","kind":"technology","name":"Sarcophagine chelation","route":"/technologies/sarcophagine-chelation/","field":"links","label":"IAEA: Copper-64 radiopharmaceuticals - production, quality control and clinical applications"}]},{"url":"https://www-pub.iaea.org/MTCD/Publications/PDF/TE-1856web.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiolabelling-quality-control","kind":"technology","name":"Radiolabelling quality control","route":"/technologies/radiolabelling-quality-control/","field":"links","label":"IAEA TECDOC: quality control methods for radiopharmaceuticals, including TLC/iTLC and HPLC procedures"},{"id":"specific-activity","kind":"term","name":"Specific activity and molar activity","route":"/terms/specific-activity/","field":"links","label":"IAEA TECDOC: determination of specific activity"},{"id":"no-carrier-added","kind":"term","name":"No-carrier-added (n.c.a.) and carrier-added production","route":"/terms/no-carrier-added/","field":"links","label":"IAEA TECDOC: specific activity determination and no-carrier-added definition"}]},{"url":"https://www-pub.iaea.org/MTCD/publications/PDF/TE-2057web.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-alpha-therapy","kind":"section","name":"Targeted alpha therapy","route":"/fronts/f-alpha-therapy/","field":"links","label":"IAEA TECDOC-2057: Production and quality control of actinium-225 radiopharmaceuticals (2024)"}]},{"url":"https://www-pub.iaea.org/MTCD/publications/PDF/TE-2127web.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/","field":"links","label":"IAEA TE-2127: good management practices of cyclotron-based Ga-68 production"}]},{"url":"https://www-pub.iaea.org/MTCD/Publications/PDF/trs465_web.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"no-carrier-added","kind":"term","name":"No-carrier-added (n.c.a.) and carrier-added production","route":"/terms/no-carrier-added/","field":"links","label":"IAEA: cyclotron produced radionuclides, principles and practice"}]},{"url":"https://www-pub.iaea.org/MTCD/Publications/PDF/trs466_web.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cold-kit-formulation","kind":"technology","name":"Cold kit formulation","route":"/technologies/cold-kit-formulation/","field":"links","label":"IAEA Technical Reports Series 466: Technetium-99m radiopharmaceuticals - manufacture of kits"}]},{"url":"https://www-pub.iaea.org/MTCD/Publications/PDF/trs468_web.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18","kind":"isotope","name":"Fluorine-18","route":"/isotopes/f-18/","field":"links","label":"IAEA TRS 468: cyclotron production of 18F"}]},{"url":"https://www.a9oncology.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","field":"links","label":"Official website"},{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","field":"website"}],"archive":"https://web.archive.org/web/20260606114220/https://www.a9oncology.com/"},{"url":"https://www.a9oncology.com/alpha-9-oncology-doses-first-patient-in-phase-1-clinical-trial-evaluating-grpr-targeted-radiotherapeutics-across-multiple-solid-tumors/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","field":"links","label":"GRPR phase 1 first patient dosed"}]},{"url":"https://www.a9oncology.com/alpha-9-oncology-inc-announces-175-million-oversubscribed-series-c-financing-to-advance-robust-clinical-pipeline-of-radiopharmaceuticals/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-9-oncology","kind":"company","name":"Alpha-9 Oncology","route":"/companies/alpha-9-oncology/","field":"links","label":"Series C press release"}],"archive":"https://web.archive.org/web/20260510210641/https://www.a9oncology.com/alpha-9-oncology-inc-announces-175-million-oversubscribed-series-c-financing-to-advance-robust-clinical-pipeline-of-radiopharmaceuticals/"},{"url":"https://www.aamr.org.ar/secciones/oncologia/evaluacion_fisiologica.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"split-function-lung-perfusion","kind":"technology","name":"Split-function perfusion scintigraphy before lung resection","route":"/technologies/split-function-lung-perfusion/","field":"links","label":"ACCP physiologic evaluation of the patient with lung cancer being considered for resectional surgery (Brunelli et al., Chest 2013): the ppo formulas and the 60% and 30% thresholds"}]},{"url":"https://www.aapm.org/meetings/08ss/documents/Kinahan.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"attenuation-correction","kind":"term","name":"Attenuation correction","route":"/terms/attenuation-correction/","field":"links","label":"AAPM (Kinahan): CT-based attenuation correction (CTAC), artifacts, and quantitation in PET/CT"}]},{"url":"https://www.abx.de","status":200,"ok":true,"finalUrl":"https://abx.de/","checked":"2026-10-21","refs":[{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","route":"/companies/abx-advanced-biochemical-compounds/","field":"links","label":"Official website"},{"id":"abx-advanced-biochemical-compounds","kind":"company","name":"ABX advanced biochemical compounds","route":"/companies/abx-advanced-biochemical-compounds/","field":"website"}],"archive":"https://web.archive.org/web/20260612141415/https://abx.de/"},{"url":"https://www.acr.org/Clinical-Resources/Publications-and-Research/ACR-Bulletin/Changes-to-Reimbursement-for-High-Cost-Radiopharmaceuticals","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-reimbursement-coding","kind":"bottleneck","name":"Reimbursement and coding for radiopharmaceuticals","route":"/bottlenecks/b-reimbursement-coding/","field":"links","label":"ACR Bulletin: Changes to reimbursement for high-cost radiopharmaceuticals"},{"id":"b-reimbursement-coding","kind":"bottleneck","name":"Reimbursement and coding for radiopharmaceuticals","route":"/bottlenecks/b-reimbursement-coding/","field":"metrics (Diagnostic radiopharmaceuticals qualifying for separate payment in 2025)"},{"id":"b-reimbursement-coding","kind":"bottleneck","name":"Reimbursement and coding for radiopharmaceuticals","route":"/bottlenecks/b-reimbursement-coding/","field":"metrics (Typical pass-through period before reimbursement can drop to zero)"}]},{"url":"https://www.acrotechbiopharma.com","status":200,"ok":true,"finalUrl":"https://acrotechbiopharma.com/","checked":"2026-10-21","refs":[{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/","field":"links","label":"Official website"},{"id":"acrotech-biopharma","kind":"company","name":"Acrotech Biopharma","route":"/companies/acrotech-biopharma/","field":"website"}],"archive":"https://web.archive.org/web/20260603191223/https://acrotechbiopharma.com/"},{"url":"https://www.actiniumpharma.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","field":"links","label":"Official website"},{"id":"actinium-pharmaceuticals","kind":"company","name":"Actinium Pharmaceuticals","route":"/companies/actinium-pharmaceuticals/","field":"website"}],"archive":"https://web.archive.org/web/20260908111317/https://www.actiniumpharma.com/"},{"url":"https://www.adacap.com","status":200,"ok":true,"finalUrl":"https://www.novartis.com/research-and-development/technology-platforms/radioligand-therapy","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/","field":"links","label":"Official website"},{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/","field":"website"}],"archive":"https://web.archive.org/web/20260512023938/https://www.adacap.com/"},{"url":"https://www.advancell.com.au","status":200,"ok":true,"finalUrl":"https://www.advancell.com.au/","checked":"2026-10-21","refs":[{"id":"advancell","kind":"company","name":"AdvanCell","route":"/companies/advancell/","field":"website"}]},{"url":"https://www.advancell.com.au/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"advancell","kind":"company","name":"AdvanCell","route":"/companies/advancell/","field":"links","label":"AdvanCell company site"}]},{"url":"https://www.advancell.com.au/news/advancell-closes-us-315-million-oversubscribed-series-d-financing-to-advance-targeted-alpha-therapies-and-expand-clinical-and-commercial-manufacturing-infrastructure/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"advancell","kind":"company","name":"AdvanCell","route":"/companies/advancell/","field":"links","label":"AdvanCell Closes US $315 Million Oversubscribed Series D Financing (2026)"}]},{"url":"https://www.aiims.edu","status":200,"ok":true,"finalUrl":"https://www.aiims.edu/index.php/en","checked":"2026-10-21","refs":[{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/","field":"links","label":"AIIMS New Delhi"},{"id":"aiims-delhi","kind":"institution","name":"All India Institute of Medical Sciences, New Delhi","route":"/institutions/aiims-delhi/","field":"website"}],"archive":"https://web.archive.org/web/20220622043214/http://www42.aiims.edu/"},{"url":"https://www.akademiska.se","status":200,"ok":true,"finalUrl":"https://www.akademiska.se/","checked":"2026-10-21","refs":[{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","route":"/institutions/uppsala-akademiska/","field":"links","label":"Homepage"},{"id":"uppsala-akademiska","kind":"institution","name":"Uppsala University Hospital / Uppsala University","route":"/institutions/uppsala-akademiska/","field":"website"}],"archive":"https://web.archive.org/web/20261005054956/https://www.akademiska.se/"},{"url":"https://www.aktisoncology.com","status":200,"ok":true,"finalUrl":"https://www.aktisoncology.com/","checked":"2026-10-21","refs":[{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/","field":"website"}],"archive":"https://web.archive.org/web/20260908151625/https://www.aktisoncology.com/"},{"url":"https://www.ans.org/news/2026-01-14/article-7675/iaeas-global-radium226-management-initiative-continues-to-progress/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-alpha-therapy","kind":"section","name":"Targeted alpha therapy","route":"/fronts/f-alpha-therapy/","field":"links","label":"IAEA: Global Radium-226 Management Initiative update (ANS, Jan 2026)"}]},{"url":"https://www.ans.org/news/2026-05-08/article-8016/eden-targets-domestic-medical-radioisotope-production/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-isotope-supply","kind":"section","name":"Isotope supply","route":"/fronts/f-isotope-supply/","field":"links","label":"Eden Radioisotopes files NRC construction permit for Mo-99/Lu-177 facility (ANS, May 2026)"}]},{"url":"https://www.ansto.gov.au","status":200,"ok":true,"finalUrl":"https://www.ansto.gov.au/","checked":"2026-10-21","refs":[{"id":"ansto","kind":"company","name":"ANSTO (Australian Nuclear Science and Technology Organisation)","route":"/companies/ansto/","field":"links","label":"Official website"},{"id":"ansto","kind":"company","name":"ANSTO (Australian Nuclear Science and Technology Organisation)","route":"/companies/ansto/","field":"website"}],"archive":"https://web.archive.org/web/20260917193114/https://www.ansto.gov.au/"},{"url":"https://www.aosp.bo.it","status":200,"ok":true,"finalUrl":"https://www.aosp.bo.it/","checked":"2026-10-21","refs":[{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/","field":"links","label":"Homepage"},{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/","field":"website"}],"archive":"https://web.archive.org/web/20261005091121/https://www.aosp.bo.it/"},{"url":"https://www.aosp.bo.it/content/ematologia","status":200,"ok":true,"finalUrl":"https://www.aosp.bo.it/il-policlinico/strutture/ematologia","checked":"2026-10-21","refs":[{"id":"sant-orsola-bologna","kind":"institution","name":"IRCCS Azienda Ospedaliero-Universitaria di Bologna, Policlinico Sant'Orsola","route":"/institutions/sant-orsola-bologna/","field":"links","label":"Haematology"}],"archive":"https://web.archive.org/web/20250518014148/https://www.aosp.bo.it/content/ematologia"},{"url":"https://www.appliedradiationoncology.com/articles/nuclear-medicine-prepares-for-greater-68ga-demand","status":200,"ok":true,"finalUrl":"https://www.appliedradiationoncology.com/news/nuclear-medicine-prepares-for-greater-68ga-demand","checked":"2026-10-21","refs":[{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/","field":"links","label":"Applied Radiation Oncology: nuclear medicine prepares for greater 68Ga demand (2021)"}]},{"url":"https://www.asco.org/abstracts-presentations/ABSTRACT383277","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-rlt-plus-checkpoint-inhibitor","kind":"idea","name":"Adding a checkpoint inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-checkpoint-inhibitor/","field":"links","label":"PRINCE trial 12-month follow-up results (ASCO abstract, 2025)"}]},{"url":"https://www.asco.org/practice-patients/guidelines","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jco","kind":"journal","name":"Journal of Clinical Oncology","route":"/journals/jco/","field":"links","label":"ASCO guidelines"}]},{"url":"https://www.asnc.org/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"asnc","kind":"institution","name":"American Society of Nuclear Cardiology","route":"/institutions/asnc/","field":"website"}]},{"url":"https://www.asnc.org/about-asnc/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"asnc","kind":"institution","name":"American Society of Nuclear Cardiology","route":"/institutions/asnc/","field":"links","label":"About ASNC"}]},{"url":"https://www.asnc.org/education-events/annual-scientific-session/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"asnc","kind":"institution","name":"American Society of Nuclear Cardiology","route":"/institutions/asnc/","field":"links","label":"ASNC2026 Annual Scientific Session, 16 to 19 September 2026, Las Vegas"}]},{"url":"https://www.asnc.org/news-publications/journal-of-nuclear-cardiology/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"asnc","kind":"institution","name":"American Society of Nuclear Cardiology","route":"/institutions/asnc/","field":"links","label":"Journal of Nuclear Cardiology (official journal)"},{"id":"journal-of-nuclear-cardiology","kind":"journal","name":"Journal of Nuclear Cardiology","route":"/journals/journal-of-nuclear-cardiology/","field":"links","label":"ASNC: Journal of Nuclear Cardiology"},{"id":"journal-of-nuclear-cardiology","kind":"journal","name":"Journal of Nuclear Cardiology","route":"/journals/journal-of-nuclear-cardiology/","field":"url"}]},{"url":"https://www.asnc.org/news/f18-flurpiridaz-fda-approval-nuclear-cardiologys-new-radiotracer-for-cardiac-pet-imaging/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-cardiac-imaging","kind":"section","name":"Cardiac imaging","route":"/fronts/f-cardiac-imaging/","field":"links","label":"ASNC: F-18 flurpiridaz FDA approval announcement"}]},{"url":"https://www.asnc.org/wp-content/uploads/2024/05/ASNC-Practice-Point-99mTechnetium-Pyrophosphate.2016.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cardiac-amyloidosis-attr","kind":"indication","name":"Cardiac amyloidosis (transthyretin, ATTR-CM)","route":"/indications/cardiac-amyloidosis-attr/","field":"links","label":"ASNC practice points: 99mTc-pyrophosphate imaging for cardiac amyloidosis"},{"id":"tc-99m-pyrophosphate","kind":"drug","name":"Technetium Tc-99m pyrophosphate","route":"/drugs/tc-99m-pyrophosphate/","field":"links","label":"ASNC practice points: 99mTc-pyrophosphate imaging for cardiac amyloidosis"}]},{"url":"https://www.asnc.org/wp-content/uploads/2024/06/s12350-016-0522-3.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"coronary-artery-disease","kind":"indication","name":"Coronary artery disease","route":"/indications/coronary-artery-disease/","field":"links","label":"ASNC/SNMMI imaging guideline: PET nuclear cardiology procedures"},{"id":"tc-99m-sestamibi","kind":"drug","name":"Technetium Tc-99m sestamibi","route":"/drugs/tc-99m-sestamibi/","field":"links","label":"ASNC/SNMMI PET nuclear cardiology procedure standard (perfusion tracer comparison and cardiac sarcoidosis protocol)"},{"id":"rb-82-chloride","kind":"drug","name":"Rubidium Rb-82 chloride","route":"/drugs/rb-82-chloride/","field":"links","label":"ASNC/SNMMI PET nuclear cardiology procedure standard"},{"id":"n-13-ammonia","kind":"drug","name":"Ammonia N-13","route":"/drugs/n-13-ammonia/","field":"links","label":"ASNC/SNMMI PET nuclear cardiology procedure standard"}]},{"url":"https://www.astro.org/getmedia/8ac4db0c-cd58-42bd-b693-7caa40928919/2025HOPPSFinalRuleSummary.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-reimbursement-coding","kind":"bottleneck","name":"Reimbursement and coding for radiopharmaceuticals","route":"/bottlenecks/b-reimbursement-coding/","field":"links","label":"ASTRO summary of the 2025 HOPPS final rule (radiopharmaceutical payment policy)"}]},{"url":"https://www.bcpm.unibe.ch","status":200,"ok":true,"finalUrl":"https://www.bcpm.unibe.ch/","checked":"2026-10-21","refs":[{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","field":"links","label":"Bern Center for Precision Medicine"}],"archive":"https://web.archive.org/web/20260401145509/https://www.bcpm.unibe.ch/"},{"url":"https://www.becquerel.fr/le-centre/decouvrir-le-centre/organisation/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/","field":"links","label":"Source: Centre Henri Becquerel organisation page"},{"id":"pierre-vera","kind":"person","name":"Pierre Vera","route":"/people/pierre-vera/","field":"profiles","label":"Centre Henri Becquerel organisation page"}]},{"url":"https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/","field":"links","label":"Official website"},{"id":"abdera-therapeutics","kind":"company","name":"Abdera Therapeutics","route":"/companies/abdera-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20260612021041/https://www.biospace.com/abdera-therapeutics-debuts-with-142-million-in-financing-to-engineer-and-advance-best-in-class-antibody-based-radiopharmaceuticals-for-cancer"},{"url":"https://www.biospace.com/press-releases/ariceum-therapeutics-appoints-david-schilansky-as-chief-executive-officer-and-announces-new-leadership-to-advance-next-phase-of-development","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/","field":"links","label":"Official website"},{"id":"ariceum-therapeutics","kind":"company","name":"Ariceum Therapeutics","route":"/companies/ariceum-therapeutics/","field":"website"}],"archive":"https://web.archive.org/web/20250917104108/https://www.biospace.com/press-releases/ariceum-therapeutics-appoints-david-schilansky-as-chief-executive-officer-and-announces-new-leadership-to-advance-next-phase-of-development"},{"url":"https://www.biospace.com/press-releases/life-molecular-imaging-expands-neuraceq-florbetaben-f-18-injection-production-in-decatur-il","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"life-molecular-imaging","kind":"company","name":"Life Molecular Imaging","route":"/companies/life-molecular-imaging/","field":"links","label":"BioSpace: Life Molecular Imaging expands Neuraceq production in Decatur, IL, with SOFIE Biosciences (2025)"}]},{"url":"https://www.biospace.com/press-releases/molecular-targeting-technologies-receives-pharma-tech-outlooks-2026-radiopharmaceutical-therapy-solution-of-the-year-award-for-evathera","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"molecular-targeting-technologies","kind":"company","name":"Molecular Targeting Technologies","route":"/companies/molecular-targeting-technologies/","field":"links","label":"BioSpace: Molecular Targeting Technologies receives Pharma Tech Outlook's 2026 Radiopharmaceutical Therapy Solution of the Year award for EvaThera"}]},{"url":"https://www.bioxconomy.com/investment/advancell-lands-315m-to-solve-radiopharmaceutical-industry-s-biggest-constraint-","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"advancell","kind":"company","name":"AdvanCell","route":"/companies/advancell/","field":"links","label":"BioXconomy: AdvanCell lands $315m for prostate cancer drug (2026)"}]},{"url":"https://www.bipm.org/en/-/resolution-cgpm-15-9","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"absorbed-dose-term","kind":"term","name":"Absorbed dose and the gray (Gy)","route":"/terms/absorbed-dose-term/","field":"links","label":"BIPM: Resolution 9 of the 15th CGPM (1975), adoption of the gray"}]},{"url":"https://www.blueearthdiagnostics.com","status":200,"ok":true,"finalUrl":"https://www.blueearthdiagnostics.com/","checked":"2026-10-21","refs":[{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/","field":"links","label":"Official website"},{"id":"blue-earth-diagnostics","kind":"company","name":"Blue Earth Diagnostics (Bracco)","route":"/companies/blue-earth-diagnostics/","field":"website"}],"archive":"https://web.archive.org/web/20260608173215/https://www.blueearthdiagnostics.com/"},{"url":"https://www.blueearthdiagnostics.com/hubfs/PR063.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"falcon","kind":"trial","name":"FALCON","route":"/trials/falcon/","field":"links","label":"Blue Earth Diagnostics: FALCON trial results announcement"}]},{"url":"https://www.bms.com","status":200,"ok":true,"finalUrl":"https://www.bms.com/","checked":"2026-10-21","refs":[{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","field":"links","label":"Official website"},{"id":"bms","kind":"company","name":"Bristol Myers Squibb","route":"/companies/bms/","field":"website"}],"archive":"https://web.archive.org/web/20260919115821/https://www.bms.com/"},{"url":"https://www.bordet.be","status":200,"ok":true,"finalUrl":"https://www.hubruxelles.be/en","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","field":"links","label":"Homepage"},{"id":"institut-jules-bordet","kind":"institution","name":"Institut Jules Bordet","route":"/institutions/institut-jules-bordet/","field":"website"}],"archive":"https://web.archive.org/web/20261004141931/https://www.bordet.be/"},{"url":"https://www.bostonscientific.com","status":200,"ok":true,"finalUrl":"https://www.bostonscientific.com/en-US/home.html","checked":"2026-10-21","refs":[{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/","field":"links","label":"Official website"},{"id":"boston-scientific","kind":"company","name":"Boston Scientific","route":"/companies/boston-scientific/","field":"website"}],"archive":"https://web.archive.org/web/20080725095130/http://www.bostonscientific.com/"},{"url":"https://www.bostonscientific.com/content/dam/bostonscientific/pi/portfolio-group/cancer-therapies/therasphere/resource-center/clinical-data/DOSISPHERE-01_Data_Sheet.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-radioembolisation","kind":"section","name":"Radioembolisation","route":"/fronts/f-radioembolisation/","field":"links","label":"DOSISPHERE-01 data sheet (Boston Scientific)"}]},{"url":"https://www.bostonscientific.com/content/dam/bsc/us/pi/ir/ioe/therasphere/downloads/TheraSphere-Systemic-Brochure.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tare-plus-durvalumab-hcc","kind":"pairing","name":"Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma","route":"/pairings/tare-plus-durvalumab-hcc/","field":"links","label":"Boston Scientific TheraSphere systemic therapy combination evidence brochure"}]},{"url":"https://www.bracco.com","status":200,"ok":true,"finalUrl":"https://www.bracco.com/","checked":"2026-10-21","refs":[{"id":"bracco","kind":"company","name":"Bracco Imaging","route":"/companies/bracco/","field":"website"}]},{"url":"https://www.bracco.com/article/bracco-imaging-expands-its-portfolio-personalized-diagnostics","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bracco","kind":"company","name":"Bracco Imaging","route":"/companies/bracco/","field":"links","label":"Bracco: Bracco Imaging expands its portfolio of personalized diagnostics (2021, rhPSMA licence)"}]},{"url":"https://www.bracco.com/en-us/oncology","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bracco","kind":"company","name":"Bracco Imaging","route":"/companies/bracco/","field":"links","label":"Bracco: oncology / rhPSMA (Blue Earth Therapeutics)"}]},{"url":"https://www.bracco.com/en-us/our-portfolio","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bracco","kind":"company","name":"Bracco Imaging","route":"/companies/bracco/","field":"links","label":"Bracco: our portfolio (nuclear medicine)"}]},{"url":"https://www.bracco.com/our-businesses","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bracco","kind":"company","name":"Bracco Imaging","route":"/companies/bracco/","field":"links","label":"Bracco: our businesses (Blue Earth Diagnostics, Blue Earth Therapeutics)"}]},{"url":"https://www.bracco.com/us-en-2020-11-24-spc-cardiogen-82","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rb-82","kind":"isotope","name":"Rubidium-82","route":"/isotopes/rb-82/","field":"links","label":"FDA label: CardioGen-82 (rubidium Rb 82 generator)"}]},{"url":"https://www.bwxt.com/opg-and-bwxt-make-significant-progress-in-production-of-life-saving-medical-isotope-at-darlington-nuclear-generating-station-2/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","route":"/companies/bwxt-medical/","field":"links","label":"BWXT/OPG: OPG and BWXT make significant progress in production of Mo-99 at Darlington (2020)"}]},{"url":"https://www.bwxtmedical.com","status":200,"ok":true,"finalUrl":"https://www.bwxtmedical.com/","checked":"2026-10-21","refs":[{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","route":"/companies/bwxt-medical/","field":"website"}]},{"url":"https://www.bwxtmedical.com/bwxt-medical-and-laurentis-complete-key-tc-99m-generator-program-milestone/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","route":"/companies/bwxt-medical/","field":"links","label":"BWXT Medical: BWXT Medical and Laurentis complete key Tc-99m generator program milestone (2023)"}]},{"url":"https://www.bwxtmedical.com/bwxt-names-nuclear-medicine-business-as-bwxt-medical/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bwxt-medical","kind":"company","name":"BWXT Medical","route":"/companies/bwxt-medical/","field":"links","label":"BWXT Medical: BWXT Names Nuclear Medicine Business as BWXT Medical (2021)"}]},{"url":"https://www.cancer.gov","status":200,"ok":true,"finalUrl":"https://www.cancer.gov/","checked":"2026-10-21","refs":[{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/","field":"links","label":"Official website"},{"id":"nci","kind":"institution","name":"National Cancer Institute (NIH)","route":"/institutions/nci/","field":"website"}],"archive":"https://web.archive.org/web/20261013115058/https://www.cancer.gov/"},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/capecitabine","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","field":"links","label":"NCI drug page"}],"archive":"https://web.archive.org/web/20260805075902/https://www.cancer.gov/about-cancer/treatment/drugs/capecitabine"},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/dexrazoxanehydrochloride","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dexrazoxane","kind":"drug","name":"Dexrazoxane","route":"/drugs/dexrazoxane/","field":"links","label":"NCI drug page"}],"archive":"https://web.archive.org/web/20260903114717/https://www.cancer.gov/about-cancer/treatment/drugs/dexrazoxanehydrochloride"},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","field":"links","label":"NCI drug page"}],"archive":"https://web.archive.org/web/20260814014614/https://www.cancer.gov/about-cancer/treatment/drugs/ibritumomabtiuxetan"},{"url":"https://www.cancer.gov/about-cancer/treatment/drugs/iobenguanei131","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"iobenguane-i-131","kind":"drug","name":"Iobenguane I-131 (therapeutic)","route":"/drugs/iobenguane-i-131/","field":"links","label":"NCI drug page"}],"archive":"https://web.archive.org/web/20260801170912/https://www.cancer.gov/about-cancer/treatment/drugs/iobenguanei131"},{"url":"https://www.cancer.gov/publications/dictionaries/cancer-terms/def/oligometastasis","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"oligometastatic","kind":"term","name":"Oligometastatic disease","route":"/terms/oligometastatic/","field":"links","label":"NCI Dictionary of Cancer Terms: oligometastasis"}],"archive":"https://web.archive.org/web/20260801182043/https://www.cancer.gov/publications/dictionaries/cancer-terms/def/oligometastasis"},{"url":"https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-04728","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-neoadjuvant-psma-therapy","kind":"idea","name":"Neoadjuvant PSMA radioligand therapy before prostatectomy","route":"/ideas/idea-neoadjuvant-psma-therapy/","field":"links","label":"Lu-177-PSMA-617 before Radical Prostatectomy (PRELUDE) (NCI trial listing, NCT06798558)"}]},{"url":"https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2025-05583","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-alpha-for-oligometastatic-disease","kind":"idea","name":"Alpha-emitting PSMA therapy for oligometastatic (few-lesion) prostate cancer","route":"/ideas/idea-alpha-for-oligometastatic-disease/","field":"links","label":"ANDROMEDA (NCI trial listing)"}]},{"url":"https://www.cancer.gov/types/bladder/hp/bladder-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","field":"links","label":"NCI PDQ: bladder cancer treatment, health professional version"},{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","field":"standardOfCare.guideline (Non-muscle-invasive disease (Ta/Tis/T1))"},{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","field":"standardOfCare.guideline (NMIBC, BCG-unresponsive)"},{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","field":"standardOfCare.guideline (Muscle-invasive disease)"},{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","field":"standardOfCare.guideline (Metastatic disease, first line)"}]},{"url":"https://www.cancer.gov/types/bone/patient/osteosarcoma-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"osteosarcoma","kind":"indication","name":"Osteosarcoma","route":"/indications/osteosarcoma/","field":"links","label":"NCI PDQ: osteosarcoma"}],"archive":"https://web.archive.org/web/20260905080813/https://www.cancer.gov/types/bone/patient/osteosarcoma-treatment-pdq"},{"url":"https://www.cancer.gov/types/breast/breast-cancer-types/triple-negative","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"links","label":"NCI: What Is Triple-Negative Breast Cancer (TNBC)?"}]},{"url":"https://www.cancer.gov/types/colorectal/hp/colon-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"links","label":"NCI PDQ: colon cancer treatment, health professional version"},{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"standardOfCare.guideline (Localised colon cancer)"},{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"standardOfCare.guideline (Metastatic disease, first line)"},{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"standardOfCare.guideline (Surveillance after curative resection)"}]},{"url":"https://www.cancer.gov/types/colorectal/hp/rectal-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"links","label":"NCI PDQ: rectal cancer treatment, health professional version"},{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"standardOfCare.guideline (Locally advanced rectal cancer)"}]},{"url":"https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/","field":"links","label":"NCI PDQ: renal cell cancer treatment"}],"archive":"https://web.archive.org/web/20260807185602/https://www.cancer.gov/types/kidney/hp/kidney-treatment-pdq"},{"url":"https://www.cancer.gov/types/lung/hp/non-small-cell-lung-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"links","label":"NCI PDQ: non-small cell lung cancer treatment (health professional)"},{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"standardOfCare.guideline (Suspected distant spread)"},{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"standardOfCare.guideline (Locally advanced unresectable disease)"}]},{"url":"https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sclc","kind":"indication","name":"Small-cell lung cancer","route":"/indications/sclc/","field":"links","label":"NCI PDQ: small cell lung cancer treatment"}],"archive":"https://web.archive.org/web/20260905054553/https://www.cancer.gov/types/lung/hp/small-cell-lung-treatment-pdq"},{"url":"https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"follicular-lymphoma","kind":"indication","name":"Follicular lymphoma","route":"/indications/follicular-lymphoma/","field":"links","label":"NCI PDQ: adult NHL"}],"archive":"https://web.archive.org/web/20260917132045/https://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq"},{"url":"https://www.cancer.gov/types/multiple-endocrine-neoplasia","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"multiple-endocrine-neoplasia","kind":"indication","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/indications/multiple-endocrine-neoplasia/","field":"links","label":"NCI PDQ: multiple endocrine neoplasia syndromes"}],"archive":"https://web.archive.org/web/20260813095204/https://www.cancer.gov/types/multiple-endocrine-neoplasia"},{"url":"https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"neuroblastoma","kind":"indication","name":"Neuroblastoma (paediatric)","route":"/indications/neuroblastoma/","field":"standardOfCare.guideline (High-risk)"},{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/","field":"links","label":"NCI PDQ: Neuroblastoma Treatment"},{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Induction)"},{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Consolidation)"},{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Local control)"},{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Post-consolidation)"},{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Relapsed or refractory)"},{"id":"neuroblastoma-high-risk","kind":"indication","name":"High-risk neuroblastoma","route":"/indications/neuroblastoma-high-risk/","field":"standardOfCare.guideline (Survivorship)"}],"archive":"https://web.archive.org/web/20260929091239/https://www.cancer.gov/types/neuroblastoma/hp/neuroblastoma-treatment-pdq"},{"url":"https://www.cancer.gov/types/pancreatic/hp/pancreatic-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","field":"links","label":"NCI PDQ: pancreatic cancer treatment, health professional version"},{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","field":"standardOfCare.guideline (Resectable or borderline resectable disease)"},{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","field":"standardOfCare.guideline (Locally advanced (unresectable) disease)"},{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","field":"standardOfCare.guideline (Metastatic disease, first line)"},{"id":"pancreatic-cancer","kind":"indication","name":"Pancreatic ductal adenocarcinoma","route":"/indications/pancreatic-cancer/","field":"standardOfCare.guideline (Metastatic disease, germline BRCA1/BRCA2-mutated)"}]},{"url":"https://www.cancer.gov/types/pheochromocytoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/","field":"links","label":"NCI PDQ: pheochromocytoma and paraganglioma"}],"archive":"https://web.archive.org/web/20260805110515/https://www.cancer.gov/types/pheochromocytoma"},{"url":"https://www.cancer.gov/types/stomach/hp/stomach-treatment-pdq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","field":"links","label":"NCI PDQ: gastric cancer treatment, health professional version"}]},{"url":"https://www.cancerbiomed.org/content/22/3/212","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cldn18-2-imaging-gastric","kind":"opportunity","name":"Claudin-18.2 imaging when one biopsy says negative","route":"/opportunities/opp-cldn18-2-imaging-gastric/","field":"links","label":"Gastric cancer biomarker testing review, naming the approved assay"},{"id":"cldn18-2","kind":"target","name":"Claudin-18.2","route":"/targets/cldn18-2/","field":"links","label":"Gastric cancer biomarker testing review, naming the approved companion assay"}]},{"url":"https://www.cancerimagingarchive.net","status":200,"ok":true,"finalUrl":"https://www.cancerimagingarchive.net/","checked":"2026-10-21","refs":[{"id":"tcia","kind":"collection","name":"The Cancer Imaging Archive (TCIA)","route":"/collections/tcia/","field":"links","label":"The Cancer Imaging Archive (TCIA)"},{"id":"tcia","kind":"collection","name":"The Cancer Imaging Archive (TCIA)","route":"/collections/tcia/","field":"url"}],"archive":"https://web.archive.org/web/20261012100916/https://www.cancerimagingarchive.net/"},{"url":"https://www.cancerimagingarchive.net/access-data/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-open-dosimetry-data-commons","kind":"idea","name":"An open data commons linking patient-level radiopharmaceutical dosimetry to outcomes","route":"/ideas/idea-open-dosimetry-data-commons/","field":"links","label":"Access the Data — The Cancer Imaging Archive (TCIA)"}]},{"url":"https://www.cancernetwork.com/view/fda-accepts-new-drug-application-for-177lu-edotreotide-in-gep-nets","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","field":"regulatoryEvents.source (2026-08-28)"}],"archive":"https://web.archive.org/web/20251211185352/https://www.cancernetwork.com/view/fda-accepts-new-drug-application-for-177lu-edotreotide-in-gep-nets"},{"url":"https://www.cancernetwork.com/view/itm-11-demonstrates-superior-pfs-vs-everolimus-in-sstr-gep-nets","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"compete","kind":"trial","name":"COMPETE","route":"/trials/compete/","field":"links","label":"CancerNetwork: COMPETE"}],"archive":"https://web.archive.org/web/20251113085238/https://www.cancernetwork.com/view/itm-11-demonstrates-superior-pfs-vs-everolimus-in-sstr-gep-nets"},{"url":"https://www.cancernetwork.com/view/lu-psma-617-pembrolizumab-shows-early-efficacy-in-metastatic-crpc","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-rlt-plus-checkpoint-inhibitor","kind":"idea","name":"Adding a checkpoint inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-checkpoint-inhibitor/","field":"links","label":"Lu-PSMA-617/Pembrolizumab Shows Early Efficacy in Metastatic CRPC (Cancer Network, summary of Lancet Oncology publication)"}]},{"url":"https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"parp","kind":"target","name":"PARP","route":"/targets/parp/","field":"prevalence.source"}],"archive":"https://web.archive.org/web/20260213164006/https://www.cbioportal.org/study/summary?id=prad_tcga_pan_can_atlas_2018"},{"url":"https://www.ccc-muenchen.de","status":200,"ok":true,"finalUrl":"https://www.ccc-muenchen.de/ccc-muenchen","checked":"2026-10-21","refs":[{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","field":"links","label":"CCC München"}],"archive":"https://web.archive.org/web/20130531012905/http://ccc-muenchen.de/"},{"url":"https://www.ccjm.org/content/93/9/515","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"links","label":"CCJM interpretive review of primary aldosteronism management"}]},{"url":"https://www.cdc.gov/blood-clots/data-research/facts-stats/index.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pulmonary-embolism-vq","kind":"indication","name":"Pulmonary embolism: ventilation/perfusion imaging","route":"/indications/pulmonary-embolism-vq/","field":"links","label":"CDC: data and statistics on venous thromboembolism"}]},{"url":"https://www.cellectar.com","status":200,"ok":true,"finalUrl":"https://www.cellectar.com/","checked":"2026-10-21","refs":[{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","route":"/companies/cellectar/","field":"links","label":"Official website"},{"id":"cellectar","kind":"company","name":"Cellectar Biosciences","route":"/companies/cellectar/","field":"website"}],"archive":"https://web.archive.org/web/20260909045426/https://www.cellectar.com/"},{"url":"https://www.centre-eugene-marquis.fr","status":200,"ok":true,"finalUrl":"https://www.centre-eugene-marquis.fr/","checked":"2026-10-21","refs":[{"id":"centre-eugene-marquis","kind":"institution","name":"Centre Eugène Marquis","route":"/institutions/centre-eugene-marquis/","field":"links","label":"Official website"},{"id":"centre-eugene-marquis","kind":"institution","name":"Centre Eugène Marquis","route":"/institutions/centre-eugene-marquis/","field":"website"}],"archive":"https://web.archive.org/web/20260718204732/https://www.centre-eugene-marquis.fr/"},{"url":"https://www.chemlin.org/isotope/phosphorus-32","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"p-32","kind":"isotope","name":"Phosphorus-32","route":"/isotopes/p-32/","field":"links","label":"Phosphorus-32 - isotopic data and properties"}]},{"url":"https://www.claritypharmaceuticals.com","status":200,"ok":true,"finalUrl":"https://www.claritypharmaceuticals.com/","checked":"2026-10-21","refs":[{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","route":"/companies/clarity-pharmaceuticals/","field":"website"}],"archive":"https://web.archive.org/web/20260603185942/https://www.claritypharmaceuticals.com/"},{"url":"https://www.claritypharmaceuticals.com/news/secure-undetectable/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-copper-theranostic-pair-standard","kind":"idea","name":"A single-molecule copper-64/copper-67 pair instead of switching ligands between scan and treatment","route":"/ideas/idea-copper-theranostic-pair-standard/","field":"links","label":"SECuRE trial update: another participant with undetectable disease (Clarity Pharmaceuticals, Feb 2026)"}]},{"url":"https://www.claritypharmaceuticals.com/news/secure-update-05-08-26/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-copper-theranostic-pair-standard","kind":"idea","name":"A single-molecule copper-64/copper-67 pair instead of switching ligands between scan and treatment","route":"/ideas/idea-copper-theranostic-pair-standard/","field":"links","label":"SECuRE update: 8 GBq Cu-67 SAR-bisPSMA dose level results (Clarity Pharmaceuticals, Aug 2026)"}]},{"url":"https://www.claritypharmaceuticals.com/technology/copper-isotopes/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cu-67","kind":"isotope","name":"Copper-67","route":"/isotopes/cu-67/","field":"links","label":"Clarity Pharmaceuticals: Copper-64 and Copper-67 - The Perfect Theranostic Pairing"}]},{"url":"https://www.cms.gov/files/document/mm14361-hospital-outpatient-prospective-payment-system-january-2026-update.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-regulation-reimbursement","kind":"section","name":"Regulation & reimbursement","route":"/fronts/f-regulation-reimbursement/","field":"links","label":"CMS: Hospital Outpatient Prospective Payment System, January 2026 update (MM14361)"}]},{"url":"https://www.cms.gov/medicare/coverage/evidence","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"medicare-ced","kind":"term","name":"Medicare coverage with evidence development","route":"/terms/medicare-ced/","field":"links","label":"CMS: coverage with evidence development"}],"archive":"https://web.archive.org/web/20261009223229/https://www.cms.gov/medicare/coverage/evidence"},{"url":"https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"access.source (US)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"access.source (US)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"access.source (US)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"access.source (US)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"access.source (US)"},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"access.source (US)"}],"archive":"https://web.archive.org/web/20260928232059/https://www.cms.gov/medicare/payment/part-b-drugs/asp-pricing-files"},{"url":"https://www.cms.gov/regulations-and-guidance/guidance/transmittals/downloads/r24ncd.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-fdg-brain","kind":"drug","name":"Fludeoxyglucose F-18 (brain metabolism)","route":"/drugs/f-18-fdg-brain/","field":"links","label":"CMS NCD 220.6.13: FDG PET for Dementia and Neurodegenerative Diseases"},{"id":"f-18-fdg-brain","kind":"drug","name":"Fludeoxyglucose F-18 (brain metabolism)","route":"/drugs/f-18-fdg-brain/","field":"dosing.source"}]},{"url":"https://www.comecer.com","status":200,"ok":true,"finalUrl":"https://www.comecer.com/","checked":"2026-10-21","refs":[{"id":"comecer","kind":"company","name":"Comecer (ATS)","route":"/companies/comecer/","field":"links","label":"Official website"},{"id":"comecer","kind":"company","name":"Comecer (ATS)","route":"/companies/comecer/","field":"website"}],"archive":"https://web.archive.org/web/20260616124252/https://www.comecer.com/"},{"url":"https://www.curanosticum.de/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/","field":"links","label":"Official website"},{"id":"curanosticum","kind":"institution","name":"Curanosticum Wiesbaden-Frankfurt","route":"/institutions/curanosticum/","field":"website"}],"archive":"https://web.archive.org/web/20260617073806/https://www.curanosticum.de/"},{"url":"https://www.curanosticum.de/en/","status":200,"ok":true,"finalUrl":"https://www.curanosticum.de/","checked":"2026-10-21","refs":[{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"links","label":"Curanosticum"},{"id":"richard-baum","kind":"person","name":"Richard P. Baum","route":"/people/richard-baum/","field":"profiles","label":"Curanosticum"}]},{"url":"https://www.curiumpharma.com","status":200,"ok":true,"finalUrl":"https://www.curiumpharma.com/","checked":"2026-10-21","refs":[{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/","field":"links","label":"Official website"},{"id":"curium","kind":"company","name":"Curium","route":"/companies/curium/","field":"website"}],"archive":"https://web.archive.org/web/20260920174210/https://www.curiumpharma.com/"},{"url":"https://www.curiumpharma.com/2026/09/14/fda-approval-bexlutry/","status":200,"ok":true,"finalUrl":"https://www.curiumpharma.com/fda-approval-bexlutry/","checked":"2026-10-21","refs":[{"id":"lu-177-dotatate-generic","kind":"drug","name":"Lutetium-177 dotatate (radioligand equivalent)","route":"/drugs/lu-177-dotatate-generic/","field":"links","label":"Curium: FDA approval of BEXLUTRY, 14 September 2026"}]},{"url":"https://www.cyclomedica.com/2023/10/02/united-states-fda-grants-approval-for-technegas/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"technegas","kind":"drug","name":"Technegas (technetium Tc-99m labelled carbon inhalation aerosol)","route":"/drugs/technegas/","field":"links","label":"Cyclomedica: FDA grants approval for Technegas"}]},{"url":"https://www.cyclomedica.com/company/cyclopharm/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cyclopharm","kind":"company","name":"Cyclopharm","route":"/companies/cyclopharm/","field":"links","label":"Cyclomedica: part of Cyclopharm Limited (ASX:CYC), 65 countries"}]},{"url":"https://www.cyclopharm.com/","status":200,"ok":true,"finalUrl":"https://www.cyclomedica.com/company/cyclopharm/","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"cyclopharm","kind":"company","name":"Cyclopharm","route":"/companies/cyclopharm/","field":"website"}]},{"url":"https://www.dana-farber.org","status":200,"ok":true,"finalUrl":"https://www.dana-farber.org/","checked":"2026-10-21","refs":[{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/","field":"links","label":"Official website"},{"id":"dana-farber","kind":"institution","name":"Dana-Farber Brigham Cancer Center","route":"/institutions/dana-farber/","field":"website"}],"archive":"https://web.archive.org/web/20260925052836/https://www.dana-farber.org/"},{"url":"https://www.diagnosticradphys.com/physicspulse/medical-health-physics/nuclear-medicine-hot-lab-design/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hot-cells-and-shielding","kind":"technology","name":"Hot cells and radiation shielding","route":"/technologies/hot-cells-and-shielding/","field":"links","label":"Nuclear medicine hot lab design and safety, half-value-layer/tenth-value-layer shielding calculations"}]},{"url":"https://www.diagnosticradphys.com/physicspulse/nuclear-medical-physics/tc-99m-generator-quality-control/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mo99-tc99m-generators","kind":"technology","name":"Molybdenum-99/technetium-99m generators","route":"/technologies/mo99-tc99m-generators/","field":"links","label":"Tc-99m generator QC: Mo-99 breakthrough testing and NRC 10 CFR 35.204 limit"}]},{"url":"https://www.discoverymedicine.com/Rodney-J-Hicks/about/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rodney-hicks","kind":"person","name":"Rodney J. Hicks","route":"/people/rodney-hicks/","field":"profiles","label":"Discovery Medicine biography"}]},{"url":"https://www.dora.lib4ri.ch/psi/islandora/object/psi:68199/datastream/PDF/Tosato-2025-Alpha_Atlas-(published_version).pdf","status":200,"ok":true,"finalUrl":"https://www.dora.lib4ri.ch/psi/dload/psi:68199/PDF/Tosato-2025-Alpha_Atlas-(published_version).pdf","checked":"2026-10-21","refs":[{"id":"ra-223","kind":"isotope","name":"Radium-223","route":"/isotopes/ra-223/","field":"links","label":"Alpha Atlas: mapping global production of alpha-emitting radionuclides for TAT (PSI, 2025)"}],"archive":"https://web.archive.org/web/20250517080211/https://www.dora.lib4ri.ch/psi/islandora/object/psi%3A68199/datastream/PDF/Tosato-2025-Alpha_Atlas-(published_version).pdf"},{"url":"https://www.eanm.org","status":200,"ok":true,"finalUrl":"https://eanm.org/","checked":"2026-10-21","refs":[{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/","field":"links","label":"EANM"},{"id":"eanm","kind":"institution","name":"European Association of Nuclear Medicine","route":"/institutions/eanm/","field":"website"}],"archive":"https://web.archive.org/web/20260922210845/https://eanm.org/"},{"url":"https://www.ecfr.gov/current/title-10/chapter-I/part-20","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alara","kind":"term","name":"ALARA (as low as is reasonably achievable)","route":"/terms/alara/","field":"links","label":"eCFR: 10 CFR Part 20, Standards for Protection Against Radiation"}]},{"url":"https://www.ecfr.gov/current/title-10/chapter-I/part-20/subpart-D/section-20.1301","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hot-lab","kind":"term","name":"Hot lab (radiopharmacy dispensing area)","route":"/terms/hot-lab/","field":"links","label":"10 CFR 20.1301, Dose limits for individual members of the public (NRC eCFR)"}]},{"url":"https://www.ecfr.gov/current/title-10/chapter-I/part-35","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nrc-regulations-part35","kind":"collection","name":"US NRC 10 CFR Part 35 (Medical Use of Byproduct Material)","route":"/collections/nrc-regulations-part35/","field":"links","label":"eCFR: 10 CFR Part 35 — Medical Use of Byproduct Material"},{"id":"nrc-regulations-part35","kind":"collection","name":"US NRC 10 CFR Part 35 (Medical Use of Byproduct Material)","route":"/collections/nrc-regulations-part35/","field":"url"},{"id":"radiation-safety-officer","kind":"term","name":"Radiation Safety Officer (RSO)","route":"/terms/radiation-safety-officer/","field":"links","label":"eCFR: 10 CFR Part 35, Medical Use of Byproduct Material"},{"id":"nrc-licensing","kind":"term","name":"NRC medical-use licensing (10 CFR Part 35)","route":"/terms/nrc-licensing/","field":"links","label":"eCFR: 10 CFR Part 35, Medical Use of Byproduct Material - full text and subpart structure"},{"id":"patient-release-criteria","kind":"term","name":"Patient release criteria after radioactive treatment","route":"/terms/patient-release-criteria/","field":"links","label":"eCFR: 10 CFR Part 35, Medical Use of Byproduct Material (subpart structure, 35.2075 recordkeeping)"}]},{"url":"https://www.ecfr.gov/current/title-10/chapter-I/part-35/subpart-D/section-35.75","status":200,"ok":true,"finalUrl":"https://www.ecfr.gov/current/title-10/chapter-I/part-35/subpart-C/section-35.75","checked":"2026-10-21","refs":[{"id":"patient-release-criteria","kind":"term","name":"Patient release criteria after radioactive treatment","route":"/terms/patient-release-criteria/","field":"links","label":"eCFR: 10 CFR 35.75, Release of individuals containing unsealed byproduct material or implants containing byproduct material"}]},{"url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radionuclide-generators-kits","kind":"technology","name":"Radionuclide generators and cold kits","route":"/technologies/radionuclide-generators-kits/","field":"links","label":"21 CFR Part 211: current good manufacturing practice for finished pharmaceuticals"}],"archive":"https://web.archive.org/web/20260802111521/https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-211"},{"url":"https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-212","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cyclotron-isotope-production","kind":"technology","name":"Cyclotron isotope production (F-18, Ga-68, Cu-64, Zr-89, At-211)","route":"/technologies/cyclotron-isotope-production/","field":"links","label":"21 CFR Part 212: current good manufacturing practice for PET drugs"},{"id":"medical-cyclotrons-synthesis-modules","kind":"technology","name":"Medical cyclotrons, hot cells, and synthesis modules","route":"/technologies/medical-cyclotrons-synthesis-modules/","field":"links","label":"21 CFR Part 212: current good manufacturing practice for PET drugs"},{"id":"pet-tracer-manufacturing","kind":"technology","name":"PET tracer manufacturing and distribution","route":"/technologies/pet-tracer-manufacturing/","field":"links","label":"21 CFR Part 212: current good manufacturing practice for PET drugs"},{"id":"radiopharmaceutical-gmp-release","kind":"technology","name":"Radiopharmaceutical GMP and releasing a drug that decays","route":"/technologies/radiopharmaceutical-gmp-release/","field":"links","label":"21 CFR Part 212: current good manufacturing practice for PET drugs"},{"id":"radiopharmacy-network","kind":"technology","name":"Radiopharmacy and cyclotron networks","route":"/technologies/radiopharmacy-network/","field":"links","label":"21 CFR Part 212: current good manufacturing practice for PET drugs"}],"archive":"https://web.archive.org/web/20260617013756/https://www.ecfr.gov/current/title-21/chapter-I/subchapter-C/part-212"},{"url":"https://www.ema.europa.eu","status":200,"ok":true,"finalUrl":"https://www.ema.europa.eu/en/homepage","checked":"2026-10-21","refs":[{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","field":"links","label":"EMA"},{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","field":"website"}],"archive":"https://web.archive.org/web/20230710083035/http://www.ema.europa.eu/"},{"url":"https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ema","kind":"institution","name":"European Medicines Agency","route":"/institutions/ema/","field":"links","label":"CHMP"}],"archive":"https://web.archive.org/web/20261004212150/https://www.ema.europa.eu/en/committees/committee-medicinal-products-human-use-chmp"},{"url":"https://www.ema.europa.eu/en/documents/assessment-report/galliapharm-epar-public-assessment-report_en.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ge68-ga68-generators","kind":"technology","name":"Germanium-68/gallium-68 generators","route":"/technologies/ge68-ga68-generators/","field":"links","label":"EMA EPAR: GalliaPharm 68Ge/68Ga generator public assessment report"}]},{"url":"https://www.ema.europa.eu/en/documents/assessment-report/pluvicto-epar-public-assessment-report_en.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"salivary-gland-toxicity","kind":"term","name":"Salivary gland toxicity (xerostomia) from PSMA radioligand therapy","route":"/terms/salivary-gland-toxicity/","field":"links","label":"EMA: Pluvicto assessment report (EPAR)"}]},{"url":"https://www.ema.europa.eu/en/documents/product-information/datscan-epar-product-information_en.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"i-123-ioflupane","kind":"drug","name":"Ioflupane I-123","route":"/drugs/i-123-ioflupane/","field":"links","label":"EMA EPAR product information: DaTSCAN"}]},{"url":"https://www.ema.europa.eu/en/documents/product-information/quadramet-epar-product-information_en.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sm-153","kind":"isotope","name":"Samarium-153","route":"/isotopes/sm-153/","field":"links","label":"EMA: Quadramet EPAR product information"}]},{"url":"https://www.ema.europa.eu/en/documents/product-information/tauvid-epar-product-information_en.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-flortaucipir","kind":"drug","name":"Flortaucipir F-18","route":"/drugs/f-18-flortaucipir/","field":"links","label":"EMA EPAR product information: Tauvid"}]},{"url":"https://www.ema.europa.eu/en/documents/product-information/vizamyl-epar-product-information_en.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-flutemetamol","kind":"drug","name":"Flutemetamol F-18","route":"/drugs/f-18-flutemetamol/","field":"links","label":"EMA EPAR product information: Vizamyl"}]},{"url":"https://www.ema.europa.eu/en/documents/scientific-guideline/draft-guideline-quality-radiopharmaceuticals-revision-2_en.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-radiochemistry","kind":"section","name":"Radiochemistry & manufacturing","route":"/fronts/f-radiochemistry/","field":"links","label":"EMA draft guideline on the quality of radiopharmaceuticals, revision 2 (consultation closed 30 April 2026)"},{"id":"f-regulation-reimbursement","kind":"section","name":"Regulation & reimbursement","route":"/fronts/f-regulation-reimbursement/","field":"links","label":"EMA: draft guideline on the quality of radiopharmaceuticals, revision 2"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/datscan","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"parkinsonian-syndromes","kind":"indication","name":"Parkinsonian syndromes","route":"/indications/parkinsonian-syndromes/","field":"links","label":"EMA EPAR: DaTSCAN (ioflupane (123I))"},{"id":"i-123-ioflupane","kind":"drug","name":"Ioflupane I-123","route":"/drugs/i-123-ioflupane/","field":"links","label":"EMA EPAR summary: DaTSCAN"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/neuraceq","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-florbetaben","kind":"drug","name":"Florbetaben F-18","route":"/drugs/f-18-florbetaben/","field":"links","label":"EMA EPAR: Neuraceq"}]},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"samarium-153-lexidronam","kind":"drug","name":"Samarium-153 lexidronam","route":"/drugs/samarium-153-lexidronam/","field":"links","label":"EPAR (EMA)"}],"archive":"https://web.archive.org/web/20260109224136/https://www.ema.europa.eu/en/medicines/human/EPAR/quadramet"},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/thyrogen","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"thyrotropin-alfa","kind":"drug","name":"Thyrotropin alfa","route":"/drugs/thyrotropin-alfa/","field":"links","label":"EPAR (EMA)"}],"archive":"https://web.archive.org/web/20260112013553/https://www.ema.europa.eu/en/medicines/human/EPAR/thyrogen"},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"capecitabine","kind":"drug","name":"Capecitabine","route":"/drugs/capecitabine/","field":"links","label":"EPAR"}],"archive":"https://web.archive.org/web/20260112014412/https://www.ema.europa.eu/en/medicines/human/EPAR/xeloda"},{"url":"https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ibritumomab-tiuxetan","kind":"drug","name":"Ibritumomab tiuxetan","route":"/drugs/ibritumomab-tiuxetan/","field":"links","label":"EPAR"}],"archive":"https://web.archive.org/web/20260910030450/https://www.ema.europa.eu/en/medicines/human/EPAR/zevalin"},{"url":"https://www.ema.europa.eu/system/files/documents/other/qualification-opinion-centiloid-measure-amyloid-pet-quantify-brain-amyloid-deposition-en.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-florbetaben","kind":"drug","name":"Florbetaben F-18","route":"/drugs/f-18-florbetaben/","field":"links","label":"EMA CHMP: qualification opinion for Centiloid measure of amyloid PET (25 June 2024)"}]},{"url":"https://www.endocrine.org/clinical-practice-guidelines/primary-aldosteronism-2","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"links","label":"Endocrine Society guideline summary page"},{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"standardOfCare.guideline (All individuals with hypertension)"},{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"standardOfCare.guideline (Positive screen, intermediate probability of lateralizing disease)"},{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"standardOfCare.guideline (Lateralizing disease, surgical candidate who wants surgery)"},{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"standardOfCare.guideline (All patients with primary aldosteronism and an adrenal adenoma)"},{"id":"opp-cxcr4-primary-aldosteronism","kind":"opportunity","name":"CXCR4 imaging instead of adrenal vein sampling","route":"/opportunities/opp-cxcr4-primary-aldosteronism/","field":"links","label":"Endocrine Society primary aldosteronism guideline 2025"}]},{"url":"https://www.endocrine.org/news-and-advocacy/news-room/2025/endocrine-society-guideline-calls-for-increased-screening-for-common-cause-of-high-blood-pressure","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"primary-aldosteronism","kind":"indication","name":"Primary aldosteronism","route":"/indications/primary-aldosteronism/","field":"links","label":"Endocrine Society news release calling for increased screening"}]},{"url":"https://www.energy.gov/articles/doennsa-partnership-us-healthcare-industry-results-fda-approval-domestically-produced-non","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"isotope-supply-roadmap","kind":"roadmap","name":"Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium","route":"/roadmaps/isotope-supply-roadmap/","field":"links","label":"DOE/NNSA: FDA approval of domestically-produced, non-uranium based Mo-99, February 2018"}]},{"url":"https://www.energy.gov/science/ip/isotope-rd-and-production-doe-ip","status":200,"ok":true,"finalUrl":"https://www.energy.gov/science/ip/isotope-rd-and-production-doe-irp","checked":"2026-10-21","refs":[{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/","field":"links","label":"DOE Isotope R&D and Production overview"}]},{"url":"https://www.energy.gov/sites/default/files/2024-03/FY2025-PresidentsRequest-IRP.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","route":"/bottlenecks/b-enriched-target-material/","field":"links","label":"DOE Isotope R&D and Production, FY2025 budget request (stable isotope enrichment priorities)"}]},{"url":"https://www.energy.gov/sites/prod/files/2013/07/f2/hdbk-1122-04_sg112_0.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"biological-half-life","kind":"term","name":"Biological half-life","route":"/terms/biological-half-life/","field":"links","label":"DOE-HDBK-1122-99: radiological control technician training, biological half-life"}]},{"url":"https://www.eqs-news.com/news/corporate/pentixapharm-receives-fda-fast-track-designation-for-phase-3-diagnostic-candidate-e281b6e281b8gaga-pentixafor-in-primary-aldosteronism/239d14bc-6e9e-4077-9909-43e52edf7a09_en","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cxcr4-primary-aldosteronism","kind":"opportunity","name":"CXCR4 imaging instead of adrenal vein sampling","route":"/opportunities/opp-cxcr4-primary-aldosteronism/","field":"links","label":"FDA Fast Track designation for 68Ga-PentixaFor in primary aldosteronism"}]},{"url":"https://www.erasmusmc.nl/en/cancer-institute","status":200,"ok":true,"finalUrl":"https://www.erasmusmc.nl/en/cancer-institute/patient-care","checked":"2026-10-21","refs":[{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/","field":"links","label":"Homepage"},{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/","field":"website"}]},{"url":"https://www.esmo.org/guidelines","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"annals-of-oncology","kind":"journal","name":"Annals of Oncology","route":"/journals/annals-of-oncology/","field":"links","label":"ESMO Guidelines"}]},{"url":"https://www.evergreentgn.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","field":"links","label":"Official website"},{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","field":"website"}],"archive":"https://web.archive.org/web/20260521073830/https://www.evergreentgn.com/"},{"url":"https://www.evergreentgn.com/2023/06/08/cam-h2-production-at-evergreen-marks-the-expansion-of-precirix-clinical-trial-to-the-us/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"precirix","kind":"company","name":"Precirix","route":"/companies/precirix/","field":"links","label":"Official website"},{"id":"precirix","kind":"company","name":"Precirix","route":"/companies/precirix/","field":"website"}],"archive":"https://web.archive.org/web/20260521074925/https://www.evergreentgn.com/2023/06/08/cam-h2-production-at-evergreen-marks-the-expansion-of-precirix-clinical-trial-to-the-us/"},{"url":"https://www.evergreentgn.com/2025/01/28/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-evolution-into-fully-integrated-radiopharmaceutical-leader/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","field":"links","label":"Lantheus acquisition release"}],"archive":"https://web.archive.org/web/20260610235723/https://www.evergreentgn.com/2025/01/28/lantheus-to-acquire-evergreen-theragnostics-for-upfront-payment-of-250-million-to-drive-strategic-evolution-into-fully-integrated-radiopharmaceutical-leader/"},{"url":"https://www.evergreentgn.com/news/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"evergreen-theragnostics","kind":"company","name":"Evergreen Theragnostics","route":"/companies/evergreen-theragnostics/","field":"links","label":"News"}],"archive":"https://web.archive.org/web/20260710195832/https://www.evergreentgn.com/news/"},{"url":"https://www.exceldiagnostics.com/","status":200,"ok":true,"finalUrl":"https://exceldiagnostics.com/","checked":"2026-10-21","refs":[{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","field":"links","label":"Excel Diagnostics"},{"id":"ebrahim-delpassand","kind":"person","name":"Ebrahim S. Delpassand","route":"/people/ebrahim-delpassand/","field":"profiles","label":"Excel Diagnostics"}]},{"url":"https://www.ezag.com","status":200,"ok":true,"finalUrl":"https://www.ezag.com/","checked":"2026-10-21","refs":[{"id":"eckert-ziegler","kind":"company","name":"Eckert & Ziegler","route":"/companies/eckert-ziegler/","field":"links","label":"Official website"},{"id":"eckert-ziegler","kind":"company","name":"Eckert & Ziegler","route":"/companies/eckert-ziegler/","field":"website"}],"archive":"https://web.archive.org/web/20260927024111/https://www.ezag.com/"},{"url":"https://www.fda.gov/about-fda/oncology-center-excellence/project-optimus","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-dose-optimisation","kind":"bottleneck","name":"Wrong doses","route":"/bottlenecks/b-dose-optimisation/","field":"links","label":"FDA Oncology Center of Excellence, Project Optimus"}]},{"url":"https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-imaging-drug-evaluation-myocardial-ischemia-and-infarction","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-18-flurpiridaz","kind":"drug","name":"Flurpiridaz F-18","route":"/drugs/f-18-flurpiridaz/","field":"links","label":"FDA news release: FDA approves imaging drug for evaluation of myocardial ischemia and infarction (27 September 2024)"},{"id":"f-18-flurpiridaz","kind":"drug","name":"Flurpiridaz F-18","route":"/drugs/f-18-flurpiridaz/","field":"toxicity.source (Dyspnoea, headache, angina pectoris, chest pain, fatigue, ST-segment changes, flushing, nausea, abdominal pain, dizziness, arrhythmia (most common, combined rest and stress imaging))"},{"id":"f-cardiac-imaging","kind":"section","name":"Cardiac imaging","route":"/fronts/f-cardiac-imaging/","field":"links","label":"FDA: approval of Flyrcado (flurpiridaz F 18) for myocardial ischemia/infarction evaluation, 27 Sep 2024"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2026-06-12)"}],"archive":"https://web.archive.org/web/20260923050621/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pembrolizumab-adjuvant-treatment-renal-cell-carcinoma"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pheochromocytoma-paraganglioma","kind":"indication","name":"Pheochromocytoma and paraganglioma (PPGL)","route":"/indications/pheochromocytoma-paraganglioma/","field":"links","label":"FDA approval of belzutifan for PPGL (May 2025)"}],"archive":"https://web.archive.org/web/20260607211324/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-belzutifan-pheochromocytoma-or-paraganglioma"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-hr-positive-her2-negative-breast","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-trop2-imaging-heterogeneity","kind":"opportunity","name":"TROP2 imaging where no tissue test is required","route":"/opportunities/opp-trop2-imaging-heterogeneity/","field":"links","label":"FDA approval of datopotamab deruxtecan, January 2025"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-datopotamab-deruxtecan-dlnk-unresectable-or-metastatic-triple-negative-breast-cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"links","label":"FDA: approval of datopotamab deruxtecan-dlnk for unresectable or metastatic TNBC"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2026-05-28)"}],"archive":"https://web.archive.org/web/20260610034649/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-durvalumab-combination-bacillus-calmette-guerin-high-risk-non-muscle-invasive-bladder"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-enfortumab-vedotin-ejfv-pembrolizumab-locally-advanced-or-metastatic-urothelial-cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"urothelial-cancer","kind":"indication","name":"Urothelial cancer","route":"/indications/urothelial-cancer/","field":"links","label":"FDA approval: enfortumab vedotin-ejfv with pembrolizumab for locally advanced or metastatic urothelial cancer"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-fam-trastuzumab-deruxtecan-nxki-her2-positive-gastric-adenocarcinomas","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","field":"standardOfCare.guideline (Metastatic disease, first line, HER2-positive)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psmaddition","kind":"trial","name":"PSMAddition","route":"/trials/psmaddition/","field":"links","label":"FDA approval 31 Jul 2026"}],"archive":"https://web.archive.org/web/20260930192453/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-lutetium-lu-177-vipivotide-tetraxetan-androgen-receptor-pathway-inhibitor-therapy"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-enfortumab-vedotin-ejfv-muscle-invasive-bladder-cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-nectin4-imaging-urothelial","kind":"opportunity","name":"A liver-cleared Nectin-4 tracer for urothelial cancer","route":"/opportunities/opp-nectin4-imaging-urothelial/","field":"links","label":"FDA: perioperative enfortumab vedotin plus pembrolizumab, November 2025"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2026-07-10)"}],"archive":"https://web.archive.org/web/20260711050606/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-pembrolizumab-or-pembrolizumab-and-berahyaluronidase-alfa-pmph-each-enfortumab-vedotin"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2026-06-24)"},{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"links","label":"FDA: approval of sacituzumab govitecan-hziy monotherapy and with pembrolizumab, first line"},{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"standardOfCare.guideline (Metastatic TNBC, first line)"}],"archive":"https://web.archive.org/web/20260625172344/https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-sacituzumab-govitecan-hziy-monotherapy-and-combination-pembrolizumab-first-line"},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-approves-zolbetuximab-clzb-chemotherapy-gastric-or-gastroesophageal-junction-adenocarcinoma","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","field":"links","label":"FDA approval of zolbetuximab-clzb (Vyloy) for CLDN18.2-positive gastric/GEJ adenocarcinoma"},{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","field":"standardOfCare.guideline (Metastatic disease, first line, HER2-negative)"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/fda-expands-pluvictos-metastatic-castration-resistant-prostate-cancer-indication","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"psma-theranostics-roadmap","kind":"roadmap","name":"PSMA theranostics roadmap: antigen discovery → PSMA PET → 177Lu-PSMA-617 → earlier lines and alpha","route":"/roadmaps/psma-theranostics-roadmap/","field":"links","label":"FDA: Pluvicto label expansion based on PSMAfore, March 2025"}]},{"url":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications","status":200,"ok":true,"finalUrl":"https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancerhematologic-malignancies-approval-notifications","checked":"2026-10-21","refs":[{"id":"ac225-psma","kind":"drug","name":"Actinium-225 PSMA agents","route":"/drugs/ac225-psma/","field":"regulatoryEvents.source (2024-06)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2017-05-01)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2018-02-16)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2020-03-27)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2022-09-02)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2022-10-21)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2024-12-04)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2025-03-28)"},{"id":"durvalumab","kind":"drug","name":"Durvalumab","route":"/drugs/durvalumab/","field":"regulatoryEvents.source (2025-11)"},{"id":"fap-2286","kind":"drug","name":"FAP-2286 (177Lu / 68Ga)","route":"/drugs/fap-2286/","field":"regulatoryEvents.source (2023-01)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"regulatoryEvents.source (2017-09-26)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"regulatoryEvents.source (2018-01-26)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"regulatoryEvents.source (2024-04-23)"},{"id":"lutathera","kind":"drug","name":"Lutetium-177 dotatate","route":"/drugs/lutathera/","field":"regulatoryEvents.source (2024-06)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2014-12-19)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2017-08-17)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2018-01-12)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2018-12-19)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2019-12-27)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2020-05-19)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2022-03-11)"},{"id":"olaparib","kind":"drug","name":"Olaparib","route":"/drugs/olaparib/","field":"regulatoryEvents.source (2023-05-31)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2014-09-04)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2015-10-02)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2017-05-23)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2020-06-16)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2020-11-13)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2021-07-26)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2023-10-16)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2025-09)"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/","field":"regulatoryEvents.source (2026-Q1)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"regulatoryEvents.source (2021-06)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"regulatoryEvents.source (2022-03-23)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"regulatoryEvents.source (2022-12)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"regulatoryEvents.source (2025-03-28)"},{"id":"pluvicto","kind":"drug","name":"Lutetium-177 vipivotide tetraxetan","route":"/drugs/pluvicto/","field":"regulatoryEvents.source (2026-07-31)"},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"dosing.source"},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"regulatoryEvents.source (2021-05-26)"},{"id":"pylarify","kind":"drug","name":"Piflufolastat F-18 / Pylarify TruVu","route":"/drugs/pylarify/","field":"regulatoryEvents.source (2026-03-09)"},{"id":"ryz101","kind":"drug","name":"Actinium-225 DOTATATE","route":"/drugs/ryz101/","field":"regulatoryEvents.source (2024-02-26)"}],"archive":"https://web.archive.org/web/20240914055742/https://www.fda.gov/drugs/resources-information-approved-drugs/oncology-cancer-hematologic-malignancies-approval-notifications"},{"url":"https://www.fda.gov/medical-devices/recently-approved-devices/theraspheretm-p200029","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"y-90-glass-microspheres","kind":"drug","name":"Yttrium-90 glass microspheres","route":"/drugs/y-90-glass-microspheres/","field":"links","label":"FDA: TheraSphere P200029 approval page"}]},{"url":"https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sterile-fill-finish","kind":"technology","name":"Sterile fill-finish and lyophilisation","route":"/technologies/sterile-fill-finish/","field":"links","label":"FDA guidance: sterile drug products produced by aseptic processing"}],"archive":"https://web.archive.org/web/20260908211432/https://www.fda.gov/regulatory-information/search-fda-guidance-documents/sterile-drug-products-produced-aseptic-processing-current-good-manufacturing-practice"},{"url":"https://www.fiercebiotech.com/biotech/1st-biotech-ipo-2026-sees-aktis-bring-318m-upsized-offering","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"aktis-oncology","kind":"company","name":"Aktis Oncology","route":"/companies/aktis-oncology/","field":"links","label":"IPO coverage"}],"archive":"https://web.archive.org/web/20260510151701/https://www.fiercebiotech.com/biotech/1st-biotech-ipo-2026-sees-aktis-bring-318m-upsized-offering"},{"url":"https://www.fiercebiotech.com/biotech/sk-inks-572m-deal-full-life-prospect-advancing-push-become-asias-radiopharma-leader","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"full-life-technologies","kind":"company","name":"Full-Life Technologies","route":"/companies/full-life-technologies/","field":"links","label":"FierceBiotech: SK inks $572M deal for Full-Life radiopharma prospect (2024)"}]},{"url":"https://www.fiercebiotech.com/medtech/blue-earth-diagnostics-sold-to-bracco-imaging-450m-deal","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bracco","kind":"company","name":"Bracco Imaging","route":"/companies/bracco/","field":"links","label":"FierceBiotech: Blue Earth Diagnostics sold to Bracco Imaging in $450M deal (2019)"}]},{"url":"https://www.fiercepharma.com/pharma/bms-and-rayzebio-halt-radiotherapy-trial-enrollment-after-isotope-runs-scarce","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/","field":"links","label":"FiercePharma: BMS and RayzeBio halt radiotherapy trial enrollment after isotope runs scarce"},{"id":"b-ac225-supply","kind":"bottleneck","name":"Actinium-225 supply","route":"/bottlenecks/b-ac225-supply/","field":"metrics (RayzeBio (BMS) paused new enrolment in phase 3 ACTION-1 trial)"},{"id":"b-rlt-trial-capacity","kind":"bottleneck","name":"Clinical trial capacity for radioligand therapy","route":"/bottlenecks/b-rlt-trial-capacity/","field":"links","label":"FiercePharma: BMS and RayzeBio halt radiotherapy trial enrollment after isotope runs scarce"},{"id":"b-rlt-trial-capacity","kind":"bottleneck","name":"Clinical trial capacity for radioligand therapy","route":"/bottlenecks/b-rlt-trial-capacity/","field":"metrics (RayzeBio (BMS) paused new-patient enrolment in phase 3 ACTION-1 trial)"}]},{"url":"https://www.fiercepharma.com/pharma/fda-approves-first-radioligand-equivalent-curiums-copycat-novartis-lutathera","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lu-177-dotatate-generic","kind":"drug","name":"Lutetium-177 dotatate (radioligand equivalent)","route":"/drugs/lu-177-dotatate-generic/","field":"links","label":"FiercePharma: FDA approves first radioligand equivalent"}]},{"url":"https://www.fredhutch.org/en/faculty-lab-directory/chen-delphine.html","status":200,"ok":true,"finalUrl":"https://www.fredhutch.org/en/people/c/delphine-chen.html","checked":"2026-10-21","refs":[{"id":"delphine-chen","kind":"person","name":"Delphine L. Chen","route":"/people/delphine-chen/","field":"links","label":"Fred Hutch faculty profile"},{"id":"delphine-chen","kind":"person","name":"Delphine L. Chen","route":"/people/delphine-chen/","field":"profiles","label":"Fred Hutch faculty profile"}]},{"url":"https://www.frontiersin.org/journals/endocrinology/articles/10.3389/fendo.2025.1716247/full","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"fixed-versus-personalised-dosing","kind":"term","name":"Fixed versus personalised (dosimetry-guided) dosing","route":"/terms/fixed-versus-personalised-dosing/","field":"links","label":"DUONEN trial: dosimetry-guided peptide receptor radionuclide therapy, Frontiers in Endocrinology 2025"}]},{"url":"https://www.frontiersin.org/journals/nuclear-medicine/articles/10.3389/fnume.2026.1935247/full","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-ai-lesion-segmentation-dosimetry","kind":"idea","name":"AI segmentation to make voxel-level radioligand dosimetry practical at scale","route":"/ideas/idea-ai-lesion-segmentation-dosimetry/","field":"links","label":"Artificial intelligence across oncologic theranostics: evidence review (Frontiers in Nuclear Medicine, 2026)"},{"id":"ai-in-nuclear-medicine","kind":"technology","name":"AI in nuclear medicine","route":"/technologies/ai-in-nuclear-medicine/","field":"links","label":"Artificial intelligence across oncologic theranostics: evidence for patient stratification, dosimetry and adaptive radiopharmaceutical therapy (Front. Nucl. Med. 2026)"}]},{"url":"https://www.full-life.com","status":200,"ok":true,"finalUrl":"https://www.full-life.com/","checked":"2026-10-21","refs":[{"id":"full-life-technologies","kind":"company","name":"Full-Life Technologies","route":"/companies/full-life-technologies/","field":"website"}]},{"url":"https://www.full-life.com/media/press-releases/26","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"full-life-technologies","kind":"company","name":"Full-Life Technologies","route":"/companies/full-life-technologies/","field":"links","label":"Full-Life: development of 177Lu-FL-091 for NTSR1-positive cancers (2024)"}]},{"url":"https://www.full-life.com/media/press-releases/28","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"full-life-technologies","kind":"company","name":"Full-Life Technologies","route":"/companies/full-life-technologies/","field":"links","label":"Full-Life: Full-Life Technologies, SK Biopharmaceuticals enter $571.5M licence agreement for FL-091 (2024)"}]},{"url":"https://www.full-life.com/media/press-releases/42","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"full-life-technologies","kind":"company","name":"Full-Life Technologies","route":"/companies/full-life-technologies/","field":"links","label":"Full-Life: SK Biopharmaceuticals receives FDA IND approval for alpha-emitter-based radiopharmaceutical therapy (SKL35501) (2026)"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:1029","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","checked":"2026-10-21","refs":[{"id":"bradykinin-b1-receptor","kind":"target","name":"Bradykinin B1 receptor (B1R)","route":"/targets/bradykinin-b1-receptor/","field":"links","label":"HGNC: BDKRB1 gene record (HGNC:1029)"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:11186","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","checked":"2026-10-21","refs":[{"id":"sortilin","kind":"target","name":"Sortilin (SORT1)","route":"/targets/sortilin/","field":"links","label":"HGNC: SORT1 gene record (HGNC:11186)"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:12004","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","checked":"2026-10-21","refs":[{"id":"tpbg-5t4","kind":"target","name":"5T4 (trophoblast glycoprotein)","route":"/targets/tpbg-5t4/","field":"links","label":"HGNC: TPBG gene record (HGNC:12004)"}]},{"url":"https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:2903","status":200,"ok":true,"finalUrl":"https://www.genenames.org/data/gene-symbol-report/","checked":"2026-10-21","refs":[{"id":"dlg4-psd95","kind":"target","name":"DLG4 (PSD-95)","route":"/targets/dlg4-psd95/","field":"links","label":"HGNC: DLG4 gene record (HGNC:2903)"}]},{"url":"https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/","field":"links","label":"MHRA"},{"id":"mhra","kind":"institution","name":"Medicines and Healthcare products Regulatory Agency","route":"/institutions/mhra/","field":"website"}],"archive":"https://web.archive.org/web/20261006172228/https://www.gov.uk/government/organisations/medicines-and-healthcare-products-regulatory-agency"},{"url":"https://www.gov.uk/guidance/clinical-trials-for-medicines-good-manufacturing-practice-and-radiopharmaceutical-investigational-medicinal-products","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-radiochemistry","kind":"section","name":"Radiochemistry & manufacturing","route":"/fronts/f-radiochemistry/","field":"links","label":"MHRA: GMP and radiopharmaceutical investigational medicinal products guidance (updated 28 April 2026)"},{"id":"f-regulation-reimbursement","kind":"section","name":"Regulation & reimbursement","route":"/fronts/f-regulation-reimbursement/","field":"links","label":"MHRA: clinical trials GMP and radiopharmaceutical IMPs guidance (updated 28 April 2026)"}]},{"url":"https://www.govinfo.gov/content/pkg/CFR-2004-title10-vol1/pdf/CFR-2004-title10-vol1-sec35-900.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiation-safety-officer","kind":"term","name":"Radiation Safety Officer (RSO)","route":"/terms/radiation-safety-officer/","field":"links","label":"10 CFR 35.900, Radiation Safety Officer (GovInfo, CFR)"}]},{"url":"https://www.hamamatsu.com","status":200,"ok":true,"finalUrl":"https://www.hamamatsu.com/jp/en.html","checked":"2026-10-21","refs":[{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","field":"links","label":"Official website"},{"id":"hamamatsu","kind":"company","name":"Hamamatsu Photonics","route":"/companies/hamamatsu/","field":"website"}],"archive":"https://web.archive.org/web/20130116053603/http://www.hamamatsu.com/"},{"url":"https://www.healthcert.com/hubfs/EJNMMI%20Castellucci%20-%20Savoia%20et%20al.%202020.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"re-188-sct","kind":"drug","name":"Rhenium-188 skin cancer therapy","route":"/drugs/re-188-sct/","field":"links","label":"Castellucci et al., high-dose brachytherapy with non-sealed 188Re for non-melanoma skin cancer, EJNMMI"}]},{"url":"https://www.healthsystemreadiness.com/app/uploads/Health-system-readiness-for-radioligand-therapy-in-the-UK-Service-provision.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","field":"links","label":"Health system readiness for radioligand therapy in the UK: service provision"},{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","field":"metrics (UK centres offering Ga-68 DOTATATE/TOC PET-CT for neuroendocrine tumours)"},{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/","field":"links","label":"Health system readiness for radioligand therapy in the UK: service provision"}]},{"url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0327/2026032704522.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"china-isotope-radiation","kind":"company","name":"China Isotope & Radiation Corporation","route":"/companies/china-isotope-radiation/","field":"links","label":"CIRC 2025 annual results announcement (revenue RMB 7,187.7 million; terbium-161 agency)"}]},{"url":"https://www.hkexnews.hk/listedco/listconews/sehk/2026/0422/2026042200023.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"china-isotope-radiation","kind":"company","name":"China Isotope & Radiation Corporation","route":"/companies/china-isotope-radiation/","field":"links","label":"CIRC 2025 annual report (HKEXnews): founding 1983, stock code 1763, CNNC control"},{"id":"hta-atom-hi-tech","kind":"company","name":"HTA (Atom Hi-Tech)","route":"/companies/hta-atom-hi-tech/","field":"links","label":"CIRC 2025 annual report (HTA listed as a subsidiary)"}]},{"url":"https://www.hollandptc.nl","status":200,"ok":true,"finalUrl":"https://www.hollandptc.nl/","checked":"2026-10-21","refs":[{"id":"erasmus-mc","kind":"institution","name":"Erasmus MC Cancer Institute","route":"/institutions/erasmus-mc/","field":"links","label":"HollandPTC"}],"archive":"https://web.archive.org/web/20260815235844/https://www.hollandptc.nl/"},{"url":"https://www.iarc.who.int/wp-content/uploads/2025/02/pr361_E.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"links","label":"IARC press release: global cancer burden 2022"}]},{"url":"https://www.iaslc.org/iaslc-news/press-release/tarlatamab-anti-pd-l1-first-line-maintenance-after-chemo-immunotherapy-es","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sclc","kind":"indication","name":"Small-cell lung cancer","route":"/indications/sclc/","field":"links","label":"IASLC: tarlatamab first-line maintenance data"}],"archive":"https://web.archive.org/web/20260414190124/https://www.iaslc.org/iaslc-news/press-release/tarlatamab-anti-pd-l1-first-line-maintenance-after-chemo-immunotherapy-es"},{"url":"https://www.iba-worldwide.com","status":200,"ok":true,"finalUrl":"https://www.iba-worldwide.com/","checked":"2026-10-21","refs":[{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","route":"/companies/iba/","field":"links","label":"Official website"},{"id":"iba","kind":"company","name":"IBA (Ion Beam Applications)","route":"/companies/iba/","field":"website"}],"archive":"https://web.archive.org/web/20260924153342/https://www.iba-worldwide.com/"},{"url":"https://www.icao.int/sites/default/files/Meetings/a42/Documents/WP/wp_439_en.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-cold-chain-logistics","kind":"bottleneck","name":"Cold chain and time-critical logistics","route":"/bottlenecks/b-cold-chain-logistics/","field":"links","label":"ICAO Assembly working paper on denial and delay of shipment of radioactive material"}]},{"url":"https://www.ich.org/page/efficacy-guidelines","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"estimand","kind":"term","name":"Estimands and intercurrent events (ICH E9(R1))","route":"/terms/estimand/","field":"links","label":"ICH E9 and E9(R1): statistical principles for clinical trials and the estimand framework"}],"archive":"https://web.archive.org/web/20261004031454/https://www.ich.org/page/efficacy-guidelines"},{"url":"https://www.icrp.org/docs/physics_icrp_found_doc_for_web_consult.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"equivalent-dose","kind":"term","name":"Equivalent dose and effective dose (sievert)","route":"/terms/equivalent-dose/","field":"links","label":"ICRP: The Use of Dosimetric Quantities in Radiological Protection"}]},{"url":"https://www.icrp.org/page.asp?id=5","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"icrp-publications","kind":"collection","name":"ICRP publications and dose coefficient databases","route":"/collections/icrp-publications/","field":"links","label":"ICRP: Publications"},{"id":"icrp-publications","kind":"collection","name":"ICRP publications and dose coefficient databases","route":"/collections/icrp-publications/","field":"url"}]},{"url":"https://www.icrp.org/publication.asp?id=ICRP%20Publication%20107","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"icrp-publications","kind":"collection","name":"ICRP publications and dose coefficient databases","route":"/collections/icrp-publications/","field":"links","label":"ICRP Publication 107: Nuclear Decay Data for Dosimetric Calculations"}]},{"url":"https://www.iislafe.es","status":200,"ok":true,"finalUrl":"https://www.iislafe.es/en/","checked":"2026-10-21","refs":[{"id":"la-fe-valencia","kind":"institution","name":"Hospital Universitari i Politècnic La Fe","route":"/institutions/la-fe-valencia/","field":"links","label":"IIS La Fe"}],"archive":"https://web.archive.org/web/20230514080249/http://www.iislafe.es/"},{"url":"https://www.indexbox.io/store/mexico-peptide-receptor-radionuclide-therapy-prrt-market-analysis-forecast-size-trends-and-insights/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-regional-radiopharmacy-network","kind":"idea","name":"In-house hospital radiopharmacy compounding to cut dose waste","route":"/ideas/idea-regional-radiopharmacy-network/","field":"links","label":"Peptide Receptor Radionuclide Therapy (PRRT) Market in Mexico (IndexBox market report, 2026)"}]},{"url":"https://www.institut-cancerologie-ouest.com","status":200,"ok":true,"finalUrl":"https://www.institut-cancerologie-ouest.com/","checked":"2026-10-21","refs":[{"id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","route":"/institutions/ico-angers-nantes/","field":"links","label":"Official website"},{"id":"ico-angers-nantes","kind":"institution","name":"Institut de Cancérologie de l'Ouest (ICO)","route":"/institutions/ico-angers-nantes/","field":"website"}],"archive":"https://web.archive.org/web/20260710115615/https://www.institut-cancerologie-ouest.com/"},{"url":"https://www.ioveneto.it","status":200,"ok":true,"finalUrl":"https://www.ioveneto.it/","checked":"2026-10-21","refs":[{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","field":"links","label":"Homepage"},{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","field":"website"}],"archive":"https://web.archive.org/web/20261005102635/https://www.ioveneto.it/"},{"url":"https://www.ioveneto.it/ricerca/","status":200,"ok":true,"finalUrl":"https://www.ioveneto.it/ricerca-scientifica/","checked":"2026-10-21","refs":[{"id":"iov-veneto","kind":"institution","name":"Istituto Oncologico Veneto IRCCS","route":"/institutions/iov-veneto/","field":"links","label":"Research"}],"archive":"https://web.archive.org/web/20250806124610/https://www.ioveneto.it/ricerca/"},{"url":"https://www.iqvia.com/insights/the-iqvia-institute/reports-and-publications/reports/developing-efficient-patient-referral-pathways-for-radioligand-therapies","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","field":"links","label":"IQVIA Institute: Developing efficient patient referral pathways for radioligand therapies (2025)"},{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","field":"metrics (Minimum referral-to-treatment-initiation time for mCRPC radioligand therapy (Germany, France, Italy, China))"}]},{"url":"https://www.ire.eu","status":200,"ok":true,"finalUrl":"https://www.ire.eu/","checked":"2026-10-21","refs":[{"id":"ire","kind":"company","name":"IRE (Institut national des Radioéléments)","route":"/companies/ire/","field":"links","label":"Official website"},{"id":"ire","kind":"company","name":"IRE (Institut national des Radioéléments)","route":"/companies/ire/","field":"website"}],"archive":"https://web.archive.org/web/20260912152531/https://www.ire.eu/"},{"url":"https://www.irst.emr.it","status":200,"ok":true,"finalUrl":"https://www.irst.emr.it/it","checked":"2026-10-21","refs":[{"id":"irst-meldola","kind":"institution","name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)","route":"/institutions/irst-meldola/","field":"links","label":"Homepage"},{"id":"irst-meldola","kind":"institution","name":"IRCCS Istituto Romagnolo per lo Studio dei Tumori 'Dino Amadori' (IRST)","route":"/institutions/irst-meldola/","field":"website"}],"archive":"https://web.archive.org/web/20200613182217/http://www.irst.emr.it:80/"},{"url":"https://www.isotopes.gov/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"actinium-225-supply","kind":"technology","name":"Actinium-225 supply: thorium stocks, accelerators and radium targets","route":"/technologies/actinium-225-supply/","field":"links","label":"US DOE Isotope Program"},{"id":"research-reactor-isotope-production","kind":"technology","name":"Research reactors for medical isotopes (Mo-99, Lu-177, I-131)","route":"/technologies/research-reactor-isotope-production/","field":"links","label":"US DOE Isotope Program"},{"id":"therapy-isotope-supply-chain","kind":"technology","name":"Therapeutic isotope supply chain (Mo-99, Lu-177, Ac-225)","route":"/technologies/therapy-isotope-supply-chain/","field":"links","label":"US Department of Energy Isotope Program"},{"id":"b-manufacturing-cell-therapy","kind":"bottleneck","name":"Manufacturing cost and time for living and radioactive medicines","route":"/bottlenecks/b-manufacturing-cell-therapy/","field":"links","label":"US Department of Energy Isotope Program"}],"archive":"https://web.archive.org/web/20260920105530/https://isotopes.gov/"},{"url":"https://www.isotopes.gov/Ensuring-steady-supply-of-strontium-89","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sr-89","kind":"isotope","name":"Strontium-89","route":"/isotopes/sr-89/","field":"links","label":"DOE Isotope Program: Ensuring a steady supply of strontium-89"}]},{"url":"https://www.isotopes.gov/node/123","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pb-212","kind":"isotope","name":"Lead-212","route":"/isotopes/pb-212/","field":"links","label":"DOE Isotope Program: Availability of radium-224/lead-212 generators"}]},{"url":"https://www.isotopes.gov/node/1517","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tb-161","kind":"isotope","name":"Terbium-161","route":"/isotopes/tb-161/","field":"links","label":"DOE/isotopes.gov: To Advance Cancer Therapy, University Starts Producing Tb-161"}]},{"url":"https://www.isotopes.gov/node/215","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"y-86","kind":"isotope","name":"Yttrium-86","route":"/isotopes/y-86/","field":"links","label":"DOE Isotope Program (NIDC): yttrium-86 availability"}]},{"url":"https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-presents-positive-topline-phase-3-compete-trial-data-with-nca-177lu-edotreotide-itm-11-a-targeted-radiopharmaceutical-therapy-in-patients-with-grade-1-or-2-gastroenteropancreatic-neuroendocrine-tumors-at-the-enets-2025-conference-688/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"itm-11","kind":"drug","name":"177Lu-edotreotide","route":"/drugs/itm-11/","field":"regulatoryEvents.source (2025-03)"}],"archive":"https://web.archive.org/web/20260315060739/https://www.itm-radiopharma.com/news/press-releases/press-releases-detail/itm-presents-positive-topline-phase-3-compete-trial-data-with-nca-177lu-edotreotide-itm-11-a-targeted-radiopharmaceutical-therapy-in-patients-with-grade-1-or-2-gastroenteropancreatic-neuroendocrine-tumors-at-the-enets-2025-conference-688/"},{"url":"https://www.itnonline.com/content/blue-earth-diagnostics-announces-efficacy-and-safety-results-phase-3-lighthouse-trial","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lighthouse","kind":"trial","name":"LIGHTHOUSE","route":"/trials/lighthouse/","field":"links","label":"Blue Earth Diagnostics: LIGHTHOUSE topline results announcement"}]},{"url":"https://www.itnonline.com/content/fda-approves-additional-molybdenum-99-mo-99-filling-lines-northstar-medical-radioisotopes","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"isotope-supply-roadmap","kind":"roadmap","name":"Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium","route":"/roadmaps/isotope-supply-roadmap/","field":"links","label":"NorthStar: FDA approves additional Mo-99 filling lines, February 2020"}]},{"url":"https://www.ivo.es","status":200,"ok":true,"finalUrl":"https://www.ivo.es/","checked":"2026-10-21","refs":[{"id":"ivo-valencia","kind":"institution","name":"Fundación Instituto Valenciano de Oncología (IVO)","route":"/institutions/ivo-valencia/","field":"links","label":"Official website"},{"id":"ivo-valencia","kind":"institution","name":"Fundación Instituto Valenciano de Oncología (IVO)","route":"/institutions/ivo-valencia/","field":"website"}],"archive":"https://web.archive.org/web/20260829184628/https://www.ivo.es/"},{"url":"https://www.jnj.com","status":200,"ok":true,"finalUrl":"https://www.jnj.com/","checked":"2026-10-21","refs":[{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/","field":"links","label":"Official website"},{"id":"johnson-johnson","kind":"company","name":"Johnson & Johnson","route":"/companies/johnson-johnson/","field":"website"}],"archive":"https://web.archive.org/web/20260927185918/http://www.jnj.com/"},{"url":"https://www.jons-online.com/special-issues-and-supplements/2020/2020-year-in-review-neuroendocrine-tumors/177lu-octreotate-prrt-temozolomide-capecitabine-in-pancreas-and-updated-midgut-nets","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prrt-plus-captem","kind":"pairing","name":"PRRT (177Lu-DOTATATE) with capecitabine and temozolomide (CAPTEM)","route":"/pairings/prrt-plus-captem/","field":"links","label":"JONS-online summary of CONTROL NET pancreatic and midgut results"}]},{"url":"https://www.jubilantradiopharma.com","status":200,"ok":true,"finalUrl":"https://www.jubilantradiopharma.com/","checked":"2026-10-21","refs":[{"id":"jubilant-radiopharma","kind":"company","name":"Jubilant Radiopharma","route":"/companies/jubilant-radiopharma/","field":"links","label":"Official website"},{"id":"jubilant-radiopharma","kind":"company","name":"Jubilant Radiopharma","route":"/companies/jubilant-radiopharma/","field":"website"}],"archive":"https://web.archive.org/web/20260710232112/https://www.jubilantradiopharma.com/"},{"url":"https://www.karolinska.se","status":200,"ok":true,"finalUrl":"https://www.karolinska.se/val-av-webbplats","checked":"2026-10-21","refs":[{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/","field":"links","label":"Official website"},{"id":"karolinska","kind":"institution","name":"Karolinska University Hospital","route":"/institutions/karolinska/","field":"website"}],"archive":"https://web.archive.org/web/20260912165616/https://www.karolinska.se/"},{"url":"https://www.kcch.re.kr/eng/conts/101001000000000.do","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"kirams","kind":"institution","name":"Korea Institute of Radiological and Medical Sciences","route":"/institutions/kirams/","field":"links","label":"Korea Cancer Center Hospital (KIRAMS), history from 1963"}]},{"url":"https://www.kegg.jp/pathway/hsa05215","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prostate-cancer-signalling","kind":"pathway","name":"Prostate cancer (KEGG map)","route":"/pathways/prostate-cancer-signalling/","field":"links","label":"KEGG map hsa05215"}],"archive":"https://web.archive.org/web/20260815131955/https://www.kegg.jp/pathway/hsa05215"},{"url":"https://www.kegg.jp/pathway/hsa05231","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"choline-metabolism-in-cancer","kind":"pathway","name":"Choline metabolism in cancer","route":"/pathways/choline-metabolism-in-cancer/","field":"links","label":"KEGG map hsa05231"}],"archive":"https://web.archive.org/web/20250908090449/https://www.kegg.jp/pathway/hsa05231"},{"url":"https://www.kfshrc.edu.sa","status":200,"ok":true,"finalUrl":"https://www.kfshrc.edu.sa/","checked":"2026-10-21","refs":[{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","route":"/institutions/kfshrc/","field":"links","label":"KFSH&RC"},{"id":"kfshrc","kind":"institution","name":"King Faisal Specialist Hospital and Research Centre","route":"/institutions/kfshrc/","field":"website"}],"archive":"https://web.archive.org/web/20261004210522/https://www.kfshrc.edu.sa/"},{"url":"https://www.kirams.re.kr/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"kirams","kind":"institution","name":"Korea Institute of Radiological and Medical Sciences","route":"/institutions/kirams/","field":"website"}]},{"url":"https://www.ksnm.or.kr/eng/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ksnm","kind":"institution","name":"Korean Society of Nuclear Medicine","route":"/institutions/ksnm/","field":"links","label":"KSNM English site (founded 1961; 65th annual meeting 6 to 7 November 2026, Sejong University, Seoul)"},{"id":"ksnm","kind":"institution","name":"Korean Society of Nuclear Medicine","route":"/institutions/ksnm/","field":"website"}]},{"url":"https://www.ksnm.or.kr/eng/pub/search.php","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ksnm","kind":"institution","name":"Korean Society of Nuclear Medicine","route":"/institutions/ksnm/","field":"links","label":"KSNM publication archive"},{"id":"nuclear-medicine-and-molecular-imaging","kind":"journal","name":"Nuclear Medicine and Molecular Imaging","route":"/journals/nuclear-medicine-and-molecular-imaging/","field":"links","label":"KSNM publication archive"}]},{"url":"https://www.lantheus.com","status":200,"ok":true,"finalUrl":"https://www.lantheus.com/","checked":"2026-10-21","refs":[{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/","field":"links","label":"Official website"},{"id":"lantheus","kind":"company","name":"Lantheus","route":"/companies/lantheus/","field":"website"}],"archive":"https://web.archive.org/web/20260922120548/https://www.lantheus.com/"},{"url":"https://www.law.cornell.edu/cfr/text/10/35.290","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"authorized-user","kind":"term","name":"Authorized User (AU)","route":"/terms/authorized-user/","field":"links","label":"10 CFR 35.290, Training for imaging and localization studies (Cornell LII)"}]},{"url":"https://www.law.cornell.edu/cfr/text/10/35.390","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"authorized-user","kind":"term","name":"Authorized User (AU)","route":"/terms/authorized-user/","field":"links","label":"10 CFR 35.390, Training for use of unsealed byproduct material for which a written directive is required (Cornell LII)"}]},{"url":"https://www.law.cornell.edu/cfr/text/10/35.60","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dose-calibrator","kind":"term","name":"Dose calibrator","route":"/terms/dose-calibrator/","field":"links","label":"10 CFR 35.60, Possession, use, and calibration of instruments used to measure the activity of unsealed byproduct material (Cornell LII)"}]},{"url":"https://www.law.cornell.edu/cfr/text/10/part-35/subpart-C","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hot-lab","kind":"term","name":"Hot lab (radiopharmacy dispensing area)","route":"/terms/hot-lab/","field":"links","label":"10 CFR Part 35, Subpart C - General Technical Requirements (dose calibrators, surveys, labelling)"}]},{"url":"https://www.life-mi.com","status":200,"ok":true,"finalUrl":"https://www.lantheus.com/","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"life-molecular-imaging","kind":"company","name":"Life Molecular Imaging","route":"/companies/life-molecular-imaging/","field":"website"}]},{"url":"https://www.lmu-klinikum.de","status":200,"ok":true,"finalUrl":"https://www.lmu-klinikum.de/","checked":"2026-10-21","refs":[{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/","field":"links","label":"Official website"},{"id":"lmu-munich","kind":"institution","name":"LMU Klinikum München","route":"/institutions/lmu-munich/","field":"website"}],"archive":"https://web.archive.org/web/20261005103236/https://www.lmu-klinikum.de/"},{"url":"https://www.lumen.luc.edu/lumen/meded/radio/nuc_med/radpharm/sect-a3.htm","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"biological-half-life","kind":"term","name":"Biological half-life","route":"/terms/biological-half-life/","field":"links","label":"Radiopharmacy teaching notes (Loyola University Chicago): effective half-life"},{"id":"effective-half-life","kind":"term","name":"Effective half-life","route":"/terms/effective-half-life/","field":"links","label":"Radiopharmacy teaching notes (Loyola University Chicago): effective, biological and physical half-life"}]},{"url":"https://www.mammotome.com/","status":200,"ok":true,"finalUrl":"https://www.mammotome.com/us/en/","checked":"2026-10-21","refs":[{"id":"gamma-probes-dose-calibrators","kind":"technology","name":"Gamma probes, handheld gamma cameras and dose calibrators","route":"/technologies/gamma-probes-dose-calibrators/","field":"links","label":"Mammotome: Neoprobe gamma detection system"}],"archive":"https://web.archive.org/web/20230610131538/https://www.mammotome.com/"},{"url":"https://www.manilatimes.net/2026/08/31/tmt-newswire/globenewswire/alpha-tau-completes-patient-enrollment-in-its-multicenter-impact-pancreatic-cancer-pilot-study-of-alpha-dart-following-strong-demand-and-multiple-expansions/2415115","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-tau-medical","kind":"company","name":"Alpha Tau Medical","route":"/companies/alpha-tau-medical/","field":"links","label":"GlobeNewswire (via Manila Times): Alpha Tau completes enrollment in IMPACT pancreatic cancer pilot study (2026)"}]},{"url":"https://www.mcguirewoods.com/client-resources/alerts/2025/4/radiopharmaceutical-industry-update-q4-q1-2024-2025/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/","field":"links","label":"McGuireWoods: Radiopharmaceutical industry update, CY2025 HOPPS rule and Mo-99 add-on payment"},{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/","field":"metrics (CMS add-on payment for Tc-99m from domestically produced (non-HEU) Mo-99)"},{"id":"b-reimbursement-coding","kind":"bottleneck","name":"Reimbursement and coding for radiopharmaceuticals","route":"/bottlenecks/b-reimbursement-coding/","field":"links","label":"McGuireWoods: Radiopharmaceutical industry update, CY2025 HOPPS rule detail"},{"id":"b-reimbursement-coding","kind":"bottleneck","name":"Reimbursement and coding for radiopharmaceuticals","route":"/bottlenecks/b-reimbursement-coding/","field":"metrics (New Mo-99 domestic-sourcing add-on payment, effective 1 January 2026)"}]},{"url":"https://www.mdanderson.org","status":200,"ok":true,"finalUrl":"https://www.mdanderson.org/","checked":"2026-10-21","refs":[{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","field":"links","label":"Official website"},{"id":"md-anderson","kind":"institution","name":"MD Anderson Cancer Center","route":"/institutions/md-anderson/","field":"website"}],"archive":"https://web.archive.org/web/20261004103719/https://www.mdanderson.org/"},{"url":"https://www.medicines.org.uk/emc/product/15771/smpc","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rb-82-chloride","kind":"drug","name":"Rubidium Rb-82 chloride","route":"/drugs/rb-82-chloride/","field":"links","label":"EMC SmPC: Cardiogen-82 (Rb-82 extraction fraction 65%)"}]},{"url":"https://www.merck.com","status":200,"ok":true,"finalUrl":"https://www.merck.com/","checked":"2026-10-21","refs":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","field":"links","label":"Official website"},{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/","field":"website"}],"archive":"https://web.archive.org/web/20260928183634/https://www.merck.com/"},{"url":"https://www.merck.com/news/fda-approves-keytruda-pembrolizumab-for-treatment-of-patients-with-high-risk-early-stage-triple-negative-breast-cancer-in-combination-with-chemotherapy-as-neoadjuvant-treatment-then-continued/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"links","label":"Merck: FDA approval of pembrolizumab for high-risk early-stage TNBC (KEYNOTE-522)"},{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"standardOfCare.guideline (Early-stage, high-risk TNBC (neoadjuvant and adjuvant))"}]},{"url":"https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-patients-with-locally-recurrent-unresectable-or-metastatic-triple%E2%80%91negative-breast-cancer-whose/","status":200,"ok":true,"finalUrl":"https://www.merck.com/news/fda-approves-mercks-keytruda-pembrolizumab-in-combination-with-chemotherapy-for-patients-with-locally-recurrent-unresectable-or-metastatic-triple-negative-breast-cancer-whose/","checked":"2026-10-21","refs":[{"id":"breast-triple-negative","kind":"indication","name":"Triple-negative breast cancer","route":"/indications/breast-triple-negative/","field":"standardOfCare.guideline (Metastatic or locally recurrent TNBC, first line, PD-L1 CPS 10 or more)"}]},{"url":"https://www.mimsoftware.com","status":200,"ok":true,"finalUrl":"https://www.mimsoftware.com/","checked":"2026-10-21","refs":[{"id":"mim-software","kind":"company","name":"MIM Software (GE HealthCare)","route":"/companies/mim-software/","field":"links","label":"Official website"},{"id":"mim-software","kind":"company","name":"MIM Software (GE HealthCare)","route":"/companies/mim-software/","field":"website"}],"archive":"https://web.archive.org/web/20260919063107/https://www.mimsoftware.com/"},{"url":"https://www.monopartx.com","status":200,"ok":true,"finalUrl":"https://www.monopartx.com/","checked":"2026-10-21","refs":[{"id":"monopar","kind":"company","name":"Monopar Therapeutics","route":"/companies/monopar/","field":"links","label":"Official website"},{"id":"monopar","kind":"company","name":"Monopar Therapeutics","route":"/companies/monopar/","field":"website"}],"archive":"https://web.archive.org/web/20260908212907/https://www.monopartx.com/"},{"url":"https://www.movementdisorders.org/MDS/Scientific-Issues/posts/The-past-present-and-future-roles-of-a-synuclein-seed-amplification-assays.htm","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-alpha-synuclein-pet-parkinsons","kind":"opportunity","name":"Alpha-synuclein PET: works for MSA, not for Parkinson's","route":"/opportunities/opp-alpha-synuclein-pet-parkinsons/","field":"links","label":"Seed amplification assays: past, present and future roles"},{"id":"alpha-synuclein","kind":"target","name":"Alpha-synuclein","route":"/targets/alpha-synuclein/","field":"links","label":"Seed amplification assays: past, present and future roles"}]},{"url":"https://www.mskcc.org","status":200,"ok":true,"finalUrl":"https://www.mskcc.org/","checked":"2026-10-21","refs":[{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","field":"links","label":"Official website"},{"id":"mskcc","kind":"institution","name":"Memorial Sloan Kettering Cancer Center","route":"/institutions/mskcc/","field":"website"}],"archive":"https://web.archive.org/web/20261005131820/https://www.mskcc.org/"},{"url":"https://www.mskcc.org/cancer-care/doctors/heiko-schoder","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"heiko-schoder","kind":"person","name":"Heiko Schöder","route":"/people/heiko-schoder/","field":"links","label":"MSK doctor profile"},{"id":"heiko-schoder","kind":"person","name":"Heiko Schöder","route":"/people/heiko-schoder/","field":"profiles","label":"MSK doctor profile"}]},{"url":"https://www.mskcc.org/cancer-care/doctors/lisa-bodei","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lisa-bodei","kind":"person","name":"Lisa Bodei","route":"/people/lisa-bodei/","field":"links","label":"MSK doctor profile"},{"id":"lisa-bodei","kind":"person","name":"Lisa Bodei","route":"/people/lisa-bodei/","field":"profiles","label":"MSK doctor profile"}]},{"url":"https://www.mskcc.org/cancer-care/doctors/michael-morris","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"links","label":"MSK profile"},{"id":"michael-morris","kind":"person","name":"Michael J. Morris","route":"/people/michael-morris/","field":"profiles","label":"MSK profile"}]},{"url":"https://www.mtarget.com","status":200,"ok":true,"finalUrl":"https://www.mtarget.com/","checked":"2026-10-21","refs":[{"id":"molecular-targeting-technologies","kind":"company","name":"Molecular Targeting Technologies","route":"/companies/molecular-targeting-technologies/","field":"website"}]},{"url":"https://www.mtic.net.au/mtic-team/professor-rodney-hicks","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rodney-hicks","kind":"person","name":"Rodney J. Hicks","route":"/people/rodney-hicks/","field":"links","label":"Melbourne Theranostic Innovation Centre"},{"id":"rodney-hicks","kind":"person","name":"Rodney J. Hicks","route":"/people/rodney-hicks/","field":"profiles","label":"Melbourne Theranostic Innovation Centre team page"}]},{"url":"https://www.mychesco.com/a/news/business/west-chester-biotech-targets-radiopharma-partnerships/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"molecular-targeting-technologies","kind":"company","name":"Molecular Targeting Technologies","route":"/companies/molecular-targeting-technologies/","field":"links","label":"MyChesCo: West Chester biotech targets radiopharma partnerships (2026)"}]},{"url":"https://www.nature.com/articles/s41467-024-50056-y","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-her3-imaging-crossover","kind":"opportunity","name":"HER3 imaging, and why three tracers stalled","route":"/opportunities/opp-her3-imaging-crossover/","field":"links","label":"No relationship between HER3-DXd efficacy and HER3 immunohistochemistry, Nature Communications 2024"},{"id":"her3","kind":"target","name":"HER3 (ERBB3)","route":"/targets/her3/","field":"links","label":"No relationship between HER3-DXd efficacy and HER3 immunohistochemistry, Nature Communications 2024"}]},{"url":"https://www.nature.com/articles/s41573-020-0073-9","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-sgouros-tat-review-nat-rev-2020","kind":"paper","name":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","route":"/key-papers/paper-sgouros-tat-review-nat-rev-2020/","field":"links","label":"Nature Reviews Drug Discovery: full text"}]},{"url":"https://www.nature.com/articles/s41591-022-02114-5","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cxcr4-primary-aldosteronism","kind":"opportunity","name":"CXCR4 imaging instead of adrenal vein sampling","route":"/opportunities/opp-cxcr4-primary-aldosteronism/","field":"links","label":"MATCH: molecular imaging against adrenal vein sampling, Nature Medicine 2023"}]},{"url":"https://www.nature.com/articles/s41591-024-03254-6","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-ceacam5-imaging-colorectal","kind":"opportunity","name":"CEACAM5 imaging for occult colorectal recurrence","route":"/opportunities/opp-ceacam5-imaging-colorectal/","field":"links","label":"GALAXY: ctDNA lead time over radiological recurrence, Nature Medicine 2024"}]},{"url":"https://www.nature.com/articles/s41591-025-03579-w","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41591-025-03579-w&code=0e2fd352-3838-42ee-93c2-97129a1dfa29","checked":"2026-10-21","refs":[{"id":"colorectal-cancer","kind":"indication","name":"Colorectal cancer","route":"/indications/colorectal-cancer/","field":"links","label":"DYNAMIC five-year results, Nature Medicine 2025"}]},{"url":"https://www.nature.com/articles/s41591-025-03981-4","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"her2","kind":"target","name":"HER2","route":"/targets/her2/","field":"prevalence.source"}],"archive":"https://web.archive.org/web/20251008233131/https://www.nature.com/articles/s41591-025-03981-4"},{"url":"https://www.nature.com/articles/s41598-021-82812-1","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Farticles%2Fs41598-021-82812-1&code=8e570935-f18d-458a-be5b-8f2cd97d6ec3","checked":"2026-10-21","refs":[{"id":"cu-67","kind":"isotope","name":"Copper-67","route":"/isotopes/cu-67/","field":"links","label":"Copper-67 radioimmunotheranostics for simultaneous immunotherapy and immuno-SPECT (Scientific Reports, 2021)"}]},{"url":"https://www.nature.com/articles/s41598-025-12337-4","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cldn18-2-imaging-gastric","kind":"opportunity","name":"Claudin-18.2 imaging when one biopsy says negative","route":"/opportunities/opp-cldn18-2-imaging-gastric/","field":"links","label":"Single-biopsy sensitivity for CLDN18.2, Scientific Reports 2025"},{"id":"cldn18-2","kind":"target","name":"Claudin-18.2","route":"/targets/cldn18-2/","field":"links","label":"Single-biopsy sensitivity against whole-section truth, Scientific Reports 2025"}]},{"url":"https://www.nature.com/nm/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","field":"url"}]},{"url":"https://www.nature.com/nm/research-articles?subject=cancer","status":200,"ok":true,"finalUrl":"https://idp.nature.com/transit?redirect_uri=https%3A%2F%2Fwww.nature.com%2Fnm%2Fresearch-articles%3Fsubject%3Dcancer&code=3b2b38b6-7477-46e5-aa41-a5e2cb792ee4","checked":"2026-10-21","refs":[{"id":"nature-medicine","kind":"journal","name":"Nature Medicine","route":"/journals/nature-medicine/","field":"links","label":"Nature Medicine cancer"}]},{"url":"https://www.ncbi.nlm.nih.gov/books/NBK232708/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dose-calibrator","kind":"term","name":"Dose calibrator","route":"/terms/dose-calibrator/","field":"links","label":"Selected sections of 10 CFR Part 35, historical §35.50 dose calibrator requirements (NCBI Bookshelf)"}]},{"url":"https://www.ncbi.nlm.nih.gov/books/NBK304365/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"p-32","kind":"isotope","name":"Phosphorus-32","route":"/isotopes/p-32/","field":"links","label":"NCBI: X- and gamma-radiation (phosphorus-32 clinical background)"}]},{"url":"https://www.ncbi.nlm.nih.gov/books/NBK396163/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"i-131","kind":"isotope","name":"Iodine-131","route":"/isotopes/i-131/","field":"links","label":"Medical Isotope Production and Utilization (NAS/NCBI, 2016)"}]},{"url":"https://www.ncbi.nlm.nih.gov/books/NBK448131/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"infection-prosthetic-joint","kind":"indication","name":"Prosthetic joint infection","route":"/indications/infection-prosthetic-joint/","field":"links","label":"StatPearls: periprosthetic joint infection, incidence data"}]},{"url":"https://www.ncbi.nlm.nih.gov/books/NBK531486/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"bone-hydroxyapatite","kind":"target","name":"Bone mineral (hydroxyapatite)","route":"/targets/bone-hydroxyapatite/","field":"links","label":"StatPearls: bone scan (mechanism of Tc-99m MDP/HDP binding to hydroxyapatite)"}]},{"url":"https://www.ncbi.nlm.nih.gov/books/NBK557653/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"glut-hexokinase","kind":"target","name":"GLUT1 / hexokinase (glucose metabolism)","route":"/targets/glut-hexokinase/","field":"links","label":"StatPearls: fludeoxyglucose (18F) mechanism of action"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101172931","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cancer-imaging","kind":"journal","name":"Cancer imaging","route":"/journals/cancer-imaging/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/101469340","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"journal-of-medical-imaging-and-radiation-oncology","kind":"journal","name":"Journal of medical imaging and radiation oncology","route":"/journals/journal-of-medical-imaging-and-radiation-oncology/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/nlmcatalog/9605408","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cancer-biotherapy-and-radiopharmaceuticals","kind":"journal","name":"Cancer biotherapy & radiopharmaceuticals","route":"/journals/cancer-biotherapy-and-radiopharmaceuticals/","field":"links","label":"NLM Catalog"}]},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7595297/","status":200,"ok":true,"finalUrl":"https://pmc.ncbi.nlm.nih.gov/articles/PMC7595297/","checked":"2026-10-21","refs":[{"id":"idea-total-body-pet-lower-dose-tracers","kind":"idea","name":"Using total-body PET's sensitivity to cut diagnostic tracer dose, not just scan time","route":"/ideas/idea-total-body-pet-lower-dose-tracers/","field":"links","label":"Total Body PET: Why, How, What for? (PMC review)"}]},{"url":"https://www.ncbi.nlm.nih.gov/sites/books/NBK565854/?report=printable","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mo99-tc99m-generators","kind":"technology","name":"Molybdenum-99/technetium-99m generators","route":"/technologies/mo99-tc99m-generators/","field":"links","label":"Mo99-Tc99m generator (StatPearls, NCBI Bookshelf)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"osteosarcoma","kind":"indication","name":"Osteosarcoma","route":"/indications/osteosarcoma/","field":"links","label":"NCCN Guidelines: Bone Cancer"},{"id":"osteosarcoma","kind":"indication","name":"Osteosarcoma","route":"/indications/osteosarcoma/","field":"standardOfCare.guideline (Localised high-grade)"}],"archive":"https://web.archive.org/web/20260829193737/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1418"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Stage I (≤2-3 cm, node-negative))"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Stage II-III, neoadjuvant)"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Post-neoadjuvant, pathologic complete response)"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Post-neoadjuvant, residual invasive disease)"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Adjuvant (upfront surgery), node-positive)"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Metastatic, first line)"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Metastatic, second line)"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Metastatic, later lines)"},{"id":"breast-her2-positive","kind":"indication","name":"HER2-positive breast cancer","route":"/indications/breast-her2-positive/","field":"standardOfCare.guideline (Brain metastases)"}],"archive":"https://web.archive.org/web/20260829193808/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1419"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"glioblastoma","kind":"indication","name":"Glioma & glioblastoma","route":"/indications/glioblastoma/","field":"standardOfCare.guideline (Glioblastoma)"},{"id":"glioblastoma","kind":"indication","name":"Glioma & glioblastoma","route":"/indications/glioblastoma/","field":"standardOfCare.guideline (IDH-mutant grade 2)"},{"id":"meningioma","kind":"indication","name":"Meningioma","route":"/indications/meningioma/","field":"standardOfCare.guideline (Incidental or small asymptomatic)"},{"id":"meningioma","kind":"indication","name":"Meningioma","route":"/indications/meningioma/","field":"standardOfCare.guideline (Symptomatic or growing, accessible)"},{"id":"meningioma","kind":"indication","name":"Meningioma","route":"/indications/meningioma/","field":"standardOfCare.guideline (Small, skull base or surgically inaccessible)"},{"id":"meningioma","kind":"indication","name":"Meningioma","route":"/indications/meningioma/","field":"standardOfCare.guideline (Grade 2, incompletely resected, and all grade 3)"},{"id":"meningioma","kind":"indication","name":"Meningioma","route":"/indications/meningioma/","field":"standardOfCare.guideline (Recurrent, no surgical or radiotherapy option)"}],"archive":"https://web.archive.org/web/20260829193940/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1425"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1440","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/","field":"standardOfCare.guideline (Localised)"},{"id":"rcc","kind":"indication","name":"Renal cell carcinoma","route":"/indications/rcc/","field":"standardOfCare.guideline (Metastatic)"}],"archive":"https://web.archive.org/web/20260829194658/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1440"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","field":"standardOfCare.guideline (Diagnosis)"},{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","field":"standardOfCare.guideline (Advanced, somatostatin receptor-positive)"},{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","field":"standardOfCare.guideline (Advanced, shrinkage needed or receptor-negative)"},{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","field":"standardOfCare.guideline (Trials)"},{"id":"grade-3-net","kind":"indication","name":"Grade 3 well-differentiated neuroendocrine tumour","route":"/indications/grade-3-net/","field":"standardOfCare.guideline (Limited disease)"},{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/","field":"standardOfCare.guideline (Localised disease)"},{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/","field":"standardOfCare.guideline (Advanced, somatostatin receptor-positive, slow tempo)"},{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/","field":"standardOfCare.guideline (Advanced, progressive)"},{"id":"lung-net","kind":"indication","name":"Lung neuroendocrine tumours (typical and atypical carcinoid)","route":"/indications/lung-net/","field":"standardOfCare.guideline (Hormone syndromes)"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/","field":"standardOfCare.guideline (Localised)"},{"id":"neuroendocrine","kind":"indication","name":"Neuroendocrine tumours","route":"/indications/neuroendocrine/","field":"standardOfCare.guideline (Advanced)"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"standardOfCare.guideline (Localised, resectable)"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"standardOfCare.guideline (Functioning syndromes)"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"standardOfCare.guideline (Progression on a somatostatin analogue)"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"standardOfCare.guideline (Liver-dominant disease)"},{"id":"pancreatic-net","kind":"indication","name":"Pancreatic neuroendocrine tumours","route":"/indications/pancreatic-net/","field":"standardOfCare.guideline (VHL-associated pancreatic NET)"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"standardOfCare.guideline (Diagnosis and staging)"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"standardOfCare.guideline (Localised or resectable disease)"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"standardOfCare.guideline (Advanced, first line)"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"standardOfCare.guideline (Progression on a somatostatin analogue)"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"standardOfCare.guideline (Carcinoid syndrome)"},{"id":"small-intestinal-net","kind":"indication","name":"Small intestinal neuroendocrine tumours","route":"/indications/small-intestinal-net/","field":"standardOfCare.guideline (After radioligand therapy)"}],"archive":"https://web.archive.org/web/20260727005913/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1448"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1450","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"links","label":"NCCN Guidelines: Non-Small Cell Lung Cancer"},{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"standardOfCare.guideline (Diagnosis and initial staging)"},{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"standardOfCare.guideline (Mediastinal nodes positive on PET)"},{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"standardOfCare.guideline (Resectable early-stage disease)"},{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"standardOfCare.guideline (Advanced metastatic disease)"}]},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/","field":"standardOfCare.guideline (Localised)"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/","field":"standardOfCare.guideline (Metastatic hormone-sensitive)"},{"id":"prostate","kind":"indication","name":"Prostate cancer","route":"/indications/prostate/","field":"standardOfCare.guideline (Castration-resistant)"},{"id":"prostate-bcr","kind":"indication","name":"Biochemical recurrence of prostate cancer","route":"/indications/prostate-bcr/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-bcr","kind":"indication","name":"Biochemical recurrence of prostate cancer","route":"/indications/prostate-bcr/","field":"standardOfCare.guideline (After prostatectomy)"},{"id":"prostate-bcr","kind":"indication","name":"Biochemical recurrence of prostate cancer","route":"/indications/prostate-bcr/","field":"standardOfCare.guideline (After radiotherapy, local recurrence)"},{"id":"prostate-bcr","kind":"indication","name":"Biochemical recurrence of prostate cancer","route":"/indications/prostate-bcr/","field":"standardOfCare.guideline (High-risk biochemical recurrence (doubling time under 9 months))"},{"id":"prostate-high-risk","kind":"indication","name":"Localised prostate cancer, high and very high risk","route":"/indications/prostate-high-risk/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-high-risk","kind":"indication","name":"Localised prostate cancer, high and very high risk","route":"/indications/prostate-high-risk/","field":"standardOfCare.guideline (High risk)"},{"id":"prostate-high-risk","kind":"indication","name":"Localised prostate cancer, high and very high risk","route":"/indications/prostate-high-risk/","field":"standardOfCare.guideline (Very high risk and node-positive)"},{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/","field":"standardOfCare.guideline (First line, androgen receptor pathway inhibitor-naive)"},{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/","field":"standardOfCare.guideline (After an androgen receptor pathway inhibitor)"},{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/","field":"standardOfCare.guideline (After docetaxel)"},{"id":"prostate-mcrpc","kind":"indication","name":"Metastatic castration-resistant prostate cancer","route":"/indications/prostate-mcrpc/","field":"standardOfCare.guideline (Bone health)"},{"id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/","field":"standardOfCare.guideline (All patients, backbone)"},{"id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/","field":"standardOfCare.guideline (Doublet therapy)"},{"id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/","field":"standardOfCare.guideline (Triplet therapy, high volume, fit for chemotherapy)"},{"id":"prostate-mhspc","kind":"indication","name":"Metastatic hormone-sensitive prostate cancer","route":"/indications/prostate-mhspc/","field":"standardOfCare.guideline (Low-volume disease)"},{"id":"prostate-nepc","kind":"indication","name":"Neuroendocrine and small-cell prostate cancer","route":"/indications/prostate-nepc/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-nepc","kind":"indication","name":"Neuroendocrine and small-cell prostate cancer","route":"/indications/prostate-nepc/","field":"standardOfCare.guideline (Small-cell or predominantly neuroendocrine)"},{"id":"prostate-nepc","kind":"indication","name":"Neuroendocrine and small-cell prostate cancer","route":"/indications/prostate-nepc/","field":"standardOfCare.guideline (Mixed adenocarcinoma and neuroendocrine, or aggressive variant)"},{"id":"prostate-nmcrpc","kind":"indication","name":"Non-metastatic castration-resistant prostate cancer","route":"/indications/prostate-nmcrpc/","field":"links","label":"NCCN Guidelines: Prostate Cancer"},{"id":"prostate-nmcrpc","kind":"indication","name":"Non-metastatic castration-resistant prostate cancer","route":"/indications/prostate-nmcrpc/","field":"standardOfCare.guideline (High-risk nmCRPC (doubling time 10 months or less))"},{"id":"prostate-nmcrpc","kind":"indication","name":"Non-metastatic castration-resistant prostate cancer","route":"/indications/prostate-nmcrpc/","field":"standardOfCare.guideline (Low-risk nmCRPC)"}],"archive":"https://web.archive.org/web/20260727005920/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1459"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sclc","kind":"indication","name":"Small-cell lung cancer","route":"/indications/sclc/","field":"standardOfCare.guideline (Limited stage)"},{"id":"sclc","kind":"indication","name":"Small-cell lung cancer","route":"/indications/sclc/","field":"standardOfCare.guideline (Extensive stage)"},{"id":"sclc","kind":"indication","name":"Small-cell lung cancer","route":"/indications/sclc/","field":"standardOfCare.guideline (Relapsed)"}],"archive":"https://web.archive.org/web/20260727005908/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1462"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"multiple-endocrine-neoplasia","kind":"indication","name":"Multiple endocrine neoplasia syndromes (MEN1, MEN2, MEN4)","route":"/indications/multiple-endocrine-neoplasia/","field":"standardOfCare.guideline (Advanced RET-mutant medullary thyroid carcinoma)"},{"id":"thyroid","kind":"indication","name":"Thyroid cancer","route":"/indications/thyroid/","field":"standardOfCare.guideline (Differentiated)"},{"id":"thyroid","kind":"indication","name":"Thyroid cancer","route":"/indications/thyroid/","field":"standardOfCare.guideline (Advanced/refractory)"},{"id":"thyroid","kind":"indication","name":"Thyroid cancer","route":"/indications/thyroid/","field":"standardOfCare.guideline (Nodule work-up)"}],"archive":"https://web.archive.org/web/20260727005930/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1470"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/","field":"standardOfCare.guideline (Frontline)"},{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/","field":"standardOfCare.guideline (Early relapse)"},{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/","field":"standardOfCare.guideline (Later)"},{"id":"dlbcl","kind":"indication","name":"Diffuse large B-cell lymphoma","route":"/indications/dlbcl/","field":"standardOfCare.guideline (Limited stage (I-II, non-bulky))"},{"id":"follicular-lymphoma","kind":"indication","name":"Follicular lymphoma","route":"/indications/follicular-lymphoma/","field":"links","label":"NCCN Guidelines: B-Cell Lymphomas"},{"id":"follicular-lymphoma","kind":"indication","name":"Follicular lymphoma","route":"/indications/follicular-lymphoma/","field":"standardOfCare.guideline (Limited stage (I-II))"}],"archive":"https://web.archive.org/web/20260829193612/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1480"},{"url":"https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"hcc","kind":"indication","name":"Hepatocellular carcinoma","route":"/indications/hcc/","field":"standardOfCare.guideline (Early)"},{"id":"hcc","kind":"indication","name":"Hepatocellular carcinoma","route":"/indications/hcc/","field":"standardOfCare.guideline (Intermediate)"},{"id":"hcc","kind":"indication","name":"Hepatocellular carcinoma","route":"/indications/hcc/","field":"standardOfCare.guideline (Advanced)"}],"archive":"https://web.archive.org/web/20260911115439/https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1514"},{"url":"https://www.nccn.org/patients/guidelines/content/PDF/stomach-patient.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","field":"standardOfCare.guideline (Resectable gastric or GEJ adenocarcinoma)"}]},{"url":"https://www.ncf.net/post/2025-highlights-in-neuroendocrine-cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cabozantinib","kind":"drug","name":"Cabozantinib","route":"/drugs/cabozantinib/","field":"regulatoryEvents.source (2025-03-26)"}],"archive":"https://web.archive.org/web/20260417083758/https://www.ncf.net/post/2025-highlights-in-neuroendocrine-cancer"},{"url":"https://www.nct-dresden.de","status":200,"ok":true,"finalUrl":"https://www.nct-dresden.de/de","checked":"2026-10-21","refs":[{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","field":"links","label":"Homepage"},{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","field":"website"}],"archive":"https://web.archive.org/web/20240907152021/http://www.nct-dresden.de//"},{"url":"https://www.nct-heidelberg.de","status":200,"ok":true,"finalUrl":"https://www.nct-heidelberg.de/","checked":"2026-10-21","refs":[{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/","field":"links","label":"Official website"},{"id":"heidelberg-nct","kind":"institution","name":"Heidelberg University Hospital / NCT / DKFZ","route":"/institutions/heidelberg-nct/","field":"website"}],"archive":"https://web.archive.org/web/20261005111005/https://www.nct-heidelberg.de/"},{"url":"https://www.nice.org.uk/guidance/ta985/chapter/2-Information-about-QuiremSpheres","status":200,"ok":true,"finalUrl":"https://www.nice.org.uk/guidance/ta985","checked":"2026-10-21","refs":[{"id":"ho-166-microspheres","kind":"drug","name":"Holmium-166 microspheres","route":"/drugs/ho-166-microspheres/","field":"links","label":"NICE TA985: QuiremSpheres for advanced HCC"},{"id":"ho-166-microspheres","kind":"drug","name":"Holmium-166 microspheres","route":"/drugs/ho-166-microspheres/","field":"dosing.source"},{"id":"ho-166","kind":"isotope","name":"Holmium-166","route":"/isotopes/ho-166/","field":"links","label":"NICE: QuiremSpheres for unresectable hepatocellular carcinoma"}]},{"url":"https://www.nihs.go.jp/dnfi/pdf/RI_PDF/USP3-1.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiopharmacy-term","kind":"term","name":"Radiopharmacy (practice and discipline)","route":"/terms/radiopharmacy-term/","field":"links","label":"USP General Chapter <825> Radiopharmaceuticals - Preparation, Compounding, Dispensing, and Repackaging (briefing/full text)"}]},{"url":"https://www.nmp.co.jp/eng/","status":200,"ok":true,"finalUrl":"https://www.nmp.co.jp/eng/index.html","checked":"2026-10-21","refs":[{"id":"nihon-medi-physics","kind":"company","name":"Nihon Medi-Physics","route":"/companies/nihon-medi-physics/","field":"website"}]},{"url":"https://www.nmp.co.jp/eng/profile/about.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nihon-medi-physics","kind":"company","name":"Nihon Medi-Physics","route":"/companies/nihon-medi-physics/","field":"links","label":"Company overview (incorporated 20 March 1973; shareholder GE HealthCare)"}]},{"url":"https://www.nordion.com","status":200,"ok":true,"finalUrl":"https://www.nordion.com/","checked":"2026-10-21","refs":[{"id":"nordion","kind":"company","name":"Nordion (Sotera Health)","route":"/companies/nordion/","field":"links","label":"Official website"},{"id":"nordion","kind":"company","name":"Nordion (Sotera Health)","route":"/companies/nordion/","field":"website"}],"archive":"https://web.archive.org/web/20260608052804/https://www.nordion.com/"},{"url":"https://www.nordion.com/wp-content/uploads/2014/10/MI_Gallium-67_Canada.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-67","kind":"isotope","name":"Gallium-67","route":"/isotopes/ga-67/","field":"links","label":"Nordion: gallium-67 fact sheet"}]},{"url":"https://www.northstarnm.com","status":200,"ok":true,"finalUrl":"https://www.northstarnm.com/","checked":"2026-10-21","refs":[{"id":"northstar-medical-radioisotopes","kind":"company","name":"NorthStar Medical Radioisotopes","route":"/companies/northstar-medical-radioisotopes/","field":"links","label":"Official website"},{"id":"northstar-medical-radioisotopes","kind":"company","name":"NorthStar Medical Radioisotopes","route":"/companies/northstar-medical-radioisotopes/","field":"website"}],"archive":"https://web.archive.org/web/20260728214704/https://www.northstarnm.com/"},{"url":"https://www.northstarnm.com/wp-content/uploads/2023/11/Accelerating-Production-of-Non-Carrier-Added-Actinium-225-n.c.a.-Ac-225.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-accelerator-ac225-at-scale","kind":"idea","name":"Scaling actinium-225 supply with proton accelerators instead of the thorium-229 cow","route":"/ideas/idea-accelerator-ac225-at-scale/","field":"links","label":"Accelerating Production of Non-Carrier Added Actinium-225 (NorthStar technical report)"}]},{"url":"https://www.novartis.com","status":200,"ok":true,"finalUrl":"https://www.novartis.com/","checked":"2026-10-21","refs":[{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","field":"links","label":"Official website"},{"id":"novartis","kind":"company","name":"Novartis","route":"/companies/novartis/","field":"website"}],"archive":"https://web.archive.org/web/20260926195804/https://www.novartis.com/"},{"url":"https://www.novartis.com/us-en/news/media-releases/novartis-lutathera-significantly-reduced-risk-disease-progression-or-death-72-first-line-treatment-patients-advanced-gastroenteropancreatic-neuroendocrine-tumors","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sstr-theranostics-roadmap","kind":"roadmap","name":"SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha","route":"/roadmaps/sstr-theranostics-roadmap/","field":"links","label":"Novartis: NETTER-2 phase 3 results, first-line PRRT, January 2024"}]},{"url":"https://www.novartis.com/us-en/sites/novartis_us/files/pluvicto.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"myelosuppression-after-rlt","kind":"term","name":"Myelosuppression after radioligand therapy","route":"/terms/myelosuppression-after-rlt/","field":"links","label":"Novartis Pluvicto prescribing information (Warnings and Precautions: myelosuppression)"}]},{"url":"https://www.nrc.gov/docs/ML0228/ML022830849.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dose-calibrator","kind":"term","name":"Dose calibrator","route":"/terms/dose-calibrator/","field":"links","label":"NUREG-1556 Vol. 9: Consolidated Guidance About Materials Licenses (dose calibrator QC criteria)"}]},{"url":"https://www.nrc.gov/docs/ml1122/ml11229a666.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"linear-energy-transfer","kind":"term","name":"Linear energy transfer (LET)","route":"/terms/linear-energy-transfer/","field":"links","label":"NRC training materials: interaction of charged particles with matter, LET and stopping power"}]},{"url":"https://www.nrc.gov/docs/ML1632/ML16328A214.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nrc-licensing","kind":"term","name":"NRC medical-use licensing (10 CFR Part 35)","route":"/terms/nrc-licensing/","field":"links","label":"NUREG-1556 Vol. 9: Consolidated Guidance About Materials Licenses for medical use, licensing overview and Agreement States"}]},{"url":"https://www.nrc.gov/docs/ML1907/ML19077A112.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-authorized-user-shortage","kind":"bottleneck","name":"Authorized user shortage for radionuclide therapy","route":"/bottlenecks/b-authorized-user-shortage/","field":"links","label":"NRC Advisory Committee on the Medical Uses of Isotopes, transcript on AU shortage evidence"},{"id":"b-authorized-user-shortage","kind":"bottleneck","name":"Authorized user shortage for radionuclide therapy","route":"/bottlenecks/b-authorized-user-shortage/","field":"metrics (NRC ACMUI subcommittee finding on AU shortage evidence)"}]},{"url":"https://www.nrc.gov/docs/ML2135/ML21356B719.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"niowave","kind":"company","name":"Niowave","route":"/companies/niowave/","field":"links","label":"NRC: Niowave public meeting presentation, domestic production of Mo-99 and other fission products without a nuclear reactor (2021)"}]},{"url":"https://www.nrc.gov/docs/ML2212/ML22129A075.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"niowave","kind":"company","name":"Niowave","route":"/companies/niowave/","field":"links","label":"NRC: Niowave pre-application meeting #2 slides (2022)"}]},{"url":"https://www.nrc.gov/materials/miau/med-use-toolkit/auth-individuals","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-authorized-user-shortage","kind":"bottleneck","name":"Authorized user shortage for radionuclide therapy","route":"/bottlenecks/b-authorized-user-shortage/","field":"links","label":"NRC: Authorized Individuals (10 CFR Part 35 training requirements)"},{"id":"radiation-safety-officer","kind":"term","name":"Radiation Safety Officer (RSO)","route":"/terms/radiation-safety-officer/","field":"links","label":"NRC: Authorized Individuals - Radiation Safety Officer and Associate RSO"},{"id":"authorized-user","kind":"term","name":"Authorized User (AU)","route":"/terms/authorized-user/","field":"links","label":"NRC: Authorized Individuals - definitions and license amendment process"}]},{"url":"https://www.nrc.gov/materials/miau/med-use-toolkit/faqs-part35","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nrc-regulations-part35","kind":"collection","name":"US NRC 10 CFR Part 35 (Medical Use of Byproduct Material)","route":"/collections/nrc-regulations-part35/","field":"links","label":"NRC: FAQs about licensing medical uses under Part 35"},{"id":"nrc-licensing","kind":"term","name":"NRC medical-use licensing (10 CFR Part 35)","route":"/terms/nrc-licensing/","field":"links","label":"NRC: Frequently Asked Questions About Licensing Medical Uses of Byproduct Material"}]},{"url":"https://www.nrc.gov/materials/toolboxes/llrw-waste","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/","field":"links","label":"NRC: Low-level radioactive waste (LLRW) toolbox overview and classification"},{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/","field":"metrics (Share of total US low-level radioactive waste volume that is Class A (least hazardous))"}]},{"url":"https://www.nrc.gov/materials/toolboxes/llrw/decay-in-storage","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/","field":"links","label":"NRC: Decay-in-storage (DIS) of low-level radioactive waste, toolbox guidance"},{"id":"b-radioactive-waste-regulation","kind":"bottleneck","name":"Radioactive waste handling and disposal regulation","route":"/bottlenecks/b-radioactive-waste-regulation/","field":"metrics (Maximum half-life NRC allows for medical decay-in-storage of radioactive waste (10 CFR 35.92))"}]},{"url":"https://www.nrc.gov/reading-rm/doc-collections/cfr/part020/part020-1003.html","status":200,"ok":true,"finalUrl":"https://www.ecfr.gov/current/title-10/chapter-I/part-20","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"alara","kind":"term","name":"ALARA (as low as is reasonably achievable)","route":"/terms/alara/","field":"links","label":"10 CFR 20.1003, Definitions - ALARA (NRC eCFR)"}]},{"url":"https://www.nsfc.gov.cn/p1/3381/2825/121910.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pexiretide-tc99m","kind":"drug","name":"Technetium (99mTc) pexiretide","route":"/drugs/pexiretide-tc99m/","field":"links","label":"National Natural Science Foundation of China: the world's first integrin-targeted innovative radiopharmaceutical approved, 2 April 2026 (Chinese)"},{"id":"pexiretide-tc99m","kind":"drug","name":"Technetium (99mTc) pexiretide","route":"/drugs/pexiretide-tc99m/","field":"regulatoryEvents.source (2026-04-02)"}],"archive":"https://web.archive.org/web/20260409093513/https://www.nsfc.gov.cn/p1/3381/2825/121910.html"},{"url":"https://www.ntp.co.za","status":200,"ok":true,"finalUrl":"https://www.ntp.co.za/","checked":"2026-10-21","refs":[{"id":"ntp-radioisotopes","kind":"company","name":"NTP Radioisotopes","route":"/companies/ntp-radioisotopes/","field":"links","label":"Official website"},{"id":"ntp-radioisotopes","kind":"company","name":"NTP Radioisotopes","route":"/companies/ntp-radioisotopes/","field":"website"}],"archive":"https://web.archive.org/web/20260308051842/https://www.ntp.co.za/"},{"url":"https://www.nusano.com","status":200,"ok":true,"finalUrl":"https://nusano.com/","checked":"2026-10-21","refs":[{"id":"nusano","kind":"company","name":"Nusano","route":"/companies/nusano/","field":"links","label":"Official website"},{"id":"nusano","kind":"company","name":"Nusano","route":"/companies/nusano/","field":"website"}],"archive":"https://web.archive.org/web/20260721035612/https://nusano.com/"},{"url":"https://www.oecd-nea.org/med-radio/reports/MO-99.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mo-99","kind":"isotope","name":"Molybdenum-99","route":"/isotopes/mo-99/","field":"links","label":"OECD/NEA: an economic study of the molybdenum-99 supply chain"}]},{"url":"https://www.oecd-nea.org/upload/docs/application/pdf/2023-10/nea_ndc_r_2023_1.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"mo-99","kind":"isotope","name":"Molybdenum-99","route":"/isotopes/mo-99/","field":"links","label":"OECD/NEA: the security of supply of medical radioisotopes, 2023-2027 demand and capacity projections"}]},{"url":"https://www.oecd-nea.org/upload/docs/application/pdf/2025-10/7743_medical_radioisotopes_supply_rev.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/","field":"links","label":"OECD-NEA: Current trends in the supply and utilisation of medical radioisotopes (Oct 2025)"},{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/","field":"metrics (Share of global Mo-99 supply from six ageing research reactors)"},{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/","field":"metrics (Oldest Mo-99-producing reactor still in service (LVR-15, Czechia))"},{"id":"b-mo99-supply","kind":"bottleneck","name":"Molybdenum-99 supply","route":"/bottlenecks/b-mo99-supply/","field":"metrics (HFR (Netherlands) unplanned shutdown)"},{"id":"f-isotope-supply","kind":"section","name":"Isotope supply","route":"/fronts/f-isotope-supply/","field":"links","label":"OECD-NEA: Current trends in the supply and utilisation of medical radioisotopes (2025)"},{"id":"tc-99m","kind":"isotope","name":"Technetium-99m","route":"/isotopes/tc-99m/","field":"links","label":"OECD/NEA: current trends in the supply and utilisation of medical radioisotopes (2025)"},{"id":"mo-99","kind":"isotope","name":"Molybdenum-99","route":"/isotopes/mo-99/","field":"links","label":"OECD/NEA: current trends in the supply and utilisation of medical radioisotopes (2025)"},{"id":"lu-177","kind":"isotope","name":"Lutetium-177","route":"/isotopes/lu-177/","field":"links","label":"OECD-NEA: Current trends in the supply and utilisation of medical radioisotopes (2025)"}]},{"url":"https://www.ohsu.edu/providers/erik-s-mittra-md-phd","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"erik-mittra","kind":"person","name":"Erik S. Mittra","route":"/people/erik-mittra/","field":"links","label":"OHSU provider profile"},{"id":"erik-mittra","kind":"person","name":"Erik S. Mittra","route":"/people/erik-mittra/","field":"profiles","label":"OHSU provider profile"}]},{"url":"https://www.onclive.com/view/177lu-psma-i-t-meets-rpfs-end-point-in-psma-mcrpc","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"lu177-psma-it","kind":"drug","name":"177Lu-PSMA-I&T","route":"/drugs/lu177-psma-it/","field":"links","label":"ECLIPSE meets rPFS (OncLive)"}],"archive":"https://web.archive.org/web/20251203101038/https://www.onclive.com/view/177lu-psma-i-t-meets-rpfs-end-point-in-psma-mcrpc"},{"url":"https://www.onclive.com/view/personalized-radioembolization-improves-os-vs-standard-dosing-in-advanced-hcc","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-dosimetry","kind":"section","name":"Dosimetry","route":"/fronts/f-dosimetry/","field":"links","label":"DOSISPHERE-01 trial (Garin et al., Lancet Gastroenterol Hepatol 2021)"},{"id":"f-radioembolisation","kind":"section","name":"Radioembolisation","route":"/fronts/f-radioembolisation/","field":"links","label":"DOSISPHERE-01 trial (Garin et al., Lancet Gastroenterol Hepatol 2021)"}]},{"url":"https://www.oncobeta.com","status":200,"ok":true,"finalUrl":"https://www.oncobeta.com/","checked":"2026-10-21","refs":[{"id":"oncobeta","kind":"company","name":"OncoBeta","route":"/companies/oncobeta/","field":"website"}]},{"url":"https://www.oncobeta.com.au/wp-content/uploads/2025/07/EPIC-Skin-12-Month-Study-Clinical-Paper_Digital_v7-2-1.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"oncobeta","kind":"company","name":"OncoBeta","route":"/companies/oncobeta/","field":"links","label":"OncoBeta Australia: EPIC-Skin 12-month study clinical paper (PDF)"}]},{"url":"https://www.oncobeta.com/company/details/personalized-irradiation-therapy-for-nmsc-by-rhenium-188-skin-cancer-therapy-a-long-term-retrospective-study","status":200,"ok":true,"finalUrl":"https://www.oncobeta.com/your-health/treatment-options-for-non-melanoma-skin-cancer-physics-based-therapies/","checked":"2026-10-21","refs":[{"id":"oncobeta","kind":"company","name":"OncoBeta","route":"/companies/oncobeta/","field":"links","label":"OncoBeta: personalized irradiation therapy for NMSC by Rhenium-188 skin cancer therapy, long-term retrospective study"}]},{"url":"https://www.oncobeta.com/media/oncobeta-reports-12-month-results-from-international-phase-iv-study-for-non-melanoma-skin-cancer/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"oncobeta","kind":"company","name":"OncoBeta","route":"/companies/oncobeta/","field":"links","label":"OncoBeta: 12-month results from international Phase IV EPIC-Skin study (2026)"}]},{"url":"https://www.oncobeta.com/patients/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"oncobeta","kind":"company","name":"OncoBeta","route":"/companies/oncobeta/","field":"links","label":"OncoBeta: patients / step-by-step treatment guide"}]},{"url":"https://www.oncobeta.com/technology/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"re-188-sct","kind":"drug","name":"Rhenium-188 skin cancer therapy","route":"/drugs/re-188-sct/","field":"links","label":"OncoBeta: Rhenium-SCT technology overview"},{"id":"oncobeta","kind":"company","name":"OncoBeta","route":"/companies/oncobeta/","field":"links","label":"OncoBeta: technology overview (Rhenium-SCT, 188W/188Re generator)"}]},{"url":"https://www.oncoray.de","status":200,"ok":true,"finalUrl":"https://www.oncoray.de/","checked":"2026-10-21","refs":[{"id":"nct-dresden","kind":"institution","name":"NCT/UCC Dresden, University Hospital Carl Gustav Carus","route":"/institutions/nct-dresden/","field":"links","label":"OncoRay"}],"archive":"https://web.archive.org/web/20260727203810/https://www.oncoray.de/"},{"url":"https://www.oranomed.com","status":200,"ok":true,"finalUrl":"https://www.oranomed.com/","checked":"2026-10-21","refs":[{"id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/","field":"links","label":"Official website"},{"id":"orano-med","kind":"company","name":"Orano Med","route":"/companies/orano-med/","field":"website"}],"archive":"https://web.archive.org/web/20260710223351/https://www.oranomed.com/"},{"url":"https://www.ornl.gov/news/tri-lab-effort-makes-strides-toward-increasing-supply-ac-225-0","status":200,"ok":true,"finalUrl":"https://www.ornl.gov/news/tri-lab-effort-makes-strides-toward-increasing-supply-ac-225-0/","checked":"2026-10-21","refs":[{"id":"idea-accelerator-ac225-at-scale","kind":"idea","name":"Scaling actinium-225 supply with proton accelerators instead of the thorium-229 cow","route":"/ideas/idea-accelerator-ac225-at-scale/","field":"links","label":"Tri-Lab effort makes strides toward increasing supply of Ac-225 (ORNL news, 2021)"}]},{"url":"https://www.oslo-universitetssykehus.no","status":200,"ok":true,"finalUrl":"https://www.oslo-universitetssykehus.no/","checked":"2026-10-21","refs":[{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","field":"links","label":"Oslo University Hospital"}],"archive":"https://web.archive.org/web/20261005104553/https://www.oslo-universitetssykehus.no/"},{"url":"https://www.osti.gov/servlets/purl/1209691","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"niowave","kind":"company","name":"Niowave","route":"/companies/niowave/","field":"links","label":"OSTI: Niowave DOE-NP SBIR Phase II final technical report, superconducting electron linac for radioisotope production"}],"archive":"https://web.archive.org/web/20250416033449/https://www.osti.gov/servlets/purl/1209691"},{"url":"https://www.ous-research.no/institute/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","field":"links","label":"Institute for Cancer Research"},{"id":"oslo-radium-hospital","kind":"institution","name":"Oslo University Hospital, The Norwegian Radium Hospital","route":"/institutions/oslo-radium-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20260912233354/https://ous-research.no/institute/"},{"url":"https://www.pcf.org/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","field":"links","label":"PCF"},{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","field":"url"}]},{"url":"https://www.pdradiopharma.com/en/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pdradiopharma","kind":"company","name":"PDRadiopharma","route":"/companies/pdradiopharma/","field":"website"}]},{"url":"https://www.pdradiopharma.com/en/about/outline/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pdradiopharma","kind":"company","name":"PDRadiopharma","route":"/companies/pdradiopharma/","field":"links","label":"Company outline (shareholder PeptiDream Inc. 100%, business start 28 March 2022)"}]},{"url":"https://www.pdradiopharma.com/en/hcw/products/diagnostic/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pdradiopharma","kind":"company","name":"PDRadiopharma","route":"/companies/pdradiopharma/","field":"links","label":"Diagnostic product list"}]},{"url":"https://www.pdradiopharma.com/en/hcw/products/therapeutic/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pdradiopharma","kind":"company","name":"PDRadiopharma","route":"/companies/pdradiopharma/","field":"links","label":"Therapeutic product list"}]},{"url":"https://www.pennmedicine.org/cancer","status":200,"ok":true,"finalUrl":"https://www.pennmedicine.org/specialties/cancer","checked":"2026-10-21","refs":[{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/","field":"links","label":"Official website"},{"id":"penn-abramson","kind":"institution","name":"Abramson Cancer Center, University of Pennsylvania","route":"/institutions/penn-abramson/","field":"website"}],"archive":"https://web.archive.org/web/20260729013209/https://www.pennmedicine.org/cancer"},{"url":"https://www.pentixapharm.com/news/ema-grants-prime-status-to-pentixapharms-lead-candidate-pentixafor","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-cxcr4-primary-aldosteronism","kind":"opportunity","name":"CXCR4 imaging instead of adrenal vein sampling","route":"/opportunities/opp-cxcr4-primary-aldosteronism/","field":"links","label":"EMA PRIME status for 68Ga-PentixaFor"}]},{"url":"https://www.peptidream.com/en/company/profile/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pdradiopharma","kind":"company","name":"PDRadiopharma","route":"/companies/pdradiopharma/","field":"links","label":"PeptiDream company profile (radiopharmaceutical business through PDRadiopharma)"}]},{"url":"https://www.perspectivetherapeutics.com/pipeline/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pb-212-psv359","kind":"drug","name":"Lead-212 PSV359","route":"/drugs/pb-212-psv359/","field":"links","label":"Perspective Therapeutics pipeline"}]},{"url":"https://www.perspectivetherapeutics.com/pr/perspective-therapeutics-announces-clinical-collaboration-and-supply-agreement-with-merck-to-evaluate-212pbpsv359-in-combination-with-keytruda-pembrolizumab-in-fap-a-positive-solid-tumors","status":200,"ok":true,"finalUrl":"https://www.perspectivetherapeutics.com/","checked":"2026-10-21","refs":[{"id":"perspective-therapeutics","kind":"company","name":"Perspective Therapeutics","route":"/companies/perspective-therapeutics/","field":"links","label":"Clinical collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 with Keytruda in FAP-alpha positive solid tumours, including NSCLC (14 September 2026)"},{"id":"pb-212-psv359","kind":"drug","name":"Lead-212 PSV359","route":"/drugs/pb-212-psv359/","field":"links","label":"Perspective Therapeutics: clinical collaboration and supply agreement with Merck to evaluate [212Pb]PSV359 with Keytruda in FAP-alpha positive solid tumours, 14 September 2026"}]},{"url":"https://www.petermac.org","status":200,"ok":true,"finalUrl":"https://www.petermac.org/","checked":"2026-10-21","refs":[{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/","field":"links","label":"Official website"},{"id":"peter-mac","kind":"institution","name":"Peter MacCallum Cancer Centre","route":"/institutions/peter-mac/","field":"website"},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","field":"links","label":"Peter MacCallum Cancer Centre"},{"id":"hofman-michael","kind":"person","name":"Michael Hofman","route":"/people/hofman-michael/","field":"profiles","label":"Peter MacCallum Cancer Centre"},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","field":"links","label":"Peter MacCallum Cancer Centre"},{"id":"sandhu-shahneen","kind":"person","name":"Shahneen Sandhu","route":"/people/sandhu-shahneen/","field":"profiles","label":"Peter MacCallum Cancer Centre"}],"archive":"https://web.archive.org/web/20261002171511/https://www.petermac.org/"},{"url":"https://www.pharmaceutical-technology.com/news/fusion-fda-ind-fpi-2068/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ac-225-fpi-2068","kind":"drug","name":"Actinium-225 FPI-2068","route":"/drugs/ac-225-fpi-2068/","field":"links","label":"Fusion Pharmaceuticals: IND clearance for FPI-2068 and FPI-2107, April 2023"}]},{"url":"https://www.pharmacy.la.gov/assets/docs/Staff/USP_825-Radiopharmaceuticals_2020-1201.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"release-criteria","kind":"term","name":"Product release criteria (radiopharmaceutical quality control)","route":"/terms/release-criteria/","field":"links","label":"USP General Chapter <825>, Radiopharmaceuticals - Preparation, Compounding, Dispensing, and Repackaging"}]},{"url":"https://www.pmda.go.jp/english/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/","field":"links","label":"PMDA"},{"id":"pmda","kind":"institution","name":"Pharmaceuticals and Medical Devices Agency","route":"/institutions/pmda/","field":"website"}],"archive":"https://web.archive.org/web/20260928153858/https://www.pmda.go.jp/english/"},{"url":"https://www.pmda.go.jp/files/000281190.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nihon-medi-physics","kind":"company","name":"Nihon Medi-Physics","route":"/companies/nihon-medi-physics/","field":"links","label":"PMDA list of approved drugs (April 2004 onwards)"}]},{"url":"https://www.prismap.eu/radionuclides/portfolio/161Tb/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"tb-161","kind":"isotope","name":"Terbium-161","route":"/isotopes/tb-161/","field":"links","label":"PRISMAP: 161Tb radionuclide portfolio page"}]},{"url":"https://www.prismap.eu/radionuclides/portfolio/224Ra/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ra-224","kind":"isotope","name":"Radium-224","route":"/isotopes/ra-224/","field":"links","label":"PRISMAP: 224Ra radionuclide portfolio page"}]},{"url":"https://www.prismap.eu/radionuclides/portfolio/47Sc/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sc-47","kind":"isotope","name":"Scandium-47","route":"/isotopes/sc-47/","field":"links","label":"PRISMAP: 47Sc radionuclide portfolio page"}]},{"url":"https://www.prnewswire.com/news-releases/artbio-announces-dosing-of-two-cohorts-with-ab001-in-artisan-a-phase-1-alpha-radioligand-therapy-clinical-trial-for-metastatic-castration-resistant-prostate-cancer-302657972.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"artbio","kind":"company","name":"ARTBIO","route":"/companies/artbio/","field":"links","label":"ARTISAN cohort dosing release (PR Newswire)"}],"archive":"https://web.archive.org/web/20260316004229/https://www.prnewswire.com/news-releases/artbio-announces-dosing-of-two-cohorts-with-ab001-in-artisan-a-phase-1-alpha-radioligand-therapy-clinical-trial-for-metastatic-castration-resistant-prostate-cancer-302657972.html"},{"url":"https://www.prnewswire.com/news-releases/clarity-pharmaceuticals-announces-secure-trial-update-on-8-gbq-67cu-sar-bispsma-dose-level-with-two-additional-complete-responses-302843184.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"clarity-pharmaceuticals","kind":"company","name":"Clarity Pharmaceuticals","route":"/companies/clarity-pharmaceuticals/","field":"links","label":"SECuRE update"}]},{"url":"https://www.prnewswire.com/news-releases/life-molecular-imaging-expands-neuraceq-florbetaben-f-18-injection-production-in-southern-california-302534927.html","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"life-molecular-imaging","kind":"company","name":"Life Molecular Imaging","route":"/companies/life-molecular-imaging/","field":"links","label":"PR Newswire: Life Molecular Imaging expands Neuraceq production in Southern California (2025)"}]},{"url":"https://www.problemgenome.com/briefs/health-yb176-enriched-isotope-single-country-supply","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","route":"/bottlenecks/b-enriched-target-material/","field":"links","label":"One country's isotope, everyone's cancer drug (Problem Genome brief on Yb-176 dependence)"},{"id":"b-enriched-target-material","kind":"bottleneck","name":"Enriched target material for therapeutic isotopes","route":"/bottlenecks/b-enriched-target-material/","field":"metrics (EU dependence on Russia for enriched ytterbium-176 supply)"}]},{"url":"https://www.qst.go.jp/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","field":"links","label":"QST Hospital (page moved; nearest live section)"},{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","field":"website"}],"archive":"https://web.archive.org/web/20261011230000/https://www.qst.go.jp/"},{"url":"https://www.qst.go.jp/site/qst-english/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"qst-hospital","kind":"institution","name":"QST Hospital (National Institutes for Quantum Science and Technology)","route":"/institutions/qst-hospital/","field":"links","label":"QST"}],"archive":"https://web.archive.org/web/20260815165245/https://www.qst.go.jp/site/qst-english/"},{"url":"https://www.radboudumc.nl","status":200,"ok":true,"finalUrl":"https://www.radboudumc.nl/patientenzorg","checked":"2026-10-21","refs":[{"id":"radboudumc","kind":"institution","name":"Radboudumc Centre for Oncology","route":"/institutions/radboudumc/","field":"links","label":"Official website"},{"id":"radboudumc","kind":"institution","name":"Radboudumc Centre for Oncology","route":"/institutions/radboudumc/","field":"website"}]},{"url":"https://www.radiomedix.com","status":200,"ok":true,"finalUrl":"https://radiomedix.com/","checked":"2026-10-21","refs":[{"id":"radiomedix","kind":"company","name":"RadioMedix","route":"/companies/radiomedix/","field":"website"}],"archive":"https://web.archive.org/web/20260611171050/https://radiomedix.com/"},{"url":"https://www.rayzebio.com","status":200,"ok":true,"finalUrl":"https://rayzebio.com/","checked":"2026-10-21","refs":[{"id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","route":"/companies/rayzebio/","field":"links","label":"Official website"},{"id":"rayzebio","kind":"company","name":"RayzeBio (BMS)","route":"/companies/rayzebio/","field":"website"}],"archive":"https://web.archive.org/web/20260902094923/https://rayzebio.com/"},{"url":"https://www.research.unipd.it/handle/11577/3611078","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"dota-chelation","kind":"technology","name":"DOTA chelation","route":"/technologies/dota-chelation/","field":"links","label":"One ring to bind them all? Review on DOTA complexes with medically relevant radiometals"}]},{"url":"https://www.royalmarsden.nhs.uk","status":200,"ok":true,"finalUrl":"https://www.royalmarsden.nhs.uk/","checked":"2026-10-21","refs":[{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/","field":"links","label":"Official website"},{"id":"royal-marsden","kind":"institution","name":"The Royal Marsden","route":"/institutions/royal-marsden/","field":"website"}],"archive":"https://web.archive.org/web/20261005110120/https://www.royalmarsden.nhs.uk/"},{"url":"https://www.rsna.org","status":200,"ok":true,"finalUrl":"https://www.rsna.org/","checked":"2026-10-21","refs":[{"id":"radiology","kind":"journal","name":"Radiology","route":"/journals/radiology/","field":"links","label":"RSNA"}]},{"url":"https://www.rsna.org/research/quantitative-imaging-biomarkers-alliance","status":200,"ok":true,"finalUrl":"https://www.rsna.org/research","checked":"2026-10-21","refs":[{"id":"quantitative-imaging-biomarkers","kind":"technology","name":"Quantitative imaging biomarkers (RECIST, PERCIST, SUV, ADC)","route":"/technologies/quantitative-imaging-biomarkers/","field":"links","label":"RSNA Quantitative Imaging Biomarkers Alliance (QIBA)"},{"id":"idea-tr2-psma-volume-qualification","kind":"idea","name":"Qualify PSMA PET tumour volume as a validated imaging biomarker","route":"/ideas/idea-tr2-psma-volume-qualification/","field":"links","label":"RSNA QIBA"}],"archive":"https://web.archive.org/web/20231208183907/https://www.rsna.org/research/quantitative-imaging-biomarkers-alliance"},{"url":"https://www.sacrocuore.it","status":200,"ok":true,"finalUrl":"https://www.sacrocuore.it/","checked":"2026-10-21","refs":[{"id":"sacro-cuore-don-calabria","kind":"institution","name":"IRCCS Sacro Cuore Don Calabria Hospital","route":"/institutions/sacro-cuore-don-calabria/","field":"links","label":"Official website"},{"id":"sacro-cuore-don-calabria","kind":"institution","name":"IRCCS Sacro Cuore Don Calabria Hospital","route":"/institutions/sacro-cuore-don-calabria/","field":"website"}],"archive":"https://web.archive.org/web/20261002093317/https://www.sacrocuore.it/"},{"url":"https://www.sahlgrenska.se/en/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sahlgrenska","kind":"institution","name":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research","route":"/institutions/sahlgrenska/","field":"links","label":"Homepage"},{"id":"sahlgrenska","kind":"institution","name":"Sahlgrenska University Hospital / Sahlgrenska Center for Cancer Research","route":"/institutions/sahlgrenska/","field":"website"}],"archive":"https://web.archive.org/web/20260923124510/https://www.sahlgrenska.se/en/"},{"url":"https://www.sakk.ch","status":200,"ok":true,"finalUrl":"https://www.swisscancerinstitute.ch/en/researchers/","domainMoved":true,"checked":"2026-10-21","refs":[{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","field":"links","label":"SAKK"}],"archive":"https://web.archive.org/web/20130815184516/http://sakk.ch"},{"url":"https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-12-05-00-00-2944919","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radiomedix","kind":"company","name":"RadioMedix","route":"/companies/radiomedix/","field":"links","label":"Sanofi licensing agreement"}],"archive":"https://web.archive.org/web/20260312222231/https://www.sanofi.com/en/media-room/press-releases/2024/2024-09-12-05-00-00-2944919"},{"url":"https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-08-05-00-00-3163053","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alphamedix","kind":"drug","name":"212Pb-DOTAMTATE","route":"/drugs/alphamedix/","field":"links","label":"Sanofi press release Oct 2025"},{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/","field":"links","label":"Sanofi press release"},{"id":"alphamedix-02","kind":"trial","name":"ALPHAMEDIX-02","route":"/trials/alphamedix-02/","field":"outcomes.source (Objective response rate (PRRT-naive))"},{"id":"alpha-therapy-roadmap","kind":"roadmap","name":"Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline","route":"/roadmaps/alpha-therapy-roadmap/","field":"links","label":"Sanofi: AlphaMedix (212Pb-DOTAMTATE) ALPHAMEDIX-02 phase 2 results, October 2025"},{"id":"sstr-theranostics-roadmap","kind":"roadmap","name":"SSTR theranostics roadmap: octreotide scintigraphy → 68Ga-DOTATATE → 177Lu-DOTATATE → alpha","route":"/roadmaps/sstr-theranostics-roadmap/","field":"links","label":"Sanofi: AlphaMedix (212Pb-DOTAMTATE) ALPHAMEDIX-02 phase 2 results, October 2025"}],"archive":"https://web.archive.org/web/20260312222203/https://www.sanofi.com/en/media-room/press-releases/2025/2025-10-08-05-00-00-3163053"},{"url":"https://www.scienceandmedicinegroup.com/resource/radiopharmaceutical-supply-chain-under-pressure-can-infrastructure-keep-up-with-demand/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-hot-lab-capacity","kind":"bottleneck","name":"Hot lab and shielded treatment room capacity","route":"/bottlenecks/b-hot-lab-capacity/","field":"links","label":"Radiopharmaceutical supply chain under pressure: can infrastructure keep up with demand?"},{"id":"b-hot-lab-capacity","kind":"bottleneck","name":"Hot lab and shielded treatment room capacity","route":"/bottlenecks/b-hot-lab-capacity/","field":"metrics (Novartis global radioligand therapy manufacturing network capacity target)"}]},{"url":"https://www.sdfmu.edu.cn","status":200,"ok":true,"finalUrl":"https://www.sdfmu.edu.cn/","checked":"2026-10-21","refs":[{"id":"shandong-cancer-hospital","kind":"institution","name":"Shandong Cancer Hospital and Institute","route":"/institutions/shandong-cancer-hospital/","field":"links","label":"Shandong First Medical University"}],"archive":"https://web.archive.org/web/20260911225317/https://www.sdfmu.edu.cn/"},{"url":"https://www.shca.org.cn","status":200,"ok":true,"finalUrl":"https://www.shca.org.cn/","checked":"2026-10-21","refs":[{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","field":"links","label":"Official website"},{"id":"fuscc","kind":"institution","name":"Fudan University Shanghai Cancer Center","route":"/institutions/fuscc/","field":"website"},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","field":"links","label":"Fudan University Shanghai Cancer Center"},{"id":"song-shaoli","kind":"person","name":"Shaoli Song","route":"/people/song-shaoli/","field":"profiles","label":"Fudan University Shanghai Cancer Center"}],"archive":"https://web.archive.org/web/20260831070350/https://www.shca.org.cn/"},{"url":"https://www.shinefusion.com","status":200,"ok":true,"finalUrl":"https://www.shinefusion.com/","checked":"2026-10-21","refs":[{"id":"shine-technologies","kind":"company","name":"SHINE Technologies","route":"/companies/shine-technologies/","field":"links","label":"Official website"},{"id":"shine-technologies","kind":"company","name":"SHINE Technologies","route":"/companies/shine-technologies/","field":"website"}],"archive":"https://web.archive.org/web/20260925222539/https://www.shinefusion.com/"},{"url":"https://www.sidley.com/en/insights/newsupdates/2025/12/medicare-payment-policy-final-rule-for-outpatient-setting-addresses-radiopharmaceuticals","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-regulation-reimbursement","kind":"section","name":"Regulation & reimbursement","route":"/fronts/f-regulation-reimbursement/","field":"links","label":"Sidley: Medicare payment policy final rule for outpatient setting addresses radiopharmaceuticals (Dec 2025)"}]},{"url":"https://www.siemens-healthineers.com","status":200,"ok":true,"finalUrl":"https://www.siemens-healthineers.com/","checked":"2026-10-21","refs":[{"id":"siemens-healthineers","kind":"company","name":"Siemens Healthineers","route":"/companies/siemens-healthineers/","field":"links","label":"Official website"},{"id":"siemens-healthineers","kind":"company","name":"Siemens Healthineers","route":"/companies/siemens-healthineers/","field":"website"}],"archive":"https://web.archive.org/web/20260921120723/https://www.siemens-healthineers.com/"},{"url":"https://www.siemens-healthineers.com/molecular-imaging/petnet","status":200,"ok":true,"finalUrl":"https://www.siemens-healthineers.com/molecular-imaging/radiopharma","checked":"2026-10-21","refs":[{"id":"petnet-solutions","kind":"company","name":"PETNET Solutions (Siemens Healthineers)","route":"/companies/petnet-solutions/","field":"links","label":"Official website"},{"id":"petnet-solutions","kind":"company","name":"PETNET Solutions (Siemens Healthineers)","route":"/companies/petnet-solutions/","field":"website"}],"archive":"https://web.archive.org/web/20251104123510/https://www.siemens-healthineers.com/molecular-imaging/petnet"},{"url":"https://www.sinotau.com/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","route":"/companies/sinotau-pharmaceutical/","field":"links","label":"Official website"},{"id":"sinotau-pharmaceutical","kind":"company","name":"Sinotau Pharmaceutical","route":"/companies/sinotau-pharmaceutical/","field":"website"}],"archive":"https://web.archive.org/web/20260710072639/https://www.sinotau.com/"},{"url":"https://www.sirtex.com","status":200,"ok":true,"finalUrl":"https://www.sirtex.com/us/","checked":"2026-10-21","refs":[{"id":"sirtex","kind":"company","name":"Sirtex Medical","route":"/companies/sirtex/","field":"links","label":"Official website"},{"id":"sirtex","kind":"company","name":"Sirtex Medical","route":"/companies/sirtex/","field":"website"}],"archive":"https://web.archive.org/web/20121114021135/http://sirtex.com:80/"},{"url":"https://www.sirtex.com/media/p1kjiw5m/sirtex-medical-announces-fda-approval-hcc-indication-us.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"y-90-resin-microspheres","kind":"drug","name":"Yttrium-90 resin microspheres","route":"/drugs/y-90-resin-microspheres/","field":"links","label":"Sirtex: FDA approval for HCC indication (7 July 2025)"}]},{"url":"https://www.snmmi.org","status":200,"ok":true,"finalUrl":"https://snmmi.org/","checked":"2026-10-21","refs":[{"id":"snmmi","kind":"institution","name":"Society of Nuclear Medicine and Molecular Imaging","route":"/institutions/snmmi/","field":"links","label":"SNMMI"},{"id":"snmmi","kind":"institution","name":"Society of Nuclear Medicine and Molecular Imaging","route":"/institutions/snmmi/","field":"website"},{"id":"journal-of-nuclear-medicine","kind":"journal","name":"Journal of Nuclear Medicine","route":"/journals/journal-of-nuclear-medicine/","field":"links","label":"SNMMI"}],"archive":"https://web.archive.org/web/20261005060148/https://snmmi.org/"},{"url":"https://www.snmmi.org/","status":200,"ok":true,"finalUrl":"https://snmmi.org/","checked":"2026-10-21","refs":[{"id":"src-snmmi","kind":"collection","name":"SNMMI Annual Meeting","route":"/collections/src-snmmi/","field":"links","label":"SNMMI Annual Meeting"},{"id":"src-snmmi","kind":"collection","name":"SNMMI Annual Meeting","route":"/collections/src-snmmi/","field":"url"},{"id":"virginia-pappas","kind":"person","name":"Virginia Pappas","route":"/people/virginia-pappas/","field":"links","label":"Society page"},{"id":"virginia-pappas","kind":"person","name":"Virginia Pappas","route":"/people/virginia-pappas/","field":"profiles","label":"Society page"}]},{"url":"https://www.spandidos-publications.com/10.3892/ijo.2014.2658/download","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"caix","kind":"target","name":"CAIX (carbonic anhydrase IX)","route":"/targets/caix/","field":"links","label":"Spandidos: monoclonal antibody G250 targeting CAIX, internalisation and epitope"}]},{"url":"https://www.srsweb.org/journal","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nuclear-medicine-and-biology","kind":"journal","name":"Nuclear Medicine and Biology","route":"/journals/nuclear-medicine-and-biology/","field":"links","label":"Society of Radiopharmaceutical Sciences: Journal page"}]},{"url":"https://www.stampedetrial.org","status":200,"ok":true,"finalUrl":"https://www.stampedetrial.org/","checked":"2026-10-21","refs":[{"id":"stampede","kind":"trial","name":"STAMPEDE","route":"/trials/stampede/","field":"links","label":"STAMPEDE trial website (MRC CTU at UCL)"}]},{"url":"https://www.targetedonc.com/view/oncologists-encounter-challenges-to-accessing-psma-targeted-therapy-in-prostate-cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","field":"links","label":"Targeted Oncology: Oncologists encounter challenges accessing PSMA-targeted therapy (Dana-Farber data)"},{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","field":"metrics (Dana-Farber: median tumour-board-to-cycle-1 wait, May vs October 2022)"},{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","field":"metrics (Dana-Farber cohort: patients who switched to a different therapy while waiting)"},{"id":"b-site-readiness-referral","kind":"bottleneck","name":"Site readiness and referral pathway delays","route":"/bottlenecks/b-site-readiness-referral/","field":"metrics (Dana-Farber cohort: approved patients who died before starting treatment)"}]},{"url":"https://www.terrapower.com/isotopes","status":200,"ok":true,"finalUrl":"https://www.terrapower.com/isotopes/","checked":"2026-10-21","refs":[{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","route":"/companies/terrapower-isotopes/","field":"links","label":"Official website"},{"id":"terrapower-isotopes","kind":"company","name":"TerraPower Isotopes","route":"/companies/terrapower-isotopes/","field":"website"}],"archive":"https://web.archive.org/web/20260911135547/https://www.terrapower.com/isotopes/"},{"url":"https://www.terrapower.com/TerraPower-Isotopes-Breaks-Ground-on-Worlds-Largest-Actinium-225-Manufacturing-Facility-in-Philadelphia","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-therapy-roadmap","kind":"roadmap","name":"Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline","route":"/roadmaps/alpha-therapy-roadmap/","field":"links","label":"TerraPower Isotopes: Bellwether Laboratory groundbreaking, May 2026"},{"id":"isotope-supply-roadmap","kind":"roadmap","name":"Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium","route":"/roadmaps/isotope-supply-roadmap/","field":"links","label":"TerraPower Isotopes: Bellwether Laboratory groundbreaking, May 2026"}]},{"url":"https://www.terrapower.com/tpi-brings-actinium-225-to-market","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"isotope-supply-roadmap","kind":"roadmap","name":"Isotope supply roadmap: reactor dependence → non-uranium production → accelerator-made actinium","route":"/roadmaps/isotope-supply-roadmap/","field":"links","label":"TerraPower Isotopes: reaches market-scale production of actinium-225, October 2024"}]},{"url":"https://www.thno.org/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"theranostics-journal","kind":"journal","name":"Theranostics","route":"/journals/theranostics-journal/","field":"links","label":"Theranostics home"},{"id":"theranostics-journal","kind":"journal","name":"Theranostics","route":"/journals/theranostics-journal/","field":"url"}]},{"url":"https://www.thno.org/indexrank","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"theranostics-journal","kind":"journal","name":"Theranostics","route":"/journals/theranostics-journal/","field":"links","label":"Theranostics: Index and ranking (impact factor history)"}]},{"url":"https://www.thno.org/v12p0232.htm","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"theranostic-pair-term","kind":"term","name":"Theranostic pair","route":"/terms/theranostic-pair-term/","field":"links","label":"Implications of physics, chemistry and biology for dosimetry calculations using theranostic pairs, Theranostics 2022"}]},{"url":"https://www.thno.org/v14p2969.htm","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-daughter-redistribution","kind":"technology","name":"Alpha-emitter daughter redistribution ('free daughter' problem)","route":"/technologies/alpha-daughter-redistribution/","field":"links","label":"Actinium-225 targeted alpha particle therapy for prostate cancer: recoil, nephrotoxicity and mitigation approaches (Theranostics 2024)"}]},{"url":"https://www.thno.org/v16p8117.htm","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-trop2-imaging-heterogeneity","kind":"opportunity","name":"TROP2 imaging where no tissue test is required","route":"/opportunities/opp-trop2-imaging-heterogeneity/","field":"links","label":"68Ga-MY6349 in breast cancer, Theranostics 2026"}]},{"url":"https://www.thno.org/v16p8447.htm","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cck2-receptor","kind":"target","name":"CCK2 receptor (gastrin receptor)","route":"/targets/cck2-receptor/","field":"links","label":"Theranostics: nastorazepide-based CCK2R antagonist radioligands"}]},{"url":"https://www.thyroid.org/professionals/ata-professional-guidelines/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","field":"dosing.source"},{"id":"radioactive-iodine","kind":"drug","name":"Radioactive iodine (I-131)","route":"/drugs/radioactive-iodine/","field":"toxicity.source (Sialadenitis / xerostomia)"}],"archive":"https://web.archive.org/web/20260824003229/https://www.thyroid.org/professionals/ata-professional-guidelines/"},{"url":"https://www.translatum.tum.de","status":200,"ok":true,"finalUrl":"https://www.translatum.tum.de/translatum/startseite/","checked":"2026-10-21","refs":[{"id":"tum-munich","kind":"institution","name":"TUM Klinikum rechts der Isar / CCC München","route":"/institutions/tum-munich/","field":"links","label":"TranslaTUM"}],"archive":"https://web.archive.org/web/20200129075103/http://www.translatum.tum.de:80/"},{"url":"https://www.trasis.com","status":200,"ok":true,"finalUrl":"https://www.trasis.com/","checked":"2026-10-21","refs":[{"id":"trasis","kind":"company","name":"Trasis","route":"/companies/trasis/","field":"links","label":"Official website"},{"id":"trasis","kind":"company","name":"Trasis","route":"/companies/trasis/","field":"website"}],"archive":"https://web.archive.org/web/20260705152405/https://www.trasis.com/"},{"url":"https://www.tumorzentrum.insel.ch","status":200,"ok":true,"finalUrl":"https://tumorzentrum.insel.ch/de/","checked":"2026-10-21","refs":[{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","field":"links","label":"Tumorzentrum Inselspital"},{"id":"inselspital-bern","kind":"institution","name":"Inselspital, Bern University Hospital / University Cancer Center Inselspital","route":"/institutions/inselspital-bern/","field":"website"}],"archive":"https://web.archive.org/web/20211027162203/https://www.tumorzentrum.insel.ch/"},{"url":"https://www.uclahealth.org/cancer","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/","field":"links","label":"Official website"},{"id":"ucla-jonsson","kind":"institution","name":"UCLA Jonsson Comprehensive Cancer Center","route":"/institutions/ucla-jonsson/","field":"website"}],"archive":"https://web.archive.org/web/20261004134947/https://www.uclahealth.org/cancer"},{"url":"https://www.uclahealth.org/news/release/nuclear-medicine-physician-scientist-dr-amir-iravani-joins","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"amir-iravani","kind":"person","name":"Amir Iravani","route":"/people/amir-iravani/","field":"links","label":"UCLA Health news release, September 2026"},{"id":"amir-iravani","kind":"person","name":"Amir Iravani","route":"/people/amir-iravani/","field":"profiles","label":"UCLA Health announcement, September 2026"}]},{"url":"https://www.uclahealth.org/providers?q=Jeremie%20Calais","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"links","label":"UCLA profile"},{"id":"jeremie-calais","kind":"person","name":"Jeremie Calais","route":"/people/jeremie-calais/","field":"profiles","label":"UCLA profile"}]},{"url":"https://www.uclahealth.org/providers?q=Johannes%20Czernin","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"links","label":"UCLA profile"},{"id":"johannes-czernin","kind":"person","name":"Johannes Czernin","route":"/people/johannes-czernin/","field":"profiles","label":"UCLA profile"}]},{"url":"https://www.ukw.de","status":200,"ok":true,"finalUrl":"https://www.ukw.de/startseite/","checked":"2026-10-21","refs":[{"id":"ccc-wuerzburg","kind":"institution","name":"Comprehensive Cancer Center Mainfranken, University Hospital Würzburg","route":"/institutions/ccc-wuerzburg/","field":"links","label":"Universitätsklinikum Würzburg"}],"archive":"https://web.archive.org/web/20170918225518/http://www.ukw.de:80/"},{"url":"https://www.ukw.de/nuklearmedizin/team/nuklearmedizin-detail/name/lassmann-michael/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"michael-lassmann","kind":"person","name":"Michael Lassmann","route":"/people/michael-lassmann/","field":"links","label":"University Hospital Würzburg profile"},{"id":"michael-lassmann","kind":"person","name":"Michael Lassmann","route":"/people/michael-lassmann/","field":"profiles","label":"University Hospital Würzburg staff page (German)"}]},{"url":"https://www.unibo.it/sitoweb/s.fanti/cv-en","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"stefano-fanti","kind":"person","name":"Stefano Fanti","route":"/people/stefano-fanti/","field":"profiles","label":"University of Bologna CV (English)"}]},{"url":"https://www.unibo.it/sitoweb/s.fanti/en","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"stefano-fanti","kind":"person","name":"Stefano Fanti","route":"/people/stefano-fanti/","field":"links","label":"University of Bologna profile"},{"id":"stefano-fanti","kind":"person","name":"Stefano Fanti","route":"/people/stefano-fanti/","field":"profiles","label":"University of Bologna staff page"}]},{"url":"https://www.uniklinik-duesseldorf.de","status":200,"ok":true,"finalUrl":"https://www.uniklinik-duesseldorf.de/","checked":"2026-10-21","refs":[{"id":"uk-duesseldorf","kind":"institution","name":"University Hospital Düsseldorf / CIO Düsseldorf","route":"/institutions/uk-duesseldorf/","field":"links","label":"Homepage"},{"id":"uk-duesseldorf","kind":"institution","name":"University Hospital Düsseldorf / CIO Düsseldorf","route":"/institutions/uk-duesseldorf/","field":"website"}],"archive":"https://web.archive.org/web/20261005094153/https://www.uniklinik-duesseldorf.de/"},{"url":"https://www.uniprot.org/uniprotkb/P09758/entry","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"trop2","kind":"target","name":"TROP2","route":"/targets/trop2/","field":"links","label":"UniProt P09758: TACSTD2 (TROP2)"}],"archive":"https://web.archive.org/web/20251114123836/https://www.uniprot.org/uniprotkb/P09758/entry"},{"url":"https://www.unispital-basel.ch/en/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/","field":"links","label":"Homepage"},{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/","field":"website"}],"archive":"https://web.archive.org/web/20260905185036/https://www.unispital-basel.ch/en/"},{"url":"https://www.unispital-basel.ch/en/tumorzentrum","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"usb-basel","kind":"institution","name":"University Hospital Basel / Tumour Centre","route":"/institutions/usb-basel/","field":"links","label":"Tumorzentrum"}],"archive":"https://web.archive.org/web/20260510082824/http://www.unispital-basel.ch/en/tumorzentrum"},{"url":"https://www.united-imaging.com","status":200,"ok":true,"finalUrl":"https://www.united-imaging.com/","checked":"2026-10-21","refs":[{"id":"united-imaging","kind":"company","name":"United Imaging","route":"/companies/united-imaging/","field":"links","label":"Official website"},{"id":"united-imaging","kind":"company","name":"United Imaging","route":"/companies/united-imaging/","field":"website"}],"archive":"https://web.archive.org/web/20260906103242/https://www.united-imaging.com/"},{"url":"https://www.usp.org/sites/default/files/usp/document/health-quality-safety/usp-decision-on-appeals-825-factsheet.pdf","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"cold-kit-formulation","kind":"technology","name":"Cold kit formulation","route":"/technologies/cold-kit-formulation/","field":"links","label":"USP fact sheet: decisions on appeals to General Chapter <825> Radiopharmaceuticals"}]},{"url":"https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"links","label":"USPSTF: lung cancer screening, final recommendation statement (2021)"},{"id":"nsclc","kind":"indication","name":"Non-small cell lung cancer","route":"/indications/nsclc/","field":"standardOfCare.guideline (Screening in people at risk)"}],"archive":"https://web.archive.org/web/20261001101438/https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/lung-cancer-screening"},{"url":"https://www.varha.fi","status":200,"ok":true,"finalUrl":"https://www.varha.fi/fi","checked":"2026-10-21","refs":[{"id":"turku-university-hospital","kind":"institution","name":"Turku University Hospital Cancer Centre","route":"/institutions/turku-university-hospital/","field":"links","label":"Official website"},{"id":"turku-university-hospital","kind":"institution","name":"Turku University Hospital Cancer Centre","route":"/institutions/turku-university-hospital/","field":"website"}]},{"url":"https://www.wpe-uk.de","status":200,"ok":true,"finalUrl":"https://www.wpe-uk.de/","checked":"2026-10-21","refs":[{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","field":"links","label":"WPE proton centre"}],"archive":"https://web.archive.org/web/20260720204601/https://www.wpe-uk.de/"},{"url":"https://www.wtz-essen.de","status":200,"ok":true,"finalUrl":"https://wtz-essen.de/","checked":"2026-10-21","refs":[{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","field":"links","label":"Homepage"},{"id":"essen-wtz","kind":"institution","name":"West German Cancer Center (WTZ), University Hospital Essen","route":"/institutions/essen-wtz/","field":"website"}],"archive":"https://web.archive.org/web/20260804094337/https://wtz-essen.de/"},{"url":"https://www.ycombinator.com/companies/atomic-alchemy","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"atomic-alchemy","kind":"company","name":"Atomic Alchemy","route":"/companies/atomic-alchemy/","field":"links","label":"Y Combinator profile"}],"archive":"https://web.archive.org/web/20260211003211/https://www.ycombinator.com/companies/atomic-alchemy"},{"url":"https://www.ymabs.com","status":200,"ok":true,"finalUrl":"https://ymabs.com/","checked":"2026-10-21","refs":[{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/","field":"links","label":"Official website"},{"id":"y-mabs","kind":"company","name":"Y-mAbs Therapeutics","route":"/companies/y-mabs/","field":"website"}],"archive":"https://web.archive.org/web/20260921163550/https://ymabs.com/"},{"url":"https://www.zelgen.com/en/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"donafenib","kind":"drug","name":"Donafenib","route":"/drugs/donafenib/","field":"links","label":"Suzhou Zelgen Biopharmaceuticals"}],"archive":"https://web.archive.org/web/20250906185308/https://www.zelgen.com/en/"},{"url":"https://zerocancer.org/","status":200,"ok":true,"checked":"2026-10-21","refs":[{"id":"prostate-cancer-foundation","kind":"collection","name":"Prostate Cancer Foundation (PCF)","route":"/collections/prostate-cancer-foundation/","field":"links","label":"ZERO Prostate Cancer"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=NETTER-2+lutetium+dotatate+first-line+Singh+Lancet","status":203,"ok":true,"finalUrl":"https://pubmed.ncbi.nlm.nih.gov/38851203/","checked":"2026-10-21","refs":[{"id":"jonathan-strosberg","kind":"person","name":"Jonathan R. Strosberg","route":"/people/jonathan-strosberg/","field":"papers","label":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours"},{"id":"simron-singh","kind":"person","name":"Simron Singh","route":"/people/simron-singh/","field":"papers","label":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours"},{"id":"paper-netter-2-lancet-2024","kind":"paper","name":"NETTER-2: lutetium-177 dotatate as first treatment for higher-grade gastroenteropancreatic neuroendocrine tumours","route":"/key-papers/paper-netter-2-lancet-2024/","field":"links","label":"PubMed search: NETTER-2 Lancet 2024"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/10070977/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"grpr","kind":"target","name":"GRPR (gastrin-releasing peptide receptor)","route":"/targets/grpr/","field":"prevalence.source"}],"archive":"https://web.archive.org/web/20250202020818/https://pubmed.ncbi.nlm.nih.gov/10070977/"},{"url":"https://pubmed.ncbi.nlm.nih.gov/15020605/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-sempet-de-santis-jco-2004","kind":"paper","name":"SEMPET: FDG-PET as a predictor of viable tumour in post-chemotherapy seminoma residuals","route":"/key-papers/paper-sempet-de-santis-jco-2004/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/23863050/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-alsympca-radium-223-nejm-2013","kind":"paper","name":"ALSYMPCA: alpha emitter radium-223 and survival in metastatic prostate cancer with bone metastases","route":"/key-papers/paper-alsympca-radium-223-nejm-2013/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24037503/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"dale-bailey","kind":"person","name":"Dale L. Bailey","route":"/people/dale-bailey/","field":"links","label":"Quantitative SPECT/CT review, EJNMMI 2014"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24136932/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"erik-mittra","kind":"person","name":"Erik S. Mittra","route":"/people/erik-mittra/","field":"papers","label":"Prognostic Utility of 90Y Radioembolization Dosimetry Based on Fusion 99mTc-Macroaggregated Albumin-99mTc-Sulfur Colloid SPECT"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/24978339/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"clinical-nuclear-medicine","kind":"journal","name":"Clinical Nuclear Medicine","route":"/journals/clinical-nuclear-medicine/","field":"links","label":"PubMed: Historic images in nuclear medicine — the first issue of Clinical Nuclear Medicine (1976)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25014687/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-clarinet-lanreotide-nejm-2014","kind":"paper","name":"CLARINET: lanreotide in metastatic enteropancreatic neuroendocrine tumours","route":"/key-papers/paper-clarinet-lanreotide-nejm-2014/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25635133/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"neuro-imaging-roadmap","kind":"roadmap","name":"Neuro-oncology imaging roadmap: FDG PET → amino acid PET → SSTR2 theranostics in meningioma","route":"/roadmaps/neuro-imaging-roadmap/","field":"links","label":"Rachinger et al., increased 68Ga-DOTATATE uptake discriminates meningioma and tumour-free tissue (J Nucl Med 2015)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/25745086/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"bradykinin-b1-receptor","kind":"target","name":"Bradykinin B1 receptor (B1R)","route":"/targets/bradykinin-b1-receptor/","field":"links","label":"Lin et al., J Nucl Med 2015: three 68Ga-labelled [des-Arg10]kallidin derivatives for B1R PET (PMID 25745086)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27332902/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016","kind":"paper","name":"RATHL: adapted treatment guided by interim PET-CT in advanced Hodgkin lymphoma","route":"/key-papers/paper-rathl-interim-pet-adapted-abvd-advanced-hodgkin-nejm-2016/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27389577/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-kratochwil-ac225-psma-jnm-2016","kind":"paper","name":"225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy of metastatic castration-resistant prostate cancer","route":"/key-papers/paper-kratochwil-ac225-psma-jnm-2016/","field":"links","label":"PubMed record"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/27390158/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"alpha-therapy-roadmap","kind":"roadmap","name":"Alpha-emitter roadmap: radium-223 → 225Ac-PSMA-617 → a phase 3 pipeline","route":"/roadmaps/alpha-therapy-roadmap/","field":"links","label":"Kratochwil et al., 225Ac-PSMA-617 for PSMA-targeted alpha-radiation therapy (J Nucl Med 2016)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28070718/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"tpbg-5t4","kind":"target","name":"5T4 (trophoblast glycoprotein)","route":"/targets/tpbg-5t4/","field":"links","label":"Shapiro et al., Invest New Drugs 2017: first-in-human anti-5T4 ADC PF-06263507 (PMID 28070718)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28076709/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-netter-1-nejm-2017","kind":"paper","name":"NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide","route":"/key-papers/paper-netter-1-nejm-2017/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28094956/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"bradykinin-b1-receptor","kind":"target","name":"Bradykinin B1 receptor (B1R)","route":"/targets/bradykinin-b1-receptor/","field":"links","label":"Kuo et al., Mol Pharm 2017: 68Ga- and 18F-labelled R954 derivatives for B1R PET (PMID 28094956)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/28182580/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"monte-carlo-dosimetry","kind":"technology","name":"Monte Carlo dosimetry","route":"/technologies/monte-carlo-dosimetry/","field":"links","label":"Internal dosimetry with the Monte Carlo code GATE: validation against ICRP/ICRU reference phantom (Phys Med Biol 2017)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29107679/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"tare-vs-sorafenib-caution","kind":"pairing","name":"Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma","route":"/pairings/tare-vs-sorafenib-caution/","field":"links","label":"Vilgrain et al., SARAH trial primary results, Lancet Oncol 2017 (PubMed)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29498924/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"tare-vs-sorafenib-caution","kind":"pairing","name":"Radioembolisation (TARE) compared with sorafenib in hepatocellular carcinoma","route":"/pairings/tare-vs-sorafenib-caution/","field":"links","label":"Chow et al., SIRveNIB trial primary results, J Clin Oncol 2018 (PubMed)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29682217/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-baum-prrt-1048-patients-oncotarget-2018","kind":"paper","name":"Results and adverse events of personalised peptide receptor radionuclide therapy in 1048 patients with neuroendocrine neoplasms","route":"/key-papers/paper-baum-prrt-1048-patients-oncotarget-2018/","field":"links","label":"PubMed record"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29752180/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-hofman-lupsma-lancet-oncol-2018","kind":"paper","name":"LuPSMA trial: single-arm phase 2 study of 177Lu-PSMA-617 in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-hofman-lupsma-lancet-oncol-2018/","field":"links","label":"PubMed: LuPSMA trial (Lancet Oncol 2018)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/29878866/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-strosberg-netter1-qol-jco-2018","kind":"paper","name":"Health-related quality of life in the NETTER-1 trial of 177Lu-Dotatate","route":"/key-papers/paper-strosberg-netter1-qol-jco-2018/","field":"links","label":"PubMed: NETTER-1 quality-of-life analysis (JCO 2018)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30291194/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019","kind":"paper","name":"Efficacy and safety of high-specific-activity 131I-MIBG therapy in advanced pheochromocytoma or paraganglioma","route":"/key-papers/paper-pryma-high-specific-activity-i131-mibg-ppgl-jnm-2019/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/30982686/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"gastric-oesophageal-cancer","kind":"indication","name":"Gastric and gastro-oesophageal junction adenocarcinoma","route":"/indications/gastric-oesophageal-cancer/","field":"links","label":"FLOT4 trial, Al-Batran et al., Lancet 2019 (PubMed)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31410539/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"pulmonary-embolism-vq","kind":"indication","name":"Pulmonary embolism: ventilation/perfusion imaging","route":"/indications/pulmonary-embolism-vq/","field":"links","label":"EANM guideline for ventilation/perfusion SPECT for diagnosis of pulmonary embolism and beyond (2019)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31482426/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-grpr-psma-negative-prostate","kind":"opportunity","name":"GRPR imaging when the PSMA scan is negative","route":"/opportunities/opp-grpr-psma-negative-prostate/","field":"links","label":"177Lu-RM2 first-in-human dosimetry in PSMA-insufficient patients"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/31924723/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"cu-64-dotatate","kind":"drug","name":"Copper-64 dotatate","route":"/drugs/cu-64-dotatate/","field":"links","label":"Delpassand et al., J Nucl Med 2020: 64Cu-DOTATATE PET/CT pivotal phase 3 trial"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32068113/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"falcon","kind":"trial","name":"FALCON","route":"/trials/falcon/","field":"links","label":"Int J Radiat Oncol Biol Phys 2020: FALCON primary results (Scarsbrook et al.)"},{"id":"falcon","kind":"trial","name":"FALCON","route":"/trials/falcon/","field":"outcomes.source (Proportion of patients with a revised management plan (pre-scan vs post-scan))"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32135118/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-herrmann-radiotheranostics-lancet-oncol-2020","kind":"paper","name":"Radiotheranostics: a roadmap for future development","route":"/key-papers/paper-herrmann-radiotheranostics-lancet-oncol-2020/","field":"links","label":"PubMed record"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32196363/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-68","kind":"isotope","name":"Gallium-68","route":"/isotopes/ga-68/","field":"links","label":"PMC: Current status of the production and supply of gallium-68"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32209449/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-propsma-hofman-lancet-2020","kind":"paper","name":"proPSMA: PSMA PET-CT versus conventional imaging for staging high-risk prostate cancer","route":"/key-papers/paper-propsma-hofman-lancet-2020/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32728207/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-sgouros-tat-review-nat-rev-2020","kind":"paper","name":"Radiopharmaceutical therapy in cancer: clinical advances and challenges","route":"/key-papers/paper-sgouros-tat-review-nat-rev-2020/","field":"links","label":"PubMed record"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/32745892/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-dll3-imaging-sclc","kind":"opportunity","name":"DLL3 imaging for small-cell lung cancer","route":"/opportunities/opp-dll3-imaging-sclc/","field":"links","label":"DLL3 expression in 1,050 patients, Lung Cancer 2020"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33356420/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"andrei-iagaru","kind":"person","name":"Andrei Iagaru","route":"/people/andrei-iagaru/","field":"papers","label":"Will FAPI PET/CT Replace FDG PET/CT in the Next Decade?-Counterpoint: No, not so fast!"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33530110/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"b-hot-lab-capacity","kind":"bottleneck","name":"Hot lab and shielded treatment room capacity","route":"/bottlenecks/b-hot-lab-capacity/","field":"links","label":"PSMA radioligand therapy could pose infrastructural challenges for nuclear medicine (German bed-capacity calculation)"},{"id":"b-hot-lab-capacity","kind":"bottleneck","name":"Hot lab and shielded treatment room capacity","route":"/bottlenecks/b-hot-lab-capacity/","field":"metrics (German nationwide nuclear-medicine therapy bed reserve for Lu-177-PSMA-RLT)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33581798/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-therap-lancet-2021","kind":"paper","name":"TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-therap-lancet-2021/","field":"links","label":"PubMed: TheraP primary results (Lancet 2021)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33622706/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"condor","kind":"trial","name":"CONDOR","route":"/trials/condor/","field":"links","label":"Clinical Cancer Research 2021: CONDOR primary results (Morris et al.)"},{"id":"condor","kind":"trial","name":"CONDOR","route":"/trials/condor/","field":"outcomes.source (Correct localisation rate vs composite standard of truth)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/33634707/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"osprey","kind":"trial","name":"OSPREY","route":"/trials/osprey/","field":"links","label":"J Urol 2021: OSPREY primary results (Pienta et al.)"},{"id":"osprey","kind":"trial","name":"OSPREY","route":"/trials/osprey/","field":"outcomes.source (Specificity for pelvic nodal disease, Cohort A, vs histopathology at prostatectomy)"},{"id":"osprey","kind":"trial","name":"OSPREY","route":"/trials/osprey/","field":"outcomes.source (Sensitivity for pelvic nodal disease, Cohort A, vs histopathology)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34116144/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-trop2-imaging-heterogeneity","kind":"opportunity","name":"TROP2 imaging where no tissue test is required","route":"/opportunities/opp-trop2-imaging-heterogeneity/","field":"links","label":"ASCENT TROP2 biomarker analysis"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34314556/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"sortilin","kind":"target","name":"Sortilin (SORT1)","route":"/targets/sortilin/","field":"links","label":"Demeule et al., Cancer Sci 2021: TH1902 for sortilin-positive triple-negative breast cancer (PMID 34314556)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/34801630/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"hcc-intermediate","kind":"indication","name":"Intermediate hepatocellular carcinoma (BCLC B)","route":"/indications/hcc-intermediate/","field":"links","label":"BCLC 2022 update (J Hepatol)"}],"archive":"https://web.archive.org/web/20260805205615/https://pubmed.ncbi.nlm.nih.gov/34801630"},{"url":"https://pubmed.ncbi.nlm.nih.gov/35454785/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"sortilin","kind":"target","name":"Sortilin (SORT1)","route":"/targets/sortilin/","field":"links","label":"Currie et al., Cancers 2022: TH1902 against sortilin-positive ovarian and endometrial cancers (PMID 35454785)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/35461266/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"dlg4-psd95","kind":"target","name":"DLG4 (PSD-95)","route":"/targets/dlg4-psd95/","field":"links","label":"Kivisäkk et al., Alzheimers Res Ther 2022: PSD-95, SNAP-25 and neurogranin in CSF (PMID 35461266)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/36456112/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"heiko-schoder","kind":"person","name":"Heiko Schöder","route":"/people/heiko-schoder/","field":"papers","label":"2022 SNMMI Highlights Lecture: Oncology and Therapy, Part 1"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37093191/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-nectin4-imaging-urothelial","kind":"opportunity","name":"A liver-cleared Nectin-4 tracer for urothelial cancer","route":"/opportunities/opp-nectin4-imaging-urothelial/","field":"links","label":"68Ga-N188 first-in-human, Clinical Cancer Research 2023"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37126069/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"spotlight","kind":"trial","name":"SPOTLIGHT","route":"/trials/spotlight/","field":"links","label":"Journal of Urology 2023: SPOTLIGHT primary results (Jani et al.)"},{"id":"spotlight","kind":"trial","name":"SPOTLIGHT","route":"/trials/spotlight/","field":"outcomes.source (Verified detection rate vs composite standard of truth (histopathology or confirmatory imaging))"},{"id":"spotlight","kind":"trial","name":"SPOTLIGHT","route":"/trials/spotlight/","field":"outcomes.source (Region-level positive predictive value)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37414702/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"lighthouse","kind":"trial","name":"LIGHTHOUSE","route":"/trials/lighthouse/","field":"links","label":"European Urology 2023: LIGHTHOUSE primary results"},{"id":"lighthouse","kind":"trial","name":"LIGHTHOUSE","route":"/trials/lighthouse/","field":"outcomes.source (Sensitivity for pelvic lymph node metastases vs histopathology at prostatectomy)"},{"id":"lighthouse","kind":"trial","name":"LIGHTHOUSE","route":"/trials/lighthouse/","field":"outcomes.source (Specificity for pelvic lymph node metastases vs histopathology at prostatectomy)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37459133/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"tare-plus-durvalumab-hcc","kind":"pairing","name":"Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma","route":"/pairings/tare-plus-durvalumab-hcc/","field":"links","label":"Aliseda et al., Y90-radioembolisation plus durvalumab phase I/IIa trial, Clin Cancer Res 2023;29:3650-3658"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37821170/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"aurora-flurpiridaz","kind":"trial","name":"AURORA","route":"/trials/aurora-flurpiridaz/","field":"links","label":"JACC 2023: AURORA primary results (Maddahi et al.)"},{"id":"aurora-flurpiridaz","kind":"trial","name":"AURORA","route":"/trials/aurora-flurpiridaz/","field":"outcomes.source (Sensitivity for coronary artery disease (≥50% stenosis by quantitative coronary angiography))"},{"id":"aurora-flurpiridaz","kind":"trial","name":"AURORA","route":"/trials/aurora-flurpiridaz/","field":"outcomes.source (Specificity for coronary artery disease)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37891072/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-neoadjuvant-psma-therapy","kind":"idea","name":"Neoadjuvant PSMA radioligand therapy before prostatectomy","route":"/ideas/idea-neoadjuvant-psma-therapy/","field":"links","label":"Administering [177Lu]Lu-PSMA-617 Prior to Radical Prostatectomy (LuTectomy): phase 1/2 study (European Urology, PubMed 2024)"},{"id":"lutectomy","kind":"trial","name":"LuTectomy","route":"/trials/lutectomy/","field":"links","label":"European Urology 2024: LuTectomy primary results (Eapen et al.)"},{"id":"lutectomy","kind":"trial","name":"LuTectomy","route":"/trials/lutectomy/","field":"outcomes.source (Highest tumour radiation absorbed dose after cycle 1)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/37922438/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-tagawa-ac225-j591-jco-2024","kind":"paper","name":"Phase I dose-escalation study of 225Ac-J591, a PSMA-targeting alpha-emitting antibody, in mCRPC","route":"/key-papers/paper-tagawa-ac225-j591-jco-2024/","field":"links","label":"PubMed record"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38043558/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-therap-lancet-2021","kind":"paper","name":"TheraP: [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer","route":"/key-papers/paper-therap-lancet-2021/","field":"links","label":"PubMed: TheraP overall survival (Lancet Oncol 2024)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38423030/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-grpr-psma-negative-prostate","kind":"opportunity","name":"GRPR imaging when the PSMA scan is negative","route":"/opportunities/opp-grpr-psma-negative-prostate/","field":"links","label":"68Ga-RM2 phase 2/3, Lancet Oncology 2024"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38542104/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"dlg4-psd95","kind":"target","name":"DLG4 (PSD-95)","route":"/targets/dlg4-psd95/","field":"links","label":"Serrano et al., Int J Mol Sci 2024: presynaptic and postsynaptic proteins against pathology in Alzheimer's disease (PMID 38542104)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38719240/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-nectin4-imaging-urothelial","kind":"opportunity","name":"A liver-cleared Nectin-4 tracer for urothelial cancer","route":"/opportunities/opp-nectin4-imaging-urothelial/","field":"links","label":"68Ga-N188 against FDG in 62 patients, Journal of Nuclear Medicine 2024"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/38950555/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-dll3-imaging-sclc","kind":"opportunity","name":"DLL3 imaging for small-cell lung cancer","route":"/opportunities/opp-dll3-imaging-sclc/","field":"links","label":"First-in-human DLL3 immuno-PET, Lancet Oncology 2024"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39060377/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-fap-theranostics-sarcoma","kind":"idea","name":"FAP-targeted radioligand therapy for sarcoma","route":"/ideas/idea-fap-theranostics-sarcoma/","field":"links","label":"Feasibility and therapeutic potential of [177Lu]Lu-FAPI-2286 in patients with advanced metastatic sarcoma (EJNMMI, 2024)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39065752/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"bradykinin-b1-receptor","kind":"target","name":"Bradykinin B1 receptor (B1R)","route":"/targets/bradykinin-b1-receptor/","field":"links","label":"Shukuri et al., Pharmaceuticals 2024: 111In-R954 derivative detects endogenous B1R in glioblastoma xenografts (PMID 39065752)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39270701/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-caix-indeterminate-renal-mass","kind":"opportunity","name":"CAIX imaging of the indeterminate renal mass","route":"/opportunities/opp-caix-indeterminate-renal-mass/","field":"links","label":"ZIRCON phase 3, Lancet Oncology 2024"},{"id":"paper-zircon-lancet-oncol-2024","kind":"paper","name":"ZIRCON: [89Zr]Zr-girentuximab PET-CT for detecting clear-cell renal cell carcinoma","route":"/key-papers/paper-zircon-lancet-oncol-2024/","field":"links","label":"PubMed: ZIRCON trial (Lancet Oncol 2024)"},{"id":"zircon","kind":"trial","name":"ZIRCON","route":"/trials/zircon/","field":"links","label":"Lancet Oncology 2024: ZIRCON primary results (Shuch et al.)"},{"id":"zircon","kind":"trial","name":"ZIRCON","route":"/trials/zircon/","field":"outcomes.source (Sensitivity for ccRCC detection vs surgical histopathology)"},{"id":"zircon","kind":"trial","name":"ZIRCON","route":"/trials/zircon/","field":"outcomes.source (Specificity for ccRCC detection vs surgical histopathology)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39282913/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-cabinet-cabozantinib-nejm-2024","kind":"paper","name":"CABINET (Alliance A021602): cabozantinib for advanced neuroendocrine tumours","route":"/key-papers/paper-cabinet-cabozantinib-nejm-2024/","field":"links","label":"PubMed"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39293461/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"upfront-psma","kind":"trial","name":"UpFrontPSMA","route":"/trials/upfront-psma/","field":"links","label":"Lancet Oncology 2024: UpFrontPSMA primary results (Azad et al.)"},{"id":"upfront-psma","kind":"trial","name":"UpFrontPSMA","route":"/trials/upfront-psma/","field":"outcomes.source (Undetectable PSA (≤0.2 ng/mL) at 48 weeks)"},{"id":"upfront-psma","kind":"trial","name":"UpFrontPSMA","route":"/trials/upfront-psma/","field":"outcomes.source (Grade 3-4 treatment-related adverse events)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39293462/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-psmafore-lancet-2024","kind":"paper","name":"PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC","route":"/key-papers/paper-psmafore-lancet-2024/","field":"links","label":"PubMed: PSMAfore primary results (Lancet 2024)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39362766/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-gpc3-hcc-china","kind":"opportunity","name":"GPC3 imaging of the indeterminate liver nodule, led from China","route":"/opportunities/opp-gpc3-hcc-china/","field":"links","label":"[68Ga]Ga-RAYZ-8009 first-in-human case series, J Nucl Med 2024"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39377811/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"tpbg-5t4","kind":"target","name":"5T4 (trophoblast glycoprotein)","route":"/targets/tpbg-5t4/","field":"links","label":"He et al., EJNMMI 2025: [68Ga]Ga-NOTA-H006 preclinical and pilot clinical study (PMID 39377811)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39956124/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"enza-p","kind":"trial","name":"ENZA-p","route":"/trials/enza-p/","field":"links","label":"Lancet Oncology 2025: ENZA-p overall survival and quality of life (secondary outcomes)"},{"id":"enza-p","kind":"trial","name":"ENZA-p","route":"/trials/enza-p/","field":"outcomes.source (Overall survival (longer follow-up))"},{"id":"enza-p","kind":"trial","name":"ENZA-p","route":"/trials/enza-p/","field":"outcomes.source (Grade 3-5 adverse events (secondary-outcomes report))"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/39978166/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-tb161-instead-of-lu177","kind":"idea","name":"Terbium-161 instead of lutetium-177 in the same ligands","route":"/ideas/idea-tb161-instead-of-lu177/","field":"links","label":"Terbium-161 in nuclear medicine: preclinical and clinical status (PubMed, 2025)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40443260/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"tpbg-5t4","kind":"target","name":"5T4 (trophoblast glycoprotein)","route":"/targets/tpbg-5t4/","field":"links","label":"Kong et al., Mol Pharm 2025: [18F]AlF-RESCA-H006 for pancreatic adenocarcinoma (PMID 40443260)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40444499/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"ai-in-nuclear-medicine","kind":"technology","name":"AI in nuclear medicine","route":"/technologies/ai-in-nuclear-medicine/","field":"links","label":"The value of artificial intelligence in PSMA PET: a pathway to improved efficiency and results, systematic review (2025)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40680993/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"paper-psmafore-lancet-2024","kind":"paper","name":"PSMAfore: 177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor in taxane-naive mCRPC","route":"/key-papers/paper-psmafore-lancet-2024/","field":"links","label":"PubMed: PSMAfore final overall survival (Ann Oncol 2025)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/40774265/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"ga-68-fapi-46","kind":"drug","name":"Gallium-68 FAPI-46","route":"/drugs/ga-68-fapi-46/","field":"links","label":"Pabst et al., Lancet Oncology 2025: 68Ga-FAPI-46 PET accuracy for cancer imaging with histopathology validation (phase 2 trial)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41087606/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-fap-theranostics-sarcoma","kind":"idea","name":"FAP-targeted radioligand therapy for sarcoma","route":"/ideas/idea-fap-theranostics-sarcoma/","field":"links","label":"Safety and efficacy of 177Lu-FAPI-XT radioligand therapy in advanced sarcoma and other cancer entities: first-in-human, dose-escalation study (EJNMMI, 2026)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41101977/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"ai-in-nuclear-medicine","kind":"technology","name":"AI in nuclear medicine","route":"/technologies/ai-in-nuclear-medicine/","field":"links","label":"PSMA PET evaluation with a deep-learning platform compared with a standard viewer and histopathology (J Nucl Med 2025)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41166032/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"ai-in-nuclear-medicine","kind":"technology","name":"AI in nuclear medicine","route":"/technologies/ai-in-nuclear-medicine/","field":"links","label":"Deep learning-based PSMA PET segmentation repeatability: test-retest analysis (2026)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41412927/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-bone-targeted","kind":"section","name":"Bone-targeted radiopharmaceuticals","route":"/fronts/f-bone-targeted/","field":"links","label":"Assessing therapeutic response to radium-223 (Semin Nucl Med, 2026)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41667280/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-neuro-imaging","kind":"section","name":"Neuro-imaging","route":"/fronts/f-neuro-imaging/","field":"links","label":"PET imaging in Alzheimer disease in the era of antiamyloid therapy (J Nucl Med Technol, 2026)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41688850/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"opp-gpc3-hcc-china","kind":"opportunity","name":"GPC3 imaging of the indeterminate liver nodule, led from China","route":"/opportunities/opp-gpc3-hcc-china/","field":"links","label":"GPC3-targeted immunoPET translational study, EJNMMI 2026"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41773941/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"sortilin","kind":"target","name":"Sortilin (SORT1)","route":"/targets/sortilin/","field":"links","label":"Gao et al., J Med Chem 2026: 89Zr/177Lu radioimmunoconjugates targeting SORT1 (PMID 41773941)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41832388/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"tpbg-5t4","kind":"target","name":"5T4 (trophoblast glycoprotein)","route":"/targets/tpbg-5t4/","field":"links","label":"Harbi et al., EJNMMI Res 2026: oncofetal surface antigens in prostate cancer and radioligand targeting (PMID 41832388)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41904043/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"cu-64-sar-bispsma","kind":"drug","name":"Copper-64 SAR-bisPSMA","route":"/drugs/cu-64-sar-bispsma/","field":"links","label":"Co-PSMA trial, European Urology 2026: prospective comparison of 64Cu-SAR-bisPSMA vs 68Ga-PSMA-11 for biochemical recurrence"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41926961/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"idea-rlt-plus-checkpoint-inhibitor","kind":"idea","name":"Adding a checkpoint inhibitor to PSMA radioligand therapy","route":"/ideas/idea-rlt-plus-checkpoint-inhibitor/","field":"links","label":"177Lu-PSMA-617 in combination with pembrolizumab for treatment of mCRPC (PRINCE): phase 1b/2 study (PubMed, 2026)"},{"id":"prince-trial","kind":"trial","name":"PRINCE","route":"/trials/prince-trial/","field":"links","label":"Lancet Oncology 2026: PRINCE final results (Sandhu et al.)"},{"id":"prince-trial","kind":"trial","name":"PRINCE","route":"/trials/prince-trial/","field":"outcomes.source (PSA50 response rate (co-primary with safety))"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/41984171/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"tpbg-5t4","kind":"target","name":"5T4 (trophoblast glycoprotein)","route":"/targets/tpbg-5t4/","field":"links","label":"Liang et al., J Med Chem 2026: [89Zr]Zr-DFO-HB5 immuno-PET and 161Tb vs 177Lu therapy in colorectal cancer (PMID 41984171)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/42570199/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"f-radioligand-therapy","kind":"section","name":"Radioligand therapy","route":"/fronts/f-radioligand-therapy/","field":"links","label":"GRADE-assessed meta-analysis of 177Lu-PSMA RCTs (Int Urol Nephrol, 2026)"}]},{"url":"https://pubmed.ncbi.nlm.nih.gov/542943/","status":203,"ok":true,"checked":"2026-10-21","refs":[{"id":"kr-81m","kind":"isotope","name":"Krypton-81m","route":"/isotopes/kr-81m/","field":"links","label":"Ventilation studies with krypton-81m: continuous-flow elution and repeated projections"}]}]}